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Abstract 
Lactadherin is a glycoprotein thought to have roles in cancer progression, through 
ligation of integrins αvβ3 and/or αvβ5 on the surface of tumour cells and their 
vasculature. It is thought to promote tumour growth through activation of integrin 
signalling pathways in both tumour and vascular endothelial cells, leading to direct 
tumour expansion and indirect tumour growth through stimulation of angiogenesis. 
HuMc3 (Angiolix®) an antibody with affinity to the integrin binding EGF-like 
domain of lactadherin, has been shown to inhibit lactadherin association with αv 
integrin expressing cell lines. This work aimed to uncover whether through its 
disruption of lactadherin αvβ3 and/or αvβ5 integrin ligation, HuMc3 could 
prevent/slow the growth of lactadherin-overexpressing tumours. This work confirmed 
the ability of HuMc3 to inhibit lactadherin binding to both tumour cell and vascular 
endothelial cell αvβ3/αvβ5 integrins. It demonstrated a concentration-dependent 
growth inhibition of tumour xenografts in vivo alone and a greater effect for 
combination with a conventional chemotherapy drug than either therapy alone. In one 
tumour model HuMc3 showed a similar therapeutic effect when applied alone to an 
approved anti-vasculature anti-cancer therapeutic bevacizumab, though a lower effect 
was observed when both were applied with chemotherapy. HuMc3 showed no 
apparent therapeutic toxicity and in biodistribution studies, no specific uptake by any 
normal murine tissue. In addition, the in vivo data for HuMc3 compared fairly well 
with that published for other anti-cancer and anti-vasculature therapeutics approved/in 
clinical development. HuMc3 was therefore indicated to have the potential as a 
successful anti-cancer therapeutic for treatment of lactadherin over-expressing 
cancers. Further work may determine the optimal monotherapy concentration and may 
uncover better combinations with other targeted agents and conventional 
chemotherapy/radiotherapy. A major drawback of this work was however the lack of 
success of the in vitro assays, so the mode of action of HuMc3 could not be 
confirmed. Further work may involve repeating these assays under conditions shown 
successful in published work with other αvβ3/αvβ5 integrin ligand-mAb 
combinations, as well as repeating the in vivo work with inclusion of an isotype-
matched control antibody, tissue analysis to examine any changes to vascular density 
and with examination of the importance of antibody effector functions in the in vivo 
effect of HuMc3 
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Chapter 1   Introduction 
 
 
1.1 Roles of integrins in tumour development 
 
1.1.1 Tumour integrin signalling 
Integrins are transmembrane glycoproteins expressed on the cell surface involved in 
cell-to-cell and cell-extracellular matrix (ECM) adhesion. They are heterodimeric 
proteins composed of one alpha and one beta subunit. There are 18 alpha and 8 beta 
subunits in mammals and 24 integrin dimers [1]. Integrins function to transmit signals 
from the ECM to the inside of the cell, allowing the cell to respond to changes on the 
extracellular environment [1]. 
 
As normal cells become tumourigenic and tumour cells more invasive, the 
composition of the extracellular environment changes, due to new matrix protein 
deposition and release of matrix degrading proteases [2]. The association of tumour 
cell and vascular endothelial cell (EC) integrins (see section 1.2.3 for the roles of 
integrins in tumour angiogenesis) with the ECM therefore changes, but it also alters 
due to both a modified affinity of existing integrins caused by conformational change 
and changes in integrin expression [2][3][4]. As receptors for ECM proteins, integrins 
are required for cell migration during tissue invasion and metastasis, but they also 
play a role in earlier stages of tumour development by promoting proliferation, 
survival and gene expression [5] signalling. There is also a growing body of evidence 
for a role of integrins in the adhesive events of metastasis [2][5] including adhesion to 
platelets aiding survival in the bloodstream, tumour arrest at the secondary site and 
extravasation [6].   
 
Integrin activation involves ECM protein association, clustering of integrins and 
RTK’s (receptor tyrosine kinases) into focal contact sites or focal adhesions and 
activation of signalling [5] (figure 1.1). As well however as outside-in signalling, 
signalling also occurs in the opposite direction. This involves binding of proteins to 
the cytoplasmic tail, altering the affinity and avidity of ECM proteins for the 
receptors, by modulating the configuration of the integrin head group and causing 
integrin clustering respectively [2]. Integrins can activate one or more signalling 
pathways following formation of focal adhesions (figure 1.1). Activation of signalling 
involves the recruitment of focal adhesion kinase (FAK) and its autophosphorylation, 
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followed by binding of adaptor proteins, leading to the activation of small GTPases 
and downstream signalling molecules (figure 1.1) [2]. Activation of these signalling 
pathways alone or through coordinated signalling with RTK pathways leads to control 
of the downstream effects of cell migration, invasion, survival and proliferation [7]. 
Examples of growth factor receptor-integrin cross-talk in activated EC’s are described 
in section 1.2.3.1.  
 
The extracellular signal related kinase (ERK) or p42/44 mitogen activated protein 
kinase (p42/44MAPK) pathway that promotes cellular proliferation and gene 
transcription is activated by several mechanisms (figure 1.1). The most simple is 
through the direct recruitment of adaptor protein; growth factor receptor bound 
protein 2 (GRB2), with activation of small G protein ras, converting it from Ras-GDP 
to Ras-GTP. It can also be activated by recruitment by FAK of SRC and SHC and 
SRC-dependant phosphorylation of SHC, followed by recruitment of GRB2 and 
activation of ras. Activation of protein kinase C (PKC) and SHC through integrin 
clustering independently of FAK binding can also lead to activation of ras and raf 
(figure 1.1) [2]. Ras activated by any of these mechanisms then recruits Raf, a serine 
threonine kinase to the membrane, with activation by protein kinases such as SRC. 
This leads to activation of the duel specificity kinase MEK, which phosphorylates and 
activates ERK, required for cell proliferation, survival, gene transcription and 
migration [2][7] (see section 1.2.2.1 for more detail on the downstream effects of this 
pathway). Activated SRC may also phosphorylate and so activate CRK-associated 
substrate (CAS), permitting binding to CRK and dedicator of cytokinesis (DOCK) 
resulting in activation of small GTPase rac. Together with CDC42, rac promotes 
activation of p21 activated kinase (PAK), which phosphorylates and activates ERK. 
The latter pathway represents a ras-independent mechanism of activating ERK 
signalling, [2] (figure 1.1).  Ras, activated by any of the mechanisms described above 
can also activate the phosphatidylinositol 3-kinase (PI3-K) pathways leading to 
motility, and survival (figure 1.1) [2]. PI3-K activity is necessary for survival through 
inhibition of the intrinsic apoptosis pathway, involving activation of Akt/PKB (protein 
kinase B) signalling and downstream inhibition of activity of initiator caspase-9 and 
of Bcl-2 (B-cell lymphoma 2) associated death promoter homolog BAD, (see 1.2.2.1 
for more detail on this apoptosis pathway) [2][5].  
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Figure 1.1 
Integrin signalling pathways  
(a) Pathway diagram showing the overlapping nature of integrin signalling pathways, leading to 
cell proliferation, survival, gene transcription and migration. Shown is ras activation of ERK 
signalling and downstream proliferation, migration and gene transcription, involving ras activated 
through several mechanisms. Ras-independent mechanisms of ERK activation are also indicated 
including a rac, cdc42 dependent pathway and direct activation of raf by PKC. Ras signalling is also 
shown to activate PI-3K, leading to survival and migration.  Modified from [2]. 
(b) Overview table of integrin signalling pathways. 
(a) 
 
 
(b) 
Effect Pathway Activated by 
Proliferation/gene 
transcription 
P42/44 MAPK (ERK) Ras activation involving direct GRB2 recruitment to activated integrin. 
Proliferation/gene 
transcription 
P42/44 MAPK (ERK) Ras activation involving indirect GRB2 recruitment by SHC (requiring 
FAK and SRC). 
Proliferation/gene 
transcription 
P42/44 MAPK (ERK) Activation of SRC by FAK association, leading to ras-independent rac-
mediated ERK activation. 
Proliferation/gene 
transcription 
P42/44 MAPK (ERK) Activation of PKC and SHC independent of FAK, leading to ras and direct 
raf activation. 
Survival PI3-K pathway. Protection against 
intrinsic apoptosis. 
Ras activation by direct/indirect GRB2 recruitment to the membrane or a 
FAK independent mechanism. 
Survival Protection against extrinsic 
apoptosis. 
Receptor ligation leading to inhibition of caspase-8 recruitment to the 
membrane. 
Migration Cdc42, rho and rac mediated 
migration by membrane ruffle 
formation. 
Rac activation by ras-mediated PI3-K activity. Integrin activation involving 
association with co-receptor syndecan-4, leading to rho activation. 
Migration Cdc42, rho and rac mediated 
migration by membrane ruffle and 
actin stress fibre formation. 
Activation of SRC by FAK association, leading to activation of CAS and 
so DOCK, then rac. Integrin activation involving association with co-
receptor syndecan-4, leading to rho activation. 
Integrin-mediated survival may alternatively involve protection against extrinsic 
apoptosis, by inhibition of recruitment of pro-caspase-8 to the plasma membrane upon 
integrin ligation, and so prevention of activation of initiator caspase-8 by cell surface 
Proliferation, survival, 
gene transcription and 
migration 
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death receptors. Both intrinsic and extrinsic apoptosis pathways converge to activate 
effector caspases 3, 6 and 7 leading to controlled cell death [2][5] and both survival 
pathways therefore protect against this. Anchorage-dependant tumour cells like 
normal cells require integrin ligation for survival through inhibition of extrinsic 
apoptosis, with removal of the substratum and so the presence of un-ligated integrins 
resulting in death due to loss of integrin survival signalling, known as anoikis [5]. 
Some tumours however, have been shown to survive in the absence of a substratum 
and so are anchorage-independent. This may occur due to constitutive activation of 
FAK survival signalling [2]. 
 
1.1.2 The roles of αv integrins in tumour development 
A function for the integrin αvβ3 in the pathology of melanoma has been suggested, 
with expression in an extensive range of melanoma tissue samples [8]. This integrin 
has been indicated to play a role in tumour cell proliferation [9] and promote survival 
by protecting cells from apoptosis in melanoma [10][11]. It has also been indicated to 
aid invasion by association with ECM proteins in the tumour stroma [11] and by 
controlling protease degradation of the ECM by localisation with matrix 
metalloprotease-2 (MMP-2) and its activating membrane-type matrix 
metalloproteinase [12][13] (section 1.2.1). In addition, increased expression has been 
shown to correlate with malignancy [14]. Co-expression of bone sialoprotein, integrin 
αvβ3 and matrix metalloprotease MMP-2 on thyroid papillary carcinoma cells 
suggests a possible role of this integrin in thyroid carcinoma, with a role in invasion 
through control of protease activity inferred [15]. Work has suggested a role for αvβ3 
in successful colonisation following prostate tumour metastasis to the bone by 
promoting prostate cancer adhesion and migration on proteins of the bone 
microenvironment; osteopontin and vitronectin [16][17][18]. A potential role for both 
integrins αvβ3 and αvβ5 in breast cancer growth and metastasis has also been implied 
by enhanced cell proliferation and adhesion in αvβ5-enriched breast carcinoma 
populations. It is also suggested by increased breast carcinoma cell migration in 
αvβ3-enriched populations, on bone sialoprotein which forms part of the bone matrix 
[19], with the bone a common secondary site for breast tumours. Evidence has also 
been provided for role of αvβ3 adhesion to platelets, to aid survival in the 
bloodstream during breast tumour metastasis [20]. Other work has suggested a role for 
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αv integrins in breast cancer cell adhesion and migration, with a αvβ5/αvβ3 inhibitor 
blocking adhesion and migration on vitronectin [21]. A role for αv integrins in breast 
cancer development is supported by work with the αv integrin receptor blocking 
antibody CNTO 95, shown to inhibit cell adhesion, migration and invasion in vitro 
and reduce cell viability by inhibition of focal adhesion formation and signalling. It 
also inhibited tumour growth and metastasis to the lung, in animal models, though it 
cannot be ruled out that the in vivo effects seen were wholly or partially due to 
inhibition of the roles of these integrins in angiogenesis [22] (section 1.2.3.1). A role 
for αvβ3 and αvβ5 integrins in ovarian cancer has been implied by expression of 
αvβ3 by primary human ovarian tumours [23] and several ovarian tumour cell lines. 
In addition, αv and β5 integrin subunits have been detected in ovarian epithelial 
carcinomas, with expression of these subunits shown to be associated with poor 
prognosis [20]. In addition, expression of αv integrins and the αvβ3/αvβ5 integrin 
ligand vitronectin has been demonstrated in three human ovarian adenocarcinoma cell 
lines IGROV1, OAW42 and SKOV3, with vitronectin organised into focal contact 
sites at the cell surface with αv integrin [24], suggesting an ability to activate these 
integrins. 
 
The overall indication from past research is therefore that the integrin αvβ3 plays a 
role in pathogenesis of many tumour types, with functions in cell proliferation, 
migration, survival in the bloodstream and formation of secondary tumours, 
particularly when the secondary tumours develop in the bone. The purpose of αvβ5 in 
tumourigenesis however appears to be restricted to breast and ovarian tumours, with 
roles in proliferation, migration and adhesion suggested and again in bone secondary 
site association. Both are implicated as oncogene products with up-regulation 
associated with cancer progression. There is also a body of work showing the roles of 
both αvβ3 and αvβ5 integrins in both normal and tumour angiogenesis through 
expression on the surface of vascular EC’s, but this will be covered in section 1.2.3.1. 
1.2  Angiogenesis 
1.2.1   Introduction to angiogenesis 
Angiogenesis is the development of new vessels from the preexisting vasculature [25] 
(figure 1.2). The basic steps of angiogenesis involve regional degradation of the 
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basement membrane (basal lamina), the proliferation of EC’s and their survival and 
migration/invasion into nearby tissue [26] towards an angiogenic stimulus [27], tube 
formation, vessel maturation and pruning back of excess/unwanted vasculature 
[28][29] (figure 1.2). Angiogenesis is a highly complex and coordinately controlled 
process involving the cooperation of many classes of receptor-ligand interaction, 
production/activation and release of various tissue factors and involvement of many 
cell types [25][30][31][32]. Positive regulators of angiogenesis include growth 
factors, cytokines and matrix proteins [31][32]. Angiogenesis inhibitors such as 
vasohibin, angiostatin, endostatin, thrombospondin (TSP) and tumstatin have direct 
roles in inhibiting EC proliferation and migration and promoting apoptosis, creating 
the balance with positive regulators during tissue stasis Angiogenesis is therefore 
controlled by both positive and negative regulation, with a balance occurring under 
normal conditions, but with a shift towards increased expression of pro-angiogenic 
and reduced production of anti-angiogenic molecules upon tissue damage [31]. 
Angiogenesis inhibitors also form part of the negative feedback mechanism for the re-
establishment of the normal tissue vasculature architecture [31].   
Normal healthy tissue blood vessels exist in a steady state [33]. Vessel EC’s are 
linked together with tight cell-cell associations and form stable interactions with the 
surrounding ECM and the basal lamina [27] and the vessels are surrounded by a 
supporting layer of pericytes (figure 1.2) [31][32]. Tissue injury and the subsequent 
acute inflammatory response promote increased vascular permeability, resulting in a 
rapid change in the composition of the ECM [28][30]. Interaction with the matrix is 
necessary for all steps involved in angiogenesis. Loss of laminin and up-regulation of 
collagen-1 integrin signaling is associated with the dissociation of VE cadherin and so 
loss of cell-cell adhesion [27] at the onset of angiogenesis. Endothelial migration 
requires matrix adhesion for traction [27] and for chemotaxis and haptotaxis; 
respectively migration in response to gradients of cytokines and immobilised ECM 
components [34]. Proliferation and survival require matrix adhesion as activation of 
cyclin dependant kinases, involved in cell cycle progression [27][35] and activation of 
p44/p42MAPK proliferation pathway activity are anchorage dependant. The latter 
pathway also has a role in survival (1.2.2.1) [33]. The formation of a lumen in EC pre-
capillary cords [25][27] by development and fusion of intracellular vacuoles also 
involves matrix adhesion and signalling [35][36][37][38]. 
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Figure 1.2 
Overview of angiogenesis 
Angiogenesis stimulated by angiogenic factor production leading to EC proliferation, migration and 
tube formation requiring remodeling of the ECM and culminating in cell differentiation and vessel 
maturation. Plus and minus symbols represent direction of angiogenic stimulus. Adapted from an 
image taken from [39]. 
 
The EC’s are proposed to become shielded from integrin activation by interstitial 
matrix components during capillary maturation, by formation of the basal lamina, 
supported by re-formation of tight intercellular junctions [27]. They form stable 
interactions with the lamina, through laminin-binding integrins, which also actively 
suppress EC proliferative signalling [27].  
Proteolysis of the ECM is also a vital component of angiogenesis, required for 
breakdown of the basal lamina during initiation of angiogenesis and degradation of 
the matrix for invasion and pre-capillary cord formation [27][40][41], lumen 
development [40], vessel regression [42][43][44], release of matrix-bound angiogenic 
factors [31] and for unveiling of ECM protein cryptic sites, to create new integrin 
1    Angiogenic factor production 
2    Release 
3     Extracellular receptor       
       binding – intracellular            
       signalling 
4   EC activation  
     ECM degradation 
5   EC proliferation 
7    ECM remodelling 
8   Tube formation 
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      migration 
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adhesion properties [33]. Proteolysis is carried out predominantly by the matrix 
metalloproteases (MMP’s). The membrane-type matrix metalloproteinases have been 
shown to be the regulators of invasion and lumen formation [40][41], with localisation 
to the invasive front of the cell by association with integrins, allowing controlled 
degradation of the matrix in the direction of required cell migration [45].  
1.2.2 Angiogenesis and the vascular endothelial growth factor pathways  
Angiogenic growth factors such as basic fibroblast growth factor (bFGF) and vascular 
endothelial growth factor (VEGF), stimulate EC’s of wound edge vessels to activate 
networks of intracellular signaling pathways, required for angiogenesis [28][29][33] 
(figure 1.2). The VEGF gene family of dimeric glycoproteins has 7 members [46], 
with the gene products binding to members of the VEGF receptor family of RTK’s 
[47] (figure 1.3). The VEGF-A165 isoform of VEGF-A is the family member most 
commonly expressed by tumours [29][48] and is the most potent angiogenesis-
inducing protein ever characterised [48]. 
 
Figure 1.3 
VEGFR-2 structure 
The VEGFR-2 receptor with the extracellular domain comprising 7 immunoglobulin-like folds, a 
membrane spanning region, juxtamembrane domain, tyrosine kinase domain with kinase insert and c-
terminal tail. Receptor shown bound to a VEGF dimer, also associated with HSPG and neuropilin-1 
co-receptors. Image adapted from [47]. 
 
There are three RTK’s to which VEGF binds; VEGFR-1 (Flt-1), VEGFR-2 (Flk-1) 
and VEGFR-3 (Flt-4) [46]. All are composed of an extracellular domain with 7 
 
Juxtamembrane domain 
 
Tyrosine kinase domain 
with kinase insert 
 
C-terminal tail 
Immunoglobulin-like 
domains 
 
VEGF dimer 
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immunoglobulin-like folds, a single membrane-spanning region, an intracellular 
juxtamembrane domain, a consensus tyrosine kinase domain interrupted by a kinase 
insert and a c-terminal tail [47] (figure 1.3). VEGFR-2 is the principle receptor on 
vascular EC’s responsible for promoting angiogenesis [46] and is activated by binding 
of VEGF-A, C, D and E [48] Stimulation of this receptor leads to activation of 
pathways promoting EC proliferation, survival by inhibition of apoptosis, migration 
and an increase in vessel permeability [25][29]. In addition, VEGF-receptor activation 
leads to expression of genes encoding proteins that regulate angiogenesis including 
integrins, MMP’s and proteins regulating their activity [29].  
The activity of RTK’s is determined by the availability of the cognate ligand [47]. 
VEGF-mediated angiogenesis is therefore regulated by VEGF expression and by 
release from ECM storage. The latter is regulated by protease activity, but expression 
of VEGF is controlled by tissue hypoxia and by growth factors and cytokines through 
activation of cell signaling pathways [29]. Expression of VEGFR-1 and VEGFR-2 are 
also regulated by tissue hypoxia [25].   
1.2.2.1 Signal transduction and downstream effects of VEGF receptor ligation 
Activation of RTK’s upon ligand binding involves receptor dimerisation, activation of 
intrinsic kinase activity and phosphorylation of specific tyrosine residues at sites in 
the cytosolic domain [47]. The phosphotyrosine residues form docking sites for Src 
homology-2 (SH2) domain-containing proteins which lead to initiation of signalling 
pathways [46]. The ERK pathway (figure 1.4 pathway 4) leads to cell proliferation, 
Akt/PKB (figure 1.4 pathway 1), endothelial nitric oxide synthase (eNOS) (figure 1.4 
pathway 1) and rac pathways to survival and migration/increased vascular 
permeability respectively, and p38MAPK (p38 mitogen activated protein kinase) and 
FAK pathways (figure 1.4 pathways 2 and 3) [25], migration by cytoskeletal 
reorganisation and focal adhesion turnover. [47].  
The p42/44MAPK pathway is thought to be activated by two mechanisms [32]. The 
first involves phosphorylation of Tyr1175 of VEGFR permitting binding of PLCγ1 
(phospholipase C gamma 1) [25] which hydrolyses the membrane phospholipid 
phosphatidylinositol 4,5 bisphosphate, with release of second messengers 1,2-
diacylglycerol (DAG) and inositol 1,4, 5-trisphosphate (IP3) [26]. The former directly 
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activates PKC and the latter indirectly, by promoting release of intracellular Ca2+ 
stores [26][32].  PKC promotes the activation of Ras. Activated Ras recruits Raf to 
the plasma membrane where it is activated and phosphorylates MEK-1, which 
phosphorylates and activates ERK [32] (figure 1.4 pathway 4). Activation of the 
p42/44 MAP kinase pathway leads to translocation of ERK into the nucleus, where it 
phosphorylates and activates transcription factors including c-Jun and the ternary 
transcription factor, leading to transcription of c-fos and cell proliferation [25]. The 
second method of p42/44 MAPK pathway activation involves binding of an adaptor 
protein GRB2 to the activated receptor through its SH2/SH3 domain, either directly or 
through association with other receptor-bound proteins. Association of GRB2 to the 
membrane leads to translocation of SOS, a guanine nucleotide exchange factor to the 
cell membrane (pathway not shown). This activates Ras and the pathway continues as 
above [32].  
There is also evidence that activation of the p42/44 MAPK pathway is necessary for 
survival by inhibition of apoptosis [32][47][49], with signaling in this pathway 
involved in survival through both a transcription-dependent and a transcription-
independent mechanism [50]. Both mechanisms have been shown to involve 
activation of the kinase Rsk, which phosphorylates the transcription factor CREB 
(cAMP response-element-binding protein) at serine-133 for the former mechanism 
and BAD at serine-112 for the latter mechanism. The transcription dependant 
mechanism results in cell survival though control of gene transcription, with 
inhibition of serine-133 phosphorylation inhibiting survival. The exact means of 
survival promotion have not however been fully elucidated. Phosphorylation of BAD 
results in suppression of BAD-mediated intrinsic apoptosis [50]. 
Ligation of the VEGFR-2 receptor is also required for activation of the PI3K pathway 
with PI3K activation leading to an increase in the levels of the lipid 
phosphatidylinositol (3,4,5)P3 [25]. This activates Akt/PKB [25].  Activated Akt 
phosphorylates and so inhibits the activity of BAD and of caspase-9, both of which 
are necessary for intrinsic apoptosis and the forkhead transcription factors required for 
expression of pro-apoptotic proteins. Akt activity also promotes expression of the 
effector caspase-3 inhibitor survivin and the anti-apoptotic protein Bcl-2 [26]. This 
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pathway therefore promotes cell survival by several mechanisms (figure 1.4, pathway 
1). 
 
Figure 1.4 
VEGFR signalling pathways 
VEGFR-2 activation and signaling encompassing VEGF-A dimer ligation, receptor dimerisation, 
autophosphorylation of key tyrosine residues and activation of signaling.  Activated signaling pathways 
include (1) , the Akt/PKB pathway resulting in, survival though protection against intrinsic apoptosis 
and increased permeability and migration through eNOS activity, (2) the p38MAPK and (3) the FAK 
pathways leading to migration, and (4) the  p42/44 MAPK, ERK pathway promoting cell proliferation 
and gene expression. Taken from [25]. 
 
 
 
VEGFR-2-mediated p42/44MAPK pathway activity and survival and proliferation 
have been shown to require adhesion to the ECM via integrins [32] (1.2.3.1). The 
angiogenic growth factor bFGF like VEGF requires ligation of an integrin for full 
activity (section 1.2.3.1) [51].  Ligation of the bFGF receptor on the vascular EC 
surface also leads to activation of the GRB2-SOS-Ras p42/44MAPK pathway [51], 
culminating in cell proliferation, gene expression and migration.  
(1)   (2)            (3)                  (4) 
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1.2.3 Integrins in angiogenesis 
At the onset of angiogenesis, when the basal lamina is degraded, the EC’s become 
exposed to interstitial and provisional matrix proteins including collagen-1, fibrin, 
fibronectin and vitronectin [35]. Vascular EC’s express the integrins α1β1, α2β1, 
α3β1, α4β1 α5β1, α6β1, α6β4, αvβ3 and αvβ5 [1] (figure 1.5). Each of the integrin 
receptors have specific subsets of ligands with which they can adhere, so the integrins 
expressed determine which components of the ECM the cell can bind and respond to 
[33]. Most of the integrins expressed on quiescent vascular EC’S bind to basal lamina 
ECM components, including basal forms of collagen and laminin 
(α1β1, α2β1, α3β1, α6β1, α6β4) [1], but αvβ5 and α5β1 expressed at low levels 
bind to components of the provisional (angiogenesis-activated) matrix containing the 
RGD (arginine-glycine-aspartic acid) amino acid sequence motif, including 
vitronectin and fibronectin [33] (figure 1.5).  
 
Figure 1.5 
Endothelial cell integrins 
Spider diagram showing integrins expressed by vascular EC’c and their ECM ligands. Taken from [1] 
 
Integrin composition and activity on vascular EC’s changes at the onset of 
angiogenesis, induced by binding of angiogenic growth factors such as bFGF or 
VEGF [33]. Integrins α1β1, α2β1, α5β1 and αvβ5 release their stable contacts with 
the matrix and other cells and form clusters at focal contact sites with growth factor 
receptors and signaling pathways are activated [33]. Integrins that bind to basal matrix 
components are down-regulated and those that bind to provisional matrix components 
and interstitial collagens such as α5β1 and αvβ5 are up-regulated. The integrins αvβ3 
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and α4β1 are expressed de novo [33]. The new integrin repertoire allows the cell to 
respond to the changing composition of the peri-vascular environment during 
angiogenesis. 
1.2.3.1  Integrins αvβ5 and αvβ3 and angiogenesis 
Integrins up-regulated during angiogenesis have been indicated to play regulatory 
roles in this process [33]. The integrin α5β1 up-regulated at angiogenesis onset 
[45][52] for example promotes angiogenesis by association with the provisional ECM 
component fibronectin, activating pathways regulating cell survival through inhibition 
of apoptosis [53]. Inhibitor studies with the anti α5β1 integrin antibody M200 have 
demonstrated induction of apoptosis of proliferating EC’s independent of growth 
factor signaling. 
 
The integrins αvβ3 and αvβ5, members of the αv family been indicated to play 
essential roles in angiogenesis through modulation of bFGF and VEGF receptor 
signalling respectively [45], though αvβ3 has also been shown to have a lesser effect 
on VEGFR2-mediated angiogenesis [54]. Both have also been implicated in control of 
angiogenesis through other mechanisms [54] described later in this section. The role 
of these integrins in bFGF/VEGF-mediated angiogenesis has been demonstrated in 
assays with αvβ3 and αvβ5 antagonists. Antibodies LM609 and P1F6 against αvβ3 
and αvβ5 respectively were shown to selectively inhibit angiogenesis induced by the 
bFGF (LM609) and VEGF (P1F6) growth factor pathways, with LM609 also 
producing a limited inhibition of VEGF angiogenesis [54]. A cyclic RGD-sequence 
containing peptide with association to both integrins inhibited angiogenesis stimulated 
by both. No effect was however observed on the pre-existing vasculature [54]. LM609 
was also shown to inhibit tumour growth and vascularisation in vivo and specifically 
to promote vascular EC apoptosis indicating a role of αvβ3 in vascular EC survival 
through inhibition of apoptosis [55]. Selective αvβ3/αvβ5 inhibitors EMD-121974, 
EMD-85189 and EMD-66203 inhibited both VEGF and bFGF mediated EC invasion 
and differentiation in in vitro assays [56]. Selective αvβ3/αvβ5 inhibitors were also 
shown to inhibit new vessel formation in animal models, with no effect on mature 
vasculature [57][58][59]. In addition, an anti-αv integrin antibody CNTO-95 shown to 
bind both αvβ3 and αvβ5, inhibited sprouting angiogenesis in an in vitro assay [60] 
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and angiogenesis induced by bFGF in in vivo models [60]. It also inhibited bFGF-
induced EC proliferation indicating a role of αvβ3 in bFGF-mediated proliferation 
[60].  
 
Ligation of the αv integrins has been shown to be essential for activation of the 
GRB2-SOS-Ras MAPK pathway (section 1.2.2.1), in both bFGF and VEGF growth 
factor signalling, leading to activation of ERK-1/2 [61] which controls cell survival, 
proliferation, differentiation and migration [61][62]. Coordinated signalling from the 
αvβ3 integrin and bFGF or αvβ5 integrin and VEGF was indicated to promote 
angiogenesis in pathways that involved FAK, ras, c-Raf and ERK activity [61], 
though these were shown to be differentially regulated by the two pathways (figure 
1.6) [61].  
 
Figure 1.6 
Coordinated growth factor αv integrin signalling 
Co-ordinately controlled VEGF-αvβ5 integrin and bFGF-αvβ3 integrin signalling leading to 
activation of p42/44 MAPK pathways. Activity of FAK, Ras, c-Raf and ERK is involved in both 
pathways, but these are differentially regulated. Both activate different survival pathways, with bFGF-
αvβ3 integrin survival independent of ERK activity Taken from [61]. 
 
 
In the αvβ5-VEGF pathway αvβ5 ligation was shown to activate FAK and so Ras, 
which recruits c-Raf to the cell membrane. Signalling appeared to require VEGF 
ligation for recruitment and activation of Src, which tyrosine phosphorylates several 
residues of FAK allowing it to associate with αvβ5 and also phosphorylate and 
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activate recruited c-Raf [61][63]. In the αvβ3-bFGF pathway the activation of ras 
appeared to be independent of FAK activity. Integrin αvβ3 ligation activated FAK 
and PAK, with bFGF receptor ligation required for Ras activity. PAK was suggested 
to phosphorylate Ras-recruited c-Raf, with FAK required for the activity of PAK 
[61][63] (figure 1.6). The bFGF and VEGF receptor pathways were shown to promote 
EC survival by respectively inhibiting stress (intrinsic) and receptor mediated 
(extrinsic) apoptosis by the differential phosphorylation of c-Raf by PAK and Src 
[61][63] (figure 1.6). The αvβ3-bFGF pathway inhibition of intrinsic apoptosis was 
independent of ERK activity, requiring PAK-dependant phosphorylation of c-Raf and 
its translocation into mitochondria. The αvβ5-VEGF survival pathway was shown to 
involve phosphorylation of c-Raf by Src, activation of ERK and protection against 
extrinsic apoptosis [61][63] (figure 1.6). Both anti αv and anti β3 integrin antibodies 
have been shown to reduce activity of PI3K in vascular EC’s stimulated with VEGF 
[64] indicating the decreased apoptosis associated with ERK activity (section 1.2.2.1) 
may involve activation of PI3K and the intrinsic apoptosis pathway of VEGFR2 
(section 1.2.2.1). This predicts a role of αv integrin-VEGF coordinated signalling in 
survival through inhibition of the intrinsic as well as the extrinsic apoptosis pathway. 
The integrin αvβ5 binds solely to vitronectin, though RGD-dependant ligation (figure 
1.5). Its steady state role is tight anchorage to the matrix [1], but it is activated by 
VEGF pathway activity, responding to vitronectin ligation by formation of focal 
adhesions and stimulation of signalling [33]. VEGF also induces increased αvβ5 
expression on the activated vascular endothelium. As described earlier in this section 
αvβ3 is expressed de novo on the vascular endothelium in response to growth factor 
signaling [33]. It is a promiscuous receptor capable of binding many ligands in both 
an RGD (figure 1.5) and non-RGD dependent manner, responding to both positive 
and negative angiogenesis signals, so the overall response by the cell depends of the 
makeup of the immediate external environment [1]. There are many ECM molecules 
with RGD motifs that stimulate angiogenic pathways upon binding to αvβ3. These 
include fibronectin, vitronectin [1], Del-1 (section 1.3.4), thrombin [65], bone 
sialoprotein [66] and angiopoietin-3 [67] as well as ECM protease cleavage products 
such as type IV collagen [68]. The negative regulators of angiogenesis that bind to 
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αvβ3, bind in a non-RDG dependent manner and exert their effects in different ways 
[1][69][70][71][72][73].  
The integrins αvβ3 and αvβ5 have both been shown be required for the activity of 
growth factor receptors other than those of bFGF and VEGF on the vascular 
endothelium. PDGF has for example been demonstrated to initiate EC migration on 
vitronectin by a αvβ3 and RGD-dependant mechanism [74].  Integrin αvβ3 has been 
deemed necessary for TNF (tumour necrosis factor)-α and αvβ5 for TGF 
(transforming growth factor)-α signaling, with LM609 and P1F6 shown respectively 
to block angiogenesis in response to these growth factors [54]. The association of 
matrix-bound isoforms of VEGF as well as bFGF with αvβ3 has also been 
demonstrated [33], so it is possible that not only are the responses of growth factor 
receptors and integrins coordinated, but the growth factors may directly influence 
integrin receptor activity. The roles of αvβ3 and αvβ5 integrins in angiogenesis and 
their coordination of signaling with growth factor receptors in angiogenesis have been 
demonstrated. As integrins are known to activate signaling leading to proliferation, 
survival and migration independently however (section 1.1.1), roles of integrins alone 
in control of angiogenesis cannot be ruled out. As however growth factor receptors 
will invariably be active in angiogenic vascular EC’s, this point may be moot. 
 
1.2.4 Tumour angiogenesis 
 
Tumours require the ability to invoke angiogenesis to grow beyond 1-2mm3 due to the 
need for new vessel formation to supply the growing tissue with nutrients including 
oxygen and to remove waste, which is diffusion limited [75]. Development of a long-
term angiogenic phenotype can involve mutation of genes controlling expression of 
key angiogenesis mediators, tipping the balance towards increased expression of pro-
angiogenic molecules and decreased expression of anti-angiogenic molecules [75]. 
Integrins play an integral role in tumour angiogenesis and the integrin repertoire of 
tumoural endothelium is altered to reflect this [6]. The integrin αvβ3 has been shown 
to be up-regulated by vascular EC’s within tumours [76][77]. Inhibition of ligation of 
this integrin has been demonstrated to lead to regression of newly formed vasculature 
of tumours (lung, melanoma, pancreas and larynx) grown on the chick chorioallantoic 
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membrane (CAM) as well as regression of the tumour itself, whilst leaving mature 
vessels intact [55]. In vivo studies with anti αvβ3 integrin monoclonal antibodies, 
peptides and other non-peptide antagonists have also demonstrated inhibition of both 
angiogenesis and tumour growth, with tumour regression observed as well as growth 
inhibition [45][77][78]. In addition, histological studies examining tumour tissue after 
treatment with αvβ3 antagonists have shown few or no viable tumour cells and blood 
vessels, [77] indicating an essential role of this integrin in tumour angiogenesis and 
tumour growth/viability. Increased expression of αvβ5 has also been observed in the 
developing vasculature of human tumours [79] and there is some limited evidence for 
a role of this integrin in tumour angiogenesis [6][54]. Although antagonists of 
both αvβ5 and αvβ3 have demonstrated anti-angiogenic and anti-tumour effects 
including RGD sequence containing cyclic pentapeptides [80] (section 1.2.3.1) and 
the anti αv integrin mAb CNTO 95 [60] (section 1.2.3.1), the anti-tumour 
angiogenesis effects of αvβ5-specific inhibitors have not so far been published. 
1.2.5 Modulating angiogenesis for treatment of cancer 
 
A key strategy in anti-cancer therapeutics has been to interfere with the control of 
angiogenesis at the molecular level and so halt new vessel formation [81]. It was 
hypothesised that this would prevent tumour growth and reduce metastasis as the 
former requires new vasculature to supply the growing tissue and the latter is aided by 
the presence of immature vessels [82][83]. Many anti-angiogenesis therapies have 
been developed or are under development including agents modulating VEGF-
mediated angiogenesis, therapeutics inhibiting tumour growth factor pathways and so 
angiogenic factor production, inhibitors of vasculature associated integrins and agents 
targeting their ligands, as well as endogenous angiogenesis inhibitors. These are 
summarised in tables 1.7 and 1.8.  
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Table 1.7 
Anti-angiogenesis drugs and anti-tumour agents with an anti-angiogenesis component 
Therapies approved or in development for cancer therapy.   
Endogenous angiogenesis 
inhibitors/synthetic versions 
   
Agent name/type Indication Mode of action Stage of development 
AE-941 (Neovastat Aeterna) 
Shark cartilage extract 
NSCLC [84][85]. Inhibition of VEGFR-1 and 
metalloproteases MMP-2, MMP-9 and 
MMP-12 and promotion of EC apoptosis 
[84]. 
Phase III [85][86] 
Angiostatin 
 
NSCLC [87]. 
 
Inhibition of EC proliferation and 
migration. [88] 
 
Phase II [87]  
Endostatin (Endostar®) Solid tumours [87]. Many anti-angiogenic effects including 
inhibition of FGFR-2 and VEGFR-2 
mediated angiogenesis [88]. 
Approved [89] 
Combretestatin A-4-phosphate  
Prodrug for combretestatin A4 
Anaplastic thyroid 
cancer/solid tumours 
[87] 
Vascular disrupting agent. Inhibition of 
microtubule polymerisation, inducing 
apoptosis/mitotic catastrophe of vascular 
EC’s [90][91]. 
Phase III [87] 
 
Other    
Agent name Indication Mode of action Stage of development 
Celecoxib (Celebrex® Pfizer) Colorectal carcinoma, 
prostate cancer, 
NSCLC, pancreatic 
cancer and head and 
neck cancer [87] 
COX-2 inhibitor, anti-angiogenesis 
through preventing tumour expression of 
angiogenic growth factors and through 
inhibition of EC signalling. Also direct 
effects on tumour cell growth [92]. 
Phase III [87] 
Approved as an adjunct 
for prevention of colon 
cancer in familial 
adenomatous polyposis 
patients [93]. 
Lenalidomide (Revlimid® Celgene)  
Thalidomide analogue 
Renal cancer, multiple 
myeloma, malignant 
melanoma prostate 
cancer, NSCLC, 
chronic lymphocytic 
leukaemia, T-cell non-
Hodgkin’s lymphoma 
[87] 
Anti-angiogenic effects include 
suppression of bFGF and VEGF 
production.  
Also has anti inflammatory, anti 
proliferative and pro-apoptotic effects on 
tumour cells [94]. 
Phase III [87] 
Approved for multiple 
myeloma in 
combination with 
dexamethasone [95]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 37
Table 1.8 
Anti-angiogenesis drugs and anti-tumour agents with an anti-angiogenesis component 1 
Therapies approved or in development for cancer therapy 
.   
VEGF/VEGFR and VEGFR 
pathway therapies 
   
Agent name/type Indication Mode of action Stage of development 
Bevacizumab (Avastin®-Genentech) 
 Humanised IgG1 mAb 
Metastatic colorectal cancer, 
NSCLC and breast cancer [96] 
VEGF-A neutralisation [97] Approved in 
combination with 
chemotherapy [96]. 
Aflibercept® (VEGF-trap) Sanofi-
Aventis/Regeneron. Extracellular 
domains of VEGFR1 and VEGFR2; 
recombinantly fused to a human IgG1 
Fc [98]. 
Advanced ovarian cancer, non-
small cell lung cancer, prostate 
cancer, and other solid 
malignancies [87] 
VEGF (all isoforms) and PlGF 
neutralisation [99] 
Phase II/III [87] 
CDP-791 (UCB-Celltech) PEGylated 
DiFab [100]. 
NSCLC [87] VEGR2 neutralisation [100] Phase II [87] 
IMC-1121B (ImClone) Fully human 
Fab fragment 
Breast cancer, NSCLC, 
melanoma, renal cell carcinoma 
and other solid tumours [87] 
VEGR2 neutralisation [101] Phase I/II/ III (none 
complete)  [87] 
Sorafenib (Nexavar®-Bayer) Small 
molecule 
Advanced and metastatic renal 
cell carcinoma [102] 
VEGFR-2 and VEGF-R3, but also B-
Raf, PDGFR-β FGFR-1, c-KIT, FLT-3 
and p38 tyrosine kinase inhibitor [102] 
Approved (single 
agent) [102] 
Sunitinib (Sutent®–C.P. 
Pharmaceuticals 
Small molecule 
Advanced and metastatic renal 
cell carcinoma [102] 
VEGFR-1, VEGFR-2, VEGFR-3, 
PDGFRα/β, c-kit, c-RET and FLT3 
tyrosine kinase inhibitor [102]. 
Approved (single 
agent) [102] 
Temsirolimus (Torisel® Wyeth) Small 
molecule 
Renal cell carcinoma, colorectal 
cancer, breast cancer and other 
solid tumours and leukaemia’s 
[87] 
Inhibitor of Ser/Thr kinase mTOR 
leading to apoptosis of tumour cells and 
vascular EC’s and inhibition of tumour 
VEGF production [103][104][105]. 
Approved for renal cell 
carcinoma. 
Tumour growth factor receptor 
inhibitors 
   
Agent name/type Indication Mode of action Stage of development 
Erlotinib (Tarceva® Roche). Small 
molecule 
NSCLC [106] EGFR/HER1 hybrid receptor inhibitor 
[106]. Inhibition of angiogenic factor 
production (amongst other anti-tumour 
effects). 
Approved [106] 
Cetuximab (Erbitux® Imclone/Bristol-
Myers Squib). Chimeric IgG1 mAb 
Metastatic colorectal cancer, head 
and neck cancer [107]. 
EGFR antagonist. Inhibition of 
angiogenic factor production (amongst 
other anti-tumour effects) 
Approved [107] 
Panitumumab (Vectibix® Amgen) 
Human IgG2 mAb 
Colon cancer [107] EGFR antagonist. Inhibition of 
angiogenic factor production (amongst 
other anti-tumour effects) 
Approved [107] 
Trastuzumab (Herceptin® Genentech) 
Humanised IgG1 mAb 
HER2 +ve metastatic breast 
cancer [107] 
HER2 antagonist. Inhibition of 
angiogenic factor production (amongst 
other anti-tumour effects) 
Approved [107] 
Tumour vascular-associated 
integrin antagonists 
   
Agent name/type Indication Mode of action Stage of development 
Abegrin (Vitaxin® Medimmune) mAb Melanoma, prostate cancer, 
colorectal carcinoma, lymphoma, 
solid tumours [87] 
Integrin αvβ3 antagonist. Induces EC 
apoptosis [108]. 
Phase II [87] 
EMD-121074 (Cilengitide® Merck). 
Cyclic pentapeptide 
Glioblastoma Multiforme, prostate 
cancer, metastatic melanoma, 
acute myeloid leukaemia [87] 
Integrin αvβ3 and αvβ5 antagonist 
[109]. 
Phase III [87] 
CNTO-95. Human IgG1 mAb Prostate cancer, melanoma and 
solid tumours [87] 
Integrin αvβ3 and αvβ5 antagonist 
(anti-tumour and anti-angiogenesis 
effects) [60]. 
Phase II [87] 
M200 (Volociximab® PDL 
Biopharma) IgG4 chimaeric mAb 
[110] 
NSCLC, melanoma, pancreatic 
cancer, renal cell carcinoma [87] 
Integrin α5β1 antagonist [110] Phase II [87] 
Tumour vascular-associated 
integrin ligand targeting 
   
Agent name/type Indication Mode of action Stage of development 
L19-SIP Small immunoprotein 
human antibody fragment. Alone or 
conjugated to 131I. 
Head and neck squamous cell 
carcinoma and colorectal 
carcinoma [111][112]. 
EDB fibronectin targeting.  Preclinical/phase I with 
131I conjugate [113]. 
L19 scFv mAb fragment IL-2/GM-
CSF/IL-15 fusions [114][115] 
B-cell lymphoma, solid tumours EDB fibronectin targeting. Pre-clinical 
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1.2.5.1  Therapies targeting the VEGF pathway 
 
As most solid tumours express VEGF-A and the VEGF pathway is the major 
controller of angiogenesis [29], most work to date has concentrated on interference 
with this pathway [116][117]. Most of the anti-angiogenesis drugs currently approved 
for therapy, target either VEGF or VEGFR signalling [102] (tables 1.8-1.9). Therapies 
developed to inhibit VEGF-mediated angiogenesis include targeted therapeutics such 
as VEGF-A [116] and VEGFR-2 neutralising antibodies [118] and a soluble VEGFR-
VEGFR hybrid decoy molecule [116], as well as small molecule tyrosine kinase 
inhibitors (TKIs) [102], an intracellular tyrosine kinase VEGFR2 pathway inhibitor 
[102] and agents that module VEGF expression.  
 
Table 1.9 
Approved anti-VEGF/VEGFR pathway therapy clinical trial results 
Phase III clinical trial results for anti-VEGF pathway therapies measured as change in response rate 
(%) and change in progression free survival (months) with addition of anti-VEGF therapy. Taken from 
[96]. 
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Bevacizumab 
The anti-VEGF-A neutralising humanised monoclonal antibody, bevacizumab 
(Avastin®-Genentech) has approval for combination with chemotherapy for treatment 
of metastatic colorectal cancer, non-small cell lung cancer (NSCLC) and breast cancer 
[96]. Bevacizumab has been shown to bind all human VEGF-A isoforms and 
bioactive proteolytic fragments with a Kd of around 0.5nM [97]. Through this 
association it is thought to neutralise VEGF binding to VEGFRs. In animal models 
with murine-derived bevacizumab prior to humanisation (A.4.6.1), inhibition of 
tumour growth was observed in vivo, with tumours formed of several human cell 
lines, with no growth inhibition in vitro with the same tumour lines [119]. This 
indicated the effects of this drug on tumour growth to be exerted indirectly on the 
stroma. A role of A.4.6.1 in inhibition of vessel development was supported by 
preclinical models with human breast tumours implanted in athymic mice, with 
application of A.4.6.1 resulting in reduced new vasculature development [120]. 
Tumour growth inhibition together with vessel regression, quantified as a reduction in 
vascular density, was also observed following A.4.6.1 application to in vivo 
preclinical human xenograft models [121]. This study also showed A.4.6.1 to reduce 
by over 70% the tumour interstitial fluid pressure (IFP), [121] a marker of vascular 
normalisation, necessary for improved drug delivery [96][122]. Maximal growth 
inhibition of human tumour xenografts was demonstrated to occur at around 1-2mg/kg 
bevacizumab, applied twice weekly [97]. A.4.6.1 was tested pre-clinically with 
several conventional chemotherapy drugs, showing an increased inhibitory effect on 
tumour growth than either drug applied individually and in some cases a more than 
additive; synergistic effect [123]. The results of phase III clinical trials of 
bevacizumab for metastatic breast cancer non-small cell lung cancer, metastatic 
colorectal cancer, pancreatic cancer and renal cell carcinoma with addition to first-line 
standard chemotherapy regimens are shown in table 1.9 as change in response rate 
and progression free survival with addition of bevacizumab [96]. Overall 
bevacizumab produced the greatest effect upon addition to paclitaxel in breast cancer 
and interferon in renal cell carcinoma [96]. Bevacizumab however showed some 
significant toxicity, with hypertension, proteinurea, thromboembolism, impaired 
wound healing, perforation, bleeding, skin rash, reversible leukoencephalopathy 
syndrome and infusion-related hypersensitivity observed, with hypertension the most 
common [124].  
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1.2.5.2  Therapies targeting tumour vascular integrins and their ligands 
Tumour vascular-associated integrin antagonists 
There are four integrin antagonists in clinical trials for anti-angiogenesis therapy. 
Abegrin (Vitaxin® Medimmune) (table 1.8) is a humanised form of mAb LM609, an 
anti αvβ3 antibody shown in pre-clinical models to block growth factor and tumour 
induced angiogenesis, as well as inhibiting tumour growth (Section 1.2.3.1 and 
section 1.2.4). Phase I single agent clinical trials with various solid tumours showed 
disease stabilisation in over 50% the participants and one patient (6% of total) with 
end stage carcinoma remained stable for over 2 years with drug therapy [108]. This 
drug showed not only therapeutic efficacy but also few side effects [108]. Phase II 
clinical trials have recently been completed with this drug for therapy of various solid 
tumours [87], but the results have yet to be published. 
 
EMD-121074 (Cilengitide® Merck) (table 1.8) is a cyclic pentapeptide containing an 
RGD motif and is an antagonist of both αvβ3 and αvβ5 integrins. It has been shown 
to inhibit both angiogenesis and tumour growth in pre-clinical models and to 
synergise with radiotherapy in EC growth inhibition in vitro and tumour growth 
inhibition in vivo [125][126]. It has also been shown to synergise with conventional 
chemotherapy drug temozolomide in inhibition of tumour cell and EC proliferation 
and tumour growth in vivo [127].  A phase II clinical trial with glioblastoma 
multiforme indicated no significant toxicity, with the higher dose group demonstrating 
significantly elevated overall survival and progression-free survival [128]. A phase II 
study in pancreatic cancer indicated a favourable combination with conventional 
chemotherapy agent gemcitabine, with a significant increase in overall survival and 
progression free survival over gemcitabine alone [109]. 
 
CNTO-95 (table 1.8) is a fully human IgG1 monoclonal antibody shown to bind αv 
integrins including αvβ3 and αvβ5. In preclinical trials it has demonstrated both anti-
tumour and anti-angiogenic effects in vitro [22][60] and anti tumour effects in vivo 
with human breast [22] and melanoma xenograft models [60]. It has also been shown 
to inhibit human melanoma xenograft mediated angiogenesis in vivo using matrigel 
implants [60]. A pre-clinical study indicated synergy with radiation therapy in tumour 
growth inhibition in vivo [129]. A phase I clinical trial with advanced solid tumours 
has been completed, with tumour localisation confirmed by biopsy. This drug was 
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considered to be well tolerated [130]. Phase II clinical trials with melanoma and 
prostate cancer are currently underway [87]. 
 
M200 (Volociximab® PDL Biopharma) (table 1.8), an IgG4 chimaeric monoclonal 
α5β1 integrin antibody has been shown to inhibit vascular EC proliferation and 
angiogenesis and induce EC apoptosis in vitro [131], as well as inhibit tumour growth 
and vascularisation in vivo [132]. Phase I clinical trials showed it to be well tolerated 
and indicated some efficacy, with a minor response in a renal cancer patient and a 
stable disease in a melanoma patient [133]. Phase II clinical trials in melanoma and 
pancreatic cancer in combination with chemotherapy have been completed but have 
yet to be published and other phase I/II trials are under way [87]. 
 
Tumour vasculature-associated integrin ligand targeting 
 
Splice variants of the integrin ligand fibronectin containing EIIIA and EIIIB domains 
form markers of the proliferating vasculature and are highly expressed on tumour 
vessels [134]. A splice variant with the EIIIB domain, EDB (extra domain B) 
fibronectin has formed a target for several anti-tumour vasculature therapies including 
L19 scFv-cytokine fusion proteins which have shown tumour targeting and greater 
efficacy in vivo than cytokine therapy alone [114][115] and in the case of IL2-L19 
fusion complete tumour remission in combination with rituximab [114]. A small 
immunoprotein fragment L19-SIP has been shown to target head and neck squamous 
cell carcinoma [111] and colorectal tumour (SW1222 and LS174T) xenografts [112] 
selectively in animal models, with tumour vessel localization for a colorectal tumour 
model demonstrated [112]. In addition tumour growth inhibition and increased 
survival has been observed for pre-clinical radioimmunotherapy studies in head and 
neck and colorectal tumour (SW1222) xenograft models [111][112] and increased 
survival for a rat C6 glioma model [135], all treated with a 131I-radiolabelled form of 
this fragment. A clinical radioimmunotherapy trial with 131I-L19-SIP is underway 
[113]. 
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1.2.5.3  Overcoming resistance to anti-angiogenic therapies 
 
Anti-angiogenic cancer therapy, by targeting signaling of the genetically stable 
vasculature rather than the highly mutagenic tumour cells was originally predicted to 
lead to less drug resistance [117]. Clinical trial results however have shown growth of 
the tumour often continues after an initial period of growth suppression [117], due 
perhaps to redundancy in the control of angiogenesis, with tumours responding to 
anti-angiogenic therapy with up-regulation of other factors. The answer may 
ultimately be to combine many anti-angiogenic therapies to reduce opportunity for 
development of resistance, or to use more broad-spectrum anti-angiogenesis agents. 
Anti-angiogenesis combination therapy has been attempted with some clinical 
success, including the combination of bevacizumab with trastuzumab and the anti 
VEGF antibody DC101 with cetuximab, described in section 1.4.3.1. The results of 
the former combinations may however be complicated by the direct anti-tumour 
effects of trastuzumab [136][137][138][139] and cetuximab [140][141][142]. The use 
of multi-spectrum anti-angiogenesis agents has been carried out in the form of the 
small molecule receptor TKI’s such as sorafenib and sunitinib (table 1.8 and table 1.9) 
[96][102][117], but again the response to therapy may be complicated by direct 
effects on tumour cell RTK’s.  Although this makes interpretation of the results 
difficult, this combined effect of targeting the tumour and its vasculature may be an 
advantage for anti-cancer therapy. Drugs with effects on both the vasculature and the 
tumour cells such TKI’s described above and those acting on integrins αvβ3 or αvβ3 
and αvβ5 may therefore be expected to have more success in clinical trials. For the 
latter this is due to their potential for inhibition of both bFGF and VEGF mediated 
angiogenesis (section 1.2.3.1) and direct tumour cell growth (section 1.1.1). This idea 
is validated by the high efficacy of the TKI sunitinib (table 1.9) and the significant 
effects of anti-αvβ3/αvβ5 and αvβ3-integrin agents, cilengitide and vitaxin (section 
1.2.5.2). The drawback of small molecule TKI may however be increased toxicity 
through a lack of tumour cell and vasculature selectivity, though clinical trial data 
with sunitinib indicated only moderate effects [117]. Toxicity is likely to be less of a 
concern for agents targeting αvβ3 or αvβ3 and αvβ5 as clinical data has 
demonstrated few side effects, (section 1.2.5.2). Another way to target both the 
vasculature and tumour cells, commonly used in both pre-clinical development and 
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clinical trials to improve the therapeutic outcome has been through combination with 
conventional cancer therapy [96][109][123][127][129][143][144], (see section 
1.4.3.1). One mechanism for synergy between angiogenic therapy and conventional 
cancer therapy has been proposed to be through increased cytotoxic drug and oxygen 
perfusion (increased oxygenation improves efficacy of radiation therapy) caused by 
the normalisation effect of anti-angiogenic drugs on the tumour vasculature [81]. The 
vascular normalisation hypothesis proposed that by preventing new vessel formation 
and inhibiting the survival of newly formed vessels, anti-angiogenesis therapies could 
effectively remove abnormal vessels from the tumour and so “normalise,” the tumour 
vascular architecture [145] (figure 1.10). The resultant loss of the high tissue 
interstitial pressure and more uniform blood flow distribution in the tissues was 
predicted to increase the delivery of cytotoxic drugs throughout the tumour [96][145].  
 
Figure 1.10 
A model of vascular normalisation  
(a) The organised venule, capillary bed and arteriole system of normal tissue, (b) the irregular, 
disorganised and dilated vessels of the tumour vasculature and (c) tumour vasculature after anti-
angiogenesis therapy, with a partial return to the normal vasculature structure. (d) An inadequate 
blood supply leading to tumour cell death. Taken from [81].  
 
 
 
 
The vascular normalisation theory has been validated with anti-VEGF therapy in 
murine tumour models [96][145] and in a phase II clinical trial with glioblastoma 
patients [146], but normalisation was consistently shown to be temporary, from days 
to weeks [145][146], creating a therapeutic window. It was proposed therefore that 
anti-angiogenic agents may improve tissue perfusion of chemotherapy if dosing was 
carefully timed [96]. Pre-clinical studies with celecoxib [144] (table 1.7) and 
cilengitide (section 1.2.5.2) have demonstrated synergy with chemotherapy and 
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radiotherapy, and preclinical synergy has also been shown with CTNO-95 and 
radiotherapy (section 1.2.5.2). In addition, bevacizumab pre-clinical studies have 
shown either additive or synergistic effects, with various chemotherapy drugs and 
direct indications of vascular normalization have been demonstrated in vivo (section 
1.2.5.1).  
 
1.3  Lactadherin 
 
1.3.1 Structure and functions 
 
Lactadherin is a glycoprotein originally determined to be a breast specific antigen 
expressed on the apical surface of milk duct epithelial cells of lactating females 
[147][148] and on the surface of milk fat globules (MFGs) [149][150] secreted from 
the mammary epithelium [151][152]. It is known to bind to cell surfaces via both 
direct membrane association and interaction with integrins [148][153][154][155] and 
is secreted in membrane-bound form in vesicles, [152][156] exosomes [157] and milk 
fat globules.   
 
Table 1.11 Normal roles of lactadherin in the human body 
Tissue/cells expressed Function Mechanism of action 
Breast epithelium and HMFG micelles 
of milk 
Protection against neonatal rotavirus 
infection [158][159][160] 
Interference with rotavirus attachment 
[160][161]/intestinal repair [162]. 
Breast epithelium and HMFG micelles 
of milk 
Breast involution following weaning – 
removal of apoptotic breast epithelial 
cells and left-over milk [147][163]. 
Opsonisation of phagocytosis by tissue 
macrophages. 
Tingible body macrophages in germinal 
centres of spleen and in lymph nodes 
Removal of low apoptotic low antigen-
affinity and auto-reactive B-cells [164]. 
Opsonisation of phagocytosis-recognition 
of (Pdt-L-Ser) [165]. 
Arterial, bone-marrow derived 
macrophages. 
Protection against atherosclerotic lipid 
lesion formation [166]. 
Opsonisation of clearance of apoptotic 
cells and debris. 
Bone-marrow derived macrophages. Development of immune tolerance 
needed for immune homeostasis [166]. 
Promotion of the suppressive effects of 
regulatory T cells 
Retina Control of the circadian rhythm [167]. Photoreceptor outer segment fragment 
apoptosis [167]. 
Brain Protection against development of senile 
plaques and so Alzheimer’s disease 
[168]. 
Opsonisation of phagocytosis of amyloid 
β-peptide (Aβ) [168]. 
Spermatozoa plasma membrane. Oocyte fertilisation [169][170][171].  Sperm association with ZP3/ZP2 
glycoproteins of the extracellular coat or 
zona pellucida of unfertilised oocytes 
[169][171].   
Intestinal epithelium Tissue repair of the intestinal epithelium 
by promotion of epithelial cell migration 
[162]. 
Activation of PKCε and reorganisation of 
the actin cytoskeleton [162]. 
(Only demonstrated in vitro) Anticoagulant through inhibition of 
formation of clotting complexes [172]. 
Competition with clotting factors V and 
VIII for binding to (Pdt-L-Ser)-containing 
membranes [172]. 
 
The four confirmed roles of lactadherin in the normal adult (table 1.11) have been 
shown to be the following; Promotion of angiogenesis through integrin ligation and 
activation of independent and VEGFR-2-coordinated signalling [173]. Recognition of 
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apoptotic cells by subsets of macrophages and dendritic cells necessary for phagocytic 
clearance, with functions including; mammary tissue involution following weaning 
and removal of self-reactive B-cells [147][164][174]. Protection of newborns from 
rotaviral infection through MFG expression [158][159] and interaction of sperm and 
egg required for fertilisation [169][170]. A fifth potential role as an anticoagulant has 
been indicated in vitro through competition with clotting factors VIII and V for 
binding to phosphatidyl-L-seine (Pdt-L-Ser) and so inhibition of the factor Xase and 
prothrombinase complexes respectively [172] (table 1.11). 
 
Lactadherin is a membrane-associated protein, with separation in the membrane 
fraction of breast carcinoma cells and in the detergent phase of breast cell lines and 
human milk fat globules (HMFG) treated with Triton-X-114 [151]. Expression on the 
cell and HMFG surface has been detected by immunofluorescence microscopy with 
lactadherin-specific monoclonal antibodies, showing a punctuate expression pattern as 
opposed to the uniform surface expression of butyrophilin, a MFG protein with a 
transmembrane domain [151]. Secretion in vesicles has been confirmed by exogenous 
(COS-7 monkey kidney cell line) and endogenous mammalian expression systems 
(COMMA-1D mouse mammary epithelial line), with the murine form showing the 
presence of lactadherin into the culture medium in association with membrane 
vesicles of 100-200nm diameter [152]. Membrane association was supported by the 
observation that 50% of released lactadherin was localised in the cell pellet when 
centrifuged at 10,000 X g [151]. 
 
The sequence of human lactadherin was discerned using lactadherin-specific 
monoclonal antibodies Mc3 and Mc8 as well as Mc15 and Mc16 to select 
complementary DNA from a λgt11 expression library from lactating breast. The 
largest complementary DNA insert (BA46-1) was then used to detect 2.2 kilobase 
lactadherin mRNA in several carcinoma cell lines [175]. Using sequence alignments 
of the determined protein sequence, lactadherin mRNA was shown to encode a 387 
residue precursor protein, composed of a 23 residue signal peptide, an N-terminal 
Notch-like type II EGF (epidermal growth factor)-like domain with the RGD cell 
adhesion sequence and two C-terminal discoidin I-like domains with similarity to 
clotting factor V and VIII C1 and C2 domains, with the C1/C2 domains showing 43% 
and 38% sequence identity respectively [175][176]. The predicted structure of the 
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EGF-like domain based on understanding of the fold pattern of EGF domains in other 
proteins indicated presentation of the RGD sequence in a hairpin loop between two 
anti-parallel β strands, stabilised by a disulphide bond, with two other disulphide 
bonds thought to be important for stabilisation of the entire EGF-domain structure 
[175]. The EGF-like domain was suggested to act as a scaffold for presentation of the 
adhesion sequence. No transmembrane domain was evident, indicating that 
lactadherin is not membrane embedded but associates with membranes by direct 
association with phospholipids via the C1 and/or C2–like domain or by binding to 
embedded proteins via the cell adhesion sequence [175]. The predicted molecular 
weight based on amino acid sequence, not taking into account glycosylation was 
41kDa, which agrees well with the determined molecular weight of 47kDa for the 
purified protein, when the 4-N-linked glycosylation sites are taken into account [175]. 
Crystal structure determination of the C2 domain of lactadherin in agreement with 
sequence analysis confirmed its similarity in structure to the C2-domains of clotting 
factors V and VIII (fVIII-C2 and fV-C2) [177].  
 
Figure 1.12 
Lactadherin C2 domain crystal structure 
Ribbon diagram of the C2 domain of bovine lactadherin, demonstrating the β-barrel core, and 
membrane interaction loops. The latter are indicated as spikes 1 and 3 and residues of these spikes 
involved in integrative membrane interaction are labelled. Diagram taken from [177]   
 
 
 
 
 
 
 
 
 
 
 
 
A β-barrel core was evident with three lower loops, including two (spikes 1 and 3) 
with four water-exposed hydrophobic amino acid residues (figure 1.12) similar to 
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those of fVIII-C2 and fV-C2 which form the membrane interaction sites of these 
molecules [178][179][180][181]. Lactadherin-C2 was also shown to have glycine 
residues at the tips of the membrane interaction loops, which are thought to provide 
additional conformational flexibility for association and spike-1 forms a hydrogen-
bonded β-hairpin (figure 1.13). The subtle differences in structure are thought to 
allow stronger association with Ptd-L-ser [177] and to allow successful competition in 
binding with both factors V and VIII, [172] which are unable to compete with one 
another, potentially due to the reduced flexibility [182][183]. The membrane 
interaction roles of the exposed hydrophobic amino acid residues and/or glycine 
residues was confirmed by mutagenesis studies, with computational ligand docking 
studies predicting two possible membrane interaction sites. The exposed hydrophobic 
acid residues are proposed in both models to integrate into the phospholipid bi-layer, 
forming hydrophobic interactions with the apolar acyl chains, with surrounding polar 
and positively charged residues interacting with the negatively charged head groups 
forming hydrogen bonds and salt-bridges (figure 1.13) [177]. The C1 domain of 
lactadherin has not yet been crystalised, but based on the sequence, the structure has 
been predicted and is similar to that of the C2 domain [184]. Like C2 it contains a 
beta-barrel core with three lower loops, including two hairpin loops, spikes 1 and 3 
which based on their amino acid composition have been predicted to associate with 
lipid bi-layers. The amino acid residues of the predicted membrane binding interface 
of spikes 1 and 3 are however different to those of the C2 domain and have been 
proposed to confer different membrane binding specificities [184] (figure 1.14). 
 
Forms of lactadherin in other species including murine MFG-E8/SED1, bovine PAS 
6/7, guinea pig GP55, rat rAGS and boar p47 all have domains that show homology 
with the EGF and C1/C2-like domains of human lactadherin, indicating evolutional 
conservation of these domains and as such an essential function. 
[169][175][185][186][187][188][189] All contain at least one N-terminal EGF 
domain with an RGD sequence and a C1 and C2 domain, but human lactadherin is the 
only form to lack an additional N-terminal EGF domain without an RGD sequence. In 
addition a second human/murine protein Del-1 (developmental endothelial locus-1), 
has been described with a similar domain structure, with three N-terminal EGF-like 
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domains, only one of which contains the RGD sequence and a C1 and C2 domain at 
the C-terminus [190]. 
 
Figure 1.13 
Lactadherin C2 domain membrane interaction site 
Ribbon diagram depicting the proposed membrane interaction conformation of lactadherin’s C2 
domain. Shown are the hydrophobic residues of spikes1 and 3, forming a binding surface integrated 
into the membrane and surrounding polar/charged residues (mainly Pdt-L-Ser), interacting with the 
membrane phospholipid head groups. Diagram adapted from [177]   
 
 
Figure 1.14 
Hypothesised lactadherin C1 domain structure 
Ribbon diagram showing the predicted structure of the C1 domain of lactadherin based on the 
sequence and crystal structure data for factor V and VIII C2 domains. Shown are the beta barrel core, 
membrane interaction loops (spikes 1 and 3) and residues involved in membrane association, including 
charged and polar residues thought to be involved in head group interaction and membrane 
integrating apolar groups.  Diagram taken from [184]. 
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All of these proteins have therefore been described as SED proteins; secreted proteins 
(S), with a cleavable signal sequence and N-terminal EGF domains (E) and C-
terminal discoidin I-like domains (D) (see figure 1.15 for domain structures) [169]. 
The C1/C2 domains of lactadherin show 60% sequence identity with those of the 
murine form [176] and the EGF domain 45% sequence identity with the RGD-
containing EGF-2 domain of murine MFG-E8, shown by sequence alignment [175]. 
Two N-linked glycosylation sites in the C2-like domain are conserved between the 
human and murine forms and 10 cysteine residues including four in the C1/C2-like 
domains and 6 in the EGF domain predicted to be required for the structural 
stabilisation described earlier [175]. The murine MFG-E8 however occurs in two 
forms, a shorter (S) form and a longer (L) splice variant, the latter which contains an 
additional proline/threonine rich domain and is only expressed in mammary tissues 
[191]. Lactadherin has been shown to occur as a double band at around 47kDa 
[149][150]. Bovine PAS6 and PAS 7 are glycosylation variants with an identical 
polypeptide core and molecular weights of 50 and 47kDa respectively [185]. It is 
likely therefore that human lactadherin occurs as two glycosylation variants but this 
has not thus far been confirmed by analysis of carbohydrate structure. 
 
Figure 1.15 
Domain structures of the SED proteins 
Domain structures of human lactadherin with 1 N-terminal EGF domain, with  a adhesion sequence 
(RGD), murine MFG-E8/SED-1 with two EFG domains, but with only one cell adhesion sequence and 
Del-1 with three EGF domains but only one cell adhesion sequence. All SED proteins contain the C-
terminal C1 and C2 domains homologous to those of factor V and VIII. Not included is the longer for 
of murine MFG-E8 with an additional proline/threonine rich domain. Adapted from [184]. 
 
 
 50
1.3.2 Binding properties of Lactadherin 
 
The cell adhesion properties of the RGD sequence of lactadherin’s EGF domain were 
investigated with both bovine and human lactadherin. As described earlier in more 
detail (section 1.2.3) some groups of the cell adhesion molecules integrins bind to 
ECM proteins with the RGD motif, so association with this group of receptors was 
investigated [153]. Interaction between bovine lactadherin and the αvβ5 integrin was 
first indicated by purification of this receptor from mammary gland tissue by affinity 
chromatography with a lactadherin agarose column [148]. This association was shown 
to involve the RGD sequence of lactadherin as the integrin was eluted from the 
column with an RGD tri-peptide [148]. Cell adhesion assays with human breast 
epithelial tumour line MCF-7 and green monkey kidney cells MA-104, (known to 
express integrins αvβ5 [154] or αvβ3 and αvβ5 [192] respectively) showed binding 
to both native and recombinant bovine lactadherin in a concentration dependant 
manner, but no association with a RGD to RGE mutant [153]. Application of a αvβ5 
integrin receptor blocking monoclonal antibody P1F6 or a synthetic peptide with an 
RGD sequence inhibited the native lactadherin–MCF-7 association [153]. For MA-
104 cells, application of a αvβ3 integrin receptor binding antibody LM609 reduced 
cell adhesion to less that 20%, whereas P1F6 reduced cell adhesion to 50% [153]. 
Taken together this indicated association between lactadherin and these cell lines to 
be integrin dependant and lactadherin to associate with both αvβ3 and αvβ5 
receptors, but more strongly with αvβ3. The binding of lactadherin to cells via αv 
integrins was confirmed by assays carried out with native human lactadherin, which 
showed RGD-dependant association with αv integrin expressing cell lines MA-104, 
mouse fibroblast line 3T3-L1 and breast carcinoma line ELL-G, which was inhibited 
by the lactadherin-specific antibody Mc3 [154]. In addition, denaturation of 
lactadherin using either heat or reducing conditions reduced cell attachment [154]. 
This confirmed the assumption from the sequencing data that optimal cell attachment 
via the RGD cell adhesion sequence, required structural presentation of this sequence 
[154][175]. 
Prior to crystal structure determination, the C2 domain of lactadherin had been 
proposed to allow association with membranes by binding to membrane phospholipid 
Pdt-L-Ser, due to sequence homology with phospholipid binding domains of blood 
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clotting factors V and VIII, which bind to anionic phospholipids, particularly Pdt-L-
Ser [176][180][181]. Evidence suggesting lactadherin binds breast epithelial 
membranes in this manner included the purification of a 30kDa truncated form of 
lactadherin from the milk fat globule membrane. This protein was sequenced and 
shown to be the C2 domain of Lactadherin [155]. The idea of direct membrane 
association was supported by western blots of proteins expressed in the MFG 
membrane, which failed to detect any αv integrin subunits [153]. Native lactadherin, 
the C2 domain alone and C1C2 domains were subsequently shown to bind to 
phospholipids by solid phase ELISA [153]. More specifically however, lactadherin 
and these domains were shown to bind by ELISA to plate-
associated phosphatidylserine in a concentration dependant manner with a similar 
affinity for the domain fragments to native lactadherin [153]. In addition this 
association was shown to be stereoselective for the L rather than the D form [193]. A 
22 amino acid peptide fragment of the C-terminal region of the C2 domain (Ala386-
Leu407) when added with lactadherin inhibited the interaction with Pdt-L-Ser in a 
concentration dependant manner [153]. This data showed lactadherin could bind 
directly to phospholipid membranes via the C2 domain terminus and interaction could 
take place specifically with Pdt-L-Ser. 
 
The membrane association via the C2-like domain was confirmed by binding studies 
with Mc3, Mc8 and Mc16 [151]. Mc3 had been shown to bind to the EGF domain and 
through epitope mapping Mc8 and Mc16 shown to bind to the C2 domain with Mc16 
closer to the C-terminus [151][194]. Both Mc3 and Mc8 could associate with 
lactadherin on the surface of transfected SP2/0 mouse myeloma cells and the HMFG 
but Mc16 could not. Lactadherin was shown to be secreted into the culture media and 
although readily detected with Mc3 and Mc8, only low levels of Mc16 binding were 
detected. After treatment of the transfected cells and culture supernatant with the 
membrane disrupting agent SDS all three antibodies bound readily [151]. This 
indicated lactadherin binds to the cell surface near the C-terminus of the C2 domain 
and that most of the secreted lactadherin is membrane associated. There has however 
been some evidence that the C1 domain is involved in membrane association and 
possibly secretion, as mutant forms of murine lactadherin, with removal of either the 
C1 or C2, were unable to localise to the membrane of lactadherin expressing COS-7 
cells or be secreted as part of membrane vesicles [152]. The C1 domain was however 
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shown not to bind to Pdt-L-Ser in an in vitro assay, indicating that this domain has 
different membrane association specificity to C2, in agreement with the structural data 
[152]. 
 
The dual binding properties of lactadherin were demonstrated by a simple cell 
adhesion assay [153]. A plate coated with Pdt-L-Ser containing phospholipid layer 
was incubated with lactadherin, followed by MCF-7 cells. Attachment occurred in a 
(lactadherin) concentration dependant manner, indicating lactadherin may act as a 
linker between two surfaces by association with integrins via its N-terminal EGF 
domain and association with Pdt-L-Ser of phospholipid membranes via the C-
terminal-C2 domain. In an otherwise identical assay, a Pdt-L-Ser negative 
phospholipid layer was used, but no adhesion was observed [153]. This showed it is 
specifically the Pdt-L-Ser within the phospholipid membrane that lactadherin binds to. 
 
1.3.3 Lactadherin as a tumour antigen 
 
1.3.3.1 Lactadherin tumour expression 
 
Lactadherin was first indicated as a potential tumour antigen by immunoperoxidase 
tissue staining with the lactadherin-specific monoclonal antibodies Mc8 and Mc3, 
tested for binding to both normal and tumour tissues. No staining was observed on 
any normal tissues including non-lactating breast tissue, but weak staining was 
evident on several breast tumours. Mc3 and Mc8 were shown to bind strongly to 
breast carcinoma cell lines MCF-7 and T47D, but failed to stain any non-breast 
carcinoma cell lines tested (HELA cervical carcinoma, HT29 colon carcinoma, BRIS-
8 lymphoma and PANC-1 pancreatic carcinoma) [195]. Mc3 was also used to detect 
the presence of high levels of lactadherin in the serum of breast cancer patients, with 
no lactadherin in the serum of either normal patients or those with non-breast tumours 
[196]. Taken together this indicated that lactadherin may be a breast tumour 
associated antigen. It may either be expressed at low levels in the non-cancerous-non-
lactating breast or not at all, but appears to be upregulated during neoplastic 
transformation. Lactadherin was subsequently detected as mRNA expression by 
carcinoma cell lines of some non-breast tumours including lung (A549), ovarian 
(SKOV3), colon (HT-29) as well as other breast carcinoma lines ELLG, HS578T, BT-
21, MDA-MB-331, MDA-MB-361 and MCF-7, with expression confirmed by 
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western blotting of the detergent soluble fraction of lysates of HS578T, A549 and 
ELLG. This indicated any roles of lactadherin as a tumour antigen may not be 
restricted to the breast. [176]  
 
1.3.3.2 Lactadherin integrin signalling and tumour progression and 
control of lactadherin expression  by tumours 
  
The non-breast restricted roles of lactadherin as a tumour antigen were confirmed in 
later work showing lactadherin to have a role in melanoma progression, through 
activation of integrin signalling on the tumour cell surface [197]. This was initially 
indicated by the high expression levels during the vertical growth phase (invasive) of 
murine melanoma with little expression in normal skin, compound melanocytic nevi 
or radial growth phase (non-invasive) melanomas. Expression was confirmed in 
human melanoma cell lines by flow cytometry.  Staining indicated expression by 
melanoma cells and/or infiltrating myeloid cells of the tumour, depending on the 
tumour model used [197].  
 
Regulation of lactadherin expression by tumours 
Lactadherin expression by macrophages and dendritic cells is triggered by the 
cytokine granulocyte-macrophage colony stimulating factor (GM-CSF), commonly 
expressed in the tumour microenvironment. The normal role of GM-CSF is to provide 
protective immunity through improved antigen presentation, including increased 
macrophage/dendritic cells expression of lactadherin, leading to apoptotic cell 
phagocytosis, antigen processing and display with activation of regulatory T cells 
[198]. This would be an advantage during tissue damage induced inflammation, which 
the tumour tissue microenvironment emulates.  
 
Expression of lactadherin has been shown to be regulated at the transcriptional level 
by p63, a member of the p53 gene family [199]. p63 can be transcribed as two 
isoforms, a trans-activator (TA) domain or an N-terminally truncated (∆N) domain, 
[199]. The p63∆N domain was shown to associate with the TA and could activate or 
suppress lactadherin expression, depending on the ratio of TA:∆N expressed in the 
cell [199]. The molecular basis for p63 gene expression is unknown, but as 
lactadherin expression can be stimulated in macrophages and dendritic cells by GM-
CSF [198] and requires p63 binding to the lactadherin promoter/enhancer, it is 
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conceivable that GM-CSF, stimulates p63 expression. p63 is required for embryonic 
epithelial tissue development [200][201][202][203], but is also commonly over-
expressed in epithelial basal cell carcinomas [199][204][205][206]. This therefore 
provides a potential mechanism for tumour overexpression of lactadherin. 
 
Lactadherin and tumour survival 
As described earlier, the integrin αvβ3 has been shown to bind to lactadherin (section 
1.3.2) and was also known to be expressed during the vertical phase of melanoma 
[207][208], so a role of lactadherin in melanoma through integrin stimulation was 
investigated. Using a melanoma model (B16) that does not express lactadherin 
directly, transformed with a vector encoding lactadherin or an RGE mutant incapable 
of engaging the αvβ3 integrin, lactadherin was shown to increase tumour growth in 
vivo through integrin ligation. In addition, myeloid cell derived lactadherin was shown 
to promote tumour growth [197], using a model of GM-CSF deficient mice with low 
lactadherin expression by macrophages and dendritic cells. The bone marrow was 
transfected with vectors encoding lactadherin, an RGE mutant or GFP. The mice were 
then transplanted with B16 cells, with the lactadherin transfectants showing 
significantly increased tumour growth over the controls [197]. As αvβ3 had been 
shown to play a role in melanoma survival by protecting cells from apoptosis (section 
1.1.2) and as Akt over-expression had been shown to convert radial growth phase 
melanoma to vertical growth phase melanoma [209], the role of lactadherin in Akt 
signalling and survival were scrutinised next. Supernatants from lactadherin 
expressing peritoneal macrophages were shown to increase the levels of 
phosphorylated Akt and S-6-kinase in B16 cells and increase resistance to ligation of 
the apoptosis inducing etoposide and fas, with these effects antagonised by αvβ3 
integrin blocking antibodies [197]. This indicated lactadherin did have a role in 
survival signalling and this was confirmed in human melanoma cell lines (K008 and 
K029) in which reduction of lactadherin expression with shRNAs reduced the levels 
of phosphorylated FAK, phosphorylated src and phosphorylated Akt, and led to 
increased apoptosis [197] (see figure 1.1 for integrin signalling pathways). This 
indicated that lactadherin produced either by melanoma cells or infiltrating 
macrophages could promote tumour cell survival through activation of integrin 
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signalling on the tumour cell surface, through an autocrine or paracrine mechanism 
respectively.  
 
A role of tumour and infiltrating leukocyte derived lactadherin in tumour survival is 
supported by work with the Rip1-Tag2 transgenic mouse pancreatic carcinoma model. 
In this model lactadherin was shown to be expressed within pancreatic tumours and 
by cell lines formed from the tumours, but with no expression in the normal pancreas 
[210]. A reduced tumour burden in lactadherin deficient mice was indicated to be 
caused predominantly by increased apoptosis, with also a small reduction in 
proliferation. This was shown by the use of a TUNEL (terminal deoxynucleotidyl 
transferase (TdT)-mediated dUDP nick end labelling) assay for apoptosis and a 
BrdUrd (bromodeoxyuridine) assay for proliferation [210]. This investigation 
indicated therefore that lactadherin may promote tumour survival by activation of 
proliferative and survival pathways. It was unclear however whether this was due to 
activity of lactadherin on the tumour cell surface, through effects on the vasculature or 
both as this model is known to require angiogenesis for tumour development. As 
lactadherin deficiency was shown to decrease the number of angiogenic pancreatic 
islets compared to the control and to reduce vascular permeability using a miles assay 
[210], it is likely that some of the survival-promoting effects of lactadherin may be 
attributed to its effects on vasculature growth. 
 
Lactadherin and invasion and metastasis 
Work with the melanoma model also indicated lactadherin to have a role in tumour 
cell invasion and metastasis. Lactadherin secreting B16 cells showed increased 
invasion in a matrigel assay compared to GFP and RGE-lactadherin expressing 
mutants and reduction in matrigel invasion of human melanoma cell lines with 
lactadherin expression knockdown by shRNA. A tumour invasion promoting role was 
also supported by work with supernatants from lactadherin expressing B16 cells 
promoting higher matrix metalloprotease MMP-9 and MMP-2 production by 
macrophages in vitro than those of B16 cells expressing the RGE mutant or GFP 
[197]. A metastasis promoting role of lactadherin was demonstrated by tail vein 
injection of lactadherin secreting B16 cells and GFP expressing control cells. The 
Lactadherin expressing cells showed formation of multiple pulmonary metastases, 
with little metastatic growth for the control. Lactadherin also induced EMT (epithelial 
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to mesenchymal transition) with altered cell adhesion necessary for cell migration 
[197]. EMT is activated through expression of transcription factors Twist and Snail 
[28][29][211], with Twist expression shown to be necessary for both invasion and 
metastasis [212]. Snail and Twist expression have themselves been shown to be 
regulated by Akt, with inhibition of Akt shown to down-regulate expression [213]. A 
role of tumour and infiltrating leukocyte derived lactadherin in tumour invasion was 
also supported by work with the Rip1-Tag2 transgenic mouse pancreatic carcinoma 
model. Lactadherin knockout mice showed a decreased tumour burden and although 
the same tumour number was evident, the tumours were mostly adenomas with 
significantly fewer invasive carcinomas. [210]. Extensive work on the melanoma 
model and some supporting evidence from the pancreatic carcinoma model has 
therefore demonstrated the role of lactadherin in tumour survival, migration and 
metastasis through activation of αvβ3 integrin Akt signalling on the tumour cell 
surface, with lactadherin derived from the tumour cells themselves, from infiltrating 
myeloid cells or both [197]. As lactadherin has been shown to be expressed by other 
tumours including extensive evidence of expression by breast tumours [176][195] and 
some evidence for expression in ovarian tumours [176] and as the integrins αvβ3 and 
αvβ5 have been shown to be expressed both by breast and ovarian tumours and have 
been indicated to play a role in tumour progression (section 1.1.2), the roles of 
lactadherin demonstrated in melanoma and indicated in the pancreatic carcinoma 
model may conceivably apply in these tumours also.  
 
1.3.4 A role for lactadherin in angiogenesis 
 
The integrins αvβ3 and αvβ5 are known to play an essential role in bFGF and VEGF 
mediated angiogenesis respectively, the two main pathways for angiogenesis (section 
1.2.3.1). As lactadherin had been shown to bind to both of these receptors (section 
1.3.2), its role in angiogenesis was investigated. 
 
Lactadherin vascular expression 
Lactadherin has been shown to be expressed within the vasculature of a murine 
melanoma (B16.F10) model [214] and a murine pancreatic tumour in Rip1-Tag2 mice 
[210], with immunohistochemistry showing co-expression with the vasculature 
marker CD31. Lactadherin was also shown in association with pericytes in Rip1-Tag2 
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pancreatic tumours, indicated by co-expression with pericyte marker NG2 [210]. 
Lactadherin has been shown to be expressed by human umbilical vein endothelial 
cells (HUVECs) with application of VEGF increasing expression, [173] indicating 
VEGFR signalling positively regulates lactadherin expression as it does pro-
angiogenic integrins (section 1.2.2). Lactadherin has also been detected within 
vascular structures by RT-PCR, western blot and immunohistochemistry. RT-PCR 
detected lactadherin mRNA in mouse aorta and hind limb muscle tissue. In addition, 
antiserum generated in rabbits immunised with a lactadherin peptide fragment 
containing the RGD sequence detected bands in western blots of mouse aorta (64 and 
56 kDa) corresponding to the molecular weight of the two murine forms of 
lactadherin. The same anti-serum was used to detect lactadherin expression in muscle 
tissue by immunohistochemistry, resulting in staining of EC’s and smooth muscle 
cells of capillaries and arterioles [173]. Lactadherin vasculature expression was 
confirmed in a lactadherin knockout (Mfge8-/-) model, in which β-galactosidase 
activity could be detected in areas of lactadherin expression. β-galactosidase activity 
was detected in heart, aorta and veins and within the blood vessels of hindlimb 
muscles. Staining of adventitial microvessels, medial smooth muscle cells and luminal 
EC’s of human coronary artery were also demonstrated [173]. 
 
Lactadherin and VEGF-mediated angiogenesis 
Lactadherin was shown to play a role in VEGF-mediated angiogenesis in vivo using 
both a Matrigel model as an assay of angiogenesis and a surgically induced hindlimb 
ischemia model. Recombinant human VEGF-A administration with Matrigel to 
normal mice caused increased vascular EC infiltration and proliferation and the 
formation of capillaries [173]. In addition the number of CD31-positive cells and 
amount of cellular DNA (signs of cellular proliferation) were increased [173]. This 
was as expected due to its role as a growth factor in the VEGF angiogenesis pathway. 
When an anti-lactadherin antibody was administered, these signs of angiogenesis were 
reduced to the no-VEGF control level [173]. A similar assay was performed with the 
Mfge8-/- mice and the signs of angiogenesis seen in the normal mice with VEGF-A 
administration were lost [173]. In the hindlimb ischemia model VEGF-A 
administration again increased the signs of angiogenesis and application of an anti-
lactadherin antibody abrogated these. As in the matrigel model, for the lactadherin 
knockout model VEGF application did not induce vessel formation. Application of 
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the two forms of murine lactadherin in the absence of exogenous VEGF to the 
hindlimb ischemia model also stimulated angiogenesis to a similar level as VEGF 
alone, indicating lactadherin may be as potent an inducer of angiogenesis as VEGF 
itself. Together these results provided strong evidence for a role of lactadherin in 
VEGF-mediated angiogenesis [173]. Both angiogenesis assays were repeated with 
bFGF to assess the effects of lactadherin on bFGF-mediated angiogenesis as 
lactadherin also binds to the αvβ3 receptor, known to co-ordinately signal with bFGF 
during angiogenesis (section 1.2.3.1). Lactadherin was however shown not to have a 
role in bFGF angiogenesis [173]. 
 
Lactadherin and EC survival through αv integrin ligation 
The survival, proliferation and migration of vascular EC’s mediated by the VEGF 
pathway upon activation of VEGFR2 have been shown to be mediated by activation 
of several branching signalling pathways (section 1.2.2.1).  As lactadherin had been 
shown to be required for activation of the VEGF-mediated pathway and as the 
integrin αvβ5 had been shown to co-signal with VEGFR-2 with coordination of 
p42/44MAPK/ERK and survival signalling indicated (1.2.3.1), a possible role of 
lactadherin in activation of these signalling pathways was investigated by using the 
level of phosphorylation of Akt or ERK as a marker of activity in the pathways [173]. 
This was carried out using the murine hindlimb ischemia model and with HUVECS. 
VEGFA application was shown to increase phosphorylated levels of both signalling 
proteins in the hindlimb ischemia model, but in the lactadherin knockout model, 
VEGF failed to increase the levels of phosphorylated Akt. Lactadherin was therefore 
indicated to be required for activity of the Akt survival pathway, but not the ERK 
pathway [173]. This was confirmed in vitro with HUVECS, in which application of an 
anti-human-lactadherin antibody reduced levels of VEGF-induced phosphorylated 
Akt, detected by western blot [173]. The anti-lactadherin antibody had no effect on 
bFGF-induced Akt phosphorylation, confirming that lactadherin in not required for 
this pathway [173]. 
 
To determine whether the role of lactadherin in promoting an increase in Akt 
signalling was mediated through ligation of integrins αvβ3 and αvβ5, assays were 
carried out with HUVECS. These indicated lactadherin association with HUVECS in 
an RGD dependant manner via ligation of the αvβ3 integrin, as both an RGD peptide 
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and a αvβ3 integrin receptor-blocking antibody interfered with association of 
HUVECS with lactadherin. A small effect was also observed with an anti-αvβ5 
antibody but this was not statistically significant [173]. The application of 
recombinant human (rHu) lactadherin increased the level of phosphorylated Akt and 
this was reduced both by blocking antibodies to the αvβ3 and αvβ5 integrins. The 
increase in Akt level upon lactadherin application was however not affected by 
application of a VEGFR-2 blocking antibody [173]. 
 
Overall this body of work indicated that lactadherin has a role in VEGF-mediated 
angiogenesis through ligation of αv integrins and is required for Akt signalling. 
Lactadherin also appeared to activate Akt signalling and potentially angiogenesis 
through integrin ligation, via a mechanism independent of VEGF receptor ligation. As 
lactadherin however was shown not to be required for bFGF angiogenesis, it is likely 
that this occurs independently of angiogenic growth factor pathways. 
 
Lactadherin and tumour angiogenesis 
A role for lactadherin in angiogenesis had therefore been indicated, but with 
expression within tumour vasculature described [214] and with lactadherin expression 
by tumour cells and/or infiltrating myeloid cells established [197], a role of 
lactadherin in tumour angiogenesis was investigated. A role of lactadherin in tumour 
angiogenesis was indicated by a study with the pancreatic tumour model of Rip1-
Tag2 transgenic mice [210], described in the previous section as a model that requires 
VEGF-mediated angiogenesis for tumour development. Expression of lactadherin by 
the tumour cells and infiltrating leukocytes was evident. In this model, the lactadherin 
deficient mouse showed decreased tumour vascular permeability and a reduced 
number of angiogenic pancreatic islets, though the vascular morphology was normal. 
This was accompanied by a reduced tumour burden, reduced tumour cell survival and 
increased apoptosis, indicating a role of lactadherin-mediated angiogenesis in tumour 
growth [210]. This could not however be conclusively determined as it is not possible 
to discriminate between any effects of lactadherin on the vasculature and through 
tumour cell proliferation and survival through direct signalling [210].  
 
A role for lactadherin in tumour angiogenesis may have been predicted based on the 
tumour expression and tumour angiogenesis promoting effects of a homologous 
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protein Del-1, of which the structure is shown in figure 1.15. This protein is expressed 
solely within EC’s during early embryonic development [215], with expression 
reactivated in the adult by tumours [216][217] and during ischemia [218].  Like 
lactadherin, Del-1 contains an EGF domain with an RGD sequence and two factor 
VIII-like C domains, as well as two other EGF domains without the RGD [215]. It has 
also been shown to bind to integrins αvβ5 and αvβ3 on the vascular endothelium 
[219][220]. Del-1 through association with αvβ3 has been shown to stimulate 
angiogenesis in the CAM assay [219] and stimulate EC attachment and migration in, 
in vitro assays, with these effects inhibited with αvβ3 integrin receptor-blocking 
antibodies [219]. It has also been shown to promote cell migration and survival as 
well as angiogenesis through αvβ5 ligation and to activate expression of αvβ3 by the 
vascular endothelium [220]. Like lactadherin Del-1 has been shown to be expressed 
both by tumour vascular EC’s and tumour cells themselves [221]. A role of Del-1 in 
tumour pathology though its angiogenesis promoting effects was demonstrated by 
work in which a Lewis lung carcinoma and osteosarcoma cell line were engineered to 
express this protein. These engineered cell lines were compared with control non-
engineered lines in their ability to produce a tumour in a murine model. The Del-1 
expressing tumours showed an accelerated growth rate and an increase in capillary 
density, with increased Del-1 expression shown to correlate with a reduction in in vivo 
tumour cell apoptosis [221].    This work was supported by a further study showing 
down-regulation of Del-1 expression in a human tumour cell line to suppress tumour 
growth and tumour angiogenesis in vivo [217].   
  
1.4 Immunotherapeutics 
 
1.4.1 Overview of immunotherapeutics 
 
The aim of development of immunotherapeutics was to produce biological molecules 
with binding specificity to disease associated antigens, which unlike small molecule 
drugs could target antigens associated with diseased tissues, sparing healthy cells. 
Targeted therapies started with polyclonal antibodies, acquired from the sera of 
immunised animals [107], followed by the development of hybridoma technology, 
leading to rodent derived monoclonal antibody therapies [222]. Problems with 
immunogenicity and poor effector functions [223][224][225] led on to the 
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development of first chimaeric [226][227][228]  then humanised antibodies [229] and 
finally to production of transgenic mice with human immunoglobulin genes that 
allowed generation of fully human antibodies [230][231], also achieved by display 
techniques [232]. Table 1.16 shows the monoclonal antibodies approved for clinical 
use in 2009 [233].  
 
Table 1.16 
Monoclonal antibodies approved for therapeutic use 
Taken from [233] 
 
 
 
Whole antibodies bind to antigens on foreign materials through specific association of 
their antigen binding arms [234] and bind to effector molecules and cells through their 
Fc domains (figure 1.17), permitting clearance of immune complexes through binding 
to complement, known as CDC (complement directed cytotoxicity) or Fcγ receptors 
on phagocytes or natural killer cells, known as ADCC (antibody directed cellular 
cytotoxicity) [235][236]. IgG is the principle serum immunoglobulin and so is the 
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form used in most therapeutic antibodies with the IgG1 isotype most commonly 
chosen for unconjugated therapeutic antibodies due to its stability and ability to 
activate both ADCC and CDC functions [234]. IgG is a multi-domain ‘Y’ shaped 
structure composed of 4 polypeptide chains; two 25kDa light chains and two 50kDa 
heavy chains, with the first domain of the light (VL) and heavy chain (VH) forming the 
variable regions containing the 6 complementarity determining regions (CDR) and the 
remainder of the heavy (CH) and light chain (CL) forming the constant region with the 
Fc formed of the heavy chain CH2 and CH3 domains (figure 1.17) [234]. The CDRs or 
hypervariable loops form the antigen binding surface and their composition 
determines the specificity of the antibody [236][237]. There are 3 CDR regions within 
the light chain and three within the heavy chain, which come together to form the 3D 
binding surface [237]. 
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Figure 1.17 
The domain structure of IgG and potential sites for engineering 
Shown are the heavy chain constant regions (CH1-3), of which the CH2 and CH3 form the Fc, and light 
chain constant region (CL). Shown also are the variable regions, variable heavy chain (VH) and 
variable light chain (VL), which contain the CDR regions. Indicated are areas commonly engineered 
including the variable regions modified to improve affinity, the Fc to alter interaction with FcγR 
receptors and complement for altered ADCC/CDC and FcRn receptors for altered circulation time, as 
well as altered glycosylation for modification of interaction with FcγR receptors in ADCC. Taken from 
[107]. 
 
 
 
 
Whole IgG molecules are bivalent as they have two binding arms and can 
simultaneously associate with two identical epitopes. This increases the functional 
affinity (avidity) and so retention time on cell surface multivalent antigens and 
allowing antigen cross-linking [234]. IgG has a long serum half life (20-21 days for 
IgG1, 2 and 4) [233] due to the presence of the Fc domain, which allows association 
with the FcRn salvage receptor expressed by vascular ECs. The antibody binds and is 
transported across the cells, whilst protected from degradation in lysosomes. This 
receptor also facilitates antibody recycling back into the bloodstream [234]. The size 
of whole IgG molecules (150kDa) also increases serum half life as proteins above 
approximately 60kDa in size cannot be removed from the blood by simple glomerular 
filtration in the kidneys [238]. 
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1.4.2 Antibody affinity, avidity, efficacy, selectivity and specificity 
 
Antibody affinity is a measure of the strength of association between an antibody and 
its target. Affinity is quantified as the equilibrium association constant Ka or its 
reciprocal, the equilibrium dissociation-constant (Kd). This applies only if the 
interaction follows the law of mass action (i.e. if neither the antibody nor the target is 
altered by the binding event). This law states that rate of association (rate constant kon) 
is equal to the number of binding events per unit of time and the rate of dissociation 
(rate constant koff) is equal to the number of dissociation events per unit of time. 
 
Kd =   [Ab-T] 
         [Ab] [T] 
 
The Kd is therefore equal to koff/kon.  
 
koff (min-1) / kon (M-1min-1) = Kd (M) 
 
Ka= 1/Kd 
 
The lower the value of the Kd, or higher the Ka the higher the affinity of the antibody 
as the koff would be slow and the kon fast, indicating the interaction forms readily and 
binds firmly. The individual rate constants are however important as they inform an 
investigator whether the affinity is high due to an ability to form an interaction rapidly 
(an on-rate driven affinity) or due to an ability once bound to bind firmly and remain 
associated (an off-rate driven affinity). Two antibodies for example may have 
identical affinities for a target, but different kon and koff rate constants and may 
therefore have different applications [107]. Antibodies for cancer imaging for 
example would require a high kon and koff for rapid imaging without background, 
toxin-conjugated antibodies for cancer therapy would require a high kon but not 
necessarily a slow off-rate due to internalisation. Toxin neutralising antibodies would 
require a slow off-rate to prevent toxin release. Antibody affinity is a major parameter 
Antibody + Target Antibody-Target kon (M-1min-1) 
 
 
koff (min-1) 
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to consider when developing an antibody or fragment, with therapeutic antibodies 
having a Kd of typically between 10-8 and 10-10M [107]. Generally the aim is to 
prepare antibodies with as high affinity as possible, although some have found that 
affinity limits tissue penetration in some models, with very high affinity anti-HER2 
antibodies becoming trapped in the perivascular tissue, apparently binding steadfastly 
to the first antigen they contact and not therefore travelling further into the tissue 
[239][240].   
 
Affinity is a measure of a single antigen-antibody binding site interaction and for a 
monovalent antibody fragment such a Fab or scFv affinity would equal the Kd for the 
association. For a divalent molecule such as an IgG or multivalent molecules such as 
IgM, the strength of the association between antibody and target is known as the 
functional affinity or avidity as it involves more than one antibody-antigen interaction 
[241]. The avidity is always much greater than the sum of the affinities as association 
of one antigen-binding arm brings the remaining antigen binding arm/s in close 
contact with the target, increasing the likelihood of association (cooperative binding). 
The functional affinity of an IgG has been observed at up to 1000-fold greater than its 
counterpart Fab, but depends on the density of the target epitope at the binding site 
[241]. Avidity for the association of a multi-valent antibody with its target is 
measured in the same way as the affinity of a monovalent antibody for its target, but 
in order to determine the affinity of a multi-valent antibody, it must first be 
fragmented to release monovalent binding arms and the affinity for the monovalent 
fragment is measured.  
 
Specificity is a measure of the exclusivity of the antibody-antigen interaction. A high 
specificity antibody may only bind to a single antigen, whereas a low specificity 
antibody would be promiscuous, binding to many targets. Selectivity however is the 
relative ability for the targeting molecule to bind to its specific target on tumour cells 
as opposed to normal cells [242]. This comes into play when the antigen target is a 
normal tissue antigen or differentiation antigen with increased expression within 
tumours, as is invariably the case rather than a tumour specific antigen, expressed 
only on tumour cells. Specificity and selectivity are important considerations when 
developing a therapeutic antibody, as non-target binding/binding to target on normal 
cells could result in undesired side effects caused by interference with normal tissue 
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functions, localisation of a toxic payload or activation of effector functions against the 
tissue. The selectivity and specificity of an antibody therefore determine its maximum 
tolerated dose, above which observable toxicity will be present due to the targeting of 
drug activity to normal cells [242]. 
 
 
1.4.3 Mechanisms of action of immunotherapeutics and relevance in cancer 
immunotherapy 
 
Targets for monoclonal antibody therapy may be an over-expressed normal tissue 
antigen, a differentiation antigen or a tumour associated antigen, which may either be 
a mutated normal antigen or an antigen silent in most normal adult tissues but 
reactivated by the tumour [243]. Targeted cancer therapies can cause tumour cell 
death by three principle mechanisms. The fist involves binding to a target in an 
unconjugated form and interfering with a function critical to tumour pathology. 
Common targets are RTK’s, but also include growth factors, integrins, death receptors 
such as TRAIL-R1/R2 and other cell surface receptors and cytokines [235][243]. 
Targeted cancer therapies can also bind to an overexpressed target and activate 
effector functions (section 1.4.1) against the tissue, or they may bind to an 
overexpressed target delivering a toxic payload to the tissue if they are genetically 
fused or conjugated to toxins, drugs or radionuclides or if a pre-targeting strategy is 
used [243]. Potential targets must generally be either surface associated or soluble 
extracellular antigens, as most antibody therapies are unable to enter the tumour cell 
to interfere with the function of intracellular targets [243]. Some therapeutics may act 
by more than one mechanism, with many unconjugated antibodies targeting an 
antigen with a role in tumour pathology but also activating effector mechanisms 
against the tissue. This is illustrated in table 1.16, showing the known effects of 
approved monoclonal antibody therapies [107]. In addition some targeted therapeutics 
are applied with conventional chemotherapeutic agents or other targeted drugs in 
cancer therapy [242][244] (section 1.4.3.1).    
  
1.4.3.1  Combined effects of targeted therapies and conventional regimes 
 
Conventional cancer therapies in widespread use include cytotoxic drugs and ionising 
radiation. Although these have significant side-effects due to activity on targets 
common to both tumour cells and proliferating normal cells, they also have potent 
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anti-tumour activity. They therefore have a continuing place in cancer therapy, but 
with the potential for increased anti-tumour activity in combination with targeted 
drugs including monoclonal antibody therapeutics [245][246][247]. This is necessary 
rather than simply moving over to targeted therapies as alone most have demonstrated 
limited effects [248]. It was predicted combination therapies may produce a greater 
therapeutic effect than individual regimes by addition of the tumour inhibition of each 
drug if they worked by an independent mechanism, (an additive effect). Alternatively 
the therapies may interact in mode of action producing a greater response than the 
addition of the two drug effects (synergy). The latter could be achieved by a drug 
effect leading to increased perfusion of the other agent throughout the tumour, 
observed for anti-vascular targeted drug combination therapies (section 1.2.5.3). It 
could also be effected by lifting of resistance [245], important as some cancers are 
intrinsically unresponsive to therapy and most become refractory to therapy at some 
point. Both additive and synergistic effects have been observed for monoclonal 
antibody-conventional chemotherapy/radiotherapy regimes, resulting in the approval 
of drugs such as bevacizumab (section 1.2.5.1), trastuzumab [235][249], cetuximab 
[140][243][245] and rituximab [250] for use in combination with conventional 
chemotherapy. It was hypothesised that as monoclonal antibody therapies are 
generally well accepted, the combinations would not result in additional toxicity over 
that of conventional therapies, which limits their therapeutic dose [242], thereby 
allowing the full therapeutic dose of each drug to be applied simultaneously. This has 
been shown to be predominantly the case, with the exception of therapeutic 
combinations with drugs such as bevacizumab, which show some inherent toxicity 
even in monotherapy due to side effects of target binding that result in reduced 
tumour selectivity (section 1.2.5.1). 
 
As development of resistance has been observed even to targeted therapies due to 
increased reliance of tumours on alternative signalling pathways, combinations of 
targeted therapies have been attempted with some success. With HER2 signalling 
indicated to modulate VEGF expression, and resistance to bevacizumab treatment 
shown to be associated with increased HER2 signalling and so VEGF expression 
[251], a phase I combination therapy study with bevacizumab and trastuzumab has 
been carried with some significant effects [251]. Further phase III studies are 
underway comparing the effectiveness of chemotherapy with bevacizumab alone and 
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chemotherapy, bevacizumab and trastuzumab [251].    EGFR signalling had also been 
shown to regulate VEGF expression, so the effects of targeting both EGFR and 
VEGFR signalling have been tested [252]. Preclinical studies examining the effects an 
anti-VEGF receptor monoclonal antibody DC101 in combination with cetuximab on a 
gastric cancer model showed a greater inhibition of tumour growth than either agent 
applied alone [248]. A phase II clinical trial with bevacizumab combined with 
cetuximab and irinotecan in irinotecan refractory metastatic colorectal cancer also 
demonstrated a significant clinical response [248]. With down-regulation of CD20 
expression demonstrated in 5 out of 9 patients with CLL-refractory to rituximab and 
fludarabine therapy and with a reduction in CD20 shown to be predictive of an 
improved clinical response of the anti-CD52 mAb alemtuzumab, combination of 
rituximab and alemtuzumab have also been assessed clinically by several groups. The 
studies indicated the combination therapy to produce a greater therapeutic effect than 
either drug applied alone, both in previously untreated patients and those refractory to 
chemotherapy, whilst maintaining an acceptable level of toxicity [253]. 
 
1.5  HuMc3, an anti-lactadherin antibody 
 
1.5.1 Development of MuMc3 
 
Cell-type specific human mammary epithelial antigens (HME-Ags) were discovered 
originally as antigens detected by polyclonal antibodies raised in rabbits against the 
delipidated HMFG after absorptions with other non-breast epithelial tissues 
[254][255]. The aim of using the HMFG as an immunogen was to uncover proteins 
expressed solely on the surface of the breast epithelium, (breast epithelial 
differentiation antigens) [254] to help identify these cells in a mixed population [256]. 
The HME-Ags are therefore the immunogenic components of the HMFG and breast 
epithelial cell surface and were detected as the 46kDa, 150kDa and 70kDa 
components now known to be lactadherin, mucin and butyrophilin respectively. As 
tumour specific antigens are rare, a protein expressed only on a single cell lineage 
non-essential for the survival of the individual, but from which tumours commonly 
arise was considered the next best type of target to limit normal tissue toxicity [257]. 
The HME-Ags were therefore postulated to be potential targets for anticancer therapy 
of tumours derived from the breast epithelium [258].  
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The HME-Ags were detected in breast tumour tissues, normal human breast 
epithelium, tissue fluid from breast carcinomas and breast epithelial tumour cell lines 
by immunofluorescence techniques [254][258][259] and by radioimmunoassays [255] 
with polyclonal antibodies. HME-Ags were not identified in tumours and tumour cell 
lines of non-breast epithelial tissue origins and normal cells and tissues other than 
breast epithelial cells [255][258]. The polyclonal antibodies were employed for 
localisation of human mammary tumour xenografts in a murine model by whole body 
imaging techniques [260]. They were also shown to detect HME-Ags shed into the 
circulation of breast cancer patients, with no HME-Ags detected in the sera of normal 
subjects and patients with non-breast tumours [260], which was mirrored in murine 
models with human mammary tumour xenografts [261] 
 
Due to the success of polyclonal antibodies in detection of breast specific antigens and 
targeting to breast tumour tissue, rodent monoclonal antibodies were raised against 
the HMFG [262]. This was carried out by immunisation of de-lipidated HMFG, with 
splenic B-cells removed and hybridised with the non-producer mouse myeloma cell 
line P3/NS1/1-Ag14. Hybridoma clones were selected for production of breast-
specific monoclonal antibodies, as those which bind to HMFG and the breast tumour 
cell lines MCF-7 and MDA-MB-157, but without association with human mammary 
fibroblasts, HeLa cervical carcinoma, HT-29 colon carcinoma and Bris-8 lymphoma 
cell lines. Mc3 (BLMRL-HMFG-Mc3) was one of the monoclonal antibodies raised 
by this technique and was shown to bind to the 47kDa component lactadherin and 
identified as the IgG1 class and a fully murine antibody [262]. 
 
Mc3 was later shown to bind to lactadherin in the EGF-like domain. The exact epitope 
to which Mc3 binds has not however been mapped [263]. Mc3 has been shown to 
block lactadherin binding to the surface of MA014 green monkey kidney cells, 3T3-
L1 mouse fibroblasts and ELL-G breast carcinoma cells, to which lactadherin binds 
through RGD-dependent attachment [264]. This indicated Mc3 binds to an epitope 
encompassing the RGD sequence, with the possibility that its binding site is a 
conformational epitope, with binding of lactadherin to αvβ3 via its RGD sequence 
dependent on the structural presentation of this sequence, lost by denaturation [264]. 
Mc3 has also been shown to bind to lactadherin on the surface of recombinant 
lactadherin expressing Sp2/0 myeloma and Chinese hamster ovary (CHO) cells as 
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well as the HMFG, indicating it can bind to lactadherin on the cell surface. It has also 
been demonstrated to bind to lactadherin released into the culture media, indicating it 
can associate with free lactadherin [263]. 
 
Mc3 was show to bind breast tumour cell lines selectively by radioimmunoassay with 
intact cells and cell membrane preparations [262][265]. Mc3 was also demonstrated to 
stain only malignant breast tumour tissue by immunohistochemistry with a range of 
human normal and tumour tissues [265]. Together this pointed towards breast tumour 
specificity.  Breast tumour specific targeting by Mc3 was supported by the detection 
of circulating lactadherin in the serum of breast cancer patients by Mc3, with no 
lactadherin in the serum of normal individuals or patients with non-breast tumours 
[266].  
 
1.5.2 In vivo biodistribution and therapy studies with MuMc3 
 
With Mc3 shown to detect its target selectively in breast tumour tissues and cell lines, 
its ability to target breast tumours in an animal model was assessed. Mc3 in its 131I-
labelled form was shown in two studies to accumulate in a MX-1 human breast 
tumour xenograft athymic (BALB/c nu/nu) mouse model. A high percentage injected 
dose/gram of tumour tissue of between 7 and 12 was maintained throughout the 
experimental period of 8 days, whilst levels in other tissues declined from day 1, as 
did the control of immunoglobulin from normal mouse serum [267][268]. Mc3 has 
also been shown to accumulate in MX-1 breast tumours in the above model using 
111In labelling by conjugation with MXDTPA. Mc3 was shown to accumulate in the 
tumour with a far higher percentage injected dose per gram of 70% [268]. This 
indicated the radioiodination method of conjugation through tyrosine side chains may 
have reduced the affinity of Mc3 for its target and the Mc3 tumour uptake predicted 
by 131I-Mc3 biodistribution studies was an underestimate. Mc3 in its unconjugated 
form was tested for its therapeutic effects against the same MX-1 human breast 
tumour xenograft model but with application of 28mg/kg immediately after tumour 
transplantation and every other day after that point [257], with a total of 
16.8mg/mouse (784mg/kg) applied. Mc3 showed no apparent toxic effects, and 
caused some tumour growth inhibition with tumour volume after 6 weeks of therapy 
400mm3, compared with the 500mm3 of the controls of nothing injected and ascites 
formed by the parent myeloma line, equating to a 20% growth inhibition [257]. The 
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therapeutic effect of unconjugated Mc3 on an established human breast tumour 
xenograft model has however not be tested alone. In combination with other anti-
HMFG monoclonal antibodies, (Mc8 an anti-lactadherin antibody and Mc1 and Mc5, 
anti-mucin antibodies) a significant therapeutic effect has been observed for both 
established (78% growth inhibition) and recently implanted (90% growth inhibition) 
MX-1 tumours and for established MCF-7 breast tumours (57.5% growth inhibition), 
though no effect was observed using non-breast tumour models, with colon CX-1 and 
lung LX-1 tumour xenografts, indicating a breast-specific anti-tumour effect of this 
antibody cocktail. Other than the model already described however the degree to 
which Mc3 played a role in this was not established. For the antibody cocktail treated 
MX-1 tissues, immunoperoxidase staining of tissue before and after therapy indicated 
antigen depletion following therapy by a 90% reduction in staining [257] with the 
potential for development of loss of response to therapy. Again however the degree to 
which if any lactadherin itself was depleted was not established. With Mc3 shown to 
target MX-1 tumour xenografts in vivo, its therapeutic effect when conjugated to 
cytotoxic radionuclides was assessed in this model [267]. Established MX-1 tumour 
growth after a single injection 500µCi of 131I-Mc3 to BALB/c nu/nu mice was 
assessed and compared with a no 131I-Mc3 control. The conjugated Mc3 showed a 
considerable growth inhibition, with a tumouristatic effect established until 25 days 
after injection, after which slow growth began, though the control tumour growth was 
not re-established. This equated to a growth inhibition of around 90% until day 25. 
The growth inhibitory effects of 131I-Mc3 were shown to be dose dependent, with a 
125µCi dose producing a reduced growth inhibition which was not tumouristatic. 
Application of multiple doses of Mc3 increased its duration of therapeutic effect. Two 
500µCi doses applied at day 1 and day 21 resulted in a tumouristatic effect until day 
40 after which growth was re-established at a slower rate to the control. At day 40 the 
growth inhibition relative to control was approximately 85% [267]. The tumour 
growth inhibitory effects of Mc3 when conjugated to a therapeutic radionuclide were 
confirmed by work with 90Y-Mc3, in which a single dose of 175µCi cured 5 out of 8 
mice of established MX-1 tumour xenografts [269]. 
 
1.5.3 Humanisation of Mc3 and comparison to the murine form 
Mc3 was humanised by a positional consensus method to enable it to be used for 
future clinical studies, by reducing the potential for development of a human anti-
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mouse antibody immune response. The humanised variable regions were designed to 
follow consensus sequences of human variable domains VκIV and VHI, the human 
light and heavy variable domains respectively that most closely match those of murine 
Mc3. The murine CDR’s (section 1.4.1) were however retained as were any residues 
in contact with the CDR’s or the opposite chain, for maximal target affinity. The 
humanised heavy and light chain variable regions were respectively inserted into the 
vectors pAH4604 and pAG4622, which encode the constant regions of the human 
IgG1 heavy and light chains. The vectors were then transfected into the non-producer 
myeloma line Sp2/0-Ag14 and antibody expressing clones selected [270].  
 
The affinity of Mc3 for delipidated HMFG determined by a binding competition 
radioimmunoassay did not appear to have been affected by humanisation with the Kd 
(section 1.4.2) of Mc3 and HuMc3 respectively 3.3nM and 1.7nM [270]. 
Biodistribution studies carried out with 131I labelled Mc3 and HuMc3 in the BALB/c 
nu/nu MX-1 model, showed humanisation had not affected the ability of this antibody 
to target to tumours in an animal model, with accumulation of HuMc3 in the tumour 
reaching a maximum after 4 days of 21%, reducing to 8% by day 8, whilst levels in all 
other tissues declined steadily over the 8 day period.  A 131I-HuIgG control in contrast 
showed no tumour accumulation [270]. Specific tumour uptake was confirmed with 
biodistribution studies with 111In labelling, which again showed superior percentage 
tumour uptake per gram and greater residence time than the 131I-labelled antibody 
[268]. The therapeutic effects of 131I-HuMc3 have been compared with those of 131I-
Mc3 in the MX-1 tumour xenograft model, in which an apparent increase in 
therapeutic effect was observed for the humanised form. Tumour regression was 
evident from day 1 following injection, with no re-emergence of growth by day 30. At 
day 30 a 43 fold reduction in tumour size compared to uninjected control was 
observed. After day 30 there was limited growth for some tumours, and 1 cure 
[268][270]. The murine form showed growth inhibition but slow growth occurred 
from day 1 and at day 25 the treated tumour was 4 fold smaller than the untreated 
control [268]. This work therefore showed humanisation of Mc3 had not detrimentally 
affected its tumour growth inhibiting effects in the radioconjugated form. The effects 
of unconjugated HuMc3 on tumour growth have however, yet to be investigated. 
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1.6 Hypothesis 
 
1.6.1 A role for lactadherin in angiogenesis  
 
A role of lactadherin in angiogenesis has been supported by its vascular expression 
patterns, vascular association with the αvβ3 integrin and potential for vascular 
association with αvβ5 integrin, in an RGD dependant manner (section 1.3.4). This is 
because, when ligated by RGD-containing ECM proteins on the surface of the 
vascular endothelium, these integrins have been shown to promote angiogenesis 
(section 1.2.3.1). This occurs by the coordinated signalling of αvβ3 and αvβ5 
integrins with growth factor bFGF and VEGF receptors respectively with some 
influence of αvβ3 on VEGFR-2 signalling also. This leads to activation of p42/44 
MAPK signalling, leading to proliferation, cell migration and survival. The latter 
occurs by protection against the extrinsic apoptosis pathway in the case of VEGF and 
intrinsic apoptosis pathway in the case of bFGF signalling, with some additional 
indication of coordinated activation of VEGFR-2 and αv integrins in intrinsic 
apoptosis signalling (section 1.2.3.1). These integrins can also activate independent 
signalling pathways (section 1.1.1), so may activate angiogenesis independently of 
growth factor ligation, through promotion of proliferation, migration, gene 
transcription and survival through inhibition of intrinsic and extrinsic apoptosis. 
Lactadherin has been shown to be required specifically for VEGF-mediated 
angiogenesis, (though not bFGF) as well as a VEGFR2 independent promotion of 
angiogenesis. More specifically lactadherin has been shown to be required for a 
VEGF-mediated increase in activity of Akt as well as promoting a VEGFR2 
independent increase in Akt activity (section 1.3.4), a kinase activated by PI3-K, 
necessary for survival through inhibition of intrinsic apoptosis by phosphorylation and 
so inactivation of initiator caspase-9, BAD and the forkhead transcription factors 
required for expression of pro-apoptotic proteins, as well as promoting expression of 
effector caspase-3 inhibitor survivin (section 1.2.2.1). From this information it was 
hypothesised that lactadherin as a αvβ5 and αvβ3 integrin ligand promotes 
angiogenesis both though direct EC integrin signalling independent of VEGF binding 
and by coordinated signalling with VEGFR2 (figure 1.18). The former would involve 
survival through inhibition of intrinsic and extrinsic apoptosis and potentially 
promotion of proliferation and migration. The latter would involve activation of 
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survival signalling, with coordinated activation of both intrinsic and extrinsic 
apoptosis and potentially proliferation.   
 
 
Figure 1.18 
Hypothesised role of lactadherin in αv integrin-VEGFR2 coordinated angiogenesis 
The proposed role of lactadherin ligation of the αvβ5/αvβ3 integrins in activation of the VEGFR-2 
mediated angiogenesis, through coordinately controlled signalling pathways 
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1.6.2 Lactadherin as a tumour-associated antigen required for tumour growth 
 
Lactadherin has been indicated to be a tumour-associated antigen with detection 
within primary human breast tumour tissues and by tumour cell lines including those 
of breast, ovarian and melanoma origin (section 1.3.3.1). With the integrins αvβ3 and 
αvβ5 indicated to play a role in the pathology of breast and ovarian cancers as well 
as melanoma (section 1.1.2) and as lactadherin has been shown to bind to the αvβ5 
integrin on breast carcinoma cells (section 1.3.2) and to αvβ3 in melanoma (section 
1.3.3.2), a role of lactadherin in the pathology of these tumours through av integrin 
ligation is suggested, with the potential for activation of integrin signalling pathways 
leading to tumour expansion through cell proliferation and survival by inhibition of 
intrinsic and extrinsic apoptosis (section 1.1.1). A role of lactadherin in melanoma 
has already been investigated. Studies with melanoma have indicated a role of 
lactadherin in survival through inhibition of both the intrinsic (caspase 9 mediated) 
apoptosis pathway by increasing activity of Akt and the extrinsic (caspase 8 mediated) 
apoptosis pathway by resistance to ligation of fas (section 1.3.3.2). 
 
1.6.3 Lactadherin as a tumour-associated antigen in tumour angiogenesis 
 
Lactadherin has been demonstrated to be expressed by tumour cells (section 1.3.3.1) 
and by tumour macrophages (section 1.3.3.2) and has been shown to play a role in 
VEGFR-2-mediated and VEGFR-2-independent angiogenesis through vascular EC 
integrin signalling (section 1.3.4). This suggested a role for tumour-derived 
lactadherin in tumour angiogenesis, permitting tumour growth beyond the critical 1-
2mm3 volume (section 1.2.4). This hypothesis is supported by work with a transgenic 
mouse model showing decreased tumour vascular permeability and a reduced number 
of angiogenic pancreatic islets in lactadherin-deficient mice, accompanied by reduced 
tumour burden. It is also supported by the confirmed tumour vascularisation effects of 
tumour-derived Del-1, a fellow human SED protein (section 1.3.4). In addition it is 
supported by the wealth of information suggesting a role for αvβ3 integrin ligation in 
tumour vascularisation (section 1.2.3.1)(section 1.2.4)(section 1.3.4). 
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1.6.4 HuMc3 as an anti-tumour therapeutic  
 
HuMc3 is an IgG1 mAb (section 1.5.3), with affinity for the EGF-like domain of 
lactadherin (section 1.5.1), inhibiting lactadherin binding to αv integrin expressing 
cells (section 1.3.2). It has been shown to target MX-1 breast tumours in vivo (section 
1.5.2) (section 1.5.3) and to bind mammary tumours by immunohistochemistry, with 
no binding to non-lactating, non-cancerous mammary tissue (section 1.5.1). In 
addition it has been shown to bind to several mammary tumour cell lines (section 
1.5.1). HuMc3 is therefore hypothesised to bind to lactadherin within tumours, 
inhibiting association of lactadherin with tumour cell and vascular EC αvβ3 and 
αvβ5 integrins. It is hypothesised to inhibit the roles of lactadherin in direct tumour 
expansion through cell surface autocrine integrin signalling and in indirect tumour 
growth through inhibition of the roles of lactadherin in angiogenesis.  
 
HuMc3 has been assessed minimally for its effects on MX-1 breast tumour growth in 
vivo. It showed strong growth inhibition of established tumours as a 
radioimmunoconjugate, but only a small inhibition of growth in unconjugated form of 
newly implanted tumours (section 1 5.2) (section 1.5.3). Its effects on established 
tumours were however not assessed, dosing schedules were limited to one drug 
concentration, only one tumour model was used and combination with other targeted 
drugs and chemotherapy was not attempted.  HuMc3 may have the potential to 
combine favourably with conventional chemotherapy drugs as has been observed for 
other targeted therapies, producing a greater effect than either drug applied alone 
(section 1.4.5.4). HuMc3 is hypothesised to act synergistically with bevacizumab, due 
to their similar proposed actions. HuMc3 is hypothesised to produce a greater 
therapeutic effect than bevacizumab, an approved cancer therapeutic, due to its 
proposed simultaneous direct tumour and anti-vasculature effects, whereas 
bevacizumab in monotherapy only exerts its effects on the vasculature (section 
1.2.5.1).  
 
1.7 Aims and objectives 
 
The aims of this project were to determine whether by its inhibition of lactadherin 
ligation of integrins αvβ3 and αvβ5 on the vascular endothelial/tumour surface 
HuMc3 could interfere with the roles of lactadherin in angiogenesis, and tumour 
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growth in vitro and in vivo and whether it could produce additive or synergistic effects 
on the latter in combination with conventional chemotherapy drugs and bevacizumab. 
This would involve; 
• Expression and/or purification of lactadherin and HuMc3. 
• Determining the kinetic parameters for association between purified 
lactadherin and HuMc3. 
• Confirming HuMc3, MCF-7 and SKOV3 tumour cell surface localisation and 
tumour localisation in vivo as a pre-requisite for therapeutic assessment. 
• Determining whether lactadherin binding to MCF-7 and SKOV3 cells via the 
αvβ3 and αvβ5 integrins can be inhibited by HuMc3. 
• Determining whether HuMc3 can inhibit clonal expansion of lactadherin 
expressing tumour cells in vitro and whether this can be enhanced by 
conventional chemotherapy drugs paclitaxel and cisplatin. 
• Determining whether lactadherin binding to vascular EC’s via the αvβ3 and 
αvβ5 integrins can be inhibited by HuMc3. 
•  Examining whether HuMc3 can inhibit the roles of lactadherin in vascular EC 
survival signalling and confirming lactadherin has no role in proliferation 
signalling. 
• Assessing the therapeutic effects of HuMc3 application on established tumours 
in vivo, using a range of HuMc3 concentrations, making comparisons with 
bevacizumab. 
• Assessing the therapeutic effect of application of HuMc3 to tumours in vivo in 
the presence and absence of conventional chemotherapy and making 
comparisons with bevacizumab plus chemotherapy. 
• Assessing the therapeutic effect of application of HuMc3 to tumours in vivo 
with bevacizumab plus/minus conventional chemotherapy. 
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Chapter 2 Materials and experimental methods 
 
2.1  Materials 
 
2.1.1  Reagents 
 
Reagent Name Composition 
PBS 0.14M NaCl, 2.7mM KCl, 2.8mM KH2PO4, 
10mM Na2HPO4 pH 7.4 
PBS-Tween 0.01% v/v Tween 20 detergent in PBS 
Phosphate buffer 10mM Na2HP04, 0.15M NaCl pH 7.2 
SDS-PAGE loading buffer X5 1M Tris-HCL pH 6.8 0.6ml, glycerol (50%) 5ml, SDS (10%) 
2ml, bromephenol blue (1%) 1ml, β-mercaptoethanol 0.5ml¸ 
dH20 0.9ml. 
Native-PAGE loading buffer X5 1M Tris-HCL pH 6.8 0.6ml, glycerol (50%) 5ml, bromephenol 
blue (1%) 1ml, dH20 3.4ml. 
SDS-PAGE running buffer 0.25M Trizma base, 2.5M glycine, 3.5mM SDS. 
Native-PAGE running buffer 0.25M Trizma base, 2.5M glycine. 
Gel fixing Solution Methanol 45%v/v, acetic acid 10% v/v 
Immunoblot transfer buffer 30mM Trizma base, 0.2M glycine, 1.4mM SDS, 20%v/v 
methanol. 
Saponin buffer Saponin 0.1%w/v, 0.15mM BSA in PBS. 
Sonication buffer 50mM Na2HPO4, 300mM NaCl, 10mM imidazole, 6.8µM 
lysozyme (lysozyme added immediately prior to use). 
Cell lysis buffer 150mM NaCl, 1%v/v Triton-X-100, 50mM Tris pH 8.0 
TAE (Tris-Acetate EDTA) DNA 
running buffer 
40mM Trizma base, 0.11%v/v acetic acid, 1mM EDTA. pH 8.3 
 
DNA loading buffer (X6) 3.7mM bromophenol blue, 4.5mM xylene cyanol FF, 30% v/v 
glycerol. 
2TY media 1.6% w/v tryptone, 1% w/v yeast, 85mM NaCl. Autoclaved to 
sterilise 
2TY agar 1.5% w/v agar, 1% w/v tryptone, 0.5%w/v yeast, 0.14M NaCl. 
Autoclaved to sterilise. 
Restriction endonuclease buffer 
Tango (1X) 
33 mM Tris-acetate, 10 mM Mg-acetate, 66 mM K-acetate, 
0.1 mg/ml BSA (pH 7.9) 
Restriction endonuclease buffer 
Red (1X) 
10 mM Tris HCl, 10 mM MgCl2, 100 mM KCl, 
0.1 mg/ml BSA (pH 8.5) 
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2.1.2  Antibodies 
 
2.1.2.1  Primary antibodies 
 
Clone Target Raised in Additional 
Information 
Manufacturer 
HuMc3 Human lactadherin EGF 
domain 
Humanised 
IgG1 
Raised against defatted 
HMFG 
Expressed 
Sp20-Ag14 
(HuMc3) 
mAb2767 Human lactadherin Mouse Raised against 
recombinant (CHO 
expressed) lactadherin 
R&D systems 
HuHMFG1 Human Muc-1 tumour 
mucin 
Humanised 
IgG1 
Recognises cryptic core 
peptide repeat. 
Cancer 
Research UK 
I5154 Unknown Human 
IgG1 
Isotype control Sigma 
mAb3050 Human αvβ3 integrin Mouse  R&D systems 
LM609 Human αvβ3 integrin Mouse Receptor blocking Millipore 
mAb2528 Human αvβ5 integrin Mouse  R&D systems 
P1F6 Human αvβ5 integrin Mouse Receptor blocking Millipore 
mAb3572 Human VEGFR-2 Mouse  R&D systems 
A7058 Poly-histidine Mouse Recognises native or 
denatured 6 residue 
poly histidine sequence 
Sigma Aldrich 
9E10 c-myc tag Mouse EQKLISEEDL peptide Cancer 
Research UK 
 
 
 
2.1.2.2  Secondary antibodies 
 
Clone Target Conjugate Raised 
in 
Manufacturer 
A0293 Human IgG Fab Horseradish 
peroxidase 
Goat Sigma 
F5512 Human IgG Fab Fluorescein 
isothiocyanate 
Goat Sigma 
A0170 Human IgG Fc Horseradish 
peroxidase 
Goat Sigma 
A9917 Murine IgG Fab Horseradish 
peroxidase 
Goat Sigma 
F5262 Murine IgG Fab Fluorescein 
isothiocyanate 
Goat Sigma 
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2.1.3  Mammalian cell lines 
 
Clone name Description Additional information Manufacturer 
SKOV3 Human ovarian 
tumour line 
Expresses αvβ3, αvβ5 Cancer 
Research UK 
MCF-7 Human breast 
tumour line 
Expresses αvβ5 Cancer 
Research UK 
HEK-293 Human embryonic 
kidney cell line 
No αvβ3 or αvβ5 
expression, so should be 
–ve for lactadherin 
binding. 
Cancer 
Research UK 
CHO Chinese hamster 
ovary cell line 
Suitable for recombinant 
glycoprotein expression  
Donated 
HUVEC Human umbilical 
vein endothelial 
cell 
Primary cells Lonza 
Sp2/0-Ag14 
(HuMc3) 
Murine myeloma 
cell line 
Transfected with 
pAH4604 and pAG4622, 
expressing heavy and 
light chains of HuMc3. 
Donated Access 
Pharmaceuticals 
MX-1 Breast tumour line Grown as tumour line 
not cell line. Expresses 
αv integrins. 
Donated Access 
Pharmaceuticals 
 
 
2.1.4  Escherichia coli bacterial strains 
 
Clone Name Antibiotic 
resistance 
Manufacturer Extra info 
E.coli XL1-
Blues 
Tetracycline Stratagene Endonuclease (endA) deficient improving 
miniprep DNA quality. Recombination 
(recA) deficient, improving insert 
stability. Has a hsdR mutation, which 
prevents the cleavage of cloned DNA by 
the EcoK endonuclease system. 
 
 
2.1.5  Expression vectors 
 
Clone Antibiotic resistance Description Manufacturer 
pEGFP-C1 Kanamycin/neomycin GFP reporter plasmid Clontech 
pCMV6-XL4 Ampicillin Lactadherin pCDNA insert, 
suitable for transient mammalian 
expression 
OriGene 
pcDNA4/To/myc-
hisA 
Ampicillin + Zeocin Contains the tetracycline 
operator 2, (2XTetO2) sequence 
for control of expression levels. 
Adds poly his and c-myc tags for 
ease of purification. 
Invitrogen 
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2.1.6  Oligonucleotide PCR primers 
 
Primer name Sequence 
Rec lac pcDNA fwrd primer 5’AAGCTTATGCCGCGCCCCCGC3’ 
 
Rec Lac pcDNA rvrse 
primer 
5’CTCGAGCAGCCCAGTAGCTCA3’ 
 
 
2.2  Methods 
 
2.2.1  Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
 
All gels were cast using the Biorad mini Protean III® gel system and comprised a 12% 
acrylamide resolving gel and a 4% stacking gel. The protocol describes the 
preparation of two gels. The resolving gels were prepared with 1.7ml of distilled 
water, 1.25ml of 1.5M Tris-HCl pH 8.8, 50µl (10% w/v) SDS, 2ml Bis-acrylamide 
(30% w/v), 50µl ammonium persulphate (APS 10% w/v) and 4ml TEMED, with the 
latter two ingredients added just prior to application into the apparatus to initiate 
polymerization. A 1.2 cm area above the gel was left for application of the stacking 
gel and a layer of ethanol added to aid flattening of the setting gel.  After around 5 
minutes the stacking gel was added composed of 3ml distilled water, 0.5ml 1M 
Tris/HCl pH 6.8, 40µl SDS (10% w/v), 40µl APS (10% w/v) and 4µl TEMED and a 
well-forming comb applied.  
 
Samples for analysis were boiled for 5 minutes in 5X SDS-PAGE loading buffer 
(section 2.1.1), then around 7µl for a small (16 well gel) and 15µl for a medium (8 
well gel) gel well, was loaded into each well with a PageRuler™ pre-stained protein 
ladder (Fermentas), included. The gels were run in SDS-PAGE running buffer 
(section 2.1.1) at 20mA per gel for around 1 hour. For staining the gels were fixed for 
2 hours in a fixing solution then transferred to Bio-safe coomassie stain G-250 (Bio-
Rad) for 2 hours. The gels were then rinsed 3 X for 5 minutes in distilled water and 
digitally scanned. For immunoblotting the gels were instead added to immunoblot 
transfer buffer (section 2.1.1) directly after the run. 
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2.2.1.1  Immunoblotting 
 
The transfer was carried out using a Bio-Rad semi-dry transfer cell. A single piece of 
nitrocellulose membrane (GE Healthcare) per gel and two pieces of 3mm whatman® 
paper (Bio-Rad) cut approximately to the size of the gel were added to the transfer 
buffer with the gel and left to soak up buffer for 10 minutes. Excess buffer was 
pressed out of the whatman® paper, then nitrocellulose membrane and gel sandwiched 
between the whatman® paper on the transfer plate, with gel uppermost. The transfer 
was run for 1 hour at 15volts.  The nitrocellulose was then removed and blocked 
overnight in a blocking buffer (3% BSA PBS). Primary antibody was added to the 
membrane in blocking buffer and incubated for 1 hour on a rocking platform at room 
temperature. For scarce antibodies, 4ml of antibody was prepared in blocking buffer 
and the blot incubated in a re-sealable bag, secured using a heat sealer.  
 
The membrane was washed 5X for 5 minutes in PBS-Tween buffer (section 2.1.1) and 
either incubated again for 1 hour with a peroxidase-conjugated secondary antibody 
and the washes repeated before being rinsed in PBS and developed, or if, directly 
conjugated, rinsed then developed directly.  Blots were developed using the ECL-
western blotting system (GE Healthcare). Blots were digitally imaged on a LAS-3000 
Fuji system.   
 
2.2.2  Protein expression and purification 
 
2.2.2.1  Isolation of HMFG (cream) from human milk 
 
The cream component of human milk was isolated by centrifugation of 100ml of milk 
at 5000xg for 20 minutes at 4ºC. The cream was washed twice in 5 volumes of a 
phosphate buffer (10mM Na2P04, 0.15M NaCl, pH 7.2) with centrifugation at 5000xg, 
also carried out at 4ºC. 
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2.2.2.2  Lactadherin purification from human milk by chemical properties 
 
All stages were carried out at 4°C unless stated otherwise. The cream component of 
100ml of human milk was isolated and washed as described in section 2.2.2.1. The 
MFG membrane was then disrupted by sonication (section 2.2.2.3) and fast churning 
on a magnetic stirrer for 1 hour to break proteins free from the membrane. The 
released proteins were pelleted by centrifugation at 100,000xg for 1 hour in an 
ultracentrifuge. The pellet was solubilised in 50ml of phosphate buffer (section 2.1.1) 
with 2.5% Triton X-114 before sonication and churning overnight. The sample was 
heated to 37°C for 1 hour then spun down at 4000xg for 20 minutes at 25°C, for phase 
separation. The aqueous phase was retrieved using a power pipette to isolate the lower 
layer and the protein precipitated in 10 volumes of acetone at -20°C overnight. The 
preparation was then centrifuged at 10,000xg for 15 minutes and the supernatant 
discarded. After evaporation of residual acetone, the pellet was re-suspended in 
phosphate buffer. The progress of the purification was followed by a coomassie-
stained SDS-PAGE gel. An anti-lactadherin western blot and ELISA were used to 
establish the presence of lactadherin in the purification product.        
 
2.2.2.3  HMFG sonication 
 
High frequency ultrasound membrane disruption of the HMFG was carried out using 
a MSE Soniprep-150 system. This involved dilution of the cream component of 
human milk into a volume of sonication buffer equal (section 2.1.1) to the starting 
milk volume and exposure of 25ml aliquots to sonication for 15 seconds, every other 
15 seconds for 4.5 minutes. 
 
2.2.2.4  HuMc3 Protein-G-sepharose immunoaffinity column 
 
HuMc3 (1mg) was incubated rolling overnight at 4°C with a 0.5ml bed volume of 
PBS-washed protein G sepharose beads for association. The beads were then washed 
and centrifuged twice at 617xg with 10 volumes of borate buffer (0.2M boric acid pH 
9.0) to remove unbound antibody. Covalent coupling of HuMc3 to the protein G was 
carried out by addition of cross-linker, solid dimethyl pimelimidate dihydrochloride to 
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a final concentration of 20mM. This was incubated on a roller at room temperature for 
30 minutes. The reaction was then stopped by two washes with 10 volumes of 0.2M 
ethanolamine (pH8.0) with centrifugation at 617xg, followed by incubation on a roller 
at room temperature for 2 hours. The beads were washed twice with 10 column 
volumes of PBS with centrifugation at 617xg to remove ethanolamine and stored at 
4°C in PBS with 0.01% sodium azide. The process of column formation was followed 
by a coomassie-stained protein gel of collected samples and anti-human western blot. 
 
2.2.2.4.1  Lactadherin purification by HuMc3 immunoaffinity 
chromatography  
 
The cream component of 100ml of human milk was isolated and washed as described 
in section 2.2.2.1. The HMFG membrane was then disrupted by sonication (section 
2.2.2.3) and rapid churning on a magnetic stirrer for 1 hour. The sonicated cream was 
incubated with 0.5ml of HuMc3-protein-G sepharose beads (section 2.2.2.4) for 2 
hours rolling at room temperature for association. The mixture was then passed 
through a 10ml polypropylene disposable column (Pierce) and the beads washed with 
100ml of PBS. Lactadherin was eluted in 1ml fractions with 0.1M glycine at 
decreasing pH; pH 5.0 (x 3), pH 3.0 (x 3) and pH 2.5 (x 6), into 50µl of 1M Tris (pH 
8.5). The progress of the purification was assessed by a coomassie-stained SDS-
PAGE gel and anti-lactadherin western blot of collected samples. 
 
2.2.2.5  Preparation of lactadherin culture supernatant for purification 
 
Lactadherin-expressing CHO cells at around 80% confluence were washed with tissue 
culture grade PBS (Invitrogen) and the media replaced with serum free media (section 
2.2.5.1). The cells were incubated for 3-4 days for lactadherin expression then the 
culture supernatant harvested. The culture supernatant was centrifuged at 3046xg and 
the supernatant retained, then concentrated X 10 and dialysed against PBS. The 
equivalent of 500ml of culture supernatant was used for purification (unless otherwise 
stated). 
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2.2.2.6  Lactadherin immobilised metal affinity chromatography (IMAC)  
 
Impure recombinant lactadherin prepared in section 2.2.2.5 was incubated with 
Talon® (Clontech) affinity resin at 1ml per 500ml starting culture supernatant (actual 
starting volume 3L), for 2 hours rolling at room temperature. This allowed 
coordination of the poly-histidine tag of recombinant lactadherin with the cobalt 
(Co2+) ions of the resin. The beads were washed with PBS through a 10ml 
polypropylene column with filter (Pierce) to remove non-specifically bound protein. 
The column was eluted in 0.5ml fractions after 1 minute incubations, with 200mM 
Imidazole pH 7.0 in PBS to disrupt the specific poly-histidine-tag Co2+ association. 
Purification samples were analysed for lactadherin content by a coomassie-stained 
SDS-PAGE gel and anti-lactadherin/anti c-myc/anti-polyHis western blots. Productive 
elutions were pooled and dialysed into PBS prior to storage. 
 
2.2.2.7  9E10 affinity purification of recombinant lactadherin 
 
Impure recombinant lactadherin prepared in section 2.2.2.5 was incubated with 9E10 
protein-G sepharose immunoaffinity beads (donated by a lab member and prepared as 
for HuMc3 in section 2.2.2.4) at 1ml bed volume (2mg 9E10) per 500ml of original 
culture for 2 hours rolling at room temperature. This allowed association of 9E10 with 
the c-myc tag of recombinant lactadherin. The beads were washed with PBS through a 
10ml polypropylene column with filter (Pierce) to remove non-specifically bound 
protein. Protein was eluted in 1ml fractions after 1 minute incubations with 0.1M 
glycine at decreasing pH, pH 5.0, 3.0 and 2.5 into 50µl of 1M Tris (pH 8.5). The 
purification progress was followed by Bradford assay (Pierce). Purification samples 
were analysed for lactadherin content by coomassie-stained SDS-PAGE gel and anti-
lactadherin western blot and productive samples pooled and dialysed into PBS prior to 
storage. 
2.2.2.8  HuMc3 purification by protein-G sepharose 
Sp2/0-Ag14 (HuMc3) culture supernatant (500ml) was concentrated X10 and dialysed 
into PBS. It was then incubated rolling overnight at 4ºC with 1ml bed volume of 
protein G sepharose beads for association through the Fc. The beads were washed 
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with PBS through a 10ml polypropylene column with filter (Pierce) to remove non-
specifically bound protein. Protein was eluted in 1ml fractions after 1 minute 
incubations with 0.1M glycine at decreasing pH, pH 5.0, 3.0 and 2.5 into 50µl of 1M 
Tris (pH 8.5). The purification progress was followed by Bradford assay (Pierce). 
Purification samples were analysed for human IgG content by coomassie-stained 
SDS-PAGE gel and anti-human western blot. 
2.2.2.9  Size exclusion chromatography using BioLogic DuoFlow System 
Size exclusion chromatography columns (Superdex™200 for HuMc3 and lactadherin) 
and the BioLogic DuoFlow System (Bio-Rad) were first equilibrated with degassed, 
filtered PBS. Molecular weight standards in the above buffer were then run on the 
column at a 0.65ml/minute (HuMc3) or 1ml/minute (lactadherin) flow rate and elution 
volumes of the molecular weight standards determined from the readout of the 
QuadTec detector at 214nm and 280nm and used to plot a standard curve of molecular 
weight/elution volume (see appendix 4 for the latter standard curve). Sample for 
purification in degassed filtered PBS was injected at a concentration of approximately 
0.7mg/ml for HuMc3 (2ml injected) and 1mg/ml for lactadherin (2ml injected), after 
centrifuging at 14200xg for 10 minutes to remove any particulate matter.   The sample 
was run at 1ml/minute for lactadherin and 0.65ml/minute for HuMc3 and 1ml and 
0.65ml fractions collected respectively. The protein content of the fractions was 
followed by the QuadTec by detection at 280nm and 214nm and plotted by the 
system. The standard curves were used for each to calculate the molecular weights of 
the component peaks.  
 
2.2.3   Antigen binding assays 
 
2.2.3.1  Immunoprecipitation (IP) of lactadherin from HMFG by HuMc3 
 
Human cream (1.5ml), prepared as described in section 2.2.2.1, was sonicated (section 
2.2.2.3) to disrupt the HMFG membrane and incubated tumbling in a 5ml tube at 4°C 
overnight with 5µg of HuMc3 for association with lactadherin. Approximately 10µl 
(bed volume) of washed, protein-G sepharose beads were then added and the 
preparation incubated for 2.5 hours at 4°c tumbling for association of protein-G with 
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HuMc3 Fc. The beads were washed 3 X with PBS, centrifuged at 2100xg for 5 
minutes to remove un-bound cream components. The beads were then boiled with 
reducing SDS-PAGE loading buffer (section 2.1.1) for 10 minutes to release bound 
protein. The progress of the IP was followed by coomassie-stained SDS-PAGE gel 
and western blot for detection of lactadherin. 
 
2.2.3.2  Native-PAGE immunoblot detection of HuMc3-lactadherin 
association 
 
A native PAGE gel was prepared and run in an identical protocol to SDS-PAGE 
(section 2.2.1), except, SDS and β-mercaptoethanol were omitted from all buffers. 
Human milk was added to a loading buffer with no reducing agent (section 2.1.1) and 
was incubated at 37°C for 10 minutes rather than boiling before loading. The sample 
was then loaded to several wells, with a PageRuler™ pre-stained protein ladder 
(Fermentas), in between each. The western blot was carried out as described in section 
2.2.1.1, but the transfer buffer used included no SDS. In addition the nitrocellulose 
was cut in the middle of the marker lanes and each piece incubated in a different 
primary antibody/primary antibody concentration. After secondary antibody 
incubation and development, the pieces of nitrocellulose were aligned in their original 
configuration for digital imaging and comparison of relative band location 
 
2.2.3.3  Enzyme-linked immunosorbant assay (ELISA) 
 
The antigen of interest or capture antibody was added to a MaxiSorp™ 96 well plate 
(Nunc) at a concentration of 5µg/ml (unless otherwise stated) in PBS, at a volume of 
50µl/well. The plate was incubated overnight at 4ºC then the wells washed 3X in 
PBS-Tween and 3X in PBS by immersion in buffer-filled troughs. A blocking buffer 
(3% BSA in PBS) was added to each well at 300µl per well and incubated at 37ºC for 
2 hours. Blocking buffer was removed and the primary antibody or antigen added, 
diluted in blocking buffer and incubated for 1 hour at 37ºC. The plate was washed as 
above and any subsequent antibody incubation steps carried out as a repeat of the last. 
The final step in all experiments involved a peroxidase-conjugated secondary 
antibody added in blocking buffer and again incubated for 1 hour at 37ºC. The plate 
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was washed again and a peroxidise substrate BM blue POD (Roche) added at 
50µl/well and the plate incubated in low light for up to 30 minutes, until development 
of a blue product. The reaction was stopped with 1M HCL and the colour change 
quantified as absorbance 450nm, using a plate reader. 
2.2.3.4  Surface plasmon resonance (SPR) 
SPR was carried out on a BIAcore® system, using a carboxymethyl dextran chip. Pure 
recombinant lactadherin was prepared in a sodium acetate buffer (10mM NaHPO4 
pH5.0) at 196nM and bound to flow cell 1 of the chip (700RU) by the amine coupling 
method, using a BIAcore® amine coupling kit. Flow cells 1 and 2 were blocked with 
1200RU BSA prepared in acetate buffer (10mM NaHPO4 pH4.5) at 149nM. HuMc3, 
whole IgG/Fab diluted in PBS/0.005% p20 detergent was prepared as a dilution series 
and binding of each concentration detected as the difference in 
association/dissociation signal between flow cell 1 and flow cell 2. The chip surface 
was regenerated between each HuMc3 binding assay with 10mM glycine pH 1.5 
incubated for 4 minutes and 10mM triethyamine incubated for 1 minute. A wash 
solution of BIAcore® ethanolamine was used throughout. A flow rate of 20µl/minute 
was used throughout. 
2.2.3.5  Preparation of Fab by IgG papain digestion 
 
HuMc3 Fab was produced from whole HuMc3 using the Pierce® Fab preparation kit, 
following the supplied instructions. The principle of the protocol was to expose whole 
HuMc3 to the non-specific thiol endopeptidase papain, immobilised on an agarose 
resin, to cleave the IgG for release of Fab fragments and the Fc. The reaction products 
were then passed through a protein-A column for specific binding to the Fc, leading to 
washing through and collection of pure Fab. Briefly, nine papain-agarose columns and 
0.5ml of pure 6667nM HuMc3 sample were equilibrated into a digestion buffer. The 
HuMc3 was diluted 1 in 10 in digestion buffer and divided into 10 equal 0.5ml 
samples. Nine were then added to the immobilised papain columns and incubated for 
between 5 minutes and 6 hours on a rocker at 37ºC. The columns were then 
centrifuged and the digest product collected and the columns washed with PBS and 
this collected also. This was repeated as a single experiment (except with no dilution 
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following equilibration) for 0.5ml of 6667nM HuMc3 with the optimised 2.5h 
incubation. The protein-A column was equilibrated into PBS, the 2.5 hour scaled-up 
experiment sample added and incubated rocking at room temperature for 10 minutes. 
The flow-through containing Fab was obtained by centrifugation and any residual Fab 
removed by 0.5ml PBS washes with additional centrifugation. The Fc was eluted by 
addition of elution buffer and centrifugation. The protein-A column was regenerated 
by washes with elution buffer and PBS.     The success of the digestion and 
purification were assessed by SDS-PAGE with coomassie-stained gels and western 
blots for detection of Fab and Fc.   
 
2.2.4   HuMc3 thermal stability assay 
 
Human milk lactadherin was coated to a MaxiSorp™ 96 well plate (Nunc) at 
approximately 53nM in PBS and incubated overnight at 4ºC to bind. The wells were 
then washed and blocked according to the standard ELISA protocol (section 2.2.3.3). 
Samples of HuMc3 of 133nM in PBS were exposed to one of a range of temperatures 
between 0ºC and 100ºC for 10 minutes and the samples returned to room temperature. 
BSA (Merck) was added to the samples, to a final concentration of 3% to block non-
specific association. The HuMc3 samples were then added to the assay plate and the 
ELISA completed according to the standard ELISA protocol (2.2.3.3), for detection of 
association of HuMc3 with lactadherin. 
 
2.2.5  Tissue culture and cell assays 
 
2.2.5.1  Tissue culture maintenance 
 
MCF-7, HEK-293, CHO and SKOV3 cells were all cultured in Dulbecco’s modified 
Eagles medium (DMEM), supplemented with 10% foetal bovine serum (FBS), 1% L-
Glutamine and 1% penicillin/streptomycin (Invitrogen). HUVECs were cultured in a 
speciality media, the EGM bulletkit (Lonza) according to the Lonza endothelial cell 
culture manual instructions. All cells were cultured in a humidified atmosphere at 
37ºC and 6% CO2 and were passaged at 60-80% confluence. Cells were sub-cultured 
by removal of media and washing with 10ml of tissue culture grade PBS (Invitrogen) 
and incubating for 5-10 minutes with accutase (PAA) (for HUVECS until cells 
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removed from plate but 5 minutes maximum). Cells were washed from the flask 
surface with media and centrifuged at 428xg (274xg for HUVECS), for 5 minutes. 
The cell pellet was re-suspended in fresh media and added to flasks, splitting the cells 
1 in 5 or 1 in 3 for HUVECs. 
 
The Sp2/0-Ag14, HuMc3 expressing cell line was cultured in suspension in protein 
free hybridoma media II (Invitrogen), supplemented with 1% L-Glutamine and 2% 
OptiMab® monoclonal antibody production enhancer (Invitrogen). The culture 
conditions were a humidified atmosphere at 37ºC and 6% CO2. The cells were sub-
cultured every 3 days by removal of 1/3 of the culture and replacement with fresh 
media, maintaining a cell number of around 1X 106 cells per ml. The supernatant was 
recovered from the waste culture by centrifugation at 3046xg to remove the cells. The 
presence of HuMc3 in the supernatant was detected by ELISA.  
2.2.5.2  Cell lysate preparation 
Cells were coated onto 9cm diameter tissue culture Petri dishes (Nunc) at a 
concentration of 3500 cells/cm2 in culture media (2.2.5.1) and cultured until 80-90% 
confluent. The cells were washed with 2ml ice cold PBS and removed from the cell 
surface by agitation with a cell scraper in a further 2ml ice cold PBS, with protease 
inhibitor cocktail (Roche, 1 tablet/50 ml). The cell material was removed and spun 
down at 14200xg for 5 minutes at 4ºC and the supernatant discarded. The cell pellet 
was re-suspended in 315µl per plate of lysis buffer with protease inhibitor cocktail 
added (1 tablet/50ml) and incubated on ice for 45 minutes to disrupt the cell 
membrane. The cells were centrifuged again at 14200xg and the supernatant collected 
and frozen at -80ºC prior to use.   
 
2.2.5.3  Single cell immunofluorescence (IF) confocal microscopy 
  
Circular 1cm diameter glass coverslips were added to sterile 24 well tissue culture 
plates (Nunc). These were sterilised in 100% ethanol for 30 minutes and rinsed with 
sterile dH20. For HUVECS coverslips were coated with at 5µg/cm2 with rat tail 
collagen I (Roche), prepared in 0.05% acetic acid. This was coated over the coverslip 
surface using a bacterial plate spreader and incubated for 1 hour under a laminar flow 
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hood. For all other cell lines the coverslips were coated with 10% poly-D-lysine and 
incubated for 2 hours before rinsing with sterile dH20. Cells were dissociated as 
described in section 2.2.5.1, centrifuged at 428xg and added to the coverslips at 5,000 
cells per well in their respective culture media (section 2.2.5.1). Cells were incubated 
for 48 hours for antigen recovery (unless otherwise stated). The plates were then 
transferred to ice and the wells washed with an ice cold bovine serum albumin (BSA) 
buffer (0.2% BSA in PBS) and incubated with primary antibody in BSA buffer on ice 
for 30 minutes. Wells were washed X 3 with BSA buffer then fixed with 2% 
paraformaldehyde for 10 minutes at 37ºC. Permeabilisation was carried out by 
incubation with saponin buffer (section 2.1.1) at room temperature for 1 hour before a 
1 hour incubation of secondary antibody diluted in saponin buffer. Coverslips were 
washed X 6 for 10 minutes with saponin buffer and 1 X in PBS, before mounting 
using forceps onto a drop of DPX neutral mounting media (Sigma) on superfrost 
microscope slides (VWR).  Cell fluorescence was imaged using a Leica SP2 confocal 
microscope.   
 
2.2.5.4  Fluorescence activated cell sorting (FACS) analysis 
 
Cells were washed with tissue culture grade PBS (Invitrogen) then removed from the 
flask surface with 0.02% EDTA (Sigma) and gentle agitation with a powerpipette. 
The cells were then washed in PBS/5% FBS blocking buffer with centrifugation at 
428xg and aliquoted into 1.5ml eppendorff tubes at 2.5X 105 cells per tube. The tubes 
were incubated rolling at 4ºC to block non-specific association, then centrifuged at 
762xg for 1 minute in a table-top centrifuge and primary antibodies or antigen added 
in 100µl of ice cold blocking buffer. After a 1 hour incubation rolling at 4ºC, the cells 
were washed X 3 with 1ml blocking buffer, using 1 minute, 762xg spin downs. The 
incubation and wash stages were repeated for all assay steps, but with the final FITC-
conjugated antibody incubated for 30 minutes. The cells were washed again as above 
but re-suspended in PBS and transferred to FACS tubes (Falcon) and single cell 
fluorescence analysed on a dual laser, 4 colour Becton Dickinson BD FACSCalibur™ 
system. 
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2.2.5.5  Cell ELISA 
 
The cells were dissociated as described in section 2.2.5.1, seeded in a 96 well tissue 
culture plate (Nunc) at 18,000 cells per well (unless otherwise stated) in the relevant 
culture media (section 2.2.5.1) and cultured overnight at 37ºC. The cells were washed 
2 X with tissue culture grade PBS and fixed with 2% paraformaldehyde for 30 
minutes at 37ºC. The wells were washed 3 X with PBS-Tween and 3 X with PBS and 
blocked for 2 hours in 5% BSA PBS block buffer (unless otherwise stated). The 
primary antibodies diluted in blocking buffer were incubated with the cells for 1 hour 
at 37ºC. The wells were washed as described above and the detection antibody anti-
human peroxidise A0293 added, diluted  1 in 40000 (unless otherwise stated) in 
blocking buffer and incubated for 1 hour at 37ºC. The cells were washed again and the 
assay plate developed as an ELISA described in section 2.2.3.3. 
 
2.2.5.6  Lactadherin-cell binding assays 
 
Lactadherin and positive control matrix protein vitronectin were coated at 50µl/well 
(213nM and 133nM respectively) in PBS to sterile 96 well tissue culture plate wells 
(Nunc) and incubated overnight at 4ºC. Wells were washed X 2 with PBS then 
blocked with 1% BSA/PBS blocking buffer for 2 hours at 37ºC to prevent non-
specific antibody association. The blocking buffer was removed and 90µl of phenol 
red free DMEM media added either alone or with test antibodies, for detection of their 
inhibition of cell binding. These were incubated for 1 hour at 37ºC. 5,000 cells were 
then added per well in 10µl of media, the cells spread evenly by plate rotation then 
incubated for 1 hour at 37ºC. The wells were gently washed twice with phenol red 
free DMEM to remove un-bound and non-specifically associated cells, then 100µl of 
fresh media added with 20µl of CellTiter 96® AQueous one solution cell proliferation 
assay reagent and incubated again for one hour. Cell binding was quantified as viable 
cell absorbance at 490nm, measured using a plate reader. 
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2.2.5.7  Cell proliferation/cell viability assays 
 
The cells were dissociated as described in section 2.2.5.1 and seeded into 96 well 
tissue culture plates (Nunc) at 5,000 cells per well in phenol red free 
DMEM/5%FBS/1%L-Glutamine/1%P/S. For HUVECS the wells were first coated 
with rat tail collagen I in 0.05% acetic acid at a concentration of 5µg/cm2 spread over 
the surface with a bacterial plate spreader and left to dry for 2 hours under laminar 
flow. The cells were incubated overnight for cell association. Media was then 
removed and test substances added at 100µl/well. The plates were incubated for 48-72 
hours, then developed by addition of 20µl of CellTiter 96® AQueous one solution cell 
proliferation assay reagent (Promega) and incubated again for one hour. Cell viability 
was detected as absorbance at 490nm using a plate reader. 
 
2.2.5.8  Caspase 3/7 apoptosis/survival assays 
 
White LumiNunc™ 96 well tissue culture plates were coated with rat tail collagen I as 
described in section 2.2.5.7. Cells were seeded at 5,000 cells per well in phenol red 
free DMEM/8%FBS/1%L-Glutamine/1%P/S and cultured overnight at 37ºC, 6% 
CO2. Media was removed and replaced with test substance/substances at 50µl/well 
diluted in phenol red free DMEM/4% FBS and the cells cultured for a further 7 hours. 
The plate was developed for detection of caspase 3/7 activity by addition of 50µl per 
well of Caspase-Glo 3/7 assay reagent (Promega), rotational agitation for 30 seconds 
to induce cell lysis and incubation for 1 hour. Luminescence was detected using a 
luminometer. 
 
2.2.6  HuMc3 in vivo studies 
 
2.2.6.1  Tumour implantation into BALB/c nu/nu mice 
 
Female BALB/c nu/nu mice were purchased from Harlan U.K. at 6-8 weeks of age. 
They were maintained in a sterile environment by the CBS facility, involving sterile 
housing (indiv-vented-cages) and bedding, with irradiation sterilised feed (Purina 
mouse chow 5058) and irradiation sterilised tap water, acidified to pH 2.5.  The living 
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environment was controlled to provide a constant temperature (25.6-28.9ºC) and a 12 
hour light-dark cycle. 
 
Murine propagated, MX-1 human breast carcinoma pieces (Access Pharmaceuticals) 
of approximately 2-3mm diameter were inserted into microchip needles and 
implanted subcutaneously, with mice under a general anaesthetic. MCF-7 and HEK-
293 cells were propagated in culture and dissociated as described in section 2.2.5.1. 
The cells were washed in ice cold tissue culture PBS, centrifuged at 428xg and re-
suspended in ice cold matrigel. Approximately 1 x 107 cells in matrigel were 
subcutaneously implanted per mouse. The tumours were permitted to grow to a 
maximum diameter of 4-8 mm. (Husbandry and injections carried out by the CBS 
facility, Imperial College). All work was carried out under Dr M.P. Deonarains home 
office licence number 70/5085.   
 
2.2.6.2  HuMc3 biodistribution studies 
 
HuMc3 was conjugated to Iodine-125 using the iodogen method. Briefly, 6667nM 
HuMc3 was exchanged into PBS using a PD10 column (GE Healthcare) according to 
the manufacturer’s instructions. Pre-coated iodination tubes (Pierce) were swilled 
with a small volume (75µl) of PBS and 5µl iodine-125 (Sigma) in the form of sodium 
iodide (0.05mCi/µl) added for exposure to the surface-bound catalyst and incubated at 
room temperature for 6 minutes.  A 1ml volume of the now 2000nM HuMc3 was 
added for iodination and incubated at room temperature for 8 minutes. The reaction 
was quenched with 500µl of tyrosine stopping buffer (1% tyrosine in PBS). The free 
iodine and tyrosine were removed using a PD10 column and the radiolabelled 
antibody filter-sterilised before injection at 200µl/mouse into the tail vein of tumour-
bearing mice (section 2.2.6.1). The mice were then transferred into cages surrounded 
by lead screening, isolated from the untreated. The mice were supplied an intravenous 
anaesthetic at the chosen time points for the studies. Cardiac puncture was used to 
remove around 500µl of blood and the mice were dispatched by cervical dislocation. 
The bodies were then dissected and samples of skin, tumour, skeletal muscle, liver, 
stomach, spleen, intestines, heart, lung, kidney and blood collected and transferred to 
pre-weighed tubes, which were weighed again and gamma emission counted along 
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with a sample of 125I-HuMc3. The data was then used to plot curves of percentage 
injected dose of 125I-HuMc3 per gram of tissue and blood to tissue ratio of 125I-
HuMc3, against time after injection. 
 
All procedures were carried out in accordance Imperial College radioisotope handling 
safety guidelines. Injections, cardiac puncture and cervical dislocation procedures 
carried out by the CBS facility. 
 
2.2.6.3  HuMc3 in vivo therapy studies 
 
Antibodies and/or cytotoxic drugs or PBS control were administered by tail vein 
injection into tumour bearing mice (section 2.2.6.1) twice/three times a week 
throughout the experimental period. Tumour size (length, width and depth) was 
measured once a day over the experimental period for each mouse using callipers. At 
the end of the experiment the mice were dispatched by cervical dislocation. Injections, 
tumour measurements and cervical dislocation procedures were carried out by the 
CBS facility Imperial College). 
 
2.2.7  Recombinant DNA Techniques and CHO cell transfections 
 
2.2.7.1  Production of electro-competent cells 
 
Aseptic technique was followed throughout this procedure. Bacteria (section 2.1.4) 
from -80ºC glycerol stocks were streaked out onto 2TY agar plates with 28µM 
tetracycline and incubated overnight at 37ºC. Single colonies were picked, added to 
5ml 2TY with tetracycline and cultured in a shaker incubator overnight at 37ºC and 
250rpm. A 2ml volume of the overnight culture was added to 100ml of fresh media, (a 
1 in 50 dilution) and cultured at 37ºC at 250rpm until an OD600 of 0.5 was reached. 
The cells were then incubated on ice for 30 minutes and centrifuged at 1700-3000xg 
for 15 minutes at 4ºC. The pellet was re-suspended in 100ml of ice cold sterile dH20, 
the cells retained on ice for 15 minutes and the 15 minute centrifugation repeated. The 
pellet was re-suspended in 50ml of ice cold dH20 and again incubated on ice for 15 
minutes. The centrifugation was again repeated and the cells re-suspended in 10ml ice 
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cold dH20 with 10% glycerol. After a 15 minute incubation on ice the centrifugation 
was again repeated and the pellet re-suspended in 2ml dH20 with 10% glycerol for 
storage at -80ºC in aliquots of 50µl prior to use. 
 
2.2.7.2  Transformation of electro-competent cells 
 
Aseptic technique was followed throughout this procedure. Two 50µl aliquots of 
electro-competent cells (section 2.2.7.1) were thawed on ice for around 30 minutes. A 
10-100ng mass of the transformation DNA was added to one of the cell aliquots and 
both were incubated on ice for a further 30 minutes. Meanwhile two electroporation 
cuvettes with a 0.2cm electrode gap were chilled on ice. Both the cells with DNA and 
negative control cells were added to a chilled cuvette and the cuvettes pulsed in the 
electro-pulse chamber of the Gene Pulser Plus (Bio-Rad). A 2.5kV pulse was used, 
with the pulse controller set to a resistance of 200ohms and a capacitance of 25µF. A 
1ml volume of 2TY media was immediately added to the cells, the cells transferred to 
25ml of media without antibiotics and incubated at 37ºC for 1 hour at 250rpm. The 
cells were spread out onto 2TY agar plates with tetracycline (28µM) and an antibiotic 
to which the transformed plasmid encodes resistance (kanamycin (62µM) or 
carbenicillin (265µM) for the plasmids pEGFP-C1 and pCMV6-
XL4/pcDNA4/TO/myc-hisA respectively). The plates were incubated inverted 
overnight at 37ºC. 
 
2.2.7.3  Temperature gradient polymerase chain reaction (PCR) 
 
A 600µl PCR reaction mastermix sufficient for 12, 50µl reactions was prepared with 
the following components; 120µl of a 1pmol/µl dilution of both forward and 
backward primer (section 2.1.6), 6µl Pfu DNA polymerase undiluted stock 
(Fermentas), 60µl 10 X Pfu buffer with MgSO4 (Fermentas), 60µl of 2mM dilution 
dNTP mix (Fermentas), pCMV6-XL4 plasmid (section 2.1.5) template DNA 1µl of a 
120µg/ml stock (10ng/reaction tube), nuclease free dH20 (Fermentas) 233µl. Dilutions 
of the primers, template DNA and dNTPs were prepared with nuclease free dH20.   
The mastermix was vortexed to mix the components and aliquoted into individual 
reaction tubes. The tubes were vortexed again and centrifuged briefly to ensure all 
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components remained at the bottom of the tube and were added to a thermocycler. As 
a temperature gradient PCR was used the tubes were positioned in a horizontal line 
along the thermocycler wells, to allow contact with the full temperature range. The 
thermocycler was set to follow the program below, consisting of an initial DNA 
denaturation and 29 cycles of DNA denaturation, primer annealing and extension, 
with a final extension step. A temperature gradient of 55ºC +/- 10ºC was used. All 
steps were carried out with PCR clean tubes and tips.    Samples of 5µl in 6X DNA 
loading buffer were then loaded and separated by DNA agarose gel electrophoresis 
(section 2.2.7.5). 
 
2.2.7.3.1  Temperature gradient PCR program 
 
Step Temperature (ºC) Time (min) Number of 
cycles 
Initial 
denaturation 
95 2 1 
Denaturation 95 1 29 
Annealing 55 (with gradient 
+/- 10) 
1 29 
Extension 73 3 (5-2 for each kb of 
insert) 
29 
Final extension 73 10 1 
 
 
2.2.7.4  Bacterial colony PCR 
 
The bacterial colony PCR was used to amplify the lactadherin insert, after new insert 
ligation and pcDNA4/To/myc-hisA (section 2.1.5) plasmid transformation into 
competent E.coli (section 2.2.7.2), to help verify the success of the ligation. Single 
colonies were first picked from the transformation plate (section 2.2.7.2) and added to 
5ml 2TY media with selection antibiotics (tetracycline 28µM for XL1-blues and 
carbenicillin 265µM for the pcDNA4/TO/myc-hisA plasmid) using aseptic technique. 
These were cultured in a shaker incubator overnight at 37ºC and 250rpm. The colony 
PCR was carried out as a standard PCR (section 2.2.7.3), but 1µl per reaction tube of 
overnight culture was added rather than template DNA and a lower fidelity Taq 
polymerase rather than Pfu polymerase was used.  
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A mastermix of 516µl, sufficient or 12 reactions was prepared with the following 
composition; 60µl 10 X Taq buffer (Fermentas), 60µl 2mM dilution of dNTP, 
(Fermentas) 120µl of a 1pmol/µl dilution of each primer (section 2.1.6), 156µl 
nuclease free dH20.  The mastermix was vortexed to mix the components and 
aliquoted into 10 individual reaction tubes at 43µl/tube. The tubes were vortexed 
again and briefly centrifuged to ensure all components remained at the bottom of the 
tube and 1µl of overnight culture, 1µl Taq DNA polymerase (Fermentas) and 5µl of 
25mM MgCl2 applied to each before the reaction tubes were added to the 
thermocycler. The thermocycler was set to follow the program below. Samples of the 
PCR product (2µl in 6X DNA loading buffer) were then analysed by DNA agarose 
gel electrophoresis (section 2.2.7.5). 
 
2.2.7.4.1  Colony PCR program 
 
Step Temperature (ºC) Time (min) Number of 
cycles 
Initial 
denaturation 
95 5 1 
Denaturation 95 1 30 
Annealing 65 1 30 
Extension 73 1.5 30 
Final extension 73 10 1 
 
 
2.2.7.5  DNA agarose gel electrophoresis  
 
Agarose gels were prepared as a 1% solution in TAE buffer (section 2.1.1) with 
ethidium bromide added to a final concentration of 2.54µM. Gels were formed and 
run using a Life Technologies gel electrophoresis system. Samples were loaded in 
DNA loading buffer and a DNA ladder, Hyperladder I included. Gels were run in 
TAE buffer at 100V for approximately 30 minutes. The DNA bands were digitally 
imaged using a LAS-3000 Fuji system on the UV setting. DNA was loaded with a 6X 
DNA loading buffer (section 2.1.1), with between 2µl and 10µl loaded per well 
depending on the size of comb used.  
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2.2.7.6  Plasmid purification 
 
Plasmid DNA was purified from 5ml overnight cultures of transformed E.coli, 
inoculated as single colonies from transformation plates (section 2.2.7.2). Included in 
the overnight culture were selection antibiotics, tetracycline (28µM) for E.coli XL-1 
blues and kanamycin, (62µM) or carbenicillin (265µM) for select for the plasmids 
pEGFP-C1 and pCMV6-XL4/pcDNA4/TO/myc-hisA respectively. The tubes were 
cultured in a shaker incubator overnight at 37ºC and 250rpm. Plasmid DNA was 
purified using Qiagen miniprep kits according to the supplied instructions. This 
protocol is a modified version of the alkaline lysis method (Birnboim and Doly 1979) 
involving alkaline cell lysis, lysate clearing, adsorption of DNA onto a silica 
membrane under high salt conditions, washing, and elution of plasmid DNA. 
 
2.2.7.7  Restriction endonuclease DNA digestion 
 
Restriction endonuclease (RE) double digests were carried out both for the product of 
the temperature gradient PCR reaction and for plasmid DNA. Included in each 
reaction were plasmid DNA, RE’s, (Fermentas) reaction buffers suitable for both 
RE’s (Fermentas) and nuclease free dH20 (Fermentas). The volume of RE’s, reaction 
buffers and dH20 varied according to the RE’s used, following the recommendations 
of Fermentas as did the incubation temperatures at timings. The amount of DNA in 
each reaction varied according to whether the digest was simply diagnostic (1µg) or 
whether the purpose was digestion of vector and insert for later ligation. For 
diagnostic digestions, single RE digests were included as controls, to verify the size of 
the uncut plasmid.  
 
2.2.7.7.1 Reporter plasmid pEGFP-C1 identity verification 
 
For the pEGFP-C1 reporter plasmid identity verification, restriction enzymes NheI 
and EcoRI were used and the buffer 1X and 2X tango. The enzyme NheI was first 
incubated with the 1µg of DNA in 1X tango buffer at 37◦C for 1 hour, then EcoRI 
added and incubated in X2 tango buffer for a further hour at 37◦C (see table below). 
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Samples of 10µl of digest products in 6X DNA loading buffer were then separated by 
agarose gel electrophoresis (section 2.2.7.5). 
 NheI (µl) Plasmid (0.5µg/µl) (µl) Nuclease free water 
(µl) 
X10Tango buffer( µl) 
for 1X  
EcoRI (µl) X10Tango buffer (µl) 
for 2X 
Double digest 2 2 41 5 2 6.25 
NheI single 
digest 
2 2 43 5 0 6.25 
EcoRI single 
digest 
0 2 43 5 2 6.25 
Undigested 
DNA 
0 2 43 5 0 6.25 
 
2.2.7.7.2 Plasmid pCMV6-XL4-Lac identity verification  
 
For the pCMV6-XL4-Lac identity verification digest the restriction enzymes SmaI and 
SacI were incubated with 1µg of DNA in 1X tango buffer and incubated for 1 hour at 
30◦C and 1 hour at 37◦C (see table below). Samples of 10µl of digest products in 6X 
DNA loading buffer were then separated by agarose gel electrophoresis (section 
2.2.7.5). 
 SmaI (µl) SacI (µl) Plasmid DNA (µl) Nuclease free water (µl) X10Tango buffer 
(µl) for 1X 
Double digest 2  2 2 39 5 
SmaI single digest 2 0 2 41 5 
SacI single digest 0 2 2 41 5 
Undigested DNA 0 0 2 43 5 
 
2.2.7.7.3 Cleavage of pcDNA4/TO/myc-hisA and lac insert for sticky ends 
 
Cleavage of the pcDNA4/TO/myc-hisA plasmid (section 1.2.5), and lactadherin insert 
created in section 2.2.7.3 was carried out to create sticky ends for later ligation 
(sections 2.2.7.8/2.2.7.9). Both the PCR product (93µl) created at 64◦C and plasmid 
(10µg) were incubated with HindIII and XhoI in red buffer overnight at 37◦C (see 
table below).  
 XhoI (µl) HindIII (µl) Plasmid (5µg/µl) /Insert 
DNA (µl) 
Nuclease free water (µl) Red buffer (µl) 
Plasmid 2 2 2 39 5 
Insert 2.5 2.5 92 2 11 
 
2.2.7.7.4 Identification of pcDNA4/TO/myc-hisA with lactadherin insert 
 
To confirm the success of ligation (sections 2.2.7.8-2.2.7.9) of cut pcDNA4/TO/myc-
hisA and lactadherin insert (section 2.2.7.7.3), plasmid DNA purified (section 2.2.7.6) 
from transformed E.coli XL-1 blues (section 2.2.7.2) was cleaved with HindIII and 
XhoI by incubation with just under 1µg of plasmid DNA in red buffer for 2 hours at 
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37◦c (see table below). Samples of 10µl of digest products in 6X DNA loading buffer 
were then separated by agarose gel electrophoresis (section 2.2.7.5). 
 
 XhoI (µl) HindIII (µl) Plasmid DNA (0.4µg/µl) 
(µl) 
Nuclease free water (µl) Red buffer (µl) 
Double digests 2 2 2 39 5 
Single digest 
(HindIII only) 
0 2 2 41 5 
 
2.2.7.8  DNA extraction and purification from agarose gels 
 
Plasmid pcDNA4/TO/myc-hisA (section 1.2.5) and insert DNA (section 2.2.7.3) from 
a double restriction enzyme digest to create sticky ends (section 2.2.7.7.3) were run on 
a DNA gel to separate the cut plasmid and insert from the cleaved sections of DNA 
(section 2.2.7.5). The entire cut PCR product and plasmid were added to 6X DNA 
loading buffer. The gel was viewed on a UV light box, and the plasmid DNA band 
(5100bp) and insert band (1164bp) cut out with a scalpel, taking care to reduce UV 
exposure and to avoid cross-contamination of the DNA samples. The DNA was then 
purified using the Qiagen QIAquick gel extraction kit, following the product 
instructions.  The procedure involved dissolving the gel in a buffer with a high salt 
content and application to a column containing a silica membrane to which the DNA 
bound. Any impurities were washed away and DNA eluted with nuclease free dH20. 
 
2.2.7.9  Lactadherin cDNA insert-pcDNA4/TO/myc-hisA vector ligation 
 
The masses of the digested vector and insert created in section 2.2.7.7.3 and gel 
extracted in section 2.2.7.8 were quantified by comparing band size on a DNA gel 
with that of the hyperladder I pre-quantified bands, allowing the volumes of insert and 
vector required for a 3:1 ratio of insert to vector to be calculated. For a 3:1 ratio, to the 
ligation mix 100ng of vector was added and 60ng of insert, equating to volumes of 
14.3µl and 8.6µl. Also added were 1µl T4 DNA ligase (Fermentas), 2µl 10X T4 
ligase ligation buffer and 4.1µl nuclease free dH20. The reaction tube was vortexed, 
centrifuged briefly to force the reaction mix to the bottom and incubated overnight at 
16ºC.  The success of the ligation was assessed by transformation into competent 
E.coli XL1-Blues (section 2.2.7.2), a colony PCR (section 2.2.7.4) and detection of 
insert by a performance of diagnostic double digest with HindIII and XhoI (section 
2.2.7.7.4) and diagnostic DNA gel. 
 102
2.2.7.10  Transient CHO transfection optimisation 
 
CHO (section 2.1.3) cells were plated under tissue culture conditions on 6 well tissue 
culture plates (Falcon) at 4 X 105 cells per well in DMEM/10% FBS, no antibiotics 
(2ml/well). The cells were cultured overnight and the media replaced with fresh. The 
transfection optimisation was carried out following the FuGENE HD protocol 
(Roche). Briefly, plasmid DNA: FuGENE HD ratios of 3:2, 4:2, 5:2, 6:2, 7:2, and 8:2 
were included. The transfection mixes were prepared in wells of a microwell plate 
before addition to the cells, each containing 2µg plasmid DNA and 100µl of DMEM 
diluent, but with volumes of transfection reagent varying from 3-8µl. The plate was 
rotated vigorously to mix the contents and incubated at room temperature. The 
reaction mixes were added to the cells drop-wise, with no contact of the tips with the 
plastic surface and the plate rotated to spread the contents. The cells were incubated 
for 8 hours at 37ºC in a humidified 6% CO2 incubator after which the media was 
replaced with DMEM/10% FBS. Identical assays were also carried out with cells in 
which FBS was excluded from the culture media for comparison of expression levels. 
After a further 48 hours of incubation the protein levels were quantified. For the 
reporter plasmid pEGFP-C1 the cells were washed and lysed as described in section 
2.2.5.2. The cell lysates were analysed for protein expression by measuring 
fluorescence emission at 509nm following excitation at 395nm on a fluorescence plate 
reader.  For the pCMV6-XL4 plasmid, lactadherin expression was detected by a 
western blot of samples of supernatant and cell lysate. 
 
2.2.7.11  Stable CHO cell transfection 
 
CHO cells were plated as described in section 2.2.7.10. The optical density 260:280 
ratios of miniprep purified DNA from the pcDNA4/TO/myc-hisA-lactadherin 
containing cultures were determined. The sample with a ratio closest to the optimum 
1.8 was chosen for the transfection. The FuGENE transfection protocol used in the 
transient transfection was repeated, but only the determined optimum transfection 
ratio of 4:2 FuGENE HD:plasmid DNA was used. In addition a control transfection 
was carried out with no DNA. After 24 hours the transfection media was removed 
from both the transfection wells and the negative control wells and the cells sub-
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cultured into 9cm2 culture dishes with DMEM/10%FBS/1831µM Zeocin for selection 
of cells transfected with pcDNA4/TO/myc-hisA.  The cells were incubated for two 
weeks with regular changes of the culture media and removal of dead cells. Once all 
control cells had been removed the cells were assessed for lactadherin expression, by 
western blot and ELISA of supernatant and cell lysate. The culture was maintained in 
DMEM/10%FBS/458µM Zeocin. 
 
2.2.8  Statistics         
 
2.2.8.1  Statistical data tables 
 
All numerical data is supplied in the form of a bar chart or scatter plot and statistical 
data table. Included in the statistical data table are the number of replicates (N), mean, 
median and minimum and maximum values (min and max respectively), as well as 
the standard deviation, all calculated using Microsoft Excel and representing the 
combined (combo) data from all experimental repeats unless otherwise stated. 
Graphical data is supplied as individual experiments plotted with error bars, 
representing the standard error from the mean value of the intra-experimental 
replicates. In the case of bar chart data, data is also presented in the form of combined 
(combo) data, in which all replicates of each experiment are combined in a single 
chart with error bars, the standard error of the combined data from the mean of all 
data. For scatter plots the data from individual experiments is supplied overlaid in a 
single plot and denoted with experiment numbers. 
 
2.2.8.2  Statistical tests 
 
2.2.8.2.1  t-test 
 
The t-test was used to determine whether the difference between two data groups is 
significant. The t-test used in this study was a two-sample assuming equal variance, 
calculated using Microsoft Excel. Both one-tail and two-tail tests were carried out but 
the difference considered significant if the P value of the one-tail test was below a 
value of 0.05. 
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2.2.8.2.2  Chi squared test 
 
A chi squared (x2) test was used to determine the goodness of fit of the BIAcore® 
HuMc3 IgG/Fab association with immobilised lactadherin binding curve data to the 
theoretical fit data, used to calculate the kinetic parameters for the association. The 
Chi squared value was calculated by the BIAcore® program and a value of below 10, 
according to the BIAcore® instruction manual was considered to constitute an 
acceptable fit. 
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Chapter 3 Expression, purification and association of HuMc3 and lactadherin 
 
3.1 Introduction 
 
Purification of native human lactadherin from human milk has been described in 
published work [160][241] using a method exploiting the chemical properties of the 
antigen. An alternative potential purification method was a HuMc3 affinity column to 
select lactadherin from sonicated human cream, by the high affinity interaction of 
HuMc3 with lactadherin. After the start of this project a clone became available 
encoding the human lactadherin gene. Expression and purification of rHu-lactadherin 
was therefore also a possibility.  
 
A Sp2/0-Ag14 mouse myeloma cell line stably transfected with plasmids containing 
heavy and light chains of HuMc3, respectively pAH4604 and pAG4622, was 
developed in past work. [270] (section 1.5.3) Mouse myeloma lines such as Sp2/0 and 
NS0 as “professional secretory cells,” are the preferred cells for production of 
engineered chimaeric and humanised antibodies as unlike traditional mammalian 
expression lines such as CHO or HEK-293, they do not need to be adapted to 
suspension culture and can produce high yields of fully functional immunoglobulin 
[271].   
 
Association of HuMc3 with lactadherin would be tested by ELISA and IP/native-
PAGE of lactadherin from human milk. The affinity and avidity (section 1.4.2) of 
HuMc3 for lactadherin would be assessed by two methods, by SPR using a BIAcore® 
system and by titration ELISA. The Ka for association of the whole HuMc3 IgG 
molecule with native lactadherin had been described in past work (section 1.5.3), but 
the affinity and kinetic parameters had not been determined and no affinity or avidity 
data was available for rHu-lactadherin.  
 
The aims of this chapter were to obtain pure lactadherin and express and purify 
HuMc3, both for use in further study and to determine association between antibody 
and antigen in vitro. The kinetic parameters for this interaction would also be studied 
and comparisons made with other neutralising antibodies to examine the potential of 
HuMc3 as a lactadherin neutralising antibody. The thermostability of HuMc3 with 
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respect to antigen association and in vitro integrin binding characteristics of 
lactadherin would also be assessed. 
 
The objectives were as follows; 
• Purify native human lactadherin and obtain sufficient 
material for all subsequent work. 
• If unsuccessful express and purify rHu-lactadherin 
• Determine affinity and avidity of association of HuMc3 
with native and/or rHu-lactadherin. 
• Determine the thermostability of HuMc3. 
• Study in vitro association of lactadherin with integrin αvβ3. 
 
 
3.2 Results 
 
3.2.1 Purification of lactadherin from human milk 
 
Human lactadherin was initially obtained from its most abundant source human milk. 
The first purification method attempted was one described in the literature exploiting 
the chemical properties of the antigen, namely its lipid solubility [160]. The procedure 
described in detail in section 2.2.2.2 involved attempts to isolate the membrane-
associated protein components of the milk fat globule, then separate lactadherin from 
transmembrane proteins. Figures 3.1a and 3.1b show respectively a coomassie-stained 
SDS-PAGE gel of samples collected during the purification, and western blot probed 
with an anti-lactadherin antibody mAb2767. From the blot it can be observed that 
lactadherin is present as the double band at 40-55kDa in the product of the 
purification, lane 10, shown boxed. This is in agreement with the literature which 
describes a double band at around 47kDa (section 1.3.1). The gel also shows a double 
band at between 40 and 55kDa, which is likely to be lactadherin, due to the western 
blot identification. The cream sample (lane 3) representing the milk fat globule 
membrane components detects 9 bands (13, 14, 25 28, 47, 60, 70, 110 and 170kDa), 
in approximate agreement with past data which has detected 4 main milk fat globule 
proteins; 47kDa (lactadherin), 60kDa, 70kDa (butyrophilin) and 150kDa 
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[254][255][262] as well as other components whose expression on the HMFG surface 
varies; 13kDa, 14kDa 30kDa, 110-120kDa, 170kDa [160]. In the purification product 
(lane 10), in addition to lactadherin there are five contaminating bands at 170, 115, 
two around 70-80kD and one at around 14kDa, all of which are similar or higher 
staining intensities to that of lactadherin, suggesting significant contamination of other 
proteins. In addition, other than the apparent loss of four bands at around 13kDa, 
25kDa, 28kDa and 60kDa, all of the starting proteins of the cream (lane 3) are 
similarly represented in lane 10. This suggests that rather than purifying lactadherin, 
most of the milk fat globule membrane proteins were retained. The bands in the final 
product in lane 10 of figure 3.1a appear to be two of the four main HMFG membrane 
components, lactadherin and butyrophilin as well as the variable components (14kDa, 
120kDa, 170kDa). The bands remaining in the purification product are likely to be 
other HMFG membrane proteins with water soluble regions, which enable them to 
remain in the aqueous phase of the Triton-X-114 phase separation. From the western 
blot it appeared lactadherin had been enriched by the process of purification with a 
relatively strong double band visible at lane 10 but with only weak bands for the 
original milk sample (lane 1) and for the milk fat globules (lane 3). The yield of 
lactadherin predicted based on determination of protein content of the final product 
and approximation of the proportion of lactadherin in the final product using the gel 
banding patterns was 1.5mg/L of starting material. The starting material was predicted 
to contain 66mg/L based on past data on lactadherin expression levels in human milk 
[160]. A yield of 2.2% was therefore approximated, indicating significant losses of 
lactadherin during this protocol, also suggested by the western blot signal (figure 
3.1b) in the various wash stages and discarded materials. The western blot data may 
have been improved by the inclusion of a control blot with an isotype-matched 
antibody, given the apparent background signal in this blot, to improve confidence of 
the specificity of the lactadherin detection signal. 
 
The product of the purification and the enriched starting material of the cream 
(HMFG), were tested by an ELISA (Figure 3.2) to confirm the presence of 
lactadherin. This was performed as a sandwich ELISA coating with one anti-
lactadherin antibody mAb2767 and detecting with another, HuMc3 and an anti-human 
IgG peroxidase (A0293), to allow high confidence of the specificity of the lactadherin 
detection signal. This assay detected lactadherin in the human milk fat globule and in 
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the purification product with a concentration dependent signal confirmed by a 
statistically significant difference between the purification product sample or cream 
samples undiluted and samples diluted 1 in 4 (figure 3.2a). This data also confirmed 
that lactadherin had been enriched by the process of purification by approximately 3 
fold by around a 3 fold increase in signal between the cream and purification product 
samples, undiluted and diluted (figure 3.3b), a difference which again was shown 
significant (figure 3.2a).  
 
Figure 3.1 
Attempted purification of lactadherin from human milk by its chemical properties 
(a) Coomassie-stained SDS-PAGE gel and (b) western blot of purification samples. Blot probed with 
anti-lactadherin antibody mAb2767 (13nM) and anti-mouse HRP A9917 (diluted 1 in 80,000).  
Loading order for (a) and (b); 1 Whole milk, 2 Supernatant from first spin, 3 cream from first spin, 4 
supernatant from second spin, 5 cream from second spin, 6 sonicated sample, 7 supernatant from 
36,000 rpm spin, 8 cream from 36,000rpm spin, 9 aqueous phase, 10 final product, 11 supernatant 
after spin out of insoluble material. Figure data representative of the results of three separate 
experiments. 
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Figure 3.2  
Capture ELISA to detect lactadherin in the milk purification product  
Lactadherin (sample) detected with HuMc3 (167nM) and an anti-human peroxidase A0293 (diluted 1 
in 40,000) using commercial anti-lactadherin antibody mAb2767 (33.3nM) for capture. A positive 
control of the human milk fat globule (HMFG) was also included. (b) Data from four separate 
experiments and an average (combo). Each error bar denotes 3 experimental repeats. Absorbance 
corrected to zero using no-HuMc3/no lactadherin controls. (a) Statistical data table displaying the 
average (combo) data and t-tests. 
 
(a) 
 
Combo data   
  
         
  Sample 
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(1 in 4) HMFG 
HMFG 
(1 in 4) 
 
 
 
t-test 
 
Sample/ 
sample (1 
in 4) 
 
HMFG/ 
HMFG (1 in 
4) 
 
 
Sample/ 
HMFG1 
Sample (1 
in 4)/ 
(HMFG1 1 
in 4) 
N 12 6 12 6 t Stat 7.51 4.12 10.71 8.62 
Mean 0.46 0.13 0.11 0.04 P(T<=t) one-tail 6.22E-07 4.05E-04 1.70E-10 3.04E-06 
SD 0.11 0.02 0.04 0.02 t Critical one-tail 1.75 1.75 1.72 1.81 
 
    P(T<=t) two-tail 1.24E-06 8.10E-04 3.41E-10 6.09E-06 
 
    t Critical two-tail 2.12 2.12 2.07 2.23 
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The next purification method attempted involved exploitation of the affinity of 
HuMc3 for human lactadherin, by formation of an immunoaffinity column of protein-
G-sepharose conjugated to the Fc region of HuMc3 (section 2.2.2.4) and purification 
of lactadherin from sonicated human cream (section 2.2.2.4.1). Samples collected 
during the coupling procedure of column preparation are show in figure 3.4a and 3.4b 
respectively as a coomassie-stained SDS-PAGE gel and western blot probed with 
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the coupling was successful with lane 3 showing binding of HuMc3 to the column 
before addition of the cross-linking agent with both heavy (upper box) and light 
(lower box) chains visible and with no heavy or light chain detected in the various 
wash stages (lane 5-7). No light chain was however visible in the post cross-linker 
sample (lane 4), except a tiny amount that is just visible in the gel but not observable 
in the blot and final bead sample (lane 8). The heavy chain as the part that binds to 
protein-G would be expected to remain on the beads treated for a reducing-PAGE, as 
they would be chemically coupled but the light chain would be expected to be 
removed upon addition of a reducing agent. It is however possible that the coupling 
agent also cross-linked the light chain covalently either to the heavy chain or to 
protein-G. 
 
Figures 3.4c and 3.4d show respectively a coomassie-stained SDS-PAGE gel and 
western blot probed with mAb2767 of samples collected at all stages of the 
immunoaffinity purification. Lane 1 shows the before column sample with several 
bands observable in the gel, milk fat globule membrane proteins [160] appearing at 
around 13, 14, 24, 30, 60, 70, 100 and 170kDa, though lactadherin (47kDa) is not 
clearly visible. Most of these bands are also present in the flow through (lane 2) but 
not in the elutions, indicating they failed to specifically associate with the column and 
so were washed away. There remain however two bands at around 70kDa and 
100kDa, butyrophilin and the 100kDa HMFG component. As 47kDa lactadherin has 
been shown to be the only protein of the HMFG that Mc3 binds to [262], it is likely 
these proteins were carried across to the purification product by non-specific 
association with protein G, or the sepharose beads. A barely visible band is also 
present at around 25kDa, confirmed by anti-human light chain western blot to be the 
light chain of HuMc3 (data not shown). There is not a visible band in the coomassie 
gel for lactadherin though the western blot detects the presence of lactadherin in the 
before column sample (lane 1) and in the latter elutions (lanes 9-15) suggesting that 
lactadherin did associate with the column. This data indicates lactadherin may have 
been partially separated from the other human milk fat globule proteins by this 
method, but it has not been separated from two of the HMFG membrane components. 
As no coomassie gel band was observed for lactadherin it was not possible to 
calculate its yield from this attempted purification, though it is likely to have been 
even lower that that obtained from the previous purification attempt. Another method 
 of affinity purification of bovine forms of lactadherin showed success in past work 
with concanavalin-A conjugated
binding of the 60kDa and 70kDa components may therefore have been removed by 
the use of agarose beads rather than protein
 
Figure 3.3 
Purification of lactadherin from human milk by HuMc3 immunoaff
 (a) Coomassie-stained SDS-PAGE gel and (b) western blot of samples collected during preparation of 
a protein-G sepharose-HuMc3 coupled immunoaffinity column. Blot probed for detection of human 
IgG with anti-human peroxidase A0293 (dil
and (d) western blot of samples collected during lactadherin purification by immunoaffinity 
chromatography. Blot probed 
A9917 (diluted 1 in 80,000).  
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3.2.2 Transient expression of rHu-lactadherin  
 
When a cDNA clone encoding human lactadherin became available it was decided 
that an attempt would be made to express rHu-lactadherin as the raw material of 
human milk was becoming difficult to obtain.  
 
A pCMV6-XL4 plasmid (appendix 1) with its insert cDNA encoding human 
lactadherin (figure 3.5c) was first used to express lactadherin transiently in CHO cells 
(figure 3.4), to determine whether the recombinant form and the recommended 
expression line would be suitable for use in this study. The main concern was whether 
the altered (non-human) glycosylation would prevent binding of HuMc3 or 
association with its integrin receptors. The plasmid along with a green fluorescent 
protein (GFP) encoding reporter plasmid pEGFP-C1 (appendix 2) was cloned by 
transformation into competent E.coli XL1-Blues, a tetracycline resistant strain and 
plated with tetracycline and ampicillin or kanamycin respectively to select for both 
the strain and the plasmid (section 2.2.7.2). Colonies were picked for overnight 5ml 
cultures and plasmid DNA purified (section 2.2.7.6).  
 
The identity of the plasmids was investigated by a double restriction digest, using 
restriction enzymes that cleave the plasmid at either side of the lactadherin cDNA 
insert/GFP tag sequence; SmaI and SacI for pCMV6-XL4-lactadherin (figure 
3.5a)(section 2.2.7.7.2) and NheI and EcoRI for pEGFP-C1 (figure 3.5b) (section 
2.2.7.7.1). The data is displayed in the form of DNA gels (section 2.2.7.5), with the 
inclusion of a DNA ladder (lane M) with a 200-10000bp separation range to help 
identify the size of the fragments. The pCMV6-XL4-lactadherin plasmid was 
identified first by linearization by a one restriction enzyme digest shown in lanes 2 
and 3, indicating a plasmid size of around the expected 6800bp, equal to the 4700bp 
vector (appendix 1) plus the 2100bp lactadherin cDNA insert (figure 3.5c). The 
double digest in lane 1 is in agreement showing the release of a small fragment around 
the expected size of the insert of 2100bp and cut plasmid of around 4700bp. The 
pEGFP-C1 plasmid was also identified with the linearised form shown in lanes 2 and 
3 over 4000bp, though the exact expected size of 4700bp consisting of the 4700kDa 
plasmid including 722kDa GFP tag sequence (appendix 2) could not be confirmed 
due to the lack of resolution of the markers at above 4000bp. This could however 
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have been improved if the run time of the gel had been elevated, so increasing the 
separation of the marker bands. The double digest in lane 1 however confirms the 
plasmid identity with a fragment released around the expected 722bp of the GFP tag 
sequence and the cut plasmid around 4000bp. The identity of the lactadherin cDNA 
was also confirmed by DNA sequencing using primers corresponding to the beginning 
and end of the coding sequence (figure 3.5c), supplied with the plasmid.  
 
With the identity of the plasmids confirmed, transfection of CHO cells using the 
lipofection reagent fuGENE® HD was optimised with the GFP reporter plasmid 
(section 2.2.7.10) (figure 3.4). This plasmid was chosen so the effectiveness of the 
transfection process and protein expression by the cell line could be followed by 
detection of GFP fluorescence. The results of the optimisation are shown in figure 3.6 
as fluorescence emission of CHO cell lysate after transfection with the recommended 
FuGENE® HD: DNA ratios. Controls of no DNA, no transfection reagent and cells 
alone were used to correct the fluorescence to zero. The results indicated although all 
ratios produced some successful transfection with protein expression evident, the ratio 
of transfection reagent: DNA for optimal protein expression was 4:2, with this ratio 
producing significantly higher (figure 3.6a) protein expression than the two ratios of 
5:2 and 3:2 with the nearest protein expression.  The transfection protocol was also 
carried out with no serum added after the transfection to determine whether the 
presence of serum affected protein expression, shown in figure 3.7 as fluorescence 
emission of cell lysate. It was hoped to omit serum from subsequent transient 
lactadherin expression protocols as it was considered potentially undesirable due to 
the similarity in molecular weight of serum albumin with lactadherin which may have 
complicated lactadherin detection and purification. The data shows the difference in 
protein detection at 4:2 with serum and without is significant (figure 3.7a) and 
although some protein expression is still evident at all ratios other that 8:1, all protein 
expression levels are lowered (figure 3.7b). This suggested serum does affect protein 
expression following transfection.  
 
The transfection optimisation was repeated using the lactadherin expression vector 
(pCMV6-XL4-lactadherin). Figure 3.8 shows western blots of both cell lysates and 
the culture supernatants of CHO cultures subjected to transfection using the 
recommended FuGENE® HD: DNA ratios, in the presence and absence of serum in 
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the media for culture. The blots were probed with mAb2767 for detection of 
lactadherin. Figure 3.8a, the supernatant from a serum containing culture shows 
visible lactadherin bands at all ratios of fuGENE® HD:DNA, but figure 3.8c the 
supernatant from a no serum culture shows little or no signal at any of the ratios. The 
cell lysate in the presence of serum (figure 3.8b) also shows higher expression than 
the no serum lysate (figure 3.8d), though both show some expression. Together this 
suggests that serum is required for optimal expression of lactadherin, in agreement 
with the reporter plasmid expression data for GFP expression. The results also 
indicate that although most of the lactadherin is retained in the cells, some is released 
into the supernatant, suggesting the possibility for later purification from culture 
supernatant. The highest levels of expression are seen at a transfection reagent: DNA 
ratio of 4:2, for detection of lactadherin expression in the cell lysate, mirroring the 
results of the reporter plasmid transfection, though the level of release of lactadherin 
into the supernatant is relatively uniform for all ratios. It is difficult however to be 
sure of whether serum albumin has affected detection of lactadherin by western blot 
and so whether it has interfered with interpretation of the supernatant detection data. 
With rHu-lactadherin detected at a molecular weight of around 47-50kDa, this 
suggested lactadherin had not been altered/had been altered only minimally by 
expression in the non-human CHO cell culture system with similar levels of 
glycosylation implied.  
 
The success of the transient expression of lactadherin was confirmed by an ELISA 
(figure 3.9) with supernatant from the 4:2 fuGENE® HD: DNA ratio transfection with 
serum, detected by association of HuMc3 and detection with anti-human HRP A0293. 
A concentration-dependent binding effect was suggested by a significantly (figure 
3.9a) higher binding signal for the HuMc3 concentration 2667nM than the 667nM 
concentration. This also showed that HuMc3 was able to bind to CHO cell expressed 
rHu-lactadherin, but any effects on affinity of recombinant expression of lactadherin 
still remained to be established. This data could however have been improved by the 
inclusion of an isotype control antibody to confirm the binding of HuMc3 to be 
specific and by the inclusion of more HuMc3 dilutions to support the concentration-
dependant binding conclusion. In addition the data would have been more supportive 
to the conclusions of the western blot data of figure 3.8 if all cell lysate and 
supernatant samples had been included. In retrospect, all of the data should have been 
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analysed in a sandwich ELISA with the use of mAb2767 as the first layer, to 
circumvent the problem of serum albumin interfering with interpretation of the data.  
 
Figure 3.4 
Flow diagram showing the process of transient transfection of pCMV6-XL4-lactadherin and 
pEGFP-C1 GFP reporter plasmid into CHO cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Identification of plasmids by RE digestion; 
 
pCMV6-XL4, with RE’s to sites in the MCS at either end of the insert; SmaI 
(CCCGGG) and SacI (GAGCTC). Expected lactadherin cDNA (figure 3.5c) insert 
size 2100bp. 
. 
 
pEGFP-C1, with RE’s to either end of the GFP tag sequence; NheI (GCTAGC) and 
EcoRI (GAATTC). Expected GFP tag (appendix 2) sequence size 722bp 
Plasmid DNA purification of an overnight culture, created from a single colony 
of transformed E.coli. 
Plasmid DNA concentration and purity determination by the OD260nm and 
relative OD260nm:OD280nm respectively, with acceptable purity as near to 2:1 as 
possible. 
Transfection optimisation with pEGFP-C1, 
using a lipofection reagent fuGENE® HD at a 
range of fuGENE® HD: DNA ratios. 
Detection of transfection efficiency as 
fluorescence (395nm excitation and 509nm 
emission) of both cell lysate and cell supernatant 
of all transfection/culture conditions, due to GFP 
tag expression. 
Transfection optimisation with pCMV6-XL4, 
using a lipofection reagent fuGENE® HD at a 
range of fuGENE® HD: DNA ratios. 
Detection of transfection efficiency by 
western blotting of cell lysate and cell 
supernatant samples of all transfection/culture 
conditions, with an anti-lactadherin antibody 
Cells cultured for 48 hours in media in the presence and absence of foetal bovine serum to detect 
whether the presence of serum affects protein expression. 
Transformation of competent E.coli with plasmids pCMV6-XL4 (lactadherin 
cDNA insert) and pEGFP-C1 (GFP reporter plasmid), using two antibiotics for 
selection of transformants; 
 
One to which the E.coli strain confers resistance 
 
One to which the plasmid confers resistance 
 Figure 3.5 
Plasmid pCMV6-XL4-Lac and GFP reporter plasmid pEGFP
(a) DNA gel of the 4707bp pCMV6
following cleavage with restriction enzymes Sma
SacI double digest, 2 SmaI single digest, 3 SacI single digest, 4 uncut plasmid.
(b) DNA gel of pEGFP-C1, cut with restriction enzymes NheI and EcoRI. Loading order; 
hyperladder I, 1 NheI, EcoRI
plasmid. (c) cDNA sequence of the 2100bp pCMV6
the results of two separate experiments.
(a)    
 
        
 
(c) 
 
Red = 5’untranslated region (UTR) 
Black = lactadherin open reading frame (ORF)
Blue = 3’ untranslated region (UTR) 
Green = translation start codon (when transcribed)
Orange= translation stop codon (when transcribed)
GGTCAGCATTTGTATACGACTCACTATAGGCGGCCGCGNAATTCGCACGAGGGTCTGAGC
AGCCCAGCGTGCCCATTCCAGCGCCCGCGTCCCCGCAGC
GCCGCGCTGTGCGGCGCGCTGCTCTGCGCCCCCAGCCTCCTCGTCGCCCTGGATATCTGT
TCCAAAAACCCCTGCCACAACGGTGGTTTATGCGAGGAGATTTCCCAAGAAGTGCGAGGA
GATGTCTTCCCCTCGTACACCTGCACGTGCCTTAAGGGCTACGCGGGCAACCACTGTGAG
ACGAAATGTGTCGAGCCACTGGGCCTGGAGAATGGGAACATTGCCAACTCACAGATCGCC
GCCTCGTCTGTGCGTGTGACCTTCTTGGGTTTGCAGCATTGGGTCCCGGAGCTGGCCCGC
CTGAACCGCGCAGGCATGGTCAATGCCTGGACACCCAGCAGCAATGACGATAACCCCTGG
ATCCAGGTGAACCTGCTGCGGAGGATGTGGGTAACAGGTGTGGTGACGCAGGGTGCCAGC
CGCTTGGCCAGTCATGAGTACCTGAAGGCCTTCAAGGTGGCCTACAGCCTTAATGGACAC
GAATTCGATTTCATCCATGATGTTAATAAAAAACACAAGGAGTTTGTGGGTAACTGGAAC
AAAAACGCGGTGCATGTCAACCTG
TACCCCACGAGCTGCCACACGGCCTGCACTCTGCGCTNTGAGCTACTGGGCTG
AACGGATGCGCCAATTCCCCTGGCCTGAAGAATAACAGCATCCTGACAAGCAGACACGGC
CTTCAGCAGCTACAAGACCTGGNGCTNGCATCTCTTCAGCTGGAACCCTNCTATGCACGG
CTGGCAA 
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-C1 identification by restriction digest. 
-XL4 plasmid vector with a human lactadherin cDNA insert 
I and SacI. Loading order; M, hyperladder I, 1 Sma
 
 double digest, 2 NheI single digest, 3 EcoRI single digest, 4 uncut 
-XL4 plasmid insert. Figure data representative of 
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Figure 3.6 
Optimisation of CHO cell transfection with GFP reporter plasmid pEGFP-C1 and fuGENE HD 
Optimisation of transient transfection of CHO cells with the GFP reporter plasmid pEGFP-C1, at a 
range of ratios of fuGENE® HD lipofection reagent to plasmid DNA of 3:2, 4:2, 5:2, 6:2, 7:2 and 8:2, 
with serum-containing media for expression. (b) Protein expression detected as corrected fluorescence 
of cell lysate, (395nm excitation and 509nm emission). Displayed is data from three separate 
experiments and an average of the three (combo). Each error bar denotes 2-3 experimental repeats. 
Absorbance corrected to zero using no-DNA/no fuGENEHD controls. (a) Statistical data table 
displaying the average (combo) data and t-tests. 
 (a) 
 
Combo data       t-test 4:2/5:2 4:2/3:2 
 3:2 ratio 4:2 ratio 5:2 ratio 6:2 ratio 7:2 ratio 8:2 ratio t Stat 3.94 5.02 
N 9 9 8 9 9 8 P(T<=t) one-tail 6.54E-04 6.33E-05 
Mean 144.11 414.84 171.64 135.91 132.82 115.22 t Critical one-tail 1.75 1.75 
SD 29.60 159.17 74.93 70.97 95.64 104.23 P(T<=t) two-tail 1.31E-03 1.27E-04 
 
      t Critical two-tail 2.13 2.12 
 
(b) 
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Figure 3.7 
Optimisation of CHO cell transfection with GFP reporter plasmid pEGFP-C1 plus and minus serum 
Optimisation of transient transfection of CHO cells with the GFP reporter plasmid pEGFP-C1 at a 
range of ratios of fuGENE® HD lipofection reagent to plasmid DNA of 3:2, 4:2, 5:2, 6:2, 7:2 and 8:2, 
repeated with media, with and without serum for expression. (b) Protein expression detected as 
corrected fluorescence of cell lysate, (395nm excitation and 509nm emission). Displayed is data from 
two separate experiments and an average of the two (combo). Each error bar denotes 2-3 experimental 
repeats. Absorbance corrected to zero using no-DNA/no fuGENEHD controls. (a) Statistical data 
table displaying average (combo) data and t-tests. 
(a) 
 
Combo data 
         
Plus serum 
3:2 
ratio 
4:2 
ratio 
5:2 
ratio 
6:2 
ratio 
7:2 
ratio 
8:2 
ratio 
 
t-test 
 
4:2 + serum/4:2 – serum 
 
N 6 6 6 6 6 5 t Stat 9.68  
Mean 161.13 518.32 183.69 166.95 173.03 158.18 P(T<=t) one-tail 1.07E-06  
SD 18.92 44.48 84.64 67.42 93.88 113.40 t Critical one-tail 1.81  
       P(T<=t) two-tail 2.14E-06  
       t Critical two-tail 2.23  
Minus serum 
3:2 
ratio 
4:2 
ratio 
5:2 
ratio 
6:2 
ratio 
7:2 
ratio 
8:2 
ratio 
 
t-test 
 
4:2 – serum / 5:2 – serum 
 
4:2 – serum / 3:3 – serum 
N 6 6 6 6 6 6 t Stat 4.25 2.99 
Mean 88.64 204.60 84.81 52.90 33.23 34.58 P(T<=t) one-tail 8.45E-04 6.82E-03 
SD 68.71 65.73 21.12 17.09 12.44 32.40 t Critical one-tail 1.81 1.81 
 
      P(T<=t) two-tail 1.69E-03 1.36E-02 
 
      t Critical two-tail 2.23 2.23 
 
(b) 
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 Figure 3.8 
Optimisation of CHO cell transfection and detection of tran
(a-d) Western blots of supernatant and cell lysate samples from transfection of CHO cells with 
pCMV6-XL4-lactadherin at a range of ratios of transfection reagent to plasmid DNA, with incubation 
in the presence and absence of FBS
(diluted 1 in 80,000). (a) Culture supernatant with serum, (b) culture cell lysate with serum, (c) culture 
supernatant without serum, (d) culture cell lysate without serum.
fuGENE®HD: DNA ratios 3:2 (3), 4:2 (4), 5:2 (5), 6:2 (6), 7:2 (7), 8:2 (8), fuGENE
DNA only (D), no fuGENE® HD
experiments. 
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sient expression of rHu
. Blots probed with mAb2767 (13nM) and anti-mouse HRP A9917 
  Loading order; marker lane (M), 
 or DNA (N). Figure data representative of the results of two separate 
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Figure 3.9 
Detection of transient expression of rHu-lactadherin  
(b) ELISA to detect binding of HuMc3 (2667, 1333 and 667nM) to transiently expressed rHu-
lactadherin (supernatant from the 4:2 fuGENE® HD: DNA ratio transfection with serum), with milk 
sourced lactadherin (HMFG) positive control. Binding detected with anti-human peroxidase A0293 
(diluted 1 in 40,000). Displayed is data from three separate experiments and an average of the three 
(combo). Each error bar denotes 2/3 experimental repeats. Absorbance corrected to zero using no-
lactadherin/no HuMc3 controls. (a) Statistical data table displaying the average (combo) data and t-
tests. 
(a) 
 
Combo data   
  
       
  
Sample 
+HuMc3 
(2667nM)  
Sample 
+HuMc3 
(1333nM) 
Sample 
+HuMc3 
(667nM) 
Milk lac + 
HuMc3 
(2667nM) 
t-test Sample + HuMc3 
(2667nM)/sample + 
HuMc3 (1333nM) 
Sample + HuMc3 
2667nM/sample + 
HuMc3 667nM 
N 9 8 8 3 t Stat 2.01 3.65 
Mean 0.09 0.05 0.03 0.28 P(T<=t) one-tail 0.03 1.20E-03 
SD  0.04 0.03 0.02 0.11 t Critical one-tail 1.75 1.75 
 
    P(T<=t) two-tail 0.06 
 
2.39E-03 
 
    t Critical two-tail 2.13 2.13 
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3.2.3 Stable expression of rHu-lactadherin 
 
As transient expression of rHu-lactadherin had proved successful and any altered 
glycosylation of lactadherin did not impede binding of HuMc3, a stable expression 
was attempted (figure 3.10). The pCMV6-XL4 plasmid unfortunately did not contain 
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a resistance gene suitable for mammalian cell selection, so it was decided to remove 
the gene and insert it into pcDNA4/TO/myc-his-A (appendix 3). The vector was 
selected for stable transfection due to the presence of a strong viral promoter CMV 
suitable for expression in CHO cells, allowing maximal gene expression, [273]. Also 
included was a polyadenylation signal needed for cleavage and polyadenylation of the 
plasmid. The main advantage over the pCMV6-XL4 plasmid was the presence of a 
mammalian selection gene conveying resistance to zeocin, as well as the addition to 
the protein of c-myc (EQKLISEEDL) and poly-histidine (6XHis) tags for ease of 
purification.  
 
The first step in this process involved PCR-amplification of the lactadherin cDNA 
open reading frame (ORF) from pCMV6-XL4 (section 2.2.7.3). This was carried out 
using primers (section 2.1.6) designed to anneal with the first 15bp at either end of the 
lactadherin insert ORF (figure 3.11a), but with an addition of a short 5bp sequence to 
add HindIII and XhoI restriction sites to aid ligation into the new vector (appendix 3). 
The PCR was carried out with a gradient of annealing temperatures of 55◦c +/-10◦c 
and the products run on a diagnostic DNA gel shown in figure 3.12a with inclusion of 
a DNA ladder, hyperladder I. Two bands can be observed for each annealing 
temperature, a stronger band at around 1164bp, the size of the lactadherin ORF 
sequence (figure 3.11a) and a weaker band can be seen at below 200bp, the primer 
sequences. The strongest lactadherin band and so the one with the most DNA occurs 
at the highest annealing temperature used, 65ºC.  
The DNA from the PCR as well as the new pcDNA4/TO/myc-his-A vector were 
doubly digested with restriction enzymes HindIII and XhoI (section 2.2.7.7.3) to 
create overhanging ends for the later ligation step and were run on a DNA gel (section 
2.2.7.5) and gel extracted (section 2.2.7.8) to obtain pure insert and cut vector DNA. 
The products of the gel extraction are shown in a diagnostic DNA gel in figure 3.12b 
with lane 1 showing pure cut plasmid with the expected size of just under 5100bp 
(appendix 3) and lanes 2 and 3 pure cut PCR product lactadherin ORF insert at around 
1164bp. A ligation of the insert and cut plasmid was next carried out (section 2.2.7.9) 
and the DNA transformed into E.coli XL1-blues (section 2.2.7.2), grown on 
tetracycline and ampicillin 2TY agar to aid selection and 10 colonies were picked and 
used to create 5ml overnight cultures (section 2.2.7.4). Colony PCR reactions were 
carried out for each of the overnight cultures (section 2.2.7.4) using the lactadherin 
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ORF primers (section 2.1.6), to confirm the presence of the insert and so the success 
of the ligation. All of the colonies were indicated to carry the pcDNA4/TO/myc-his-
A-lactadherin plasmid, shown in a diagnostic DNA gel in figure 3.12c as a band at 
1164bp for the insert, with a weak band at below 200bp, the primers.  The plasmid 
DNA of five of the overnight cultures was then purified (section 2.2.7.6) and a 
HindIII and XhoI double digest (section 2.2.7.7.4) carried out as a second method of 
confirming the identity of the insert, shown in figure 3.12d as a diagnostic gel. The 
digest products for the five colonies appear in lanes 1-5 and uncut plasmid lane 6. The 
insert and cut plasmid run at the expected size of 1164bp and 5100bp respectively and 
the uncut plasmid slightly larger than the digested plasmid at approximately 6264bp; 
the size of the cut plasmid and insert combined. To further confirm the presence of the 
insert and to show it to be whole and undamaged and fused with the purification tags 
(figure 3.11), DNA sequence analysis should have been carried out, but this was 
unfortunately omitted. 
 
The pcDNA4/TO/myc-his-A-lactadherin plasmid was transfected into CHO cells 
(section 2.2.7.11) using the 4:2 ratio of fuGENE®HD transfection reagent to plasmid 
DNA optimised in the transient transfection, with the presence of serum in the media 
to maintain viability of the transfectants and the antibiotic zeocin to aid selection of 
transfected cells. After two weeks, most of the cells were dead but patches of live 
cells remained. The cells were then maintained on complete media with lower levels 
of zeocin to enable the plasmid DNA to be retained. As sufficient lactadherin was 
detected in the supernatant it was not initially deemed necessary to develop single cell 
lines and lactadherin was expressed from a mixed cell population. For protein 
expression verification and later larger scale expressions for purification the complete 
media was removed and a serum free media was added for 2-3 days before collection 
of the supernatant. This was carried out as the transient expression studies had not 
ruled out the possibility that serum albumin may complicate lactadherin detection and 
purification. Figures 3.13a and 3.13b show respectively a western blot and ELISA to 
detect lactadherin expression by a transfected, mixed CHO cell population. The 
western blot detected with mAb2767 and a peroxidase-conjugated secondary (A9917) 
verified the presence of lactadherin in the cell lysate (lane 4) and supernatant (lane 3) 
with a clear band and just visible one respectively suggesting lactadherin expression 
at around 55kDa, but with lower levels of release. 
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Figure 3.10  
Flow diagram showing the process of cloning of the lactadherin ORF into pcDNA4/To/myc-hisA 
and stable transfection into CHO cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCR, to clone the ORF of lactadherin from the lactadherin cDNA insert 
containing-pCMV6-XL4,  
 
Primers used containing the first 15 bp of the beginning and end of the 
lactadherin ORF (figure 3.11a), with addition of HindIII (AAGCTT) and XhoI 
(CTCGAG) RE cleavage sites. 
RE cleavage of modified lactadherin ORF and pcDNA4/To/myc-hisA plasmid 
DNA, with HindIII and XhoI RE’s to create “sticky ends,” for later ligation.  
HindIII and XhoI RE cleavage products run on a DNA gel and the cut 
lactadherin ORF and pcDNA4/To/myc-hisA plasmid bands isolated, gel 
extracted and purified.  
Ligation of pure cut lactadherin ORF and pcDNA4/To/myc-hisA plasmid  
Transformation of competent E.coli with the pcDNA4/To/myc-hisA-lactadherin plasmid using two 
antibiotics for selection of transformants; 
 
One to which the E.coli strain confers resistance 
 
One to which the plasmid confers resistance 
 
Colony PCR of transformants, using overnight cultures of single colonies, with the lactadherin ORF 
primers described above. 
 
Detection of insert ligation and transformation success, by DNA gel of colony PCR product.  
 
Expected cut lactadherin ORF insert size; 1164bp (figure 3.11a). 
Detection of insert ligation and transformation success by RE digest with HindIII and XhoI RE’s to 
release the insert and identification on a DNA gel. 
 
 Expected cut lactadherin ORF insert size; 1164bp (figure 3.11a). Expected cut plasmid size; 5100bp 
(appendix 3). 
Transfection of CHO cells using conditions optimised in the transient transfection 
Selection of transfectants by addition to the media zeocin, to which the pcDNA4/To/myc-hisA plasmid 
confers resistance. 
Plasmid purification and plasmid DNA concentration and purity determination by the OD260nm and 
relative OD260nm:OD280nm respectively, with acceptable purity as near to 2:1 as possible. 
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Figure 3.11 Proposed lactadherin-c-myc-poly-His gene and protein fusion sequences 
(a) The gene fusion sequence.  Included are the 1164bp ORF from the pCMV6-XL4 plasmid and the 
linker and purification tag sequences of pcDNA4/TO/myc-his-A. (b) The protein fusion sequence. 
Included are the lactadherin protein sequence as well as linker and c-myc and polyHis tag sequences.  
 
(a) 
 
Green = translation start codon (when transcribed) 
Black = lactadherin ORF 
Dark blue = linker sequences 
Orange  = c-myc epitope 
Pale blue = polyhistidine (6XHis) region 
Magenta = stop codon (when transcribed) 
 
ATGCCGCGCCCCCGCCTGCTGGCCGCGCTGTGCGGCGCGCTGCTCTGCGCCCCCAGCCTCCT 
CGTCGCCCTGGATATCTGTTCCAAAAACCCCTGCCACAACGGTGGTTTATGCGAGGAGAT 
TTCCCAAGAAGTGCGAGGAGATGTCTTCCCCTCGTACACCTGCACGTGCCTTAAGGGCTAC 
GCGGGCAACCACTGTGAGACGAAATGTGTCGAGCCACTGGGCCTGGAGAATGGGAACAT 
TGCCAACTCACAGATCGCCGCCTCGTCTGTGCGTGTGACCTTCTTGGGTTTGCAGCATTGGG 
TCCCGGAGCTGGCCCGCCTGAACCGCGCAGGCATGGTCAATGCCTGGACACCCAGCAGCAA 
TGACGATAACCCCTGGATCCAGGTGAACCTGCTGCGGAGGATGTGGGTAACAGGTGTGGTG 
ACGCAGGGTGCCAGCCGCTTGGCCAGTCATGAGTACCTGAAGGCCTTCAAGGTGGCCTACA 
GCCTTAATGGACACGAATTCGATTTCATCCATGATGTTAATAAAAAACACAAGGAGTTTGTG 
GGTAACTGGAACAAAAACGCGGTGCATGTCAACCTGTTTGAGACCCCTGTGGAGGCTCAGTA 
CGTGAGATTGTACCCCACGAGCTGCCACACGGCCTGCACTCTGCGCTNTGAGCTACTGGGCTG 
CTCGAGTCTAGAGGGCCCTTC GAACAAAAACTCATCTCAGAAGAGGATCTG AATATGCATACCG 
GTCATCATCACCATCACCATTGA 
 
(b) 
 
Red = signal sequence (1-23) 
Blue = EGF-like domain (24-67) 
Pink = cell adhesion sequence (46-48) 
Green = C1 domain (70-225) 
Orange = C2 domain (230-387) 
Black = inter-domain sequence 
Blue = additional linker sequence and tags 
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         c-myc tag        polyHis tag 
 Figure 3.12 
Cloning of human lactadherin cDNA into a pcDNA4/TO/myc
(a). DNA gel showing the products of a temperature gradient PCR amplification of lactadherin ORF 
from pCMV6-XL4-lactadherin with addition of restriction sites to aid annealing with pcDNA4/TO/myc
his A.  Loading order numbers denote the 
(b) DNA gel of pcDNA4/TO/myc
HindIII and XhoI double digest,
(c) DNA gel of colony PCR product of plasmid DNA from 10 XL1
ligated pcDNA4/TO/myc-his A–
(d) DNA gel of a Hind III/XhoI 
1-5) and a control of linearised
results of a single experiment. M in all data is hyperladder I DNA ladder.
(a)    
 
(c)    
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-his-A plasmid vector
approximate annealing temperatures used. 
-his A (lane 1) and the PCR product (lanes 2 and 3) following a 
 gel extraction and purification.  
-blue colonies transformed with 
lactadherin DNA.  
double digest of plasmid DNA from colonies 6-10 of figure 3.10c (l
 (just HindIII) plasmid DNA (lane 6). Figure data representative of the 
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Figure 3.13 
Detection of stable transfection of pcDNA4/TO/myc-his-A-lactadherin into CHO cells, and 
expression of rHu-lactadherin 
(a) Western blot and (b) cell ELISA of supernatant (snt) and cell lysate (lte) from cultures of 
pcDNA4/TO/myc-his A-lactadherin transfected (tfected) CHO cells. Blot probed with mAb2767 (13nM) 
and A9917 (diluted 1 in 80,000). Loading order; 1, untransfected CHO cell supernatant, 2 
untransfected CHO cell lysate, 3 transfected CHO cell supernatant, 4 transfected CHO lysate, 5 
commercial pure recombinant lactadherin (2170nM). Blot data representative of two separate 
experiments. (b)(ii) ELISA probed with HuMc3 (167nM) and A0293 (diluted 1 in 40,000). Controls 
include commercial recombinant lactadherin (109nM) and cell lysate and supernatant from 
untransfected (utfected) CHO cells. Displayed is data from two separate experiments and an average 
of the two (combo). Each error bar denotes 3 experimental repeats. Absorbance corrected to zero 
using no-HuMc3/no lactadherin controls. (b)(i) Statistical data table displaying the average (combo) 
data and t-tests. 
(a) 
 
 
 
 
 
 
 
 
 
(b)(i) 
Combo data   
    
       
Statistics Tfted snt Tfted lte Pure rec lac Utfected snt Utfected lte 
 
t-test 
Tfted snt/ 
utfected snt 
Tfted lte/ 
utfected lte 
N 6 6 6 6 6 t Stat 12.85 9.44 
Mean 0.35 0.58 0.38 0.08 0.09 P(T<=t) one-tail 7.64E-08 1.34E-06 
SD 0.03 0.12 0.10 0.04 0.05 t Critical one-tail 1.81 1.81 
 
     P(T<=t) two-tail 1.53E-07 2.69E-06 
 
     t Critical two-tail 2.23 2.23 
    (ii) 
 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
Exp 1 Exp 2 Combo
Co
rr
ec
te
d 
ab
s
o
rb
an
c
e 
(45
0n
m
)
Tfected snt Tfected lte Pure rec lac
Utfected snt Utfected lte
 
 
 
100 
72 
 
55 
 
40 
 
33 
 
24 
 
 
 
 
17 
 
 
           M             1        2         3         4        5       
Lactadherin 
55kDa 
 127
Controls included were cell lysate (lane 2) and supernatant (lane 1) from an 
untransfected CHO line as negatives and a commercial rHu-lactadherin (lane 5) 
positive control. The ELISA, with the same controls used as in the blot, but with 
detection using HuMc3, confirmed significant levels of expression of lactadherin by 
the CHO cells and significant release into the supernatant (figure 3.13bi). The 55kDa 
molecular weight of lactadherin was higher than the 47kDa of the milk lactadherin 
and that observed for the transient expression of rHu-lactadherin of around 47-50kDa. 
The elevated molecular weight may be partially accounted for by the addition of the 
two tags; poly-His and the c-myc epitope tag and intervening protein sequence 
totalling 3.4kDa (figure 3.11b). It is likely the remaining difference may be accounted 
for by altered glycosylation occurring as a result of use of a non-human expression 
cell line and potentially by the addition of O-linked glycan chains. The latter may 
have occurred by the addition of serine and serine residues as part of the tags and/or 
additional linker sequences (figure 3.11b). There are a total of three potential O-linked 
glycosylation sites within the additional protein sequence, with the addition of two 
serine residues at positions 390 and 400 and one threonine residue at position 407 
(figure 3.9b). In particular the addition of a serine (390), positioned three residues 
upstream of a proline residue (figure 3.11b) is likely to produce O-linked 
glycosylation based on past studies analysing O-linked glycosylation frequency [274].  
Aliquots of the mixed cell population were frozen early on and were used for 
expression and purification of lactadherin. Unfortunately however the expression of 
lactadherin by these cells dwindled, despite the use of frozen stocks. The western blot 
of figure 3.13a represents one of the latter cultures. From this, the low expression of 
the latter cultures is evident, with weak bands both for the cell lysate and supernatant. 
This suggested the loss of cells with lactadherin expression despite inclusion of 
recommended levels of zeocin in the media, perhaps due to the growth advantage of 
cells which had retained the plasmid zeocin gene but not an active lactadherin gene 
due to the way in which the plasmid DNA integrated into the genome.  
 
3.2.4 Purification of rHu-lactadherin 
 
Purification of rHu-lactadherin was attempted by several methods. The first was a size 
exclusion chromatography of 10-fold concentrated tissue culture supernatant carried 
out with a BioRad system using a Superdex™200 column (section 2.2.2.9). The size 
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exclusion trace showed three protein peaks, with the second corresponding with the 
molecular weight of lactadherin (data not shown). Figure 3.14a shows a coomassie-
stained SDS-PAGE gel and figure 3.14b a western blot (probed with mAb2767) of 
samples eluted from the column corresponding with the second protein peak. From 
the gel it can be observed that the purification of lactadherin was not successful. 
Although strong bands near the molecular weight of lactadherin at just above and 
below 55kDa (shown boxed) are present in the later column fractions (lanes 11-15), a 
smear of other protein bands still remain. The western blot suggests that neither of 
these bands are actually lactadherin as each appears to run a little higher and a little 
lower than that observed for the anti-lactadherin blot and as the banding patterns do 
not match that of the anti-lactadherin blot, with the strongest lactadherin bands at 
lanes 5-8, near the start of the protein peak for the blot, whereas the bands in the 
coomassie-stained SDS-PAGE gel appear most strongly at lanes 11-15. The western 
blot indicates some enrichment of lactadherin occurring at just below the 55kDa 
marker (shown boxed), with stronger bands at lanes 5-8 than in the pre-column 
sample (lane 1), but with no prominent band visible in the coomassie-stained SDS-
PAGE gel at the molecular weight of lactadherin, just a series of weak bands 
throughout the gel, this suggested there are many proteins of a similar native size in 
the CHO culture media, so size-exclusion chromatography was not a suitable first step 
for purification of this protein and a more discriminating method would be therefore 
needed. The next method attempted was an affinity purification (sections 2.2.2.5 and 
2.2.2.7) taking advantage of the c-myc tag added by the new pcDNA4/TO/myc-his-A 
plasmid expression vector. An anti-myc column formed by the covalent cross-linking 
of a murine anti-myc antibody 9E10 to protein-G sepharose, was used for its specific 
association with the c-myc tag of rHu-lactadherin. Samples collected during the 
purification were analysed by a coomassie-stained SDS-PAGE gel (figure 3.14c) and 
anti-lactadherin antibody mAb2767 probed western blot (figure 3.14d). The western 
blot indicated lactadherin bound specifically to the column with little lactadherin in 
the flow through (lane 1) and none in the column wash material (lane 2), but with 
detection in the glycine elutions (lanes 3-11), with a double band observable at just 
below 55kDa. This also suggested the c-myc tag was present in the expressed protein. 
A band could not however be observed at the same molecular weight in the gel, with 
the only visible band at a higher molecular weight around 70kDa, likely to be residual 
bovine serum albumin in the culture media . The presence of this contaminant in the 
 product of purification indicated this method may not be the most suitable for rHu
lactadherin purification as albumin has been shown to 
recombinant protein-G used to make commercially available protein
despite removal of the albumin
remove the BSA prior to application to the anti
have been possible if no other
 
Figure 3.14 
Attempted purification of rHu-
(a) Coomassie-stained SDS-PAGE gel and 
chromatography purification samples. 
80,000). Loading order for (a) and (b); 1, before column sample, 2
protein peak. (c) Coomassie stained SDS
sepharose column, lactadherin purification samples. Blot probed 
(diluted 1 in 80,000). Loading order for (c) and (d);1 flow through, 2 wash, 3
3.0 elutions, 10-13 pH 3.5 elutions. Figure data representative of a single experiment.
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IMAC column (sections 2.2.2.5 and 2.2.2.6). Initially a similar small-scale 
purification was carried out as for the anti-c-myc column. The results (not shown) 
indicated specific binding of lactadherin to the column and enrichment by a mAb2767 
blot, but only a very weak band could be seen on the gel. As no contaminating bands 
were evident as for the 9E10 purification, the IMAC purification was therefore scaled-
up with a much larger starting volume of 3L of culture supernatant rather than the 
0.5L used in the previous purification attempts. Samples collected were analysed on a 
coomassie-stained SDS-PAGE gel (figure 3.15a) and blotted with detection with 
mAb2767 (figure 3.15b), an anti-poly histidine antibody (figure 3.15c) and an anti-
myc antibody (figure 3.15d). The gel indicated and the three blots confirmed the 
success of the purification. The lactadherin double band is boxed in all figures at 
around 55kDa, with some lactadherin in the starting material and in the flow through 
suggesting not all of the lactadherin was captured by the column, but with much 
stronger bands for elutions 1-4 (lanes 4-7) suggesting enrichment of lactadherin. The 
strongest lactadherin elution bands in the gel and blots occur at elutions 1-4 (lanes 4-
7), though some lactadherin is detected in elutions 5-7 (lanes 8-10). The three blots 
were carried out to be sure of the identity of lactadherin and also to confirm the 
presence of the two tags in the expressed protein, with a control poly-His and c-myc 
tagged protein included as a positive control, visible in lane 14 of figure 3.15c-d. The 
gel showed lactadherin to be by far the most prominent band in elutions 1-7, with 
relatively low levels of contamination by other bands at a range of sizes, but to be no 
more highly represented than other proteins in the starting material (lane 1), indicating 
the success of the purification. The presence of other protein bands in the purification 
product suggested however the need for a further protocol for full purification.  To 
complete the purification elutions 1-3 were pooled and separated on a size exclusion 
column with a separation range of 10,000-600,000kDa (section 2.2.2.9). The plot 
shown in figure 3.16a displays elution time, (minutes) against protein absorbance 
(214nm). Detected are three protein peaks with red, blue and black arrows 
respectively showing the boundaries of peaks 1-3 and a large fourth peak for the small 
molecule imidazole present as a result of elution in the previous purification stage. 
Peak 1 represents proteins of above the 600,000kDa range, known as the void. Peaks 
two and three represent proteins around the size of a lactadherin-fusion protein 
monomer (approximately 50-55kDa) and dimer (approximately 100-110kDa). All 
protein peak molecular weights were deduced through matching elution volume to 
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molecular weight using a molecular weight elution volume standard curved formed 
from molecular weight standards run before the purification (appendix 4). Samples 
collected from the three peaks were run on an SDS-PAGE gel and blotted with 
detection by mAb2767, shown as figures 3.16b-e, again with the peak boundaries 
revealed by the coloured arrows as previously described. All demonstrate the presence 
of lactadherin, but the first peak, is the only one with the characteristic lactadherin 
double band (figure 3.16b-c). This, together with the above 600,000kDa molecular 
weight suggested the presence of lactadherin in a large structure, likely expression in 
the form of vesicles as has been described in past work [152]. The absence of the 
double band in the blot data for peaks two (figure 3.16d) and three (figure 3.16e) 
suggested free lactadherin in both monomeric and dimeric form occurs in only one of 
the two variant sizes of lactadherin that usually form the double band. This data 
therefore suggested lactadherin is present free as both a monomer and dimer, as well 
as in the form of vesicles. Figure 3.17 shows a coomassie-stained SDS-PAGE gel of 
pooled, concentrated samples from the protein peaks. The peak 2 well is the only well 
with visible levels of what appears to be lactadherin, by the presence of a band at just 
above 55kDa. Although western blots were produced of all samples in figure 3.16, a 
blot of this gel should have been carried out to be absolutely sure of the identity of 
this protein, as it appears on the coomassie gel at a slightly higher level than that 
observed for the peak two anti-lactadherin blot. As it corresponds with the most 
prominent band of the IMAC purification product (lane 1), it is however fairly likely 
to be this protein. As a second-step purification technique, size exclusion 
chromatography therefore appears to have been relatively successful, with only one 
contaminant at low levels in the peak-two purification product.  
 
Although the double purification by IMAC and size exclusion chromatography 
appeared to have near to completely purified rHu-lactadherin, protein was lost during 
each purification step. The yield of partially pure lactadherin from the IMAC column 
was approximately 2mg/L, but the yield of pure lactadherin from the two-step 
purification, (taking into account not all of the IMAC column product was added onto 
the size exclusion column), was the equivalent of less than 0.1mg/L, showing a 
considerable loss at this stage. Losses from the first purification step were also 
apparent through detection of lactadherin in the column flow though (figure 3.15b-d), 
though the flow-though was retained so the lactadherin was not actually lost. 
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This purification method showed lactadherin to be present in three protein peaks, not 
only that of the expected molecular weight. The first attempt at purification of rHu-
lactadherin by size exclusion chromatography of culture supernatant as a first step in 
the purification (figure 3.14a-b) may therefore have resulted in inadvertent loss of 
lactadherin, as lactadherin was likely to be present in the two other principle peaks 
observed in the size exclusion trace. It is not however possible to confirm this as the 
trace was not retained. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3.15 
IMAC purification by His-tag of rHu
(a) Coomassie-stained SDS-PAGE gel and (b)
purification of rHu-lactadherin. (b) Probed for detection of lactadherin with mAb2767 (13.3nM) and 
A9917 (diluted 1 in 80,000), (c) probed for detection of his
for detection of myc-tag with 9E10 (diluted 1 in 10) and A9917 (1 in 80,000).   Loading order for (a) 
and (b); 1, before column sample, 2 flow
and (d); 1, before column sample, 2 flow through, 3 wash, 4
(poly-His and myc tag positive control 
separate experiments and (c) and (d) data, a single experiment.
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-lactadherin from CHO-lactadherin supernatant 
-(d) western blots of samples collected during IMAC 
-tag with A7058 (1 in 4000) and (d) probed 
-through, 3 wash, 4-14 column elutions. Loading order for (c) 
-13 column elutions, 14 a human scFv 
– unknown conc). (a) and (b) data representative of two 
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 Figure 3.16 
Second purification step for rHu
and Superdex™ 200 column. 
(a) The 214nm protein absorbance trace for fractions collected during size exclusion chromatography 
of the product of IMAC purificat
(minutes). Three protein peaks
fractions collected from the three protein peaks identified as peak 1 (red arrow), peak 2 (blue arrow) 
and peak 3 (black arrow) Blots probed for detection of lactadherin with mAb2767(13nM
(diluted 1 in 80,000). Loading order; B4 = pre
numbers as they appear on the absorbance trace. Figure data representative of a single experiment.
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-lactadherin; size exclusion chromatography using a BioRad system 
ion (IMAC elutions 1-3). Absorbance is plotted against elution time 
 are shown with red, blue and black arrows. (b)-(e) Western blots of 
-column sample, followed by column elution fraction 
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 Figure 3.17 
Analysis of purity of lactadherin from IMAC and size exclusion chromatography double purification
Coomassie-stained SDS-PAGE gel of pooled, (X10) concentrated, protein peak samples from the 
lactadherin size exclusion chromatography column. L
p2 peak 2, p3 peak 3. Figure data representative of the results of a single experiment.
 
 
 
                                                                                 
3.2.5 Expression, purification and thermostability analysis of HuMc3
 
HuMc3 was obtained from Access 
Sp2/0-Ag14 stably transfected with pAH4604 an pAG4622. Optimal growth 
conditions were determined to be a cell density of between 0.5 X 10
cells/ml (data not shown) in a protein free hybridoma med
antibiotics. Figure 3.18a shows the results of a sandwich ELISA to detect the presence 
of human/humanised IgG in the culture supernatant, with coating of unconjugated 
anti-human antibody and detection with anti
human IgG positive control. HuMc3 could clearly be seen to be expressed, with the 
average concentration of HuMc3 detected in the tissue culture supernatant calculated 
using human IgG standard curves (data not shown) to be approximately 173nM 
(26mg/L). This appeared high relative to the 10mg/l reported for a Sp2/0 cell line 
expressing an anti-c-erb B
reported levels of 100mg/L by hybridoma cultures [273]. The levels produced were 
however sufficient to supply the needs of all preclinical work.
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HuMc3 was purified from concentrated conditioned media by affinity 
chromatography using protein-G sepharose beads to permit binding via the Fc (section 
2.2.2.8). Samples collected during the purification are shown in figure 3.18bi as a 
coomassie-stained SDS-PAGE gel and 3.18bii as a western blot probed with anti-
human HRP antibody A0293. Lane 1 the pre-column sample can be observed to 
contain the heavy and light chains of HuMc3, shown as bands at around 50 and 
25kDa respectively in the gel and confirmed by western blot. Also present in the pre-
column sample are other protein bands of a range of molecular weights. All of the 
non-HuMc3 components remain in the flow through (lane 2) in which little of the IgG 
bands are visible. There is however some HuMc3 present in the wash buffer, detected 
in the blot but not the gel. HuMc3 elutions are shown in lanes 4-13 in which HuMc3 
can be observed to have been enriched with much stronger bands than in the pre-
column sample. The purity of the elutions also appears to be fairly high with only two 
other visible bands in the gel at 33kDa and just below 24kDa, which are weak, with 
no signs of enrichment from the pre-column sample. The presence of these bands may 
reflect the need for more washing of the column to remove non-specifically bound 
protein, suggested by the fact that other attempts showed no observable other bands in 
the elutions (data not shown).  This indicated that although some HuMc3 was lost in 
the flow-through and washes, overall the purification was successful with little 
apparent loss of protein and with nearly pure elutions. The protein yields for the single 
protein-G sepharose purification averaged at around 18mg/L. With the supernatant 
containing around 26mg/L, this suggested a loss of 8mg/L (31%). As however the 
column flow-through was recovered and the protein-G purifications repeated, little 
HuMc3 was in reality lost. The loss of some HuMc3 in the flow-through of the 
column suggested a surplus of HuMc3, indicating the bed volume of beads should 
have been increased or supernatant volume reduced for full purification in one step. 
 
To create 100% purity HuMc3, the product of protein-G sepharose purification was 
run on a size exclusion Superdex™200 column which has a separation range of 
between 10,000 and 600,000kDa (section 2.2.2.9). The protein absorbance at 280 and 
214nm was recorded for each column elution fraction and is shown plotted against 
elution time in figure 3.19. The pre-column sample can be seen to be nearly 
completely pure. A sharp peak (peak 1) eluted at between approximately 65 and 75 
minutes was determined to occur at around the molecular weight of the whole native 
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IgG (150 kDa) using the elution volume of the peak and known elution volumes of 
molecular weights standards used to form a standard curve (data not shown). A 
second shallower peak (peak 2) eluted later at approximately 120-130 minutes 
represents the lower molecular weight impurities. The peak 1 samples were pooled for 
a 100% purity sample. Little, if any protein loss was observed for the second 
purification step.  
 
A thermostability assay (section 2.2.4) was carried out for HuMc3 to find out the 
temperature ranges within which it could maintain full association with its target. 
Samples of HuMc3 were subjected to a range of temperatures between 0 and 100ºC 
for 10 minutes and binding to plate-coated lactadherin by ELISA assessed (figure 
3.20). Full binding was maintained until above 70ºC, at which point affinity dropped 
off sharply, agreeing well with past work with other IgG1 molecules [277]. A low 
level (approximately 30%) of association with lactadherin however remained after 
this point. It may have been useful to have carried out an isotype control experiment 
to determine if this effect was background association or actual residual specific 
binding. Only two experimental repeats were performed for this study with three 
replicates in each. The values determined for Tm were however close, indicating the 
confidence in this data may be high. 
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Figure 3.18 
Expression and purification of HuMc3 from Sp2/0-Ag14-HuMc3 cell culture 
(a)(ii) Sandwich ELISA to detect the presence of HuMc3 in the sp2/0-Ag14 culture supernatant (snt), 
with anti-human IgG unlabelled antibody I5260 (33.3nM) used for capture and anti-human peroxidase 
A0293 (1 in 40,000) detection. Controls included were an isotype-matched human IgG1 positive 
control (I Con 0.07 and 190nM). Shown is data from four separate experiments and an average 
(combo). Each error bar denotes 2-3 experimental repeats. Absorbance corrected to zero using a no-
HuMc3 control. (a)(i) Statistical data table displaying the average (combo) data and t-test. (b)(i) 
Coomassie-stained SDS-PAGE gel and (b)(ii) western blot of samples from a protein-G sepharose 
affinity purification of HuMc3 from culture supernatant. Blot probed for detection of human IgG with 
A0293 (1 in 100,000).  Loading order for (b)(i) and (ii); lane 1 pre- column sample, lane 2 flow 
through, lane 3 wash, lane 4-13 column elutions. Data representative of the results of 8 separate 
experiments. 
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Figure 3.19 
Second purification step for HuMc3; size exclusion chromatography using a BioRad system and 
Superdex™200 column 
Shown is data from the 280nm and 214nm protein absorbance trace for fractions collected during size 
exclusion chromatography of the product of protein-G sepharose purification of HuMc3 (1mg). Plotted 
is absorbance against elution time (minutes). A single clear protein peak is evident, with a second 
minor blip. Figure data representative of the results of a single experiment. 
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Figure 3.20 
Thermostability assay to determine the melting temperature of HuMc3 
(a) Binding ELISA to detect association with lactadherin (109nM), samples of HuMc3 (6nM) heat 
treated for 10 minutes at temperatures between 0 and 100ºC. Association detected with an anti-human 
peroxidase A0293 (diluted 1 in 40,000). Displayed is data from two separate experiments. Each error 
bar denotes 3 experimental repeats. Absorbance corrected to zero using no-HuMc3/no-lactadherin 
controls. (b) Statistical data table displaying the average (combo) melting temperature (Tm) data. 
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(b) HuMc3 melting temperature (Tm) 
 
 
N 2 
Mean 72.05 
SD 1.48 
 
 
 
 
 
 
Curves fitted by Sigmaplot11.0  using the equation sigmoidal sigmoid, 4 parameter. Exp 1 Normality test (Shapiro-Wilk) Passed (P = 0.3270, W 
statistic= 0.9247, significance level = 0.0500. Constant variance test passed (P = 0.7831). Exp 2 Normality test (Shapiro-Wilk) Passed (P = 0.3553) 
W statistic= 0.9276, significance level = 0.0500. Constant variance test passed (P = 0.6032) 
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3.2.6 Association of HuMc3 with lactadherin 
 
The specific association of HuMc3 with lactadherin had already been indicated by 
sandwich ELISA for both naturally sourced (section 3.2.1) and rHu-lactadherin using 
another anti-lactadherin antibody (mAb2767) for capture (section 3.2.2) but was 
investigated further using IP (section 2.2.3.1) and native-PAGE blots (section 2.2.3.2). 
Native-PAGE was used to detect HuMc3 binding to lactadherin in a milk sample as 
HuMc3 was thought to bind to a cryptic epitope of lactadherin [154]. Its binding site 
is believed to be a 3 dimensional structure requiring the protein to be in its native 
form (section 1.5.1).  Figures 3.21a and 3.21b, show images of blots in which a milk 
sample was added to every other lane, interspersed with marker. The blot was cut at 
the marker lane then each piece incubated with HuMc3, HuMc3-biotin or with 
positive control mAb2767. Peroxidase-conjugated secondaries were used for 
detection. Figure 3.21a shows increasing signal with increased HuMc3 concentration, 
with single bands at the same position as that of the mAb2767 blot, suggesting 
association with lactadherin. This was supported by the data of figure 3.21b showing 
detection of mAb2767 binding and HuMc3 and HuMc3-biotin association, with no 
detection of signal with extravadin HRP and non-biotinylated HuMc3.  The presence 
of only one band at the same position for all the samples may have indicated binding 
with only one component within human milk, suggesting the specificity of the 
association of HuMc3 with lactadherin. As however all of the bands appeared at the 
top of the blots, it could not be concluded that the components of the milk had 
separated in the native gel. The presence of lactadherin bands at the top of the native-
PAGE gel in the native blots may in fact suggest lactadherin is present in large 
vesicular structures despite the use of sonication. It is possible that vesicular structures 
had re-formed prior to application to the gel and were not disrupted, as neither a 
denaturing agent was applied nor was a high temperature incubation used as in the 
SDS-PAGE. 
  
An IP experiment was carried out with HuMc3 to confirm the specificity of 
association with lactadherin in human milk (figure 3.22). Samples collected during the 
procedure were analysed by SDS-PAGE using a coomassie-stain (figure 3.22a) and 
western blot, with detection by mAb2767 (figure 3.22b). Bands at 50kDa and 25kDa 
in lane E of the coomassie-stained gel, the bead elution, are likely to be the heavy and 
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light chain of HuMc3 respectively. A band positioned between the 40kDa and 55 kDa 
marker bands is also present in the coomassie-stained gel and western blot. This 
suggested a specific association of HuMc3 with lactadherin. The coomassie-stained 
gel showed no discernable band at 47kDa for the before IP sample of human cream, 
but a clear band at this molecular weight for the elution. The western blot however 
shows a band of similar apparent strength to the elution sample, suggesting the 
possibility that the coomassie band is not lactadherin. As however lactadherin is the 
only known HMFG membrane protein at a 40-55kDa molecular weight range 
[160][262], the observed band is with all likelihood lactadherin. There is another band 
visible at just above 72kDa in the elution sample (upper box), butyrophilin. This band 
is however highly represented in the starting material and the band in the elution 
sample is much weaker than in the starting material suggesting non-specific 
association with the protein-G sepharose beads. To confirm the specificity of the 
association of lactadherin with HuMc3 and lack of specificity of butyrophilin binding 
with the HuMc3-protein G sepharose structure, this experiment may have been 
repeated with an isotype control antibody. Past work has however demonstrated Mc3 
does not specifically associate with the 70kDa component of human lactadherin [262], 
so we can be reasonably certain that this is not the case.  Taken together, the ELISA 
data, the native PAGE and the IP experiment strongly indicate association of HuMc3 
with lactadherin, both in the naturally occurring and recombinant forms.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3.21 
Detection of association between HuMc3 and milk
Aligned individually probed western blots of human milk samples p
HuMc3/HuMc3 biotin association, detected with anti
or extravadin HRP (1 in 2000 dilution). Positive control included with detection of lactadherin using 
mAb276 (13.3n) and anti-mouse IgG p
(a) Loading order; 1 HuMc3 (1.67nM), 2 HuMc3 (3.33nM), 3 HuMc3 (26.7nM), 4 HuMc3 (53.3nM), 
(all with A0293 detection), 5 mAb2767 (13.3nM). (b) 
detection, 2 HuMc3 (26.7nM) with extravadin HRP detection,
extravadin HRP detection, 4 mAb2767 with A9917 detection.  Figure data representative of two (a) 
and one (b) experiment respectively
(a)    
 
    
 
Figure 3.22  
Analysis of the specificity of association between milk
(a) Coomassie-stained SDS-PAGE gel and (b) western blot of samples coll
lactadherin from human cream by incubation with HuMc3 and protein
probed with an anti-lactadherin antibody mAb2767 (13.3 nM) and A9917 (1 in 80,000). Loading ord
for (a) and (b); B4 cream sample, FT
W1, W2 and W3 supernatant from bead washes,
Figure data representative of the results of two separate experiments.
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-derived lactadherin by native PAGE
robed for analysis of 
-human peroxidase A0293 (diluted 1 in 100,000) 
eroxidase A9917 (diluted 1 in 80,000).  
Loading order; 1 HuMc3 (26.7nM) with A0293 
 3 HuMc3-biotin (26.7nM) with 
. 
  (b) 
  
-derived lactadherin and HuMc3 by IP
ected during IP
-G sepharose.  Western blot 
 supernatant from incubation of HuMc3 and cream with beads, 
 E supernatant from heat/loading buffer treated beads. 
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3.2.7 Lactadherin binding to the extracellular domains of integrin αvβ3 
 
The recombinant extracellular domains of integrin αvβ3 were tested by ELISA 
(section 2.2.3.3) for association with lactadherin. This assay was attempted by two 
methods, the first with lactadherin coating and αvβ3 binding, detected with an anti-
αvβ3 antibody mAb3050 and A9917 (figure 3.23) and the second with αvβ3 coating, 
with lactadherin binding detected with mAb2767 and A9917 (figure 3.24). The 
controls for the assay detecting association of lactadherin with directly-coated integrin 
(figure 3.24a) showed what appeared to be a positive result, however the absorbance 
was not significantly different (3.24ai) from that observed in the absence of integrin 
and the signal did not alter with an integrin concentration titration (figure 3.24b). This 
false positive is likely to have been caused by the direct binding of lactadherin to the 
plate despite blocking. Neither assays indicated any binding of αvβ3 to lactadherin 
despite a confirmation that the experiments were working with inclusion of controls 
of lactadherin alone, detected with mAb2767 and A9917. The positive control with 
fibronectin coating (figure 3.21a) however did not show binding either and as this 
ECM protein has been well documented to bind to αvβ3 on the cell surface (section 
1.2.3), it is possible that the integrin is not able to bind in the recombinant form due to 
the absence of the membrane-embedded and/or intracellular regions or there may have 
been something about the assay conditions that were sub-optimal for association. 
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Figure 3.23 
Detecting association of lactadherin with the recombinant extracellular domains of integrin αvβ3 by 
ELISA with directly coated lactadherin 
Integrin αvβ3 binding to lactadherin (109nM) detected with anti-αvβ3 antibody mAb3050 (67nM) and 
anti-mouse peroxidase A9917 (diluted 1 in 60,000). (a) Single αvβ3 integrin (96nM) concentration 
ELISA with positive and negative assay controls. Controls included are fibronectin (fn 109nM) coating 
positive, no integrin just fibronectin negative, no integrin just lactadherin (lac) negative and 
lactadherin alone with detection antibody mAb2767 (6.67 nM) positive. (a)(i) Statistical data table 
displaying the average (combo) data. (a)(ii) Absorbance data from four experiments and an average 
(combo data). (b) Integrin αvβ3 titration ELISA. (b)(i) Statistical data table displaying highest αvβ3 
integrin concentration absorbance data (192nM). (b)(ii) Absorbance data from three experiments and 
an average (combo data).Each error bar denotes 3 experimental replicates. Absorbance corrected to 
zero using a no lactadherin or fibronectin control. 
(a)(i) 
Combo data 
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Figure 3.24 
Detecting association of lactadherin with the recombinant extracellular domains of integrin αvβ3 by 
ELISA with integrin coating 
Lactadherin binding detected with anti-lactadherin antibody mAb2767 (6.67nM) and anti-mouse 
peroxidase A9917 (diluted 1 in 60000). (a) Single αvβ3 integrin (192nM) concentration ELISA with 
positive and negative assay controls. Controls included are no integrin negative and directly coated 
lactadherin alone with detection antibodies positive. (b) Directly coated αvβ3 integrin titration. 
Displayed in (a) and (b) is data from two separate experiments, with (a) also including average of the 
two (combo). Each error bar denotes 3 experimental replicates. Absorbance corrected using (a) 
integrin - lactadherin and (b) lactadherin – integrin data. (a)(i) Statistical data table displaying the 
average (combo) data and t-test. (b)(i) Statistical data table displaying difference data for the highest 
(192nM) and lowest (0.78nM) αvβ3 integrin concentrations and t-test. 
(a)(i)  
Combo data   
  
    
Statistics Lac + integrin Lac – integrin Lac + mAb2767 
 
t-test 
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N 6 6 6 t Stat 1.55 
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3.2.8 Kinetic parameters for association of HuMc3 and lactadherin 
 
The avidity for the association of HuMc3 IgG with recombinant and milk-derived 
human lactadherin was determined by titration ELISA, involving detection of binding 
of a titration of concentrations of HuMc3 to surface-associated lactadherin with 
A0293. The results for recombinant and milk lactadherin shown in figure 3.25a and 
3.25b respectively depict a sigmoidal curve. The equilibrium dissociation constant Kd 
was used as a reciprocal measure of avidity and calculated using SigmaPlot11.0 as the 
molar concentration required for half maximal association. The avidity of 0.51nM for 
the milk derived form is similar to the published value of 1.7nM [270] obtained using 
a similar assay format.  The avidities at 0.51nM and 1.42nM for the milk and 
recombinant form are shown to be significantly different (figure 3.23c), but within a 
similar range and within the same range of the published milk lactadherin binding 
value, indicating HuMc3 retains full/near to full avidity for the recombinant form and 
that any altered glycosylation by a non-human expression system has minimally 
affected HuMc3 binding.  
 
The avidity determination was repeated using SPR analysis (section 2.2.3.4), 
detecting association of HuMc3 with rHu-lactadherin, conjugated to a BIAcore® chip, 
to gain more information about the interaction. This is possible as SPR measures the 
rate of association (kon) and the rate of dissociation (koff), not simply the Kd. The 
binding curves and kinetic parameters are shown in figure 3.26a and 3.26c 
respectively. The association of HuMc3 with lactadherin is shown to be similarly on-
rate and off-rate driven, with kon rate and koff rate contributing similarly to the low Kd 
value, indicating the avidity occurs as a result of both fast association and slow 
release. The Kd is in the same order of magnitude for SPR to that calculated from the 
titration ELISA at 0.35nM (figure 3.26c). The SPR data is shown to be a sufficiently 
good fit to the fit curve with a chi squared value of less than 10 (figure 3.26c). The 
data does however show some limited variation from the fit, demonstrated by the 
residuals (figure 3.26b). The confidence in this data may have been improved by 
performance of further repeats of this experiment, though the consistency of the data 
is suggested by the close values of the intra-experimental replicates. 
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In order to determine the affinity of HuMc3 for rHu-lactadherin, HuMc3 IgG was 
subjected to a papain digest (figure 3.27), which cleaves immunoglobulins to release 
the 50kDa antigen binding arms (Fab fragments) and the 50kDa Fc domain (section 
2.2.3.5). An optimisation of the papain digest incubation time is shown in figure 3.27a 
and 3.27b, with the former a coomassie-stained SDS-PAGE gel and the latter an anti-
Fab (A0293) western blot. From the gel both heavy and light chain can be observed in 
the before digestion sample (lane 1) at the expected 50 and 25 kDa respectively. 
Bands at around 24kDa, which could be whole IgG light chain or reduced Fab 
fragments are present in all digestion samples (lanes 2-10). The heavy chain is not 
visible in lanes 4-8 and is diminished in lanes 2-3 compared to the before digestion 
sample, indicating some digestion of the IgG has taken place. Only lanes 5-8 (1, 2, 2.5 
and 3 hour papain incubations) contain a strong band around 30kDa, likely to be the 
Fc as it runs comparably to the Fc of a standard coomassie gel shown on the Pierce 
website. Lanes 9-10 (4 and 5 hour digestions) show all weak bands indicating over-
digestion. Due to the diminished observed heavy chain and appearance of an Fc band 
in the 1-3 hour incubation samples, a 2-hour incubation was chosen for subsequent 
HuMc3 digestion. Figure 3.27c and 3.27d, respectively a coomassie-stained SDS-
PAGE gel and anti-Fab western blot show samples collected during purification of 
HuMc3 Fab produced by a large-scale papain digest at the optimised papain 
incubation time, on a protein-A sepharose column. This column binds to the IgG Fc 
so Fab fragments would be expected to be washed through the column, with the Fc 
and uncut HuMc3 eluted after. The pre-column sample (lanes 1-2) contains what 
appears to be uncut IgG with bands at the molecular weights of the heavy and light 
chain at 50kDa and 25kDa respectively, though the band at around 25kDa will also 
contain Fab light and heavy chain. A band at around 30kDa is likely to be the Fc. The 
elution and wash steps in lanes 3-9 show a single band at around 24kDa and is 
suggested in the western blot to be Fab. It is difficult however to be certain of this as 
the light chain is also detected by this antibody. As however whole HuMc3 IgG would 
not be expected to be washed through the column due to the presence of a Fc and as 
no heavy chain is evident in the flow through and washes, the identity of this band as 
pure Fab fragment can be made with some confidence. The elutions shown in lanes 
10-14 contain uncut light chain and/or Fab, confirmed by the western blot and another 
band at around 30kDa, likely to be the Fc domain as well as a faint band at 50kDa, 
likely to be the uncut IgG heavy chain. The identity of the 30kDa fragment was 
 149
confirmed to be the Fc fragment in figure 3.27e-f, a coomassie-stained SDS-PAGE 
gel and anti-Fc (A0170) western blot respectively showing samples of the before 
digestion material (lane 1), washes in (lane 2) and elutions (lane 3).  
  
The affinity of HuMc3 for rHu-lactadherin was determined by SPR (section 2.2.3.4) 
using the pure HuMc3 Fab obtained in figure 3.27. The binding curves and kinetic 
data are shown in figure 3.28 and all kinetic data from the binding studies are 
summarised in figure 3.29. The HuMc3 Fab monovalent binding Kd at 6.24nM is 
around an order of magnitude higher than the values determined for bivalent 
association by the whole IgG by both SPR and ELISA. The monovalent association 
appears again to be more on-rate driven with the kon rate contributing more to the Kd 
value (figure 3.28c), indicating the association occurs more as a result of faster 
binding than slow release. As for the whole IgG SPR data, a sufficiently good fit to 
the fit curve is evident by with a chi squared value of less than 10 (figure 3.28c). The 
data does however show some considerable visible variation from the fit, also 
indicated by the residuals (figure 3.28b). The confidence in this data may have been 
improved by performance of further repeats of this experiment. 
 
As the proposed mode of action of HuMc3 involved neutralising lactadherin binding 
to cell surface integrins, the kinetic measurements for HuMc3 were compared with 
those of other neutralising antibodies approved for clinical therapy, also measured by 
SPR. The affinity of HuMc3 is reasonably comparable to the affinity of the VEGF 
neutralising antibody bevacizumab approved for metastatic cancer therapy, with both 
demonstrating high nM affinities, with a Kd for the monovalent fragment of HuMc3 at 
6nM, compared with the 1.8nM of bevacizumab [278]. The affinity of bevacizumab is 
however shown to be more off-rate driven than that of HuMc3 with koff and kon rate 
constants of 6.3 X 10-5 –s and 3.5 X 104 M-s [278], compared to the 9.74X 10-4 –s and 
1.56X 105 M-s of HuMc3 fab. Its high affinity is provided by a tendency to keep hold 
of the antigen once bound, rather than to bind more rapidly (section 1.4.2). This 
combination is ideal for a neutralising antibody, which needs to bind to its target fairly 
swiftly, but more importantly once bound remain tightly associated, as if the antigen 
is released it will have the opportunity to bind to activate its receptor. The avidity of 
HuMc3 for lactadherin at a Kd of 0.35nM by SPR is also comparable to that of 
bevacizumab which has demonstrated a SPR Kd of 0.5nM [97]. Its avidity is also 
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comparable with those of other approved anti-cancer monoclonal antibodies including 
trastuzumab with a Kd of 0.1nM [279] and rituximab with a Kd of 5.5nM [280]. Full 
avidity information has unfortunately not been published for bevacizumab so 
comparisons were made with another neutralising antibody adalimumab (Humira) a 
drug approved for treatment of arthritis. It binds to both soluble and membrane-bound 
forms of the growth factor TNF-α, inhibiting ligation of the receptor TNF-R. The Kd 
value of 3.50 X 10-10 M for HuMc3 is an order of magnitude higher than the Kd of 3 X 
10-11M for adalimumab [281]. The kon and koff  rate constant values at 2.20X 105 M-s 
and 7.74X10-5 –s for HuMc3 however shows that the association is more off-rate 
driven than that of adalimumab with kon and koff values of 1.69X 106 M-s and 4.71X 
10-5–s. The kinetic parameters for adelimumab were almost identical to those of two 
other clinically approved anti TNF-α, neutralising antibodies infliximab and 
etanercept [281]. 
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Figure 3.25 
HuMc3 whole IgG titration ELISAs with human milk-derived and recombinant lactadherin for 
affinity determination. 
HuMc3 binding to recombinant (a) and milk-derived (b) human lactadherin (lac) (109nM) detected 
with anti-human peroxidase A0293 (diluted 1 in 40,000). (c) Statistical data table displaying the 
combined kd data, (calculated from the curves using SigmaPlot 11.0) for milk-derived and recombinant 
lactadherin and a t-test comparing the milk and recombinant lactadherin kd values. Displayed is data 
from three separate experiments. Each error bar denotes 3 experimental replicates. Absorbance 
corrected to zero using no-lactadherin controls.  
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(c) 
kd (nM) rHu- lac Milk lac t-test kD milk lac /kD rec lac 
N 3 3 t Stat -9.01 
Mean 1.42 0.51 P(T<=t) one-tail 4.20E-04 
SD 0.16 0.07 t Critical one-tail 2.13 
 
  P(T<=t) two-tail 8.39E-04 
 
  t Critical two-tail 2.78 
 
 
 
Curves fitted bySigmaplot11.0 using the equation sigmoidal logistic 4 parameter. (a) Exp 1 Normality test (Shapiro-Wilk) Passed (P = 0.2464), W statistic= 0.9359, significance level = 0.0500. Constant 
variance test passed (P = 0.3971). Exp 2 Normality test (Shapiro-Wilk) Passed (P = 0.5733, W statistic= 0.9569, significance level = 0.0500. Constant variance test passed (P = 0.1726)Exp 3 Normality test 
(Shapiro-Wilk) Passed (P = 0.2464), W statistic= 0.9359, significance level = 0.0500. Constant variance test passed (P = 0.3971.  (b) Exp 1 Normality test (Shapiro-Wilk) Passed (P = 0.7585), W statistic= 
0.9721, significance level = 0.0500. Constant variance test failed (P = 0.0001). Exp 2 Normality test (Shapiro-Wilk) Passed (P = 0.3300), W statistic= 0.9510, significance level = 0.0500. Constant variance 
test passed (P = 0.5077). Exp 3 Normality test (Shapiro-Wilk) Passed (P = 0.1953), W statistic= 0.9204, significance level = 0.0500. Constant variance test passed (P = 0.1801) 
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Figure 3.26 
SPR analysis of association between HuMc3 and lactadherin 
Binding of whole IgG HuMc3 (200, 100, 50, 25, 12.5 and 6.25nM) to amine-coupled human 
recombinant lactadherin (700RU) was analysed using a BIAcore system. Shown are (a) the binding 
curves with fit for each HuMc3 concentration, (b) the residuals and (c) the kinetic parameters 
calculated from the fit curve equation including the kon, koff and kd. Also included is the Chi squared 
value of goodness of fit of the data to the fit curve equation. Figure data represents the results of a 
single experiment but includes two replicates of each binding experiment.  
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Figure 3.27 
Preparation of HuMc3 Fab by papain digestion of HuMc3 whole IgG 
(a) Coomassie-stained SDS-PAGE gel and (b) anti-Fab (A0293 diluted 1 in 100,000) western blot 
showing optimisation of papain digestion incubation time. Loading order; 1 undigested HuMc3 
(667nM), 2 digest 5 min, 3 digest 10 min, 4 digest 30 min, 5 digest 1 hour, 6 digest 2 hour, 7 digest 3 
hour, 8 digest 4 hour, 9 digest 5 hour, 10 digest 6 hour. (c) Coomassie-stained SDS-PAGE gel and (d) 
anti-Fab (A0293 diluted 1 in 100,000) western blot showing purification of Fab from 2-hour digested 
HuMc3 (6667nM), by protein-A sepharose chromatography. Loading order; 1 and 2 pre-column 
sample, 3 flow through, 4-9 washes, 10-14 elutions. (e) Coomassie-stained SDS-PAGE gel and (f) anti-
Fc (A0170 diluted 1 in 100,000) western blot of combined protein-A sepharose purification samples. 
Loading order; 1 HuMc3 before digestion (6667nM), 2 combined column flow through and washes, 3 
combined column elutions. 
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Figure 3.28 
SPR analysis of association between HuMc3 Fab and lactadherin 
Binding of HuMc3 Fab fragment (375, 118, 93.8, 46.9, 23.4 and 11.7nM) to amine-coupled human 
recombinant lactadherin (700RU) was analysed using a BIAcore system. Shown are (a) the binding 
curves and fit for each HuMc3 concentration, (b) the residuals and (c) the kinetic parameters 
calculated from the fit curve equation including the kon, koff and kd. Also included is the Chi squared 
value of goodness of fit of the data to the fit curve equation. Figure data represents the results of a 
single experiment but includes two replicates of each binding experiment.  
(a) 
 (b) 
 (c)      
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Figure 3.29 
Table showing all kinetic data for association between human lactadherin (recombinant and milk) 
and HuMc3 whole IgG/Fab 
Kinetic data is included for HuMc3 IgG and Fab binding to rHu-lactadherin by SPR analysis. The 
ELISA derived Kd for binding of whole HuMc3 IgG to recombinant and milk lactadherin is also 
included. 
 
 kon M –1s–1 
(SPR) 
koff  s-1 (SPR) Kd nM  (SPR)  Kd nM (ELISA) 
recombinant lac 
 
Kd nM (ELISA) milk 
lac 
IgG 2.20E05 7.74E-05 0.35 1.42 0.51 
Fab 1.56E05 9.74E-04 6.24 
  
 
 
3.3 Discussion 
 
In this chapter all of the objectives were attempted and the aims were mostly met. 
Lactadherin was expressed recombinantly using both transient and stable transfection 
methods and was purified from the stable culture supernatant by a two-step process 
involving affinity chromatography, recognising the presence of a polyHis tag and by 
size exclusion chromatography. Lactadherin was shown to be expressed in samples of 
human milk and was enriched by a purification method exploiting the chemical 
properties of the antigen, though purification of milk lactadherin was not achieved. 
Sufficient lactadherin was obtained for performance of much of the work in this 
thesis, though it was necessary to purchase some pure rHu-lactadherin for a small 
portion of the work due to loss of expression by the stable cell line. HuMc3 was 
successfully expressed and purified, with sufficient produced for performance of all 
experimental work. It was shown to associate specifically with both milk-derived and 
rHu-lactadherin by ELISA and to milk lactadherin by native-PAGE western blotting 
and IP from cream samples. HuMc3 was shown by titration ELISA to maintain most 
of its association with lactadherin expressed in recombinant form, in a non-human cell 
line. The avidity and affinity of HuMc3 for lactadherin were determined by ELISA 
and SPR analysis and found to be comparable with those of other clinically successful 
mAb therapeutics including neutralising antibodies. The koff and kon rate constants for 
the avidity and affinity experiments also compared reasonably well with those of 
successful neutralising antibodies. HuMc3 was shown to retain full association with 
lactadherin at temperatures up to 70 degrees centigrade, demonstrating a thermal 
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stability comparable to other clinical whole IgG therapeutics. It also suggested 
HuMc3 should retain maximal association with its target under pre-clinical and 
clinical conditions as well as during in vitro procedures carried out later in this work. 
Lactadherin was tested by ELISA for association with the recombinant extracellular 
domains of the integrin αvβ3. No association was however evident. As past work had 
demonstrated rHu-lactadherin association with cell-surface αvβ3 integrin, this 
suggested lactadherin is either unable to bind to this integrin in the absence of its 
transmembrane domain, or that the assay conditions did not favour association.  
 
3.3.1 Lactadherin purification/expression and purification 
 
Although lactadherin appeared to be successfully expressed recombinantly by creation 
of a stably expressing cell line, a major flaw in this data is the omission of sequencing 
of the fusion protein of lactadherin with linker and tags. In theory it is possible that 
the lactadherin gene sequence or the tag sequences could have been altered during the 
cloning process resulting in a loss of part of the gene sequences leading to truncation 
of parts of the protein or loss of the correct reading frame leading to expression of the 
wrong amino acid sequence. Areas in which this could have occurred were during 
restriction endonuclease digestion and for lactadherin the PCR amplification and 
addition of new restriction enzyme cleavage sites. It is unlikely that this occurred 
however as the restriction enzymes were chosen as they had no cleavage sites within 
the lactadherin coding sequence and as after the digest of both insert and vector, the 
size of each were altered so minimally as to be undetectable with the hyperladder 
marker used, as would be expected if small regions at either end of the insert were 
removed and a small region in the multiple cloning site (MCS) of the vector. In 
addition the primers sequences used should not have allowed for truncation during 
PCR amplification, binding to the first 15bp of either end of the ORF of the 
lactadherin gene. The subsequent gene fusion expression data also suggested the 
presence of the whole lactadherin gene fusion, with detection of the polyHis and c-
myc tags by both western blotting and affinity purifications. In addition the 
lactadherin sequence was suggested to be present and unaltered by the detection of 
both HuMc3 and mAb2767 association. The binding of HuMc3 suggested the 
presence of a correctly folded EGF-like domain. The detection of this fusion in the 
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culture supernatant suggested the presence of the signal sequence in the protein prior 
to maturation, leading to entrance into the secretory pathway [163]. In addition, the 
detection of lactadherin in large structures during size exclusion chromatography 
strongly suggested secretion in the form of vesicles as was expected based on past 
work with recombinant cell lines expressing this gene. This indicated therefore the 
presence of functional C1 and C2 domains, both of which have been shown to be 
necessary for membrane localisation.  Another concern with the stable expression data 
was the dwindling protein expression by this cell line. In retrospect, after transfection 
and removal of cells without zeocin resistance, single cell lines with uniform plasmid 
integration should have been created and those with the highest lactadherin expression 
selected. This would not only have ensured high lactadherin expression and 
expression of solely a whole undamaged fusion protein with both tags, but as long as 
fresh stocks were frequently used would have reduced the chances of loss of 
lactadherin expression through selection of cells with the survival advantage of the 
zeocin resistance gene, but without the lactadherin gene fusion protein. The lack of 
consistent detection of forms of the lactadherin fusion protein of different molecular 
weights however, at least suggested expression solely of the whole fusion molecule 
and not some altered product caused by loss of parts of the protein sequence by 
suboptimal integration. 
 
The purification of lactadherin from milk samples was not successful. In retrospect, 
the attempted purification of lactadherin by its chemical properties most likely failed 
due to the similar aqueous: detergent solubility of this protein to other MFG 
membrane components. Past work using this protocol, used it as a first step in a two-
stage purification [160], so enrichment of lactadherin was possibly the most that could 
have been expected from this procedure. In addition, past work suggests the presence 
of lactadherin in the detergent phase during phase separation [160], so it was likely a 
lot of lactadherin was lost at this stage that could have been retrieved. The purification 
by a protein sepharose HuMc3 column was unsuccessful in separating lactadherin 
from all other HMFG membrane components. The IP was however much more 
successful in isolating lactadherin from the milk, with only a small amount of 70kDa 
butyrophilin remaining. The only difference in these two techniques was the fact that 
HuMc3 was pre-incubated with the milk before protein G sepharose association with 
HuMc3, suggesting it is to the protein G itself or the sepharose beads that the other 
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HMFG components bound non-specifically during the purification attempt.  As other 
work has shown success in full affinity purification of PAS6/7 a bovine form of 
lactadherin from milk, involving the use of concanavalin-A conjugated to agarose 
beads, better results may have been obtained by the production of a column of  
HuMc3 conjugated to agarose beads. 
 
Both recombinant and native lactadherin were shown in all SDS-PAGE western blots 
to occur as a closely-spaced double band, in agreement with past work [149][150]. It 
is possible lactadherin may occur in two glycosylation variants with an identical 
polypeptide core as observed for bovine lactadherin, which has two variants with an 
identical amino acid sequence but with molecular weights of 50kDa and 47kDa, due 
to altered glycosylation [185]. Lactadherin was also indicated to be predominantly 
expressed in association with vesicles in agreement with past work [152][156] as well 
as to a lesser extent in free form [151]; both as a monomer and a dimer, as suggested 
in published work [184] 
 
3.3.2 HuMc3-lactadhein association 
 
The similar ELISA-derived Kd values for recombinant and milk lactadherin suggested 
rHu-lactadherin may be a suitable alternative to the less readily available milk 
lactadherin for use in further study into the mode of action of HuMc3 as an anti-
lactadherin, anti tumour/angiogenesis agent. The fact that the in vitro αvβ3 integrin 
binding ELISA with milk lactadherin was unsuccessful was unfortunate as it was not 
therefore possible to determine whether the altered glycosylation/addition of tag 
sequences had altered the ability of rHu-lactadherin to bind to its integrin receptors. 
As however the EGF-like domain is at the N-terminus, whereas the tag sequences 
were added to the C-terminus (figure 3.11b), the likelihood of interference with 
binding to the αvβ3/αvβ5 integrin receptors of this added sequence is low. In 
addition, as HuMc3 binds at the EGF-like domain and has been indicated to inhibit 
binding to these receptors [154], it is likely their binding sites encompass a similar 
region, so the fact that the HuMc3 Kd is so minimally altered is encouraging for the 
ability of this protein to associate with its integrin receptors. The ability of rHu-
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lactadherin to bind to αv integrins in the cell surface would however be studied later 
in chapters 5 and 6.  
 
With the SPR-derived kinetic data for HuMc3-lactadherin association reasonably 
comparable to that of other clinically successful whole mAb therapeutics, including 
neutralising antibodies, this data indicated that if HuMc3 were subsequently shown to 
neutralise lactadherin binding to cell surface integrins, it may in its bivalent whole 
IgG form have a sufficient avidity and tendency to remain associated once bound to 
stop lactadherin from being released to activate integrin signalling and to permit 
clearance of lactadherin in the form of immune complexes. As however the high 
avidity was shown to be similarly on-rate and off-rate driven, this left open the 
possibility of lower potential for HuMc3 as a neutralising antibody than an antibody 
with an identical Kd, but with more off-rate driven avidity.   
 
3.3.3 Thermal stability of HuMc3 and lactadherin-αvβ3 integrin association 
 
The ability of HuMc3 to retain full association with lactadherin at temperatures of up 
to 70 degrees centigrade was encouraging as it indicated HuMc3 would be sufficiently 
stable to withstand the conditions used in all in vitro work. This was important as it 
would ensure the data obtained was accurate for the concentrations of antibody used 
and should make the data more reproducible. More importantly this data suggested 
HuMc3 would be stable at the 37 degrees centigrade temperatures of the murine 
model for in vivo studies and in the human subject for later clinical studies. Serum 
stability analysis was however omitted. This was unfortunate as this would have 
provided further information about the potential stability of HuMc3 in the chemical 
environment of the circulation in both the murine model and human subject. From this 
information together with the thermal stability information, predictions may have 
been made about the serum half-life of the drug, and how it may vary from other 
whole IgG monoclonal antibodies, whose serum and thermal stability information has 
been published. In addition the thermal stability of lactadherin may have been studied 
to determine whether it would remain intact at the 37 degrees centigrade temperatures 
used for some of the in vitro work. It is however reasonable to expect that it would as 
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lactadherin is produced naturally and is functional inside the human subject at this 
temperature. 
 
The observed lack of association between native human lactadherin and the 
recombinant extracellular domains of integrin αvβ3 is unlikely to suggest the inability 
of lactadherin to bind to this integrin as the positive control integrin binding protein 
fibronectin (section 1.2.3) also failed to show association and as past work has 
demonstrated lactadherin association with this integrin on the cell surface [153][192]. 
It is possible that either the absence of the transmembrane and/or intracellular 
domains prevented association, but past work suggests this is not the case [282]. 
Alternatively there may be something in the chemical environment of the assay was 
suboptimal for binding. The most likely cause of the lack of ligand binding to this 
receptor may be the lack of divalent cat-ions Mg2+ and Mn2+, known to promote 
integrin-ligand association [283], in the buffer used throughout the ELISA procedure. 
Calcium Ca2+ ions are known to be inhibitory to ligand-integrin binding [283], but as 
these should not have been present in the binding buffer, it is unlikely Ca2+ ions were 
the cause. In retrospect the buffer should have been prepared with not only the 
absence of Ca2+ ions, but with addition of Mg2+ and Mn2+.  
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Chapter 4  HuMc3 binding to lactadherin-expressing tumour cells and tissues 
in vivo and in vitro 
 
4.1 Introduction 
 
The human tumour cell lines MCF-7, a breast cancer cell line and SKOV3, an ovarian 
line were chosen for studying tumour cell surface HuMc3-lactadherin binding and 
HuMc3 localisation in a tumour-bearing model due to past work identifying 
expression of both lactadherin [176][195] and its αv integrin receptors [22][231] and 
as work had shown the importance of αv integrin signalling in the pathology of breast 
and ovarian cancer (section 1.1.2). In addition, these cell lines were chosen because 
they have both been used successfully in preclinical studies to identify anti-cancer 
drug efficacy [120][257][284][285][286][287]. Of particular interest was the fact that 
bevacizumab had been tested with success in vivo with xenografts formed from both 
of these cell lines [120][284]. This was important as bevacizumab was the gold 
standard anti-angiogenesis, anti-cancer therapeutic to which the efficacy of HuMc3 
would be compared in subsequent chapters. 
 
HuMc3 animal model localisation would also be analysed using a human tumour line 
MX-1. This would be used as a positive control as it not only had been shown to 
express αv integrins [22], and been used with some success in past studies to examine 
preclinical drug efficacy [257][286][288], but past work had shown localisation of 
HuMc3 to this tumour in a biodistribution study as well as some therapeutic effect 
when conjugated to a radioisotope (section 1.5.3).  
 
HuMc3 binding to cell lines would be investigated to confirm association with 
lactadherin on the cell surface primarily, but would also enable quantification of 
antigen expression, allowing comparisons to be made from cell line to cell line and 
would permit visualisation of staining patterns over the cell surface, giving 
information about antigen distribution. Past work had shown breast tumour integrins 
including αvβ3 to be localised at the surface in focal contact sites, appearing as 
punctate areas of bright staining in association with the underlying actin cytoskeleton 
[289]. As lactadherin has been shown to bind to αvβ3 as well as αvβ5 at the cell 
surface (section 1.3.2) and integrin ligation is required for focal contact assembly 
(section 1.1.1), lactadherin surface distribution was predicted to be similar to the 
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published work. Detection of HuMc3 binding to MCF-7 cells was expected, as this 
cell line was used in the original selection of MuMc3 [262] as an anti-lactadherin 
antibody and because several other studies since have reported MuMc3 
binding/lactadherin expression to this cell line [176][255][265].  
 
The humanised monoclonal antibody HuHMFG1 was included as a positive control in 
most tumour surface binding experiments as it binds to a cryptic epitope exposed by 
altered glycosylation in a tumour form of mucin [290] It is over-expressed on the 
surface of both breast and ovarian [291][292] tumours. 
 
Biodistribution studies would be carried out to assess HuMc3 as a potential cancer 
therapeutic by its high affinity and high specificity association with lactadherin, its 
tumour selectivity (section 1.4.2) and its ability to remain in the circulation long 
enough to exert a biological effect. The model chosen for the biodistribution study 
was the athymic BALB/c nu/nu mouse with subcutaneous xenografts. This model was 
selected as athymic mice are immune-compromised due to a T-cell deficiency [293] 
and have as a result been shown in many studies not to reject human tumour implants 
[267][294][295]. This model was also chosen as it had been used in past work with 
MX-1 tumours to study the biodistribution of HuMc3 [268][270], with tumour 
targeting evident. Biodistribution studies provide information about how and where 
the drug is distributed. This type of study involves intravenous injection of radio-
labelled antibody. Drug distribution may then be measured by either whole body 
imaging using a gamma camera [296] for detection of radiolabel at regular time points 
over a number of days, or by cardiac puncture and dissection to respectively remove 
blood and other tissue samples for analysis of drug distribution by measurement of 
gamma radiation [267][296][297]. The former is a less time-consuming method and 
potentially requires less material as animals do not necessarily need to be sacrificed at 
each time point. As however it requires specialised equipment and may not provide 
precise information about normal organ uptake of drug, biodistribution studies were 
carried out in this study using the tissue dissection method.  In addition, prior studies 
detecting HuMc3 distribution in a MX-1 xenograft model used this method 
[268][270], so direct comparisons could be more accurately made.  
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In vivo antibody affinity is measured as absolute uptake (percentage injected dose of 
drug per gram of tissue), relative uptake (tumour to blood ratio), and retention time in 
the tumour [296][297].  Tumour selectivity/specificity is determined by measuring the 
tissue to blood ratios and percentage injected dose per gram in samples of normal 
tissues and making comparisons to those of the tumour [296]. The half life of a drug 
(t1/2) is the time taken for the drug concentration in the blood to fall by half. The t1/2 
can be used to calculate the rate of clearance, (the volume of blood cleared of the drug 
in a given unit of time) [298]. Drug t1/2 is also relevant as a determinant of likely 
therapeutic outcome as the longer the drug remains in circulation, the greater the 
opportunity for tumour uptake [299] and in theory the greater the biological effect. If 
drugs have normal tissue damaging effects however, such as those with low 
specificity/selectivity, or those conjugated to a tissue damaging agent, a high t1/2 may 
not be desirable [238]. For an unconjugated antibody such as HuMc3 however 
providing it proves tumour selective, the greater the t1/2 the greater the potential 
therapeutic outcome. 
 
The aims of this chapter were to study the ability of HuMc3 to target lactadherin-
expressing tumours in vivo and confirm tumour lactadherin expression by detection of 
cell surface HuMc3 association in vitro as a pre-requisite for subsequent therapeutic 
experimentation with these tumours. 
Objectives; 
• Investigate HuMc3 binding to tumour cells known to express 
lactadherin by cell ELISA, FACS analysis and IF confocal microscopy. 
• Study the biodistribution of HuMc3 in murine models with lactadherin-
expressing tumour xenografts. 
 
4.2 Results 
 
 
4.2.1 HuMc3 binding to lactadherin-expressing tumour cells 
 
Cell ELISA (section 2.2.5.5) experiments were carried out to detect HuMc3 binding 
to SKOV3 cells. These assays involved detection of HuMc3, or positive control anti-
tumour (MUC-1) mucin antibody HuHMFG1 association with paraformaldehyde-
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fixed, plate coated SKOV3 cells using an HRP-conjugated anti-human IgG secondary. 
The results are shown in figures 4.1-4.3 as absorbance (450nm) for HuMc3 (Figures 
4.1-4.3b) and HuHMFG1 (figures 4.1-4.3c) corrected to zero using no-
HuMc3/HuHMFG1 controls. Included are negative controls of HuMc3/HuHMFG1 
and secondary antibody but no cells. Also included are data tables, (figures 4.1-4.3a), 
containing statistical information for the combined (combo) data and t-tests. Figure 
4.1b shows the result of a cell ELISA prior to optimisation, indicating strong binding 
of HuMc3 to the plate surface in the absence of cells, an effect mirrored by the 
positive control in figure 4.1c. This indicated insufficient plate blocking, so the 
experiment was repeated with use of a higher BSA blocking concentration throughout 
(figure 4.2).  In figure 4.2b, the no-cells binding of HuMc3 is visibly reduced and a 
significant difference (figure 4.2a) is observed between the highest HuMc3 
concentration (2667nM) and the HuMc3 (2667nM) with no cells control. A 
significant difference is also observed between the 2667nM concentration and the 
1333nM concentration as well as the 1333nM concentration and the 2667nM with no 
cells control (figure 4.2a). The binding signal is however small, considering the very 
high HuMc3 concentrations used, with an absorbance (450nm) of less than 0.2. The 
positive control (figure 4.2c) also shows a visible reduction in the no cells value 
compared to that of figure 4.1c. The difference between the highest (1333nM) 
HuHMFG1 concentration and the 1333nM HuHMFG1 with no cells control is 
however insignificant (figure 4.2a), so no HuHMFG1 SKOV3 cell binding can be 
inferred from this data.  To further reduce any background effects of primary antibody 
plate well association, the concentration of secondary antibody used for detection was 
reduced and the results are shown in figure 4.3. The dilution of 1 in 40,000 was 
selected as that recommended in the manufacturer’s instructions, with the previous 1 
in 5,000 dilution used in previous assays an accidental oversight. In figure 4.3b the 
HuMc3 values are little changed with the upper HuMc3 (2667nM) concentration just 
below 0.2 absorbance (450nm) units. The HuMc3 (2667nM) – cells control has 
however been reduced from 0.05 to 0.01, increasing the difference between the 
control and test values and again the difference is shown to be significant (figure 
4.3a). A significant difference in signal for the HuMc3 concentrations 2776nM and 
1333nM as well as 1333nM and 333nM (figure 4.3a) was demonstrated, suggesting 
concentration-dependent HuMc3 binding to SKOV3 cells. The positive control data 
(figure 4.3c) is much improved by the greater dilution of secondary antibody, with the 
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no cells control visibly reduced despite the use of a higher HuHMFG1 concentration 
of 2000nM. The difference between the HuMc3 2000nM and HuMc3 2000nM-cells 
control is also shown in this assay to be significant (figure 4.3a) suggesting 
association of HuHMFG1 with the surface of SKOV3 cells. Overall this data 
indicated binding of both HuMc3 and positive control HuHMFG1 to SKOV3 cells. 
The signal for both HuMc3 and the positive control though significant was however 
weak which in the case of HuHMFG1 was at odds with the known high tumour 
surface expression [291]. It was considered that the low signal observed may be 
attributed to the pre-HuMc3/HuHMFG1 binding fixation, causing conformational 
change to these surface-associated antigens, leading to loss of the antibody epitopes. 
A FACS analysis method of detecting surface mAb binding was therefore adopted 
next, using live cells throughout and so avoiding fixation. 
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Figure 4.1 
Cell binding ELISAs for detection of association of HuMc3 with SKOV3 cells – before optimisation 
Binding of (b) HuMc3 (2667nM) and (c) HuHMFG1 positive control (667nM) to SKOV3 cells detected 
with anti-human HRP A0293 (diluted 1 in 5,000).  3 % BSA blocking buffer used throughout. Included 
are no-cells controls. Displayed is corrected absorbance 450nm data from three (HuMc3) and two 
(HuHMFG1) separate experiments and an average (combo). Each error bar denotes 4/5 assay repeats. 
Absorbance corrected to zero using no-primary antibody controls. (a) Statistical data table for each 
experiment and an average (combo) in presence and absence of cells. 
(a) 
 
HuMc3 + cells     HuMc3 – cells     
 Day 1 Day 2 Day 3 Combo  Day 1 Day 2 Day 3 Combo 
N 4 5 5 14 N 4 5 5 14 
Mean  0.16 0.08 0.12 0.12 Mean 0.22 1.21 0.50 0.65 
SD 0.02 0.01 0.02 0.02 SD 0.06 0.12 0.02 0.07 
HuHMFG1+ 
cells     HuHMFG1 – cells   
 
 
 Day 1 Day 2 Combo   Day 1 Day 2 Combo  
N 5 5 10  N 5 5 10  
Mean 0.32 0.36 0.34  Mean 0.94 1.10 1.02  
SD 0.04 0.05 0.05  SD 0.04 0.11 0.07  
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Figure 4.2 
Cell binding ELISAs for detection of association of HuMc3 with SKOV3 cells – higher blocking 
concentration 
Binding of (b) HuMc3 (2667, 1333 and 667nM) and (c) HuHMFG1 positive control (1333, 667 and 
333nM), to SKOV3 cells detected with anti-human HRP A0293 (diluted 1 in 5,000).  A 5 % BSA 
blocking buffer was used throughout. Included are no-cells controls with HuMc3 (2667nM) or 
HuHMFG1 (1333nM). Displayed is corrected absorbance (450nm) data from two separate 
experiments and an average (combo). Each error bar denotes 5 assay repeats.  Absorbance corrected 
to zero using no primary antibody controls. (a) Statistical data table displaying the average of two 
separate experiments (combo data) and t-tests. 
 
(a) 
Combo 
data 
HuMc3 
(2667nM) 
HuMc3 
(1333nM) 
HuMc3 
(667nM) 
HuMc3 
(2667nM) 
 – cells 
t-test HuMc3 
(2667nM)/ 
(1333nM) 
HuMc3 
(1333nM
)/  
(667nM) 
HuMc3  
(2667nM) / 
(2667nM) – 
cells 
HuMc3  
(1333nM) / 
(2667nM) – 
cells 
N 10 10 10 10 t Stat 3.01 1.28 10.73 3.05 
Mean 0.15 0.10 0.08 0.05 P(T<=t) one-tail 3.76E-03 0.11 1.49E-09 3.48E-03 
SD 0.02 0.05 0.02 0.02 t Critical one-tail 1.73 1.73 1.73 1.73 
 
    P(T<=t) two-tail 7.52E-03 0.22 2.98E-09 6.95E-03 
 
    t Critical two-tail 2.10 2.10 2.10 2.10 
  
HuHMFG1 
(1333nM) 
HuHMFG1 
(667nM) 
HuHMF
G1 
(333nM) 
HuHMFG1 
(1333nM) – 
cells 
t-test HuHMFG1 
(1333nM)/ 
(667nM) 
HuHMF
G1 
(667nM)/ 
(333nM) 
HuHMFG1 
(1333nM) / 
(1333nM) – 
cells  
N 10 10 10 10 t Stat 7.13 3.52 1.37  
Mean 0.35 0.22 0.15 0.30 P(T<=t) one-tail 6.06E-07 1.23E-03 9.41E-02  
SD 0.03 0.05 0.05 0.12 t Critical one-tail 1.73 1.73 1.73  
 
    P(T<=t) two-tail 1.21E-06 2.45E-03 0.19  
 
    t Critical two-tail 2.10 2.10 2.10  
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Figure 4.3 
Cell binding ELISAs for detection of association of HuMc3 with SKOV3 cells – higher secondary 
antibody dilution 
Binding of (b) HuMc3 (2667, 133, 667, 333 and 167nM) and (c) HuHMFG1 positive control 
(2000nM), to SKOV3 cells detected with anti-human HRP A0293 (diluted 1 in 40,000).  5 % BSA 
blocking buffer used throughout. Included are no-cells controls with HuMc3 (2667nM) or HuHMFG1 
(2000nM). Displayed is data from two (HuMc3) and three (HuHMFG1) separate experiments and an 
average (combo). Each error bar denotes 4/5 assay repeats.  Absorbance corrected to zero using no 
primary antibody controls. (a) Statistical data table displaying the average (combo data) and t-tests. 
(a) 
Combo data 
HuMc3 
(2667nM) 
HuMc3 
(1333nM) 
HuMc3 
(667nM) 
HuMc3 
(333nM) 
HuMc3 
(167nM) 
HuMc3 
(2667nM) - 
cells 
HuHMFG1 
(2000nM) 
HuHMFG1 
(2000nM) – 
cells 
N 10 10 10 10 10 10 12 12 
Mean 0.19 0.12 0.10 0.07 0.065 0.01 0.35 0.14 
SD 0.12 0.05 0.07 0.04 0.05 0.03 0.06 0.09 
t-test HuMc3 
(2667nM)/ 
(1333nM) 
HuMc3 
(1333nM)/ 
(333nM) 
HuMc3 
(2667nM)/ 
(333nM) 
HuMc3 
(2667nM) / - 
cells 
HuMc3 
(333nM) / 
- cells 
HuHMFG1 
(2000nM)/  - 
cells   
t Stat 1.81 2.08 3.02 4.71 3.71 6.93   
P(T<=t) one-tail 0.04 0.03 3.66E-03 8.78E-05 8.03E-04 2.92E-07   
t Critical one-tail 1.73 1.73 1.73 1.73 1.73 1.72   
P(T<=t) two-tail 0.09 0.05 7.32E-03 1.76E-04 1.61E-03 5.84E-07   
t Critical two-tail 2.10 2.10 2.10 2.10 2.10 2.07   
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Figures 4.4-4.10 show the results of a FACS analysis study (section 2.2.5.4) to 
investigate HuMc3 binding to the surface of the tumour cell lines SKOV3 (figures 
4.4-4.5) and MCF-7 (figures 4.6-4.7). HEK-293 (figures 4.8-4.9) as a non-tumour 
human cell line and non-human cell line CHO (figure 4.10) were included as negative 
controls for lactadherin expression. The FACS study involved detection of HuMc3 
(167, 333 and 667nM) and an isotype control (167, 333 and 667nM) cell association 
using a FITC-conjugated anti-human IgG secondary. The data was considered relative 
to that of both a secondary antibody alone and cells alone control. The FACS data is 
presented as two figures including a representative data figure showing an overview 
table with information including percentage FL1+ve gated cells and median FL1-H 
intensity of gated cells (a). Also included are single shifts plotted with cells alone and 
secondary antibody alone controls (b). In addition to the representative data, a second 
figure combines the percentage FL1+ve gated cells (c) and median FL1-H intensity of 
gated cells (b) data from multiple studies and includes a statistical data table with t-
tests for the combined data (a). The HEK-293 data differs in only including the upper 
(667nM) isotype control concentration and CHO data in only including a 
representative data figure and no isotype control. In addition HuMc3 concentrations 
of 667nM and 2667nM were used and compared relative to a secondary antibody 
alone control only. In an attempt to prevent loss of lactadherin from the cell surface 
by enzymatic cleavage and so potentially maximise signal, cells were removed from 
the flask surface during the FACS protocol (section 2.2.5.4) by a non-enzymatic 
method. For the SKOV3 cells representative data (figure 4.4) as observed in the cell 
ELISA a weak signal for HuMc3 binding is evident relative to the secondary antibody 
and cells alone controls (figure 4.4bi-iii), with a small shift at 167nM, a very slightly 
higher signal at 333nM and again for 667nM. This is mirrored by the combination 
data (figure 4.5) showing a small but apparently concentration dependent increase in 
signal for both percentage FL1+ve gated cells (figure 4.5b) and median FL1-H 
intensity (figure 4.5c). The apparent HuMc3 association is however shown to be non-
specific with similar (if a little higher) shifts evident in the representative data for the 
isotype control (figure 4.4iv-vi) and in the combination data (figure 4.5), with t-tests 
confirming no significant difference in either percentage FL1+ve gated cells or 
median FL1-H intensity for the highest (667nM) concentrations of HuMc3 and 
isotype control (figure 4.5a). Similar results are also shown for MCF-7 cells (figures 
4.6-4.7), which despite showing a small HuMc3 shift for the representative data 
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(figure 4.6bi-iii) and small increases in both percentage FL1+ve gated cells (figure 
4.7b) and median FL1-H intensity of gated cells (figure 4.7c) for the HuMc3 
concentrations relative to the secondary alone and cells alone controls, again the 
isotype control concentrations also show shifts in the representative (figure 4.6biv-vi) 
data and an increase in both percentage FL1+ve gated cells (figure 4.7b) and median 
FL1-H intensity of gated cells (figure 4.7c) such that there is no significant difference 
in either percentage FL1+ve gated cells and median FL1-H intensity of gated cells 
signal between HuMc3 (667nM) and isotype control (667nM) (figure 4.7a). The 
HEK-293 FACS data supports the implication of HuMc3 binding to SKOV3 and 
MCF-7 cells by a non-specific mechanism, with similar results of low level HuMc3 
and isotype control binding shifts evident in the representative data (figure 4.8b), 
relative to the secondary alone and cells alone controls as well as small increases in 
percentage FL1+ve gated cells (figure 4.9b) for HuMc3 and the isotype control in the 
combination data, though no increase in median FL1-H intensity of gated cells was 
evident (figure 4.9c). The CHO cell control data (figure 4.10) however showed no 
binding of HuMc3 with no shift in signal in the representative data (figure 4.10bi-ii) 
or increase in either percentage FL1+ve gated cells or median FL1-H intensity of 
gated cells signal (figure 4.10a) relative to the secondary antibody alone control 
despite the use of very high (2667nM) concentrations of HuMc3. This data therefore 
suggested HuMc3 is unable to bind to MCF-7 and SKOV3 tumour cells by specific 
association with cell-surface associated lactadherin. Alternatively it was possible that 
either lactadherin is not expressed by these cells or that the protocols used removed 
lactadherin from the surface, preventing specific HuMc3 binding. In order to verify 
HuMc3 binding to these cell lines therefore an alternative technique of IF confocal 
microscopy was used for visualisation of cell surface staining, with time allowed for 
re-expression of antigen following cell dissociation before commencement of the 
protocol.  
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Figure 4.4 
FACS analysis for detection of surface association of HuMc3 with SKOV3 cells 
Binding of HuMc3 (167, 333 and 667nM), detected with anti-human FITC secondary F5512 (1 in 1000 
dilution). IgG1 isotype (167, 333 and 667nM), secondary antibody alone and cells alone negative 
controls included. (a) Overview table with sample name and description, percentage gated cells, 
percentage of gated cells positive for fluorescence (FL1+), median fluorescent intensity of gated cells 
(FL1-H) and percentage FL1+ve total cells. (b) Individual shifts plotted against cells alone and 
secondary alone controls, with FSC-H, SSC-H plots attached; (i-vi) HuMc3 (167, 333, 667nM), I con 
(167, 333, 667nM). Data representative of two experiments. 
(a) 
 
Sample description Sample name Percentage gated 
cells (%) 
Percentage FL1+ve 
gated cells (%) 
Median FL1-H 
intensity of gated cells 
Percentage FL1+ve 
total cells (%) 
Cells alone SKOV3 1.009 96.71 4.63 4.24 4.48 
Secondary antibody alone  SKOV3 2.010 96.08 6.78 5.11 6.52 
HuMc3 (167nM) SKOV3 3.011 96.43 10.29 6.38 9.92 
HuMc3 (333nM) SKOV3 4.012 96.40 11.78 6.66 11.35 
HuMc3 (667nM) SKOV3 5.013 96.52 14.67 7.03 14.16 
I Con (167nM) SKOV3 6.014 96.66 11.44 6.32 11.06 
I Con (333nM) SKOV3 7.015 96.65 16.15 7.71 15.61 
I Con (667nM) SKOV3 8.016 97.06 15.54 7.52 15.08 
  
 
 
 
 
(b)(i)       (ii) 
 
 
 
 
 
 
 
 
 
 
 
 
(iii)       (iv) 
 
 
 
 
 
 
 
 
 
 
 
(v)       (vi) 
 
  
 172
Figure 4.5 
FACS analysis for detection of surface association of HuMc3 with SKOV3 cells – combined data  
Displayed is the percentage FL1+ve gated cells (b) and median FL1-H intensity of gated cells (c) data 
from four separate experiments as described in figure 4.4 and an average (combo). (a) Statistical data 
table displaying the average (combo) FL1-H intensity of gated cells and percentage FL1+ve gated 
cells data and t-tests. 
(a) 
Percentage 
FL1+ve gated 
cells 
 
Cells 
alone 
 
 
No p 
HuMc3 
(667nM) 
HuMc3 
(1333nM) 
HuMc3 
(2667nM) 
 
I Con  
(167nM) 
I Con 
(333nM) 
 
I Con 
(667nM) 
 
 
t-test 
HuMc3 
(667nM)/ I 
Con (667nM) 
N 4 4 4 4 4 2 2 3 t Stat 0.22 
Mean 4.36 6.64 15.42 19.76 22.78 11.48 18.18 21.63 P(T<=t) one-tail 0.42 
SD 1.71 0.22 5.07 5.40 6.36 0.05 2.87 7.31 t Critical one-tail 2.02 
 
        P(T<=t) two-tail 0.83 
 
        t Critical two-tail 2.57 
Median FL1-H 
intensity of gated 
cells 
 
Cells 
alone 
 
 
No p 
HuMc3 
(167nM) 
HuMc3 
(333nM) 
HuMc3 
(667nM) 
 
I Con  
(167nM) 
I Con 
(333nM) 
 
I Con 
(667nM) 
 
 
t-test 
 
HuMc3/ICon 
(667nM) 
N 4 4 4 4 4 2 2 3 t Stat -0.27 
Mean 4.03 4.70 6.41 7.59 7.93 5.27 7.82 8.28 P(T<=t) one-tail 0.40 
SD 1.02 1.41 2.08 1.69 2.04 1.49 0.16 0.90 t Critical one-tail 2.02 
 
        P(T<=t) two-tail 0.80 
 
        t Critical two-tail 2.57 
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Figure 4.6 
FACS analysis for detection of surface association of HuMc3 with MCF-7 cells 
Binding of HuMc3 (167, 333 and 667nM), detected with an anti-human FITC secondary F5512 (1 in 
1000 dilution). IgG1 isotype control (167, 333 and 667nM), secondary antibody alone and cells alone 
negative controls included. (a) Overview table with sample name and description, percentage gated 
cells, percentage of gated cells positive for fluorescence (FL1+), median fluorescent intensity of gated 
cells (FL1-H) and percentage FL1+ve total cells. (b) Individual sample shifts plotted against cells 
alone and secondary alone controls, with FSC-H, SSC-H plots attached; (i-vi) HuMc3 (167, 333, 
667nM), I con (167, 333, 667nM). Data represents two experiments. 
(a)  
 
Sample description Sample name Percentage gated 
cells (%) 
Percentage FL1+ve gated 
cells (%) 
Median FL1-H 
intensity of gated cells 
Percentage FL1+ve total 
cells (%) 
Cells alone MCF 1.009 97.94 6.14 2.69 6.02 
Secondary antibody alone MCF 2.010 99.16 6.79 3.12 6.74 
HuMc3 (167nM) MCF 3.011 99.38 10.65 3.30 10.58 
HuMc3 (333nM) MCF 4.012 99.23 18.08 3.63 17.95 
HuMc3 (667nM) MCF 5.013 99.26 23.60 4.39 23.42 
I Con (167nM) MCF 6.014 99.40 24.15 5.38 24.01 
I Con (333nM) MCF 7.015 99.36 31.75 6.37 31.55 
I Con  (667nM) MCF 8.016 99.37 26.53 5.43 26.37 
  
 
 
 
 
 
 
(b)(i)       (ii) 
 
 
 
 
 
 
 
 
 
 
 
 
(iii)       (iv) 
 
 
 
 
 
 
 
 
 
 
 
 
(v)       (vi) 
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Figure 4.7  
FACS analysis for detection of surface association of HuMc3 with MCF-7 cells – combined data 
Displayed is the percentage FL1+ve gated cells (b) and median FL1-H intensity of gated cells (c) data 
from four separate experiments as described in figure 4.6 and an average (combo). (a) Statistical data 
table displaying the average (combo) FL1-H intensity of gated cells and percentage FL1+ve gated 
cells data and t-tests. 
 (a) 
Percentage 
FL1+ve gated 
cells 
 
Cells 
alone 
 
 
No p 
HuMc3 
(667nM) 
HuMc3 
(1333nM) 
HuMc3 
(2667nM) 
 
I Con  
(167nM) 
I Con 
(333nM) 
 
I Con 
(667nM) 
 
 
t-test 
HuMc3 
(667nM)/ I 
Con (667nM) 
N 4 4 2 2 4 2 2 4 t Stat -0.46 
Mean 4.48 6.75 8.75 14.01 17.70 17.76 24.45 19.73 P(T<=t) one-tail 0.33 
SD 2.14 0.36 2.69 5.76 5.47 9.04 10.33 6.84 t Critical one-tail 1.94 
 
        P(T<=t) two-tail 0.66 
 
        t Critical two-tail 2.45 
Median FL1-
H intensity of 
gated cells 
 
Cells 
alone 
 
 
No p 
HuMc3 
(167nM) 
HuMc3 
(333nM) 
HuMc3 
(667nM) 
 
I Con  
(167nM) 
I Con 
(333nM) 
 
I Con 
(667nM) 
 
 
t-test 
HuMc3 
(667nM)/ I 
Con (667nM) 
N 4 4 2 2 4 2 2 4 t Stat -0.19 
Mean 2.23 2.70 3.26 3.44 4.17 4.40 5.25 4.30 P(T<=t) one-tail 0.43 
SD 0.82 0.70 0.06 0.27 0.64 1.39 1.58 1.24 t Critical one-tail 1.94 
 
        P(T<=t) two-tail 0.86 
 
        t Critical two-tail 2.45 
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Figure 4.8 
FACS analysis for detection of surface association of HuMc3 with HEK293 negative control cell 
line 
Binding of HuMc3 (167, 333 and 667nM), detected with anti-human FITC secondary F5512 (1 in 1000 
dilution). IgG1 isotype (667nM), secondary antibody alone and cells alone negative controls included. 
(a) Overview table with sample name and description, percentage gated cells, percentage of gated cells 
positive for fluorescence (FL1+), median fluorescent intensity of gated cells (FL1-H) and percentage 
FL1+ve total cells. (b) Individual shifts plotted against cells alone and secondary alone controls, with 
FSC-H, SSC-H plots attached; (i-iv) HuMc3 (167, 333, 667nM), I con (667nM). Data represents two 
experiments. 
(a) 
 
Sample description Sample name Percentage 
gated cells (%) 
Percentage FL1+ve 
gated cells (%) 
Median FL1-H intensity 
of gated cells 
Percentage FL1+ve total cells 
(%) 
Cells alone HEK-293 1.001 97.62 4.71 1.02 4.60 
Secondary antibody alone HEK-293 2.002 98.15 6.39 1.18 6.27 
HuMc3 (167nM) HEK-293 3.003 98.22 8.55 1.31 8.39 
HuMc3 (333nM) HEK-293 4.004 98.66 13.71 1.51 13.53 
HuMc3 (667nM) HEK-293 5.005 98.06 14.11 1.45 13.84 
I Con (667nM) HEK-293 6.006 98.32 14.34 1.49 14.09 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
(b) 
(i)       (ii) 
 
 
 
 
 
 
 
 
 
 
 
 
(iii)           (iv) 
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Figure 4.9 
FACS analysis for detection of surface association of HuMc3 with HEK293 negative control cell 
line – combined data 
Displayed is the percentage FL1+ve gated cells (b) and median FL1-H intensity of gated cells (c) data 
from four separate experiments as described in figure 4.8 and an average (combo). (a) Statistical data 
table displaying the average (combo) FL1-H intensity of gated cells and percentage FL1+ve gated 
cells data and t-tests. 
 (a) 
Percentage 
FL1+ve gated 
cells 
 
Cells 
alone 
 
 
No p 
HuMc3 
(667nM) 
HuMc3 
(1333nM) 
HuMc3 
(2667nM) 
I Con 
(2667nM) 
 
 
t-test 
 
HuMc3 (667nM)/ I 
Con (667nM) 
N 4 4 4 4 4 2 t Stat -1.2 
Mean 4.36 6.72 8.25 13.36 13.91 17.92 P(T<=t) one-tail 0.15 
SD 2.06 0.25 1.28 3.49 3.35 5.06 t Critical one-tail 2.13 
 
      P(T<=t) two-tail 0.29 
 
      t Critical two-tail 2.78 
Median FL1-H 
intensity of 
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HuMc3 (667nM)/ I 
Con (667nM) 
N 4 4 4 4 4 2 t Stat 1.10 
Mean 2.20 2.43 2.49 2.81 2.69 1.32 P(T<=t) one-tail 0.17 
SD 1.40 1.54 1.54 1.91 1.66 0.25 t Critical one-tail 2.13 
 
      P(T<=t) two-tail 0.33 
 
      t Critical two-tail 2.78 
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Figure 4.10 
FACS analysis for detection of surface association of HuMc3 with CHO negative control cell line 
Binding of HuMc3 (667 and 2667nM), detected with an anti-human FITC secondary F5512 (1 in 1000 
dilution). Secondary antibody alone negative control included. (a) Overview table with sample name 
and description, percentage gated cells, percentage of gated cells positive for fluorescence (FL1+), 
median fluorescent intensity of gated cells (FL1-H) and percentage FL1+ve total cells. (b) Individual 
sample shifts plotted against a secondary antibody alone control, with FSC-H, SSC-H plots attached; 
(i-ii) HuMc3 (667 and 2667nM). Figure data representative of the results of a single experiment. 
 
(a) 
 
Sample description Sample name Percentage gated 
cells (%) 
Percentage FL1+ve 
gated cells (%) 
Median FL1-H 
intensity of gated cells 
Percentage 
FL1+ve total 
cells (%) 
HuMc3 (667nM) Data 002 93.51 8.22 11.02 7.69 
HuMc3 (2667nM) Angiolix-400 94.36 6.08 10.34 5.74 
Secondary antibody alone  No prim 93.88 5.79 10.26 5.43 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
(i) 
 
(ii) 
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The IF confocal microscopy (section 2.2.5.3) studies to detect HuMc3 binding to 
MCF-7 and SKOV3 tumour cells involved detection of HuMc3 binding to coverslip-
coated cells with a FITC-conjugated anti-human IgG secondary antibody. Control 
experiments included were either an isotype-matched control or both cells alone and 
secondary antibody alone negatives and detection of binding of HuHMFG1, as a 
positive control to confirm the effectiveness of the protocol. This technique requires a 
fixation step, but due to concerns over loss of HuMc3 binding caused by 
paraformaldehyde-mediated antigen cross-linking the paraformaldehyde fixation of 
cells was carried out after primary antibody association to reduce the possibility of 
loss of antibody binding. As a result the cells were applied to coverslips pre-coated 
with poly-D-lysine to reduce loss of cells from the surface which was indicated in 
previous attempts (data not shown) to occur due to the late fixation.  Initially MCF-7 
cells were stained after overnight culture on the slides and the results are shown in 
figure 4.11. Concentrations of 333nM, 667nM and 1333nM HuMc3 were used, but no 
staining was evident at any concentration. The 667nM HuMc3 data is shown in figure 
4.11a, though the others are omitted. The positive control HuHMFG1 (667nM figure 
4.11b) shows visible cell surface staining indicating the protocol has been successful. 
Due to the lack of observed HuMc3 signal the staining protocol was repeated with an 
increased slide culture time of 48 hours. The results shown in figure 4.12 indicate 
surface localisation of HuMc3 (667nM) to MCF-7 cells (figure 4.12a). Cell surface 
staining occurs in a discontinuous pattern, with some brighter areas of intense 
staining, whereas the isotype control (figure 4.12c) is clear of surface staining. The 
HuHMFG1 (667nM) positive control also shows surface localisation (figure 4.12b). 
The staining appears stronger when compared to the previous figure, indicating a 
longer culture time allows greater expression of both surface-associated lactadherin 
and MUC-1 tumour mucin, lost during cell dissociation. The SKOV3 confocal 
microscopy (figure 4.13) like the MCF-7 study showed strong surface staining for the 
positive control HuHMFG1 (figure 4.13b), but no HuMc3 binding was detected 
(figure 4.13a). The IF confocal microscopy results therefore indicated the presence of 
surface-localised lactadherin and HuMc3 binding to lactadherin on MCF-7 cells, with 
a surface fluorescence detected, but with no surface fluorescence for the isotype 
control. No surface-localised fluorescence was however detected for HuMc3 on 
SKOV3 cells (figure 4.13a), which in agreement with the FACS data, suggests lack of 
cell-surface localised lactadherin in this cell line.  
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Figure 4.11 
IF confocal microscopy for detection of surface association of HuMc3 with MCF-7 cells, with 
overnight slide incubation. 
Binding of (a) HuMc3 (667nM) and (b) HuHMFG1 positive control (667nM) detected with the anti-
human FITC F5512 (1 in 1000 dilution). Also included is a detection antibody only (c) and a cells-
alone control (d). This figure is representative of the results of a single experiment.   
(a) 
 
(b) 
 
(c)       
 
(d) 
 
 
 
Sizing bar = 300µm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sizing bar = 300µm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sizing bar =300µm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sizing bar 300µm 
  
 180
Figure 4.12 
IF confocal microscopy for detection of surface association of HuMc3 with MCF-7 cells, with 48-
hour slide incubation  
Binding of (a) HuMc3 (667nM) and (b) HuHMFG1 positive control (667nM) detected with the anti-
human FITC F5512 (1 in 1000 dilution). Also included is an isotype control (667nM) (c). This figure is 
representative of the results of three separate experiments.   
 (a) 
 
 (b) 
 
(c) 
 
 
 
 
 
 
 
 
Sizing bar = 300µm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sizing bar = 179µm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sizing bar =113µm 
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Figure 4.13 
IF confocal microscopy for detection of surface association of HuMc3 with SKOV3 cells, with 48-
hour slide incubation 
Binding of (a) HuMc3 (667nM) and (b) HuHMFG1 positive control (667nM) detected with the anti-
human FITC F5512 (1 in 1000 dilution). Also included are a detection antibody only (c) and an isotype 
control (667nM) (d). This figure is representative of the results of three separate experiments.   
(a) 
 
(b) 
 
(c)       
 
 
 (d) 
 
   
 
 
Sizing bar = 300µm 
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Sizing bar 300µm 
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4.2.2 HuMc3 tumour targeting in vivo 
 
With lactadherin indicated to be expressed by MCF-7 breast tumour cells in vitro the 
in vivo targeting of HuMc3 to MCF-7 tumour xenografts in a murine model was 
assessed, using xenografts formed from the MX-1 breast tumour line as a positive 
control. Targeting to a HEK-293 tissue mass was used as a negative control due to its 
lack of lactadherin expression. Tumours were formed by subcutaneously implanting 
tumour pieces in the case of the MX-1 tumour line or tumour cells in a matrigel 
matrix for the MCF-7 and HEK-293 cell lines, into immune-compromised BALB/c 
(nu/nu) mice (section 2.2.6.1). HuMc3 labelled with a gamma emitting I125 isotope 
was injected and distribution of the drug in normal murine tissues, blood and the 
implant determined by measuring the gamma radiation levels over a time-course and 
plotting the percentage injected dose and tissue to blood ratio for all tissues against 
time after injection. Shown also are tables of statistical data for the percentage 
injected dose per gram of tumour and tumour to blood ratio and with t-tests to display 
the significance of the difference in uptake of labelled antibody in the tumour to the 
normal lung tissue. Lung tissue was chosen for comparison as it had shown the 
highest background of normal tissues in past work with MuMc3/HuMc3 
[267][268][270]. 
 
A time-course biodistribution study with MX-1 tumour implants was carried out over 
a 5.75 day period, with samples obtained at 6 hours, 1 day, 3 days and 6 days 
following injection (figure 4.14). HuMc3 localisation to the tumour was suggested by 
the percentage injected dose/gram of tissue data (figure 4.14b), with levels maintained 
in the tumour at around 15% throughout the experimental period whilst the levels in 
the blood fell from 15.5% at 6 hours to 5.3 % at day 6. Tumour uptake was also 
suggested by the tumour to blood ratios (figure 4.14c) which rose throughout the 
experimental period starting at 0.92:1 at 6 hours, increasing to over 2.2:1 by 24 hours, 
2.4:1 by 3 days and 3.3:1 by day 6. The percentage injected dose per gram levels in all 
normal tissues other than the lung and blood began at 6.8% or below at 6 hours, (with 
most well below 5%) and remained below 5% to the end (figure 4.14b). The levels in 
the lung followed approximately the blood levels, with the percentage injected dose 
per gram beginning high at 13.8% at 6 hours and clearing to 5.3% by day 6 (figure 
4.14b) and with the tissue to blood ratio near to 1:1 throughout the experiment (figure 
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4.14c). The tissue to blood ratios of all other tissues remained below 1:1, other than 
the skin which rose just above 1:1 by the end of the time course (figure 4.14c). This is 
however likely to be insignificant given the low percentage injected dose per gram 
data for this tissue. With the difference in both percentage uptake per gram of tissue 
and tissue to blood ratio data at days 1 and 6 between lung (the normal tissue with the 
highest percentage uptake per gram of tissue and tissue to blood ratio) and tumour 
tissue shown to be statistically significant (figure 4.14a), this data provided evidence 
of specific retention of HuMc3 in the MX-1 tumour. Unfortunately however a 
significant difference in percentage uptake per gram of tissue and tissue to blood ratio 
data at day 3 between tumour and lung tissue was not apparent, due to the large 
amount of variation at this time point for both the lung and tumour HuMc3 uptake. 
This may have been improved by increasing the number of animals at this time point.  
 
The MX-1 data agrees fairly well with past work in which MuMc3 and HuMc3 (using 
a similar radiotracer linkage system), showed specific HuMc3 uptake by MX-1 
tumours and maintenance at a near constant level of between 8% and 15% over the 8 
day experimental period for the different experiments [267][268][270]. For the three 
experiments carried out in past work, all but one were in close agreement with one-
another and with this work, showing maximum uptake around 15% [268][270]. The 
MX-1 data in this study also agreed with past work using a different linker system, 
that although showing a much higher percentage injected dose per gram of tumour 
and a greater separation between HuMc3 uptake by the tumour and normal murine 
tissues, showed a maintenance of a constant level of HuMc3 in the tumour from day 2 
to the end of the study at day 8 [268]. 
 
A small-scale pilot study was next carried out to assess whether HuMc3 targeted the 
MCF-7 tumour in the animal model and so help determine the validity of this model 
for further study. Samples were taken at days 3 and 8 following injection and the 
results are shown in figure 4.15.  The data appeared to show tumour selective uptake 
with 12.63% of the injected dose per gram of HuMc3 (figure 4.15b) in the tumour 
tissue at day 3 falling to 9.96% at day 8 and with the tumour to blood ratio data 
(figure 4.15c) above 1:1, at 1.95:1 on day 3, raising to 2.24:1 on day 8. The levels of 
HuMc3 in most normal tissues mirror that seen for the MX-1 studies with the 
percentage injected dose per gram starting at 3.8% or lower at day 3 and ending at day 
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8 below 2%  (figure 4.15b) and with tissue to blood ratios of around 0.56:1 or lower 
(figure 4.15c). Both the percentage injected dose per gram (figure 4.15b) and tissue to 
blood ratio (figure 4.15c) values for the lung tissue were however higher at 9.6% and 
1.5:1 respectively at day 3 and 4.8% and 1.1:1 at day 8. The day 8 percentage injected 
dose per gram and tissue to blood ratio values for the lung are significantly lower than 
for the tumour suggesting specific tumour uptake (figure 4.15a). The difference at day 
3 is not however significant (figure 4.15a). This may be due to the higher than 
expected values for the lung tissue, which suggests specific uptake into the tissue with 
higher levels of HuMc3 than the blood. This is however likely to be an artefact of the 
low number of mice used for each time point of just two. With the indication of 
tumour retention from this pilot study, a larger-scale study was commenced. 
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Figure 4.14 
In vivo localisation of I-125 labelled HuMc3 to MX-1 tumours implanted in BALB/c nu/nu mice  
HuMc3 injected at an activity of 0.05mCi/µl, detected as gamma emission of dissected tissues over a 
period of 5.5 days following injection. Tissue uptake displayed as percentage injected dose per gram of 
tissue (b) and tissue to blood ratio (c). (a) Statistical data table for percentage injected dose per gram 
and tissue to blood ratio data, plus t-tests. Three mice were included per time point and an average is 
shown. This figure is representative of the results of a single experiment.   
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A larger scale time-course study was carried out with the MCF-7 model over a 6.75 
day period, using three mice per time point and with samples taken at 6 hours, 1 day, 
3 days and 7 days post-injection (figure 4.16). The percentage injected dose per gram 
(4.16b) of HuMc3 in all normal tissues other than the blood, lung and kidney at 6 
hours post-injection was low at below 5% and fell throughout the experiment to 
2.86% or below by day 7. The kidney level began at 6 hours with elevated levels at 
8.2% but this rapidly fell by day 1 to 4.48, with levels similar to the other normal 
tissues from day 1 onwards (figure 4.16b). All non-lung normal tissues showed a 
tissue to blood ratio (figure 4.16c) of less than 1 throughout the experimental period, 
in agreement with MX-1 data and the pilot MCF-7 study. Like the MX-1 data, the 
levels in the lung followed the blood levels, with the percentage injected dose per 
gram beginning high at 9.49% at 6 hours and falling to 3.3% by day 7 (figure 4.16b) 
and with a tissue to blood ratio of near to 1:1 maintained through the experiment 
(figure 4.16c). Specific tumour uptake and retention is indicated by the percentage 
injected dose per gram data, beginning at around 5% at 6 hours similar to that of the 
normal tissues but rising to 8.21% at day 1, falling only slightly to 7.33% by day 7, 
whilst levels in the blood fall from 9.7% at day 1 to 3.7% by day 7 (figure 4.16b). The 
tumour to blood ratio consequently rises from 0.51:1 at 6 hours to 1.07:1 on day 1, 
through to 1.40:1 on day 3 to 1.99:1 by day 7 (figure 4.16c). Both the percentage 
injected dose per gram and tissue to blood ratio values for the tumour tissue at day 7 
are significantly higher than the lung tissue indicating specific uptake and retention of 
HuMc3 by the tumour tissue (figure 4.16a). The absolute values for tumour uptake 
between the pilot study and the scaled-up study however vary with the presence of 
12% injected dose per gram of tumour at day 3 in the pilot study, though the levels 
fell on day 8 to 10%, near to the value expected in the second study for this time 
point. As the initial study vas very small with only two mice per time point the larger 
scale data may be considered the more reliable. Again the day 3 time point percentage 
injected dose per gram and tissue to blood ratio data shows a less than significant 
difference between the tumour and lung tissue (figure 4.16a). With a variation in 
tumour uptake appearing to account for this, again this experiment may have been 
improved by including more animals in each time point for closer error bars and more 
reliable data. 
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Figure 4.15 
In vivo localisation of I-125 labelled HuMc3 to MCF-7 tumours implanted in BALB/c nu/nu mice - 
pilot study 
HuMc3 injected at an activity of 0.05mCi/µl, detected as gamma emission of dissected tissues at 3 and 
8 days following injection. Tissue uptake displayed as percentage injected dose per gram of tissue (b) 
and the tissue to blood ratio (c). (a) Statistical data table for percentage injected dose per gram and 
tissue to blood ratio data, plus t-tests. Two mice were included per time point and an average is shown. 
This figure is representative of the results of a single experiment.   
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Figure 4.16 
In vivo localisation of I-125 labelled HuMc3 to MCF-7 tumours implanted in BALB/c nu/nu mice 
HuMc3 injected at an activity of 0.05mCi/µl, detected as gamma emission of dissected tissues over a 
period of 6.5 days following injection. Tissue uptake displayed as percentage injected dose per gram of 
tissue (b) and tissue to blood ratio (c). (a) Statistical data table for percentage injected dose per gram 
and tissue to blood ratio data, plus t-tests. Three mice were included per time point and an average is 
shown. This figure is representative of the results of a single experiment.   
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A small-scale biodistribution study with the negative control HEK-293 cell line 
implant (figure 4.17) was carried out, with samples taken at 1 and 7 days post 
injection and including three mice per time point. The percentage injected dose per 
gram data (figure 4.17b) showed no specific implant uptake with levels at both time 
points no higher than in the other normal tissues at 4.78% on day 1 and 2.82% on day 
7. The tissue to blood ratio data was in agreement (figure 4.17c) showing no implant 
retention, with values below 1 at 0.60:1 at day 1 and 0.95:1 at day 7. The normal 
tissues other than the lung and the blood all began with a percentage injected dose per 
gram value of 6 or below on day 1 with levels falling to below 3 on day 7 (figure 
4.17b) and all demonstrated a tissue to blood ratio of below 1 (figure 4.17c). An 
unexpected aspect of the HEK-293 data however is the lack of elevated percentage 
injected dose per gram data for the lung tissue relative to other non-blood normal 
tissues at day 1 (figure 4.17b). It was considered that this may reflect an increased 
blood clearance of HuMc3 in this model, caused by lack of retention in the implant 
tissue mass. Past data with an MX-1 tumour model comparing distribution of HuMc3 
and an isotype-matched control antibody however disputes this, with similar values 
for percentage injected dose per gram in all normal tissues including the blood for the 
isotype control as HuMc3 [270]. The difference in expected values may simply reflect 
the small-scale nature of this study, though the small error bars indicate the data from 
the three mice at this time point to be in agreement. Taken together the biodistribution 
study data indicated specific tumour uptake of HuMc3 to both MX-1 and MCF-7 
human breast tumour xenografts in the BALB/c (nu/nu) murine model, with no 
consistent evidence of specific uptake of this antibody in any normal murine tissues or 
in the negative control non-tumour human tissue mass. HuMc3 was indicated to 
accumulate in the tumours with high levels maintained over the 6/7 day period of the 
larger-scale studies despite clearance from the blood. The higher percentage injected 
dose and tumour to blood ratios of HuMc3 achieved for the MX-1 than the MCF-7 
tumour model suggests higher expression of lactadherin by MX-1. 
 
The blood clearance of HuMc3 in the BALB/c (nu/nu) murine model was calculated 
by plotting the percentage injected dose per gram of blood for an earlier MX-1 pilot 
study (data not shown) and the scaled-up MX-1 and MCF-7 studies against time, 
shown in figure 4.18a (exp 1-3 respectively). The MCF-7 pilot study and HEK-293 
study were not included due to use of only two time points. The curves are 
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exponential and as they start at 6 hours post injection, they represent the β or terminal 
blood clearance. The β half life (t1/2β) is calculated as the time taken for the 
concentration of HuMc3 in the blood to fall by half. A mean value of 4.13 days 
(figure 4.18b) is determined, with all three values close, indicating the accuracy of 
this data. Although the rate of blood clearance in these studies is in close agreement, 
the starting percentage injected dose per gram of blood varies. The percentage 
injected dose per gram of blood in the two MCF-7 studies (figures 4.15-4.16) and the 
HEK-293 study (figure 4.17) are in agreement with that of past work [267][270] with 
levels at day 1 around 7-8%, falling to around 6 at day 3 and to around 3-4 by day 7. 
The data from the larger scale MX-1 study (figure 4.14) is near the expected values 
with the level at day 1 at 8%, day 3 at 7% and day 6 at 4.6%, though the pilot study 
showed some variation with a value of 10% at day 3 and 4.9% by day 7 (figure 
4.18a). The 6 hours post injection values also varied, with MX-1 at 15% and MCF-7 
10%, but no published data is available for HuMc3 clearance at this time point.  
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Figure 4.17 
In vivo localisation of I-125 labelled HuMc3 to HEK-293 negative control tissue mass implanted in 
BALB/c nu/nu mice. 
HuMc3 injected at an activity of 0.05mCi/µl, detected as gamma emission of dissected tissues at 1 and 
7 days following injection. Tissue uptake displayed as percentage injected dose per gram of tissue (b) 
and the tissue to blood ratio (c). (a) Statistical data table for percentage injected dose per gram and 
tissue to blood ratio data, plus t-tests. Three mice were included per time point and an average is 
shown. This figure is representative of the results of a single experiment.   
(a)  
(b) 
0
5
10
15
20
25
Pe
rc
e
n
ta
ge
 
in
jec
te
d 
do
se
 
12
5 I-
Hu
M
c3
 
pe
r 
gr
a
m
 
o
f t
is
su
e
Day 1
Day 7
 
(c)  
0
1
2
3
4
5
Ti
ss
u
e
 
to
 
bl
oo
d 
ra
tio
 
12
5 I-
H
u
M
c3
Day 1
Day 7
 
Tumour % injected dose per gram Day 1 Day 7 t-test Tumour / lung day 1 Tumour/ lung day 7 
N 3 3 t Stat -3.11 -0.90 
Mean 4.78 2.82 P(T<=t) one-tail 0.02 0.21 
SD 0.42 0.27 t Critical one-tail 2.13 2.13 
 
  P(T<=t) two-tail 0.04 0.42 
 
  t Critical two-tail 2.78 2.78 
Tumour : blood ratio Day 1 Day 7 t-test Tumour / lung day 1 Tumour/ lung day 7 
N 3 3 t Stat -2.92 -1.48 
Mean 0.60 0.95 P(T<=t) one-tail 0.02 0.11 
SD 0.01 0.06 t Critical one-tail 2.13 2.13 
 
  P(T<=t) two-tail 0.04 0.21 
 
  t Critical two-tail 2.78 2.78 
  
 192
Figure 4.18 
Exponential decay curves for calculation of the t1/2β of HuMc3 in the murine circulation 
(a) Percentage injected dose of 125I-HuMc3 per gram of blood, plotted against time after injection. 
Displayed is data from three separate experiments. Each error bar denotes 3 experimental repeats. The 
exponential decay, single, 2-parameter curves have been formed using SigmaPlot11.0.  Included are 
the β-half lives of HuMc3, calculated from the curves as time taken for the percentage injected dose/ 
gram of blood to fall by half. (b) Statistical data table displaying β-half life data.  
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Curves fitted by Sigmaplot11.0  using the equation exponential decay, single, 2 parameter.  Exp 1 Normality test (Shapiro-Wilk) Passed (P = 
0.2002), W statistic= 0.8346, significance level = 0.0500. Constant variance test failed (P =<0.0001). Exp 2 Normality test (Shapiro-Wilk) Passed 
(P = 0.0518), W statistic= 0.7641, significance level = 0.0500. Constant variance test failed (P =<0.0001). Exp 3 Normality test (Shapiro-Wilk) 
Passed (P = 0.5071), W statistic= 0.9146, significance level = 0.0500. Constant variance test failed (P =<0.0001).  
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4.3 Discussion 
 
The findings of this chapter were as follows; Confirmation of lack of HuMc3 
localisation to a tissue mass formed by HEK-293 cells in vivo.  Indication of a lack of 
lactadherin expression by the tumour cell line SKOV3, but expression of lactadherin 
by the tumour cell line MCF-7. The in vivo biodistribution studies demonstrated 
specific uptake and retention of HuMc3 to both MCF-7 and MX-1 tumour xenografts 
with maximal levels maintained in the tumour masses and with tissue to blood ratios 
rising, from the beginning (1 day for MCF-7 percentage injected dose per gram data) 
until the end of the studies. The high tumour to blood ratios, percentage injected dose 
per gram of tumour tissue, maintenance of high levels of HuMc3 in both MX-1 and 
MCF-7 tumours and lack of specific uptake by normal murine tissues indicated a high 
in vivo affinity of HuMc3 for tumour lactadherin, as well as high specificity and 
selectivity in its association. HuMc3 was however shown to clear from the blood of 
the murine model with t1/2β of just 4.1 day, far below the expected 21 days of this 
antibody isotype [233], though whether this was caused by lack of HuMc3 or tracer 
stability was not determined. This work overall suggested the potential suitability of 
MX-1 and MCF-7 tumour models as targets for HuMc3 therapy studies and HEK-293 
as a negative control, though the effect of the potentially low HuMc3 serum half life 
would need to be determined.  It also showed the potential of HuMc3 as a selective 
tumour targeting drug with limited predicted toxicity. 
 
4.3.1 HuMc3 tumour cell binding studies 
 
HuMc3 MCF-7 tumour cell surface localisation in vitro was suggested by confocal 
microscopy studies with surface fluorescence detected with HuMc3 application, but 
with none in the isotype-matched control. SKOV3 cells showed no surface 
fluorescence with HuMc3 application, implying no association of this antibody. A 
weakness of the MCF-7 data however was the lack of a non-tumour cell line negative 
control such as HEK-293, to allow confirmation that the fluorescence observed 
occurred as a result of specific HuMc3 binding to cell surface lactadherin expressed 
by this cell line. The specificity of this binding is however supported by the lack of 
isotype control binding. In addition the specificity of the association for tumour 
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expressed lactadherin was suggested by the lack of HuMc3 binding and limited 
HuHMFG1 binding to MCF-7 after an overnight incubation of cells with media. Only 
after 48 hours in media was HuMc3 binding and a greater HuHMFG1 signal evident, 
suggesting time is needed for re-expression of these antigens following cell 
dissociation. This correlates well with past data showing loss of the majority of 
lactadherin and other HME-Ags including MUC1 tumour mucin by breast tumour cell 
lines following cell dissociation [255].  
 
With hindsight it has been realised that using HuMc3 to detect lactadherin expression 
by tumour cells may have been to some degree misleading. The epitope of lactadherin 
to which HuMc3 associates has been mapped to the integrin-binding EGF domain 
[263] and HuMc3 has been shown in past work (in its murine form) [154] and in this 
thesis (sections 5.2.2 and 6.2.2) to inhibit lactadherin binding to 
αvβ3/αvβ5expressing cell lines. HuMc3 may therefore only be expected to detect 
lactadherin on the cell surface when in association with membrane phospholipids by 
its C2 domain and not when in association with αvβ3/αvβ5 integrins by its integrin 
binding domain.   As past work has however demonstrated lactadherin to be expressed 
and transported to the cell surface in association with the C2 domain 
[151][152][153][155][177], it would have been expected that if SKOV3 did express 
this antigen, some HuMc3 binding would have been observed. A more thorough study 
would however have detected lactadherin expression on the cell surface in association 
with C2 alone, using HuMc3, with integrins alone using C2 terminus binding Mc16, 
or both, with the C2 binding Mc8 [151][194]. This was not however a possibility 
during this project as these antibodies could not be made available. With the antibody 
mAb2767 indicated later in this thesis (section 6.2.1) to bind to the EGF domain, cell 
surface staining by this antibody could however have been used and comparisons 
made with the staining patterns of HuMc3, thereby providing another means to 
confirm the specificity of this association.  
 
As the FACS and cell ELISA study results proved inconclusive, with no specific 
HuMc3 association detected by SKOV3, MCF-7 or HEK-293 cells, lactadherin 
expression may have been studied by RT-PCR to provide supporting evidence to the 
confocal microscopy data. The detection of expression by RT-PCR would have been 
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useful to confirm past work [176] which used this method to demonstrate expression 
of lactadherin in SKOV3 and MCF-7 cells. It is however possible that the past paper 
which showed strong lactadherin expression by SKOV3 cells using RT-PCR was 
inaccurate, as it also showed expression by the tumour line HT-29, which is one of the 
cell lines that Mc3 and the other anti-HMFG mAbs were adsorbed against and so 
showed no binding to [262]. 
 
4.3.2 HuMc3 biodistribution studies 
 
As observed in the past studies [267][268][270] no specific uptake of HuMc3 was 
detected in any normal murine tissues. Neither was any specific uptake observed by a 
tissue mass formed by the HEK-293 cell line, indicating both the selectivity and 
specificity of this antibody for lactadherin expressed by these tumours. As however a 
murine model was used, it is not possible to be certain of the specificity data. 
Although HuMc3 had been shown not to associate with any normal murine antigen, 
there cannot be certainty it will not cross-react with a human antigen when applied 
therapeutically. It is also possible that HuMc3 may associate with human lactadherin 
expressed by normal human tissues despite showing no association with murine 
lactadherin expressed in normal murine tissues of the model. The sequences of murine 
MFG-E8 and human lactadherin only show 45% homology in the EGF-like domain 
[175] so the confidence that HuMc3 would bind to murine lactadherin is not high. In 
retrospect a plate-based binding assay should have been carried out to confirm this. 
As however past work detected no Mc3 binding to a panel of normal human tissues by 
immunohistochemistry, but association with primary human breast tumours [265] 
some confidence in the selectivity of HuMc3 for human tumour tissues and lack of 
potential for clinical toxicity may be afforded. 
 
A higher percentage injected dose per gram of tissue and tissue to blood ratio was 
achieved for the MX-1 study than the MCF-7, suggesting higher lactadherin 
expression by MX-1 tumours. The variation in percentage uptake per gram of tissue 
between the pilot MCF-7 study and scaled-up study do however cast some doubt on 
this, though the pilot study data was considered less reliable due to the inclusion of 
only two mice per time point. Further repeats of the MCF-7 study may have allowed 
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greater confidence in the conclusion of higher expression of lactadherin by MX-1 
tumours.   
 
A weakness of the biodistribution data is the lack of control studies using an isotype 
control antibody, to rule out the possibility that the observed tumour localisation is a 
non-specific effect caused by non-specific tumour uptake of this antibody isotype. 
Past work with the MX-1 cell line in which an isotype control study was included 
[270] may however to some degree allay this concern. The overall quality of this data 
could however have been improved by the inclusion of more animals at each time 
point, as there were some data points in which although a large difference between the 
tumour and lung data could be observed the difference was not statistically 
significant. This was put down to the variation in the data, particularly for the tumour, 
resulting, perhaps from a variation in the level of lactadherin expression. In hindsight, 
at least five mice should have been included per time point rather than the three used, 
to reduce the error of the studies and increase confidence in the data interpretation. In 
addition, had the budget of the project permitted, the studies would have been 
repeated, again for increased data confidence and to confirm the reproducibility of the 
MCF-7 and HEK-293 data. In addition, the time-course of the studies would have 
been extended to see how long HuMc3 percentage injected dose per gram levels were 
maintained in the tumour, how long the tissue to blood ratio continued to rise and how 
long it took for the levels of this antibody to fall to those of the normal tissues. This 
may have been helpful as a starting point for in vivo therapy study dosing schedules.  
 
The low t1/2β of 4.1 days for HuMc3 compared to the expected value for an IgG1 of 
21 days [233] was initially a concern. As HuMc3 would later be tested therapeutically 
as an unconjugated antibody, it was considered the longer this antibody was available 
for target association the more potentially effective. It is however possible that the 
t1/2β derived in this experimental series was not accurate, as it is possible that the 
radiotracer or linker was degraded more quickly than the antibody itself and so the 
t1/2β determined does not represent that of the antibody itself, but the rate of 
degradation of the conjugate. As the linker system used was suggested in past work to 
interfere with HuMc3/lactadherin association [268] it is also possible that HuMc3 in 
its unconjugated form may be retained in the tumour longer due to the higher affinity 
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for its target and so increase the t1/2β further than suggested by these studies. There 
was therefore reason to be hopeful that HuMc3 may be retained for a sufficient time 
to have the potential to show some therapeutic effect. The serum stability of HuMc3 
should have been assessed by ELISA and compared with other IgG1 isotype 
antibodies. The stability of the tracer and linker should also have been determined by 
a similar assay but with detection of the radiotracer (radioimmunoassay). This would 
have allowed confirmation of whether the low t1/2β was caused by an unstable tracer 
system or by degradation of the antibody itself. In addition, it may have been better to 
use an alternative radiotracer linkage system as described in past work [268]. If this 
were the case, either higher HuMc3 targeting would have been expected as a result of 
the higher target affinity or alternatively it is possible that the radiotracer system used 
in past work [268] showed higher apparent tumour targeting and retention as a result 
of higher tracer/linker/HuMc3 stability, with much of the detection of tumour uptake 
lost in this study a result of decay of the conjugate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 198
Chapter 5  Investigating the roles of lactadherin in angiogenesis 
 
 
5.1 Introduction 
 
 
To investigate whether the role of lactadherin expression by tumours could be 
promotion of vascular growth, the ability of lactadherin to promote and HuMc3 
interfere with vascular EC proliferation and survival in vitro would be examined. 
HUVECs were in themselves chosen as a model cell to study the effects of lactadherin 
and HuMc3 as they are relatively easy to grow in tissue culture conditions and have 
been shown to express the integrins αvβ3 and αvβ5 [173]. 
 
FACS and plate based cell binding assays with HUVECS would be included to 
confirm whether lactadherin associates with the cell surface via integrins αvβ3 and 
αvβ5. This would be investigated using antibodies LM609 and P1F6, previously 
shown to block ligand binding to αvβ3 and αvβ5 integrins respectively (section 1.3.2) 
and a soluble αvβ3 integrin receptor which was predicted to bind to lactadherin and 
so reduce cell-surface integrin association. Other ligands for the integrins αvβ3 and 
αvβ5 known to bind via a RGD sequence would also be tested for their ability to 
interfere with lactadherin binding to the cell surface, including vitronectin, known to 
bind to both receptors and fibronectin (section 1.2.3) known to associate with αvβ3. 
The FACS and plate based cell binding assays would also be used to test whether 
HuMc3 could neutralise the interaction of lactadherin with the cell surface. The plate 
based method was chosen as this assay had been used successfully in past work to 
show lactadherin binding to HUVECS, [173] MA-104 and MCF-7 cells (section 
1.3.2). 
 
HUVEC cell proliferation and apoptosis assays were chosen to confirm the roles of 
lactadherin in coordinated VEGF-A-αvβ5/αvβ3-mediated angiogenesis and VEGF-
A-independent αvβ3/αvβ5-mediated angiogenesis. The effects of application of 
lactadherin in the presence and absence of VEGF and the effects of inhibition of 
lactadherin integrin ligation with HuMc3 and of VEGFR2 ligation with bevacizumab 
on angiogenesis would be assessed. A role of lactadherin in survival and proliferation 
was possible as activation of cell survival through signalling inhibiting both intrinsic 
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and extrinsic apoptosis and signalling promoting proliferation had been demonstrated 
in cells through integrin ligation (section 1.1.1). In addition, a role of lactadherin in 
survival through integrin ligation independent of VEGFR-2 was likely as this had 
been demonstrated both in a tumour cell model and in HUVECS [173][197]. 
Lactadherin was also predicted to be required for VEGFR2-αv integrin coordinated 
survival pathways as past work had not only demonstrated the requirement of 
lactadherin for the angiogenesis-response induced by VEGF application, but more 
specifically for the elevation of activated intrinsic apoptosis survival pathway 
intermediate Akt, induced by VEGF [173]. Integrin ligation had also been 
demonstrated to be required for coordinated VEGFR2-αv integrin activation of 
extrinsic apoptosis.  Lactadherin was predicted not to be required for VEGFR2-
mediated proliferation as past work had ruled this out, [173] but this would be 
assessed anyway to confirm this.  
 
HuMc3 was predicted to inhibit the roles of lactadherin in both independent and 
VEGF-mediated angiogenesis due to its ability to neutralise lactadherin binding to 
integrins. Bevacizumab had already been indicated to block VEGF-binding to 
VEGFR2 (section 1.2.5.1). This antibody was therefore expected to block VEGF-
mediated proliferation and survival through intrinsic apoptosis. The effects of 
bevacizumab and HuMc3 on HUVEC proliferation and survival would also be 
compared. The aim would be to assess the potential of HuMc3 as an anti-angiogenesis 
therapeutic and determine whether it could match that of the “gold standard,” anti 
angiogenesis therapeutic bevacizumab. 
 
The apoptosis assay to be used would detect apoptosis using the Caspase-Glo® 3/7 
(Promega) reagent, chosen for its sensitive measurement of levels of the effector 
caspase enzymes caspase 3 and 7, which would be suitable to detect changes in levels 
of intrinsic apoptosis in the absence of an apoptosis activator and changes in the level 
of extrinsic apoptosis in the presence of a TRAIL (tumour necrosis factor-related 
apoptosis-inducing ligand) death receptor ligand. Staurosporine was chosen as a 
TRAIL ligand as it has been documented to activate intrinsic apoptosis in human 
endothelial cells [300]. 
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It was thought these assays may not only give information about the roles of 
lactadherin in these specific pathways, but be predictive of the results of in vivo 
angiogenesis assays. Past work had shown a correlation between the results of these 
types of in vitro angiogenesis assays and measurement of angiogenesis in animal 
models as well as the results of more complex in vitro assays such as tube formation 
[301][302].  
 
The aims of this chapter were to confirm past data indicating lactadherin promotion of 
angiogenesis through ligation of the integrins αvβ3 and αvβ5, though activation of 
VEGF-independent and VEGF-mediated angiogenesis and to study the ability of 
HuMc3 to neutralise lactadherin binding to vascular EC’s and inhibit its roles in 
angiogenesis. 
 
The objectives were as follows; 
• Ascertain whether HuMc3 interferes with lactadherin binding to vascular EC 
integrins by FACS and cell binding assays. 
• Study whether lactadherin may play a role in protection against extrinsic 
apoptosis as well as confirming roles in protection against intrinsic apoptosis and 
confirming a lack of a role in proliferation. 
• Investigate the ability of HuMc3 to interfere with the roles of lactadherin in 
VEGF dependent and independent HUVEC survival and proliferation. 
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5.2 Results 
 
5.2.1 Lactadherin expression by human vasculature EC’s and binding 
via integrin receptors 
 
The first question tackled in this chapter was whether lactadherin is expressed by 
human vascular EC’s themselves and therefore if it could have a self-stimulating or 
autocrine effect on the vasculature. This was investigated using HUVECS to detect 
binding of a commercial anti-lactadherin antibody mAb2767 and HuMc3 by both 
FACS analysis (section 2.2.5.4) (figures 5.1-5.2 and figures 5.3-5.4) and IF confocal 
microscopy (section 2.2.5.3) (figure 5.9), using FITC-conjugated secondary 
antibodies for detection of association. Antibodies against the VEGFR-2 receptor 
(mAb3572) and αvβ3 integrin (mAb3050) were used as positive controls for the 
FACS (figures 5.5-5.6 and figures 5.7-5.8) and IF confocal microscopy (figure 5.9). 
Steps were taken to reduce the likelihood of missing lactadherin expression including 
reducing cleavage from the cell surface during the FACS protocols by avoiding 
enzymatic cell dissociation methods. In addition, in the IF microscopy protocol, to 
allow lactadherin to be expressed de novo, the cells were cultured for 48 hours after 
adding to coverslips. This was considered justified as this had been shown (section 
4.2.1) to allow detection of lactadherin on the surface of MCF-7 tumour cells.  
 
The FACS data is presented as two figures including a representative data figure 
supplied first showing an overview table (a), with information including percentage 
FL1+ve gated cells and median FL1-H intensity of gated cells, (b) all shifts overlaid 
on a single plot and (c) single shifts plotted with the negative controls. A second 
figure combines the percentage FL1+ve gated cells (b) and median FL1-H intensity of 
gated cells (c) data from three studies and includes a statistical data table with t-tests 
(a). 
 
Figures 5.1-5.2 show the results of a FACS study detecting binding of mAb2767 to 
HUVECS. Included are a range of concentrations of mAb2767 between 13nM and 
267nM. Negative controls were cells alone and secondary antibody alone, and any 
shift in signal was considered relative to these. For the representative data (figure 5.1) 
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no shift in signal was evident for any of the concentrations used (figure 5.1b and 
figure 5.1c). The combined data (figure 5.2) however shows a small, statistically 
significant (figure 5.2a) increase in both FL1-H intensity of the gated cells, (figure 
5.2c) and FL1+ve gated cells (figure 5.2b) between the lowest and highest mAb2767 
concentrations. Figures 5.3-5.4 show the result of a FACS assay detecting binding of 
HuMc3 to HUVECs at concentrations of 6.67, 66.7 and 167nM. An isotype-matched 
IgG1, used at the corresponding concentrations was included as a negative control as 
well as cells alone and secondary antibody alone and any shift in signal considered 
relative to the latter two. No shift in signal was evident for any of the HuMc3 
concentrations (figure 5.3b and figure 5.3c). This was confirmed by the combined 
data (figure 5.4) in which no significant difference (figure 5.4a) was observed for 
either percentage of FL1 +ve gated cells (figure 5.4b) or median FL1-H intensity 
(figure 5.4c) between the HuMc3 concentrations and their corresponding isotype 
controls. Taken together the FACS data therefore indicated lactadherin is not present 
on the surface of HUVECs. Figures 5.5-5.8 show the positive control HUVECS 
FACS assays for VEGFR-2 and integrin αvβ3 expression respectively.  The integrin 
αvβ3 is confirmed to be a good positive control as a highly expressed surface 
receptor; with strong shifts from controls in the representative data (figure 5.7b-c) and 
significant (figure 5.8a) increases in percentage FL1+ve gated cells (figure 5.8b) and 
median FL1-H intensity of gated cells (figure 5.8c) confirmed by the combined data. 
VEGFR-2 as a more minimally expressed surface receptor proved a less ideal positive 
control (figures 5.5-5.7). Although a small visible shift was evident from the controls 
(figure 5.5b-c), the combined data showed the difference in both percentage FL1+ve 
gated cells (figure 5.6b) and median FL1-H intensity of gated cells (figure 5.6c) 
signals to be insignificant (figure 5.6a). This may however have been improved by the 
performance of further assay repeats as both experiments showed a percentage 
FL1+ve gated cells and median FL1-H intensity of gated cells increase from control, 
but varied in the magnitude.  
 
In order to determine with more confidence whether or not lactadherin is expressed by 
HUVECs, IF confocal microscopy was carried out with mAb2767 and HuMc3 used at 
high concentrations to detect expression, allowing 48 hours after coating of cells onto 
coverslips to permit re-expression of antigen. Figure 5.9 shows the results of IF 
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confocal microscopy, with mAb2767 (1333nM figure 5.9a), HuMc3 (1333nM figure 
5.9b) and the positive control anti-αvβ3 (66.7nM figure 5.9c). No signal was 
observed for mAb2767 and HuMc3 despite the use of high antibody concentrations. 
Again the experimental procedure was shown to be working by the visible signal in 
the positive control. To confirm lactadherin was not expressed by this cell but had 
failed to become localised to the cell surface/had been lost from the surface during the 
procedures, a western blot of HUVEC cell lysate (section 2.2.5.2) was carried out to 
detect lactadherin expression within the cell, the results of which are shown in figure 
5.10. Although the structure of lactadherin was likely to be altered by the reducing 
conditions of the cell interior due to the presence of di-sulphide bonds (section 1.3.1), 
a signal was expected if lactadherin were expressed as mAb2767 had been shown 
(and was documented in its accompanying literature) to bind to lactadherin under both 
reducing and denaturing conditions (section 3.2). Again however lactadherin was 
indicated not to be expressed, with no detection by mAb2767. 
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Figure 5.1 
FACS analysis with mAb2767 to investigate lactadherin expression by HUVECS 
Binding of mAb2767 (13.3, 33.3, 66.7, 133 and 267nM), detected with an anti-mouse FITC secondary 
F5262 (1 in 1000 dilution). Secondary antibody alone and cells alone negative controls included. (a) 
Overview table describing the sample name and description, percentage gated cells, percentage of 
gated cells positive for fluorescence (FL1+), median fluorescent intensity of gated cells (FL1-H) and 
percentage FL1+ve total cells. (b) Half offset overlay plot of all samples. (c) Individual sample shifts 
plotted against a secondary antibody alone and cells alone controls, with FSC-H, SSC-H plots 
attached; (i-v) mAb2767 concentrations (13.3, 33.3, 66.7, 133 and 267nM). Data represents three 
experiments. 
(a) 
Sample description Sample name Percentage gated 
cells (%) 
Percentage FL1+ve 
gated cells (%) 
Median FL1-H 
intensity of gated cells 
Percentage FL1+ve 
total cells (%) 
mAb2767 (13.3nM 2mg_ml. 002 87.12 15.01 3.02 13.08 
mAb2767 (33.3nM) 5mg_ml. 003 86.60 16.39 3.13 14.19 
mAb2767 (66.7nM) 10mg_ml. 004 86.34 18.07 3.26 15.60 
mAb2767 (133nM) 20mg_ml. 005 86.96 17.65 3.20 15.34 
mAb2767 (267nM) 40mg_ml. 006 85.00 19.81 3.35 16.83 
Secondary antibody alone  No p. 001 84.79 15.86 2.99 13.45 
Cells alone Just cells. 007 85.15 14.22 2.85 12.11 
 
(b)        (c)(i) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(ii)       (iii) 
 
 
 
 
 
 
 
 
 
 
 
 
(iv)       (v) 
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Figure 5.2 
FACS analysis with mAb2767 to investigate lactadherin expression by HUVECS– combined data 
Displayed is the corrected percentage FL1+ve gated cells (b) and median FL1-H intensity of gated 
cells (c) data from three separate experiments as described in figure 5.1 and an average of the three 
(combo). Absorbance corrected to zero using a secondary antibody alone control. (a) Statistical data 
table displaying the average of three separate experiments (combo data) and t-tests. 
(a) 
Combo data           
Percentage FL1+ve gated cells mAb2767 
(13nM) 
mAb2767 
(67nM) 
mAb2767 
(133nM) 
mAb2767 
(267nM) 
t-test mAb2767 (267nM)/mAb2767 
(13nM) 
N 3 3 3 3 t Stat 2.68 
Mean -0.53 0.75 0.96 2.12 P(T<=t) one-tail 0.03 
SD  0.53 1.27 0.74 1.63 t Critical one-tail 2.13 
 
    P(T<=t) two-tail 0.06 
 
    t Critical two-tail 2.78 
Median FL1-H intensity of gated cell 
mAb2767 
(13nM) 
mAb2767 
(67nM) 
mAb2767 
(133nM) 
mAb2767 
(267nM) 
t-test mAb2767 (267nM)/mAb2767 
(13nM 
N 3 3 3 3 t Stat 2.49 
Mean -0.03 0.25 0.38 0.50 P(T<=t) one-tail 0.03 
SD 0.26 0.05 0.21 0.26 t Critical one-tail 2.13 
 
    P(T<=t) two-tail 0.07 
 
    t Critical two-tail 2.78 
(b) 
 
(c) 
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Figure 5.3 
FACS analysis with HuMc3 to investigate lactadherin expression by HUVECS 
Binding of HuMc3 and IgG1 isotype matched antibody (6.67, 66.7 and 167nM), detected with an anti-
human FITC secondary F5512 (1 in 1000 dilution). Also included are cells alone and secondary 
antibody alone controls (a) Overview table describing the sample name and description, percentage 
gated cells, percentage of gated cells positive for fluorescence (FL1+), median fluorescent intensity of 
gated cells (FL1-H) and percentage FL1+ve total cells. (b) Individual sample shifts plotted against 
assay controls, with FSC-H, SSC-H plots attached; (i-vi) HuMc3 and corresponding isotype control 
concentrations (6.67, 66.7 and 167nM). Data represents four experiments. 
(a) 
 
Sample description Sample name Percentage gated 
cells (%) 
Percentage FL1+ve 
gated cells (%) 
Median FL1-H 
intensity of gated cells 
Percentage FL1+ve 
total cells (%) 
Cells alone  HUVEC 1.001 64.66 5.79 6.27 3.75 
Secondary antibody alone HUVEC 2.002 55.64 6.50 6.95 3.62 
HuMc3 (6.67 nM) HUVEC 3.003 67.03 7.13 7.73 4.78 
HuMc3 (66.7nM) HUVEC 4.004 63.24 9.57 8.09 6.05 
HuMc3 (167nM) HUVEC 5.005 63.79 8.05 7.73 5.14 
IgG1 isotype –ve control (6.67 nM) HUVEC 6.006 58.00 6.31 7.20 3.66 
IgG1 isotype –ve control (66.7nM) HUVEC 7.007 64.05 7.10 7.17 4.55 
IgG1 isotype –ve control (167nM) HUVEC 8.008 66.00 5.83 6.74 3.85 
 
 
 
 
 
(b) 
(i)       (ii) 
 
 
 
 
 
 
 
 
 
 
 
 
(iii)       (iv) 
 
 
 
 
 
 
 
 
 
 
 
 
(v)       (vi) 
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Figure 5.4 
FACS analysis with HuMc3 to investigate lactadherin expression by HUVECS– combined data 
Displayed is the percentage FL1+ve gated cells (b) and median FL1-H intensity of gated cells (c) data 
from three separate experiments as described in figure 5.3 and an average of the three (combo). (a) 
Statistical data table displaying the average of three separate experiments (combo data) and t-tests. 
(a) 
Combo data            
Percentage FL1+ve gated cells HuMc3 
(67nM) 
HuMc3 
(167nM) 
I Con 
(67nM) 
I Con 
(167nM) 
t-test HuMc3 (167nM)/I 
Con (167nM) 
HuMc3 (67nM)/I 
Con (67nM) 
N 4 4 4 4 t Stat 0.94 0.75 
Mean 7.84 7.47 6.62 6.24 P(T<=t) one-tail 0.19 0.24 
SD 1.45 1.12 2.92 2.39 t Critical one-tail 1.94 1.94 
 
    P(T<=t) two-tail 0.39 0.48 
 
    t Critical two-tail 2.45 2.45 
Median FL1-H intensity of gated 
cells 
HuMc3 
(67nM) 
HuMc3 
(167nM) 
I Con 
(67nM) 
I Con 
(167nM) t-test 
HuMc3 (167nM)/I 
Con (167nM) 
HuMc3 (67nM)/I 
Con (67nM) 
N 4 4 4 4 t Stat 0.23 0.22 
Mean 4.36 4.24 3.98 3.87 P(T<=t) one-tail 0.41 0.42 
SD 2.58 2.43 2.26 2.07 t Critical one-tail 1.94 1.94 
 
    P(T<=t) two-tail 0.82 0.83 
 
    t Critical two-tail 2.45 2.45 
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Figure 5.5 
FACS analysis to investigate lactadherin expression by HUVECS – VEGFR-2 positive control 
Binding of anti-VEGFR2 antibody mAb3572 (66.7, 133 and 267nM), detected with anti-mouse FITC 
secondary F5262 (1 in 1000 dilution). Secondary antibody alone negative control included. (a) 
Overview table describing the sample name and description, percentage gated cells, percentage of 
gated cells positive for fluorescence (FL1+), median fluorescent intensity of gated cells (FL1-H) and 
percentage FL1+ve total cells. (b) Half offset overlay plot of all samples. (c) Individual sample shifts 
plotted against secondary antibody alone control, with FSC-H, SSC-H plots attached; (i-iii) mAb3572 
concentrations 6.67, 66.7 and 167nM. Data represents two separate experiments. 
(a) 
 
Sample description Sample name Percentage gated 
cells (%) 
Percentage FL1+ve 
gated cells (%) 
Median FL1-H 
intensity of gated cells 
Percentage FL1+ve 
total cells (%) 
anti-VEGFR2 (66.7nM) Anti VEGFR2 10.002 70.66 45.57 12.70 32.20 
anti-VEGFR2 (133nM) Anti VEGFR2 20.003 68.86 44.46 12.49 30.61 
anti-VEGFR2 (267nM) Anti VEGFR2 40.004 58.91 49.81 13.78 29.34 
Secondary antibody alone No p.001 66.38 4.58 5.91 3.04 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(c) 
(i)       (ii) 
 
 
 
 
 
 
 
 
 
 
 
(iii) 
  
 209
Figure 5.6 
FACS analysis to investigate lactadherin expression by HUVECS – VEGFR-2 positive control 
combined data 
Displayed is the corrected percentage FL1+ve gated cells (b) and median FL1-H intensity of gated 
cells (c) data from two separate experiments as described in figure 5.5 and an average (combo). (a) 
Statistical data table displaying the average of three separate experiments (combo data) and t-tests 
(a) 
Combo data            
Percentage 
FL1+ve gated cells 
 
 
No P 
mAb3572 
(67nM) 
mAb3572 
(133nM) 
mAb3572 
(267nM) 
t-test No P/ 
mAb3572 
(133nM) 
 
mAb3572 (267nM)/ 
mAb3572 (133nM) 
 
mAb3572 
(267nM)/ No P 
N 2 2 2 2 t Stat -1.64 -0.19 1.89 
Mean 4.52 30.04 30.38 34.13 P(T<=t) one-tail 0.12 0.43 0.10 
SD  0.09 21.96 19.91 22.17 t Critical one-tail 2.92 2.92 2.92 
 
    P(T<=t) two-tail 0.24 0.87 0.20 
 
    t Critical two-tail 4.30 4.30 4.30 
Median FL1-H 
intensity of gated 
cells 
 
 
No P 
mAb3572 
(67nM) 
mAb3572 
(133nM) 
mAb3572 
(267nM) 
t-test No P/ 
mAb3572 
(133nM) 
 
mAb3572 (267nM)/ 
mAb3572 (133nM) 
 
mAb3572 
(267nM)/ No P 
N 2 2 2 2 t Stat -1.02 -0.20 1.14 
Mean 4.67 8.83 8.85 9.61 P(T<=t) one-tail 0.21 0.43 0.19 
SD 1.75 5.48 5.15 5.90 t Critical one-tail 2.92 2.92 2.92 
 
    P(T<=t) two-tail 0.41 0.86 0.37 
 
    t Critical two-tail 4.30 4.30 4.30 
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Figure 5.7 
FACS analysis to investigate lactadherin expression by HUVECS – αvβ3 integrin positive control 
Binding of anti-αvβ3 integrin antibody mAb3050 (66.7nM), detected with anti-mouse FITC secondary 
F5262 (1 in 250, 1 in 500 and 1000 dilutions). Secondary antibody alone and cells alone negative 
controls included. (a) Overview table describing the sample name and description, percentage gated 
cells, percentage of gated cells positive for fluorescence (FL1+), median fluorescent intensity of gated 
cells (FL1-H) and percentage FL1+ve total cells. (b) Half offset overlay plot of all samples. (c) 
Individual sample shifts plotted against secondary antibody alone and cells alone controls, with FSC-
H, SSC-H plots attached; (i-iii) 1 in 250, 1 in 500 and 1 in 1000 secondary dilutions. Data represents a 
single experiment. 
 (a) 
Sample description Sample name Percentage 
gated cells (%) 
Percentage FL1+ve 
gated cells (%) 
Median FL1-H 
intensity of gated cells 
Percentage FL1+ve 
total cells (%) 
mAb3050 (66.7nM) with 1 in 250 F5262 1 in 250.007 88.37 98.55 27.90 87.08 
mAb3050 (66.7nM) with 1 in 500 F5262 1 in 500.005 89.39 97.38 24.29 87.05 
mAb3050 with 1 in 1000 F5262 1 in 1000.003 89.92 96.49 22.63 86.76 
1 in 250 F5262 alone –ve  No P 1 in 250.006 89.19 5.20 3.17 4.63 
1 in 500 F5262 alone –ve  No P 1 in 500.004 88.82 4.57 3.06 4.06 
1 in 1000 F5262 alone –ve  No P 1 in 1000.001 88.70 4.65 3.02 4.13 
Cells alone –ve Just cells.001 90.22 4.08 2.97 3.68 
(b) 
 
 
 
 
 
 
 
 
 
 
 
(c) 
(i)       (ii) 
 
 
 
 
 
 
 
 
 
 
 
 
(iii)   
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Figure 5.8 
FACS analysis to investigate lactadherin expression by HUVECS – αvβ3 integrin positive control 
combined data 
Displayed is the corrected percentage FL1+ve gated cells (b) and median FL1-H intensity of gated 
cells (c) data from three separate experiments as described in figure 5.7 and an average of the three 
(combo) (but only including mAb3050 with 1 in 1000 dilution of F5262secondary antibody and 1 in 
1000 secondary antibody alone control). (a) Statistical data table displaying the average of three 
separate experiments (combo data) and t-tests. 
(a) 
Combo data      
Percentage FL1+ve 
gated cells 
mAb3050 (67nM) with F5262 
(1 in 1000) 
1 in 1000 F5262 
alone –ve 
t-test F5262 (1 in 1000) + 
mAb3050/ (1 in 1000) 
N 3 3 t Stat 36.49 
Mean 92.55 4.44 P(T<=t) one-tail 1.68E-06 
SD  4.18 0.21 t Critical one-tail 2.13 
 
  P(T<=t) two-tail 3.37E-06 
 
  t Critical two-tail 2.78 
Median FL1-H 
intensity of gated 
cells 
mAb3050 (67nM) with F5262 
(1 in 1000) 
1 in 1000 F5262 
alone –ve 
t-test 
 
N 3 3 t Stat 3.48 
Mean 15.52 2.67 P(T<=t) one-tail 0.01 
SD 6.36 0.75 t Critical one-tail 2.13 
 
  P(T<=t) two-tail 0.03 
 
  t Critical two-tail 2.78 
 
 (b) 
 
 
(c)  
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Figure 5.9 
IF confocal microscopy to determine lactadherin expression by HUVECS 
Binding of (a) mAb2767 (1333nM), detected with anti-mouse FITC F5262 (diluted 1 in 1000) and 
binding of (b) HuMc3 (1333nM) detected with anti-human FITC F5512 (diluted 1 in 1000) . Also 
included is positive control staining (c) with anti-αvβ3 antibody mAb3050 (66.7nM), detected with 
F5262 and (d) a negative secondary antibody (F5262) only control. This data is representative of the 
results of 2(mAb2767 and HuMc3) /3 (mAb3050) separate experiments.  
(a)      (b) 
   
 
(c)      (d) 
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Figure 5.10 
Western blot of HUVEC cell lysate for detection of lactadherin expression 
Lactadherin expression detected with mAb2767 (13nM) and anti-mouse HRP A9917 (diluted 1 in 
80,000). Loading order; 1 HUVEC cell lysate (8µl of lysate prepared as described in section 2.2.5.2), 2 
positive control natural lactadherin (milk derived) (21nM approx). This figure is representative of the 
results of a single experiment. 
    
With lactadherin shown not to be expressed by HUVECS the next step was to find out 
whether exogenously applied lactadherin could bind to human vasculature EC’s and if 
so whether this association occurred via integrins αvβ3 and αvβ5. rHu-Lactadherin 
binding to HUVECS was studied by FACS analysis with detection by both mAb2767 
(figures 5.11-5.12 and figures 5.13-5.14) and HuMc3 (figures 5.15-5.16) as well as by 
a plate-based cell adhesion assay (section 2.2.5.6) (figure 5.17). For the FACS assays 
the supernatant from transfected CHO cells, expressing rHu-lactadherin (section 
3.2.3) was incubated with HUVECS, followed by detection with mAb2767 or 
HuMc3, then a FITC-conjugated secondary antibody.  
 
The data in figures 5.11.5.12 shows a FACS assay with a constant lactadherin 
concentration but with dilution of mAb2767. The transfected CHO supernatant has 
been concentrated X20 and binding detected with mAb2767 (66.7, 133 and 267nM). 
Controls include cells alone and cells with no lactadherin but detection alone. For the 
representative data (figure 5.11) all of the negative control shifts (figure 5.11b) 
overlap indicating no background binding. A strong fluorescence shift (figure 5.11b-
c) for lactadherin binding is however detected with all concentrations of mAb2767 
compared with the negative controls. All of the positive shifts (figure 5.11b) however 
overlap indicating saturating concentrations of rHu-lactadherin and mAb2767 have 
been used. The combination data (figure 5.12) is in agreement showing a significant 
difference in both percentage of FL1+ve gated cells and median FL1-H intensity 
between the 66.7nM mAb2767 concentration sample plus lactadherin and its 
M       1         2 
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corresponding no-lactadherin control (figure 5.12a). This equates to an increase in 
percentage of cells positive for fluorescence from 8.7% to 88% (figure 5.12b) and 
average level of fluorescence from 3.3 to 20.9 (figure 5.12c). Figures 5.13-5.14 show 
a FACS assay with a constant mAb2767 concentration of 66.7nM, the lowest 
concentration shown in figure 5.11 to produce a positive signal with X20 concentrated 
transfected CHO supernatant. The rHu-lactadherin concentration was however varied 
in this study including unconcentrated supernatant and supernatant concentrated X2, 
X5, X10 and X20. A no-lactadherin (untransfected CHO supernatant) with detection 
only, control was also used and all signal shifts were considered relative to this. From 
the representative data (figure 5.13) all concentrations of lactadherin can be seen to 
produce a shift (figure 5.13b-c), with the smallest shift for undiluted lactadherin, a 
greater shift by X2 and an even stronger shift by X5 and further by X10, with a 
maximum reached at this point. This indicated a lactadherin-concentration-dependant 
binding of mAb2767 to HUVECS.  The combination data (figure 5.14) was in 
agreement, with a concentration-dependant increase in both percentage FL1+ve gated 
cells (figure 5.14b) and median FL-1H intensity (figure 5.14c) appearing to increase 
with rising lactadherin concentration from 12% and 3.3 in the untransfected control, 
through 56% and 8.9 for X2, to  88% and 19.2 in the X 10 concentrated sample. 
Lactadherin binding was confirmed to be statistically significant (figure 5.14a) with 
both a significant difference in percentage FL1+ve gated cells and median FL1-H 
intensity of gated cells between the untransfected CHO supernatant and X10 
concentrated lactadherin expressing supernatant. The data could not however be used 
to confirm a concentration-dependent binding however as the difference in signal 
between the lactadherin concentrations was not found to be statistically significant 
(figure 5.14a). This data may have been improved by the inclusion of more repeats as 
this appeared to have resulted from signal variability. The data confidence may also 
have been elevated by the addition of an isotype-matched antibody control.  Figures 
5.15-5.16 depict a FACS study using HuMc3 to detect binding of lactadherin to the 
surface of HUVECs. In this study HuMc3 concentrations of 66.7 and 167nM were 
used to detect binding of lactadherin in the form of X20 concentrated CHO 
supernatant. Negative controls included were cells with HuMc3 (66.7 and 167nM) 
minus lactadherin and an isotype-matched control (66.7 and 167nM), plus and minus 
lactadherin. In the representative data figure (figure 5.15) a strong shift is observable 
for HuMc3 at both concentrations used (figure 5.15b-c) signifying lactadherin 
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association. The signal shift is however the same for both concentrations indicating a 
maximum has been reached. The negative control peaks (figure 5.15b and 5.15d) all 
overlap suggesting all observed binding of HuMc3 to lactadherin on the surface of 
HUVECs to be specific association. The combined data confirmed findings with the 
difference in percentage FL1+ve gated cells and median FL1-H intensity of gated 
cells (figure 5.16a) between the HuMc3 and isotype control samples shown to be 
significant, but with no significant difference between the two HuMc3 concentrations. 
The combination data HuMc3 (66.7nM concentration) sample showed 66% FL1+ve 
gated cells with a median FL1-H intensity of 8 compared with the -0.05%, and 0 
respectively of the isotype control when corrected against the no-lactadherin controls.  
This data may however have been improved by the inclusion of lower HuMc3 
concentrations or by the use of lactadherin dilutions to show a concentration-
dependent binding effect. A cell adhesion assay was next carried out to confirm 
HUVEC binding to lactadherin, coated to the surface of tissue culture plate wells 
(figure 5.17). In this assay, cell binding was detected as the presence of live cells in 
microtiter plate wells using a proliferation assay reagent (section 2.2.5.6). Vitronectin, 
a vasculature associated matrix protein known to bind to EC αvβ3 and αvβ5 integrins 
in an RGD dependant manner (section 1.2.3) was used as a positive control and an 
uncoated well (cells alone) control included, as well as a wells alone control used to 
correct the signal to zero. A positive signal for lactadherin (200nM) coating was 
evident (figure 5.17b) with a signal of approximately 7 X the uncoated well control in 
the combined data, with the difference between lactadherin-coated and un-coated 
signal shown to be significant (figure 5.17a). The positive control vitronectin coated 
at a slightly lower molarity of 130nM again showed a significant binding signal 
(figure 5.17a). Although coated at a lower molarity however, it produced a greater 
binding signal at approximately 13 X the uncoated well control in the combined data, 
suggesting a stronger association of vitronectin with HUVECs than lactadherin. Data 
confidence may however have been improved by inclusion of multiple 
lactadherin/vitronectin concentrations for observation of a concentration-dependent 
cell association effect. 
 
Taken together the results of this series of experiments indicated that although 
lactadherin is not expressed by HUVECS, it is able to bind to the surface of these 
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cells, albeit to a lesser extent than the αvβ3/αvβ5 integrin ligand vitronectin. In 
addition, both mAb2767 and HuMc3 were able to detect lactadherin in association 
with the surface of HUVECs.   
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Figure 5.11 
Detection of lactadherin binding to HUVECS by FACS – mAb2767 concentration optimisation 
Binding of rHu-lactadherin (lac) from transfected CHO supernatant (concentrated X 20) detected with 
mAb2767 (66.7, 133 and 267nM), followed by an anti-mouse FITC secondary F5262 (1 in 1000 
dilution). Cells alone and secondary antibodies alone negative control included. (a) Overview table 
with the sample name and description, percentage gated cells, percentage of gated cells positive for 
fluorescence (FL1+), median fluorescent intensity of gated cells (FL1-H) and percentage FL1+ve total 
cells. (b) Half offset overlay plot of all samples. (c) Individual sample shifts plotted against cells alone 
and no-lactadherin controls with FSC-H, SSC-H plots attached; (i-iii) mAb2767 (66.7, 133 and 
267nM). Data represents a single experiment. 
 (a) 
Sample description Sample name Percentage gated 
cells (%) 
Percentage FL1+ve 
gated cells (%) 
Median FL1-H 
intensity of gated cells 
Percentage FL1+ve 
total cells (%) 
mAb2767 (66.7nM) + lac 10ug_ml lac.002 83.24 98.58 47.01 82.05 
mAb2767 (66.7nM) – lac 10ug_ml no lac.005 86.85 9.19 4.91 7.98 
mAb2767 (133nM) + lac 20ug_ml lac.003 86.87 98.88 46.21 85.89 
mAb2767 (133nM) - lac 20ug_ml no lac.006 87.57 11.47 5.23 10.04 
mAb2767 (267nM) + lac 40ug_ml lac.004 84.16 99.26 50.84 83.54 
mAb2767 (267nM) - lac 40ug_ml no lac.007 86.46 13.43 5.43 11.61 
Cells alone Just cells with media .008 85.70 7.35 4.31 6.30 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
(c) 
(i)       (ii) 
 
 
 
 
 
 
 
 
 
 
 
 
(iii) 
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Figure 5.12 
Detection of lactadherin (lac) binding to HUVECS by FACS with mAb2767 -combined data 
Displayed is the percentage FL1+ve gated cells (b) and median FL1-H intensity of gated cells (c) data 
and an average (combo) from six separate experiments as described in figure 5.11 (but only including 
the 67nM mAb2767 antibody concentration and no lac with mAb2767 (67nM) control). (a) Statistical 
data table displaying the average of three separate experiments (combo data) and t-tests. 
(a) 
 
Combo data      
Percentage FL1+ve gated cells  mAb2767 (66.7nM) + Lac mAb2767 (66.7nM) – Lac t-test  mAb2767 (66.7nM) + Lac/-Lac 
N 6 6 t Stat 22.77 
Mean 88.43 8.70 P(T<=t) one-tail 3.01E-10 
SD  8.57 0.38 t Critical one-tail 1.81 
 
  P(T<=t) two-tail 6.01E-10 
 
  t Critical two-tail 2.23 
Median FL1-H intensity of gated 
cells  mAb2767 (66.7nM) + Lac 
mAb2767 (66.7nM) – Lac t-test mAb2767 (66.7nM) + Lac/-Lac 
N 6 6 t Stat 2.87 
Mean 20.89 3.29 P(T<=t) one-tail 8.31E-03 
SD  14.99 0.98 t Critical one-tail 1.81 
 
  P(T<=t) two-tail 1.66E-02 
 
  t Critical two-tail 2.23 
 
(b)  
 
(c) 
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Figure 5.13 
Detection of lactadherin binding to HUVECS by FACS analysis 
Binding of rHu-lactadherin from transfected CHO supernatant detected with mAb2767 (66.7nM), 
followed by an anti-mouse FITC secondary F5262 (1 in 1000 dilution). Primary and secondary 
antibodies alone negative control included. (a) Overview table with the sample name and description, 
percentage gated cells, percentage of gated cells positive for fluorescence (FL1+), median fluorescent 
intensity of gated cells (FL1-H) and percentage FL1+ve total cells. (b) Half offset overlay plot of all 
samples. (c) Individual sample shifts plotted against control with FSC-H, SSC-H plots attached; (i-v) 
transfected CHO supernatant unconcentrated and concentrated X2, X5, X10 and X20. Figure data 
representative of the results of three separate experiments. 
(a) 
Sample description Sample name Percentage 
gated cells 
(%) 
Percentage 
FL1+ve gated 
cells (%) 
Median FL1-H 
intensity of 
gated cells 
Percentage 
FL1+ve total cells 
(%) 
mAB2767 detection alone –ve control No lactadherin.001 89.06 12.05 3.85 10.73 
Transfected CHO supernatant unconcentrated Undiluted lactadherin.002 90.09 40.59 7.56 36.57 
Transfected CHO supernatant concentrated X 2 Conc 1 in 2 lactadherin.003 88.88 56.10 9.46 49.87 
Transfected CHO supernatant concentrated X 5 Conc 1 in 5 lactadherin.004 83.53 74.88 13.70 62.55 
Transfected CHO supernatant concentrated X 10 Conc 1 in 10 lactadherin.005 77.05 82.92 18.04 63.89 
Transfected CHO supernatant concentrated X 20 Conc 1 in 20 lactadherin.006 86.08 84.04 17.14 72.34 
 
(b)        (c)(i) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(ii)       (iii) 
 
 
 
 
 
 
 
 
 
 
 
 
 
(iv)       (v) 
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Figure 5.14 
Detection of lactadherin binding to HUVECS by FACS analysis-combined data 
Displayed is the corrected percentage FL1+ve gated cells (b) and median FL1-H intensity of gated 
cells (c) data from three separate experiments as described in figure 5.13 and an average of the three 
(combo). (a) Statistical data table displaying the average of three separate experiments (combo data) 
and t-tests. Transfected (tfected), untransfected (untfected). 
(a) 
Combo 
data 
 
          
 
    
Percentage 
FL1+ve 
gated cells 
Untfected 
CHO snt 
Tfected 
CHO snt 
Tfected 
CHO snt 
(X2) 
Tfected 
CHO snt 
(X5) 
Tfected 
CHO snt 
(X10) 
Tfected 
CHO snt 
(X20) 
t-test  No 
lac/CHO 
snt X10 
CHO 
snt 
X1/X 2 
CHO 
snt X 
2/X5 
CHO 
snt 
X5/X10 
N 3 3 3 3 3 3 t Stat -14.83 -0.77 -0.80 -0.88 
Mean 11.95 38.13 56.18 75.33 87.61 88.36 P(T<=t) one-tail 0.06E-03 0.24 0.23 0.21 
SD  0.42 20.27 34.94 22.58 8.83 8.50 t Critical one-tail 2.13 2.13 2.13 2.13 
 
      P(T<=t) two-tail 0.01E-02 0.48 0.47 0.43 
 
      t Critical two-tail 2.78 2.78 2.78 2.78 
Median 
FL1-H 
intensity 
of gated 
cells 
Untfected 
CHO snt 
Tfected 
CHO snt 
Tfected 
CHO snt 
(X2) 
Tfected 
CHO snt 
(X5) 
Tfected 
CHO snt 
(X10) 
Tfected 
CHO snt 
(X20) 
t-test  No 
lac/CHO 
snt X10 
CHO 
snt 
X1/X 2 
CHO 
snt X 
2/X5 
CHO 
snt 
X5/X10 
N 3 3 3 3 3 3 t Stat -2.60 -0.91 -0.96 -0.15 
Mean 3.33 5.82 8.92 17.64 19.24 19.05 P(T<=t) one-tail 0.03 0.21 0.20 0.44 
SD 0.60 2.46 5.34 14.76 10.59 10.68 t Critical one-tail 2.13 2.13 2.13 2.13 
 
      P(T<=t) two-tail 0.06 0.41 0.39 0.89 
 
      t Critical two-tail 2.78 2.78 2.78 2.78 
(b) 
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Figure 5.15 
Detection of lactadherin association with HUVECS by FACS with HuMc3 
Binding of HuMc3 (66.7 and 167nM), following incubation of rHu-lactadherin (X20 concentrated 
transfected CHO supernatant) detected with an anti-human FITC secondary F5512 (1 in 1000 
dilution). IgG1 isotype matched antibody and no-lactadherin controls included. (a) Overview table 
describing the sample name and description, percentage gated cells, percentage of gated cells positive 
for fluorescence (FL1+), median fluorescent intensity of gated cells (FL1-H) and percentage FL1+ve 
total cells. (b) Half offset overlay plot of HuMc3 and isotype control samples with no-lactadherin 
controls included. (c) Individual HuMc3 and (d) isotype control sample shifts plotted against no-
lactadherin controls, with FSC-H, SSC-H plots attached; (i-ii) Concentrations 66.7nM and 167nM. 
Figure data representative of the results of three separate experiments. 
(a) 
Sample description Sample name Percentage 
gated cells 
(%) 
Percentage 
FL1+ve gated 
cells (%) 
Median FL1-H 
intensity of gated 
cells 
Percentage 
FL1+ve total cells 
(%) 
HuMc3 (66.7nM) - lactadherin Ang 10 no lac. 005 94.92 6.06 4.04 5.75 
HuMc3 (66.7nM + lactadherin Ang 10 plus lac. 004 94.21 94.85 19.19 89.35 
HuMc3 (167nM) - lactadherin Ang 25 no lac. 006 94.12 5.95 4.04 5.60 
HuMc3 (167nM) + lactadherin Ang 25 plus lac. 002 95.28 92.50 17.24 88.13 
IgG1 isotype  -ve control (66.7nM) - lactadherin I con 10 no lac. 007 93.99 5.95 3.97 5.60 
IgG1 isotype -ve control (66.7nM) + lactadherin I con 10 plus lac. 003 93.40 6.49 4.04 6.06 
IgG1 isotype -ve control (167nM) - lactadherin I con 25 no lac. 008 91.88 5.88 4.03 5.40 
IgG1 isotype -ve control (167nM)  + lactadherin I con 25 plus lac. 001 92.03 6.80 4.09 6.26 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(c) 
(i)       (ii) 
 
 
 
 
 
 
 
 
 
 
 
 
(d) 
(i)       (ii) 
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Figure 5.16 
Detection of lactadherin (lac) association with HUVECS by FACS with HuMc3-combined data 
Displayed is the corrected percentage FL1+ve gated cells (b) and median FL1-H intensity of gated 
cells (c) data from three separate experiments as described in figure 5.15 and an average of the three 
(combo). Absorbance corrected to zero using no-lactadherin controls. (a) Statistical data table 
displaying the average of three separate experiments (combo data) and t-tests. 
(a) 
 Corrected 
combo data        
 
   
Percentage 
FL1+ve gated 
cells 
HuMc3 
(67nM) + 
lac 
HuMc3 
(167nM) + 
lac 
I Con (67nM) 
+ lac 
I Con 
(167nM) + 
lac 
t-test HuMc3 (67)/I 
Con (67) 
HuMc3 (167) 
/ I Con (167) 
HuMc3 (167) 
/ HuMc3 (67) 
N 3 3 3 3 t Stat 5.89 5.91 0.11 
Mean 66.30 64.74 -0.05 0.21 P(T<=t) one-tail 2.08E-03 2.05E-03 0.46 
SD  19.51 18.89 0.70 0.96 t Critical one-tail 2.13 2.13 2.13 
 
    P(T<=t) two-tail 4.17E-03 4.10E-03 0.92 
 
    t Critical two-tail 2.78 2.78 2.78 
Median FL1-H 
intensity of 
gated cells 
HuMc3 
(67nM) + 
lac 
HuMc3 
(167nM) + 
lac 
I Con (67nM) 
+ lac 
I Con 
(167nM) + 
lac 
t-test HuMc3 (67)/I 
Con (67) 
HuMc3 (167) 
/ I Con (167) 
HuMc3 (167) 
/ HuMc3 (67) 
N 3 3 3 3 t Stat 2.26 2.50 0.14 
Mean 8.06 7.36 0 0.01 P(T<=t) one-tail 0.04 0.03 0.45 
SD  6.18 5.10 0.08 0.05 t Critical one-tail 2.13 2.13 2.13 
 
    P(T<=t) two-tail 0.09 0.07 0.90 
 
    t Critical two-tail 2.78 2.78 2.78 
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Figure 5.17 
Determination of lactadherin association with HUVECS by a cell-binding assay 
Shown is a cell-binding assay detecting HUVEC association with immobilised rHu-lactadherin (lac 
200nM) or positive control vitronectin (vitron 130nM) (b). A no-well coating, cells alone control (cells) 
is also included. Absorbance at 490nm denotes cell binding as the presence of live cells detected by 
MTS assay. Displayed is data from five/two separate assays and an average (combo). Each error bar 
denotes 4/5 assay repeats. Absorbance corrected to zero using a no cells control. (a) Statistical data 
tables displaying the average (combo data) and t-tests. 
(a) 
Statistics 
      
Lac Day 1 Day 2 Day 3 Day 4 Day 5 Combo 
N 5 5 5 5 4 24 
Mean 0.18 0.23 0.42 0.39 0.24 0.30 
SD 0.03 0.07 0.08 0.03 0.03 0.11 
Vitron Day 1 Day 2 Combo 
t-test Combo cells/ cells + 
lac  
Combo cells/ cells + 
vitron 
N 5 5 10 t Stat -9.76 -11.43 
Mean 0.36 0.68 0.52 P(T<=t) one-tail 6.94E-13 9.24E-13 
SD 0.05 0.10 0.19 t Critical one-tail 1.68 1.70 
 
   P(T<=t) two-tail 1.39E-12 1.85E-12 
 
   t Critical two-tail 2.02 2.04 
 
 (b) 
 
 
With lactadherin shown to bind to vascular EC’s, its ability to ligate integrins αvβ3 
and αvβ5 was assessed. FACS analysis had already been completed to confirm 
expression of integrin αvβ3 by HUVECs (figures 5.7-5.8). FACS analysis (figures 
5.18-5.19) was next completed to confirm integrin αvβ5 expression on the surface of 
HUVECS.  Integrin αvβ5 expression was demonstrated by a strong shift from control 
in the representative data (figure 5.18b-c) and by a significant increase, (figure 5.19a) 
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in both percentage FL1+ve gated cells (figure 5.19b) and median FL1-H intensity of 
gated cells (figure 5.19c) relative to control in the combined data.  
The binding of lactadherin to the cell surface via association with integrins αvβ3 and 
αvβ5 was initially tested by FACS analysis to detect loss of lactadherin binding 
through competition for receptor ligation with the αvβ3 and αvβ5 integrin ligand 
vitronectin (figures 5.20-5.21). In this procedure HUVECS were pre-incubated with a 
range of concentrations of vitronectin (13.3, 66.7, 133 and 667nM), then lactadherin 
was added to the assay tubes with the cells and vitronectin and a further incubation 
step completed. The lactadherin binding signal was assessed as earlier with mAb2767 
and a FITC-conjugated secondary. Controls included lactadherin alone for a full 
signal control (100% binding) and detection antibodies but no lactadherin for a no-
signal (0% binding) control, with full inhibition expected to alter the signal from full 
to none. The pre-incubation step was used to maximise the potential inhibitory effect 
of vitronectin on lactadherin association. Lactadherin concentrated X5 from 
transfected CHO supernatant was chosen based on the optimisation data shown in 
figures 5.13-5.14, as a sufficiently strong lactadherin-binding signal would have been 
expected, whilst minimising excess lactadherin, which may have obscured inhibition.  
The shift data (figure 5.20b-c) showed the large expected shift for the 100% signal 
control relative to the 0% control. There was no visible shift from the no-vitronectin 
control by 13.3nM vitronectin, but a small shift was observable for the 66.7nM 
concentration and slightly greater for the 133nM. The shifts were however very small 
and a maximum reached after 133nM. The apparent binding inhibition by vitronectin 
was shown in the combined data to be insignificant (figure 5.21a) with the reduction 
in percentage FL1+ve cells (figure 5.21b) and median FL1-H intensity (figure 5.21c) 
of the first study not shown to be reproducible.   A similar assay to the above was 
repeated with the αvβ3 integrin receptor ligand fibronectin (native human plasma 
derived), used at concentrations of 11.4, 22.7, 45.5, 114 and 227nM (figures 5.22-
5.23). Again for the shift data (figure 5.22b-c) a significant shift was evident for the 
100% binding) control relative to the 0% binding control. No difference in shift was 
however visible for any fibronectin concentration suggesting no inhibition of 
lactadherin association. For the combination data (figure 5.23) both the percentage 
FL1+ve gated cells (figure 5.23b) and median FL1-H intensity of gated cells (figure 
5.23c) data were in agreement, with no visible difference between the no-fibronectin 
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control and any of the fibronectin concentration samples, confirmed by statistical 
testing (figure 5.23a). Taken together, the results of these two lactadherin inhibition 
binding studies indicated lactadherin does not bind to either αvβ3 or αvβ5. As 
expression of both integrins was confirmed in figures 5.7-5.8 and figure 5.18-5.19 and 
given past work had demonstrated lactadherin binding to αvβ3 on HUVECS [173] 
and both receptors on other cell lines [148][154][192], further investigation was 
carried out. FACS analysis was completed to detect loss of lactadherin binding to the 
cell surface by the pre-incubation of lactadherin with soluble recombinant 
extracellular domains of the αvβ3 integrin (5.26, 26.3, 52.6, 105 and 211nM) prior to 
incubation of both with HUVECs (figures 5.24-5.25). The lactadherin-binding signal 
was assessed as earlier with mAb2767 and a FITC-conjugated secondary. Controls 
again included a full signal and a no-signal control. If lactadherin associated with the 
integrin αvβ3 on the cell surface it was expected it would bind to this receptor in 
solution and thereby reduce the lactadherin-binding signal on the cell, with full 
inhibition reducing the binding signal to the no-lactadherin control level. The 
representative shift data (figures 5.24b-c) suggested concentration-dependent 
inhibition of lactadherin binding, with the 26.3, 52.6, 105 and 211nM samples 
producing a graduated reduction in signal from the no-αvβ3 integrin control, though 
the no-lactadherin control level was not reached showing lack of full inhibition, with 
around 50% inhibition suggested by the shift difference. The combined data was 
however inconclusive, despite completion of five repeats, with all showing a 
reduction in both percentage FL1+ve gated cells (figure 5.25b) and median FL1-H 
intensity of gated cells (figure 5.25c) but with the reduction shown not to be 
statistically significant by t-tests (figure 5.25a). With the unexpected results from the 
FACS experiments, a plate-based cell adhesion assay (as described earlier to detect 
HUVEC binding to lactadherin in figure 5.17) was adopted as an alternative method 
to examine lactadherin binding to the cell surface by the αvβ5 and αvβ3 integrins.  
This was carried out through detection of inhibition of HUVEC binding to lactadherin 
and positive control αvβ3/αvβ5 integrin ligand vitronectin using αvβ3 and αvβ5 
receptor neutralising antibodies LM609 (figure 5.26b) and P1F6 (figure 5.26c) 
respectively. Included were full adhesion controls with lactadherin or vitronectin but 
no P1F6 or LM609, used to calculate 100% cell adhesion and cells alone controls with 
no lactadherin or vitronectin, representing 0% adhesion.  In agreement with past work 
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[173] the results demonstrated statistically significant (figure 5.26a) inhibition of 
HUVEC binding to lactadherin by LM609, with no significant inhibition of binding 
lactadherin with P1F6, indicating lactadherin association with HUVEC via αvβ3 but 
not αvβ5 integrins. For the positive control vitronectin both LM609 (figure 5.26a) and 
P1F6 (figure 5.26b) showed significant inhibition of cell binding. In the combined 
data LM609 reduced cell association to lactadherin by 82%, close to the published 
value to around 60-70% [173] and LM609 and P1F6 reduced binding to vitronectin by 
64% and 21% respectively, leaving 18% of attachment to lactadherin and a minimum 
of 15% of attachment to vitronectin despite use of high antibody concentrations, 
suggesting some residual association of both lactadherin and vitronectin via non-
αvβ3/αvβ5 binding. This was supported by past work with HUVECS showing 20% 
of native lactadherin association with an RGD to RGE mutant, which should prevent 
integrin binding and by the only partial inhibition of vitronectin binding to HUVECS 
in past work with an RGD peptide [173]. This data could however have been 
improved by the inclusion of higher antibody concentrations to confirm a maximum 
binding inhibition effect had been achieved and by the use of isotype-matched 
antibodies, to confirm the specificity of the binding inhibition effect.  
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Figure 5.18 
Detection of integrin αvβ5 expression on the surface of HUVECS by FACS analysis 
Binding of an anti-αvβ5 antibody mAb2528 (3.33nM, 6.67nM, 33.3nM, 66.7nM), detected with an anti-
mouse FITC secondary F5262 (1 in 1000 dilution). Secondary antibody alone control included. (a) 
Overview table with the sample name and description, percentage gated cells, percentage of gated cells 
positive for fluorescence (FL1+), median fluorescent intensity of gated cells (FL1-H) and percentage 
FL1+ve total cells. (b) Half offset overlay plot of all samples. (c) Individual sample shifts plotted 
against control, with FSC-H, SSC-H plots attached; (i-iv) mAb2528 concentrations, (3.33nM, 6.67nM, 
33.3nM, 66.7nM). Figure data representative of the results of a single experiment. 
(a) 
Sample description Sample name Percentage gated 
cells (%) 
Percentage FL1+ve 
gated cells (%) 
Median FL1-H 
intensity of gated cells 
Percentage FL1+ve 
total cells (%) 
mAb2528 (3.33nM) 0.5ug_ml anti avb5 
antibody. 002 92.18 56.38 7.30 51.96 
mAb2528 (6.67nM) 1ug_ml anti avb5 
antibody. 003 92.19 77.77 9.85 71.70 
mAb2528 (33.3nM) 5ug_ml anti avb5 
antibody. 004 91.58 89.21 12.37 81.70 
mAb2528 (66.7nM) 10ug_ml anti avb5 
antibody. 005 91.10 89.40 12.63 81.45 
Secondary antibody alone No primary. 001 92.12 4.49 2.60 4.13 
(b) 
 
 
 
 
(c) 
(i)       (ii) 
 
 
 
 
 
 
 
 
 
 
 
 
(iii)       (iv) 
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Figure 5.19 
Detection of integrin αvβ5 expression on the surface of HUVECS by FACS analysis-combined data 
Displayed is the corrected percentage FL1+ve gated cells (b) and median FL1-H intensity of gated 
cells (c) data from three separate experiments as described in figure 5.18 and an average (combo), (but 
only including the mAb2528 6.7nM concentration and a secondary antibody alone control). (a) 
Statistical data table displaying the average of three separate experiments (combo data) and t-tests. 
(a) 
Combo data       
Percentage FL1+ve 
gated cells 
mAb2528 
(6.7nM) 
Secondary 
antibody alone 
t-test mAb2528 (6.7nM) / secondary 
antibody alone 
N 3 3 t Stat 6.22 
Mean 61.46 4.53 P(T<=t) one-tail 1.70E-03 
SD 15.84 0.11 t Critical one-tail 2.13 
 
  P(T<=t) two-tail 3.39E-03 
 
  t Critical two-tail 2.78 
Median FL1-H intensity 
of gated cells 
mAb2528 
(6.7nM) 
Secondary 
antibody alone 
t-test mAb2528 (6.7nM) / secondary 
antibody alone 
N 3 3 t Stat 3.64 
Mean 12.37 4.05 P(T<=t) one-tail 0.01 
SD 3.66 1.50 t Critical one-tail 2.13 
 
  P(T<=t) two-tail 0.02 
 
  t Critical two-tail 2.78 
 
(b)  
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Figure 5.20 
Detecting inhibition of lactadherin association with HUVECS by pre-incubation with vitronectin 
Binding of mAb2767 (66.7nM), following incubation of vitronectin (13.3, 66.7, 133, 266 and 667nM), 
then vitronectin (as above) and rHu-lactadherin (transfected CHO supernatant 5X concentrated) 
detected with an anti-mouse FITC secondary F5262 (1 in 1000 dilution). No-vitronectin negative and 
no-lactadherin positive controls included. (a) Overview table including the sample name and 
description, percentage gated cells, percentage of gated cells positive for fluorescence (FL1+), median 
fluorescent intensity of gated cells (FL1-H) and percentage FL1+ve total cells. (b) Half offset overlay 
plot of all samples. (c) Individual sample shifts plotted against both positive and negative controls, with 
FSC-H, SSC-H plots attached; (i-v) vitronectin concentrations, (13.3, 66.7, 133, 266 and 667nM). 
Figure data representative of the results of a single experiment. 
(a) 
Sample description Sample name Percentage 
gated cells 
(%) 
Percentage 
FL1+ve gated 
cells (%) 
Median FL1-H 
intensity of gated 
cells 
Percentage FL1+ve total 
cells (%) 
Vitronectin (13.3nM) 1ug_ml vitronectin. 003 95.52 61.46 9.63 58.71 
Vitronectin (66.7nM) 5ug_ml vitronectin. 004 94.46 52.46 8.42 49.56 
Vitronectin (133nM) 10ug_ml vitronectin. 005 95.42 47.50 7.86 45.32 
Vitronectin (266nM) 20ug_ml vitronectin.006 95.23 58.01 9.11 55.24 
Vitronectin (667nM) 50ug_ml vitronectin. 007 96.08 49.11 8.04 47.19 
No lactadherin with mAb2767 
detection alone +ve control No lactadherin. 001 94.46 7.72 4.01 7.29 
Lactadherin with mAb2767 
detection alone –ve control No vitronectin. 002 95.92 62.31 9.71 59.77 
(b)  
 
       (c)(i) 
 
 
 
 
 
 
 
 
 
 
 
 
(ii)       (iii) 
 
 
 
 
 
 
 
 
 
 
 
 
(iv)       (v) 
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Figure 5.21 
Detecting inhibition of lactadherin association with HUVECS by pre-incubation with vitronectin -
combined data 
Displayed is the percentage FL1+ve gated cells (b) and median FL1-H intensity of gated cells (c) data 
from three separate experiments as described in figure 5.20 and an average (combo), (but only 
including the highest vitronectin concentration (667nM) and both a no-lactadherin with mAb2767 
detection positive and lactadherin + mAb2767 with no vitronectin negative control. (a) Statistical data 
table displaying the average of three separate experiments (combo data) and t-tests 
(a) 
 
Combo data         
Percentage FL1+ve gated cells No lac Lac + mAb2767 - vitron Vitron (667nM) t-test - vitron / vitron  (667nM) 
N 3 3 3 t Stat 0.26 
Mean 7.80 37.06 33.01 P(T<=t) one-tail 0.40 
SD 0.13 22.75 14.73 t Critical one-tail 2.13 
 
   P(T<=t) two-tail 0.81 
 
   t Critical two-tail 2.78 
Median FL1-H intensity of gated 
cells 
No lac Lac + mAb2767 - vitron Vitron (667nM) t-test - vitron / vitron  (667nM) 
N 3 3 3 t Stat 0.23 
Mean 3.14 5.83 5.27 P(T<=t) one-tail 0.41 
SD 0.75 3.38 2.42 t Critical one-tail 2.13 
 
   P(T<=t) two-tail 0.83 
 
   t Critical two-tail 2.78 
 
(b) 
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Figure 5.22 
Detecting inhibition of lactadherin association with HUVECS by pre-incubation with fibronectin 
Binding of mAb2767 (66.7nM), following incubation of fibronectin (11.4, 22.7, 45.5, 114 and 227nM), 
then fibronectin (11.4, 22.7, 45.5, 114 and 227nM) and rHu-lactadherin (transfected CHO supernatant 
5X concentrated) detected with an anti-mouse FITC secondary F5262 (1 in 1000 dilution). No-
fibronectin negative and no-lactadherin positive controls included. (a) Overview table including 
sample name and description, percentage gated cells, percentage of gated cells positive for 
fluorescence (FL1+), median fluorescent intensity of gated cells (FL1-H) and percentage FL1+ve total 
cells. (b) Half offset overlay plot of all samples. (c) Individual sample shifts plotted against both 
positive and negative controls, with FSC-H, SSC-H plots attached; (i-v) fibronectin concentrations; 
(11.4, 22.7, 45.5, 114 and 227nM). Figure data representative of two experiments. 
(a) 
Sample description Sample name Percentage gated 
cells (%) 
Percentage FL1+ve 
gated cells (%) 
Median FL1-H 
intensity of gated 
cells 
Percentage 
FL1+ve total cells 
(%) 
Fibronectin (11.4nM) Lac, 10ug_ml anti-lac 5 fibr. 003 91.38 95.46 34.82 87.23 
Fibronectin (22.7nM) Lac, 10ug_ml anti-lac 10 fibr. 004 91.80 94.62 33.78 86.87 
Fibronectin (45.5nM) Lac, 20ug_ml anti-lac 10 fibr. 005 91.16 95.12 32.66 86.72 
Fibronectin (114nM) Lac, 10ug_ml anti-lac 50 fibr. 006 91.90 94.16 34.44 86.53 
Fibronectin (227nM) Lac, 10ug_ml anti-lac 100 fibr. 007 90.48 94.78 35.67 85.76 
Lactadherin with mAb2767 
detection alone –ve control Lac, 10ug_ml anti-lac. 002 91.25 94.46 35.60 86.19 
No lactadherin with mAb2767 
detection alone +ve control No lac, 10ug/_ml anti-lac. 001 91.23 13.82 3.72 12.61 
 (b) 
 
 
(c)(i)    
    
 
 
 
 
 
 
 
 
 
 
(ii)       (iii)    
  
 
 
 
 
 
 
 
 
 
 
 
(iv)       (v) 
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Figure 5.23 
Detecting inhibition of lactadherin association with HUVECS by pre-incubation with fibronectin-
combined data 
Displayed is the corrected percentage FL1+ve gated cells (b) and median FL1-H intensity of gated 
cells (c) data from three separate experiments as described in figure 5.22 and an average of the three 
(combo). Absorbance corrected to zero using a no-lactadherin control. (a) Statistical data table 
displaying the average of three separate experiments (combo data) and t-tests 
(a) 
Corrected 
combo 
data             
  
Percentage 
FL1+ve 
gated cells 
Lac + 
mAb2767 – 
fibron 
Fibron 
(11.4nM) 
Fibron 
(22.7nM) 
Fibron 
(45.5nM) 
Fibron 
(114nM) 
Fibron 
(227nM) 
t-test - fibron / 
fibron 
(227nM) 
N 2 2 2 2 2 2 t Stat 0.16 
Mean 79.73 79.35 78.88 79.99 77.41 79.44 P(T<=t) one-tail 0.44 
SD 1.29 3.24 2.72 1.85 4.15 2.15 t Critical one-tail 2.92 
 
      P(T<=t) two-tail 0.89 
 
      t Critical two-tail 4.30 
Median 
FL1-H 
intensity 
of gated 
cells 
Lac + 
mAb2767 – 
fibron 
Fibron 
(11.4nM) 
Fibron 
(22.7nM) 
Fibron 
(45.5nM) 
Fibron 
(114nM) 
Fibron 
(227nM) 
t-test - fibron / 
fibron 
(227nM) 
N 2 2 2 2 2 2 t Stat 0.16 
Mean 21.54 20.56 20.05 19.93 20.08 21.25 P(T<=t) one-tail 0.44 
SD 14.63 14.91 14.16 12.75 15.05 15.14 t Critical one-tail 2.92 
 
      P(T<=t) two-tail 0.89 
 
      t Critical two-tail 4.30 
(b) 
 
(c) 
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Figure 5.24 
Detecting inhibition of lactadherin association with HUVECS by pre-incubation with a soluble αvβ3 
integrin 
Binding of mAb2767 (66.7nM), following incubation with pre-incubated αvβ3 (5.26, 26.3, 52.6, 105 
and 211nM) and rHu-lactadherin (transfected CHO supernatant 5X concentrated) detected with an 
anti-mouse FITC secondary F5262 (1 in 1000 dilution). No-αvβ3 negative and no-lactadherin positive 
controls included. (a) Overview table including the sample name and description, percentage gated 
cells, percentage of gated cells positive for fluorescence (FL1+), median fluorescent intensity of gated 
cells (FL1-H) and percentage FL1+ve total cells. (b) Half offset overlay plot of all samples. (c) 
Individual sample shifts plotted against both positive and negative controls, with FSC-H, SSC-H plots 
attached; (i-v) integrin αvβ3 concentrations, (5.26, 26.3, 52.6, 105 and 211nM). Figure data 
representative of a single experiment.  
(a) 
Sample description Sample name Percentage 
gated cells (%) 
Percentage FL1+ve 
gated cells (%) 
Median FL1-H 
intensity of gated cells 
Percentage FL1+ve 
total cells (%) 
Soluble αvβ3 (5.26nM) 1ug_ml avb3 integrin. 003 76.60 75.90 14.75 58.14 
Soluble αvβ3 (26.3nM) 5ug_ml avb3 integrin. 004 79.01 58.36 10.91 46.11 
Soluble αvβ3 (52.6nM) 10ug_ml avb3 integrin. 005 79.26 54.67 10.30 43.33 
Soluble αvβ3 (105nM) 20ug_ml avb3 integrin. 006 72.4 49.41 9.55 35.77 
Soluble αvβ3 (211nM) 40ug_ml avb3 integrin. 007 75.5 38.28 8.11 28.91 
No lactadherin with mAb2767 
detection alone +ve control No lactadherin. 001 66.61 13.94 4.51 9.28 
Lactadherin with mAb2767 
detection alone –ve control No avb3 integrin. 002 75.94 71.84 13.80 54.56 
(b)       (c)(i)  
 
 
 
 
 
 
 
 
 
(ii)       (iii) 
 
 
 
 
 
 
 
 
 
 
 
 
(iv)       (v) 
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Figure 5.25 
Detecting inhibition of lactadherin association with HUVECS by pre-incubation with a soluble αvβ3 
integrin-combined data 
Displayed is the corrected percentage FL1+ve gated cells (b) and median FL1-H intensity of gated 
cells (c) data from five separate experiments as described in figure 5.24 and an average (combo), (but 
only including the highest αvβ3 integrin concentration (211nM) and both a no-lactadherin with 
mAb2767 detection positive and lactadherin + mAb2767 with no αvβ3 integrin negative control). (a) 
Statistical data table displaying the average of five separate experiments (combo data) and t-tests 
(a) 
Combo data         
Percentage FL1+ve gated cells 
No lac + 
mAb2767 
Lac + mAb2767 
- αvβ3 
αvβ3 
(211nM) 
t-test - avβ3 / (211nM) 
N 5 5 5 t Stat 1.18 
Mean 13.90 53.56 38.63 P(T<=t) one-tail 0.14 
SD  0.48 20.86 19.18 t Critical one-tail 1.86 
 
   P(T<=t) two-tail 0.27 
 
   t Critical two-tail 2.31 
Median FL1-H intensity of 
gated cells 
No lac + 
mAb2767 
Lac + mAb2767 
- αvβ3 
αvβ3 
(211nM) 
t-test - avβ3 / (211nM) 
N 5 5 5 t Stat -0.84 
Mean 2.96 6.53 4.79 P(T<=t) one-tail 0.21 
SD 0.98 4.18 2.02 t Critical one-tail 1.86 
 
   P(T<=t) two-tail 0.43 
 
   t Critical two-tail 2.31 
(b) 
 
 (c) 
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Figure 5.26   
Cell binding assays to detect inhibition of HUVEC binding to lactadherin and vitronectin with 
integrin-blocking antibodies 
Shown is a cell-binding assay detecting inhibition of HUVEC association with immobilised rHu-
lactadherin (lac), or positive control vitronectin (vitron), by incubation with, anti-αvβ3 antibody 
LM609 (166.7nM) (b) and anti-αvβ5 antibody P1F6 (166.7nM) (c). Negative controls included are 
cells + lactadherin alone and cells + vitronectin alone. Displayed is data from three separate assays 
and an average of the three (combo). Each error bar denotes 3-4 assay repeats. Absorbance corrected 
to zero using a no-lactadherin/vitronectin control. (a) Statistical data table displaying the average of 
three separate experiments (combo data) and t-tests. 
 (a) 
Combo data      
Statistics Lac + P1F6 Vitron + P1F6 
 
t-test 
Lac / lac + 
LM609 
Vitron / vitron + 
LM609 
N 10 10 t Stat 7.79 14.67 
Mean 109.23 79.39 P(T<=t) one-tail 2.64E-07 9.36E-12 
SD 33.53 23.28 t Critical one-tail 1.74 1.73 
 
  P(T<=t) two-tail 5.27E-07 1.87E-11 
 
  t Critical two-tail 2.11 2.10 
Statistics Lac + LM609 Vitron + LM609 
 
t-test 
 
Lac / lac + P1F6 
Vitron/ vitron + 
P1F6 
N 10 10 t Stat -0.74 2.76 
Mean 17.73 35.99 P(T<=t) one-tail 0.24 0.06E-01 
SD 25.36 12.58 t Critical one-tail 1.74 1.73 
 
  P(T<=t) two-tail 0.47 0.01 
 
  t Critical two-tail 2.11 2.10 
 (b)  
 
 (c) 
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5.2.2 Inhibition of lactadherin binding to HUVEC integrins by HuMc3 
 
The following work aimed to ascertain whether the antibody HuMc3 could inhibit 
lactadherin binding to the vascular EC surface. This was initially tested by FACS 
analysis (figures 5.27-5.28). Lactadherin was pre-incubated with a range of 
concentrations of HuMc3 (66.7, 167 and 333nM), then HUVECs added and a further 
incubation step completed. The lactadherin cell-binding signal was assessed as earlier 
with mAb2767 and a FITC-conjugated secondary, including both 100% binding and 
0% binding controls (though the latter was omitted from the representative data figure 
data). The representative shift data (figures 5.27b-c) showed a concentration-
dependent peak migration from the 100% binding control. The combined data 
mirrored this with a concentration dependent reduction in both percentage FL1+ve 
gated cells (figure 5.28b) and median FL1-H intensity (figure 5.29c) from the 100% 
binding control, with partial inhibition by the 66.7nM concentration and full inhibition 
above 167nM, in all experimental repeats. The difference between the no-
HuMc3/HuMc3 66.7nM and HuMc3 66.7nM/167nM percentage FL1+ve gated cells 
data was shown to be statistically significant. For the median FL1-H intensity data 
however the difference was not statistically significant.  Alongside the above FACS 
assay, a negative control experiment was completed with an isotype-matched control 
antibody (figures 5.29-5.30) The representative shift data (figure 5.29b-c) and both 
the percentage FL1+ve gated cells and median FL1-H intensity of gated cells data 
(figure 5.29a) all indicated no inhibition of lactadherin association with no shift or 
alteration in value from the 100% lactadherin binding control. This suggested the 
observed inhibition of lactadherin by HuMc3 in figures 5.27-5.28 to be a result of 
specific association of HuMc3 with lactadherin through its antigen binding arms and 
not a result of a non-specific association. This is supported by the combination data 
showing no visible (5.30b-c) or significant (5.30a) difference in either percentage 
FL1+ve gated cells or median FL1-H intensity data between the 100% lactadherin 
binding control negative control and the isotype control 333nM concentration. In 
order to confirm the observed loss of lactadherin-binding signal in the above FACS 
experiment was due to HuMc3 inhibition of lactadherin binding to the cell surface and 
not simply the result of competition for a binding site on the surface of lactadherin by 
HuMc3 and the detection antibody mAb2767, a competition ELISA was carried out 
with HuMc3 and mAb2767 (figure 5.31). In this ELISA the ability of a titration of 
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HuMc3, incubated with a constant mAb2767 concentration, to inhibit mAb2767 
association with immobilised lactadherin was detected using an anti-mouse 
peroxidase secondary antibody. Controls included were a titration of HuMc3 in the 
absence of either lactadherin, or mAb2767.  A statistically significant (5.31a) 
concentration-dependent inhibition of mAb2767 binding was demonstrated (figure 
5.31b), reaching a maximum after 6.25nM HuMc3. A small but significant (figure 
5.31a) amount of residual mAb2767 binding however suggested HuMc3 is unable to 
remove all mAb2767 association with lactadherin. Overall this data suggested 
inhibition of mAb2767 binding to lactadherin by HuMc3. With HuMc3 known to bind 
to lactadherin in the EGF-like domain of lactadherin [263], this suggested mAb2767 
may bind to a nearby epitope in this domain. The above FACS data was therefore 
invalidated and could not be relied upon alone to confirm inhibition of lactadherin 
binding to HUVECs by HuMc3.  
 
A HUVEC cell adhesion assay was therefore attempted to ascertain the ability of 
HuMc3 to interfere with lactadherin binding to human vascular EC’s (figure 5.32). 
This assay type was chosen to eliminate the complication of detecting lactadherin 
binding with mAb2767. HuMc3 (2, 20 and 200nM) was pre-incubated with the 
lactadherin-coated wells to allow HuMc3-lactadherin association prior to incubation 
with HUVECs. Included were a full adhesion control with lactadherin but no HuMc3, 
and a no cell adhesion control, with no lactadherin coating. An isotype-matched 
negative control antibody (200nM) was also tested. A concentration-dependent 
inhibition of lactadherin binding by HuMc3 was demonstrated (figure 5.32b) with a 
significant (figure 5.32a) reduction in binding signal between the isotype control 
(200nM) and HuMc3 2nM, HuMc3 2nM/HuMc3 20nM and HuMc3 20nM/HuMc3 
200nM. An apparent 100% inhibition of HUVEC association by the 200nM 
concentration of HuMc3 was evident, an over 90% inhibition by the 20nM 
concentration and 56% inhibition by the 2nM concentration. As however some 
significant (figure 5.32a) binding inhibition was demonstrated for the isotype control 
(43%), there may be proposed to be up to a 43% background binding inhibition 
occurring as a result of non-specific binding of the antibody. The actual level of 
binding inhibition concentration would therefore be at a minimum 13.5 for the 2mM 
concentration, 47.1 for the 20nM and 59.4 for the 200nM concentration.  
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With HuMc3 shown to inhibit lactadherin binding to the cell surface as well as bind to 
it on the cell surface, this suggested lactadherin is able to bind to HUVECS by both an 
integrin-mediated and integrin-independent means. With both HuMc3 and mAb2767 
suggested to bind to nearby epitopes of the EGF domain, both antibodies were 
therefore suggested to bind to lactadherin on the surface, with lactadherin ligated not 
with a αv integrin, as this needed to be exposed for antibody ligation, but by perhaps 
its C2-domain, to which it has been shown in past studies [151][152][153][155] to be 
anchored on the cell surface following expression. This data therefore also offered an 
explanation as to why no inhibition of lactadherin binding to the cell surface by 
vitronectin or fibronectin was evident in the earlier FACS studies (figures 5.20-5.21 
and 5.22-5.23), with mAb2767 only suggested to detect lactadherin in its C2-bound 
state.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 5.27 
Detecting inhibition of lactadherin association with HUVECS by pre
Binding of mAb2767 (66.7nM), following
and rHu-lactadherin (X20 transfected CHO supernatant) detected with an anti
F5262 (1 in 1000 dilution). No
sample name and description, percentage gated cells, percentage of gated cells positive for 
fluorescence (FL1+), median fluorescent intensity of gated cells 
cells. (b) Half offset overlay plot of all samples. (c) Individual sample shifts plotted against control, 
with FSC-H, SSC-H plots attached;
representative of three separate
 
(a) 
 
Sample description Sample name
Lactadherin with mAb2767 
detection alone –ve control 1 no angiolix. 001
HuMc3 (66.7nM)  2 ang 10. 002
HuMc3 (167nM) 3 ang 25. 003
HuMc3 (333nM) 4 ang 50. 004
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
(c)(i)    
 
 
 
 
 
 
 
 
 
 
 
 
(iii)    
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-incubation with HuMc3
 incubation of pre-incubated HuMc3 (66.7, 167 and
-mouse FITC secondar
-HuMc3 negative control included. (a) Overview table including the 
(FL1-H) and percentage FL1+ve total 
 (i-iii) HuMc3 concentrations; (66.7, 167 and 333nM).
 experiments. 
 Percentage gated 
cells (%) 
Percentage FL1+ve 
gated cells (%) 
Median FL1-H 
intensity of gated cells 
 89.24 94.14 34.07
 90.02 78.87 15.27
 87.41 19.48 5.67
 91.36 14.02 4.96
   (ii) 
 
 333nM) 
y 
 Figure data 
Percentage FL1+ve 
total cells (%) 
 84.01 
 71.00 
 17.03 
 12.81 
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Figure 5.28 
Detecting inhibition of lactadherin (lac) association with HUVECS by pre-incubation with HuMc3-
combined data 
Displayed is the percentage FL1+ve gated cells (b) and median FL1-H intensity of gated cells (c) data 
from three separate experiments as described in figure 5.27 and an average of the three (combo). (a) 
Statistical data table displaying the average of three separate experiments (combo data) and t-tests 
(a) 
 
Combo data               
 Percentage 
FL1+ve 
gated cells 
Lac + 
mAb2767 
- HuMc3 
HuMc3 
(66.7nM)  
HuMc3 
(167nM) 
HuMc3 
(333nM) 
No 
lac 
t-test -HuMc3/ 
HuMc3 
(66.7nM) 
HuMc3 
(66.7nM0/ 
(167nM) 
HuMc3 
(167nM)/ 
(333nM) 
-
HuMc3/HuMc3 
(167nM) 
N 3 3 3 3 2 t Stat 5.99 13.97 2.69 43.42 
Mean 93.06 71.93 18.19 13.69 14.04 P(T<=t) one-tail 1.95E-03 7.61E-05 0.03 8.41E-07 
SD 0.97 6.03 2.83 0.65 0.21 t Critical one-tail 2.13 2.13 2.13 2.13 
 
     P(T<=t) two-tail 3.90E-03 1.52E-04 0.05 1.68E-06 
 
     t Critical two-tail 2.78 2.78 2.78 2.78 
 Median 
FL1-H 
intensity of 
gated cells 
Lac + 
mAb2767 
- HuMc3 
HuMc3 
(66.7nM)  
HuMc3 
(167nM) 
HuMc3 
(333nM) 
No 
lac 
t-test -HuMc3/ 
HuMc3 
(66.7nM) 
HuMc3 
(66.7nM0/ 
(167nM) 
HuMc3 
(167nM)/ 
(333nM) 
-
HuMc3/HuMc3 
(167nM) 
N 3 3 3 3 2 t Stat 1.17 1.48 0.26 1.91 
Mean 18.57 8.72 3.62 3.27 2.45 P(T<=t) one-tail 0.15 0.11 0.40 0.06 
SD 13.43 5.68 1.78 1.46 0.06 t Critical one-tail 2.13 2.13 2.13 2.13 
 
     P(T<=t) two-tail 0.31 0.21 0.81 0.13 
 
     t Critical two-tail 2.78 2.78 2.78 2.78 
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Figure 5.29 
Detecting inhibition of lactadherin association with HUVECS by pre-incubation with HuMc3- 
isotype control FACS 
Binding of mAb2767, (66.7nM) following incubation of pre-incubated HuMc3 isotype-matched control, 
(66.7, 167 and 333nM) and rHu-lactadherin (transfected CHO supernatant) detected with an anti-
mouse FITC secondary F5262 (1 in 1000 dilution). No-isotype control, negative control included. (a) 
Overview table including the sample name and description, percentage gated cells, percentage of gated 
cells positive for fluorescence (FL1+), median fluorescent intensity of gated cells (FL1-H) and 
percentage FL1+ve total cells. (b) Half offset overlay plot of all samples. (c) Individual sample shifts 
plotted against control, with FSC-H, SSC-H plots attached; (i-iii) Isotype control concentrations (66.7, 
167 and 333nM). Figure data representative of a single experiment. 
(a) 
Sample description Sample name Percentage gated 
cells (%) 
Percentage FL1+ve 
gated cells (%) 
Median FL1-H 
intensity of gated cells 
Percentage FL1+ve 
total cells (%) 
Lactadherin with MAB2767 
detection alone –ve control 1 no angiolix. 001 89.24 94.14 34.07 84.01 
IgG1 isotype 
-ve control (66.7nM) 
6 I C 10. 006 
89.08 95.58 40.84 85.14 
IgG1 isotype 
-ve control (167nM) 
7 I C 25. 007 
89.07 91.76 29.04 81.73 
IgG1 isotype 
-ve control (333nM) 
8 I C 50. 008 
87.27 94.76 39.39 82.7 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
(c) 
(i)       (ii) 
 
 
 
 
 
 
 
 
 
 
 
 
(iii) 
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Figure 5.30 
Detecting inhibition of lactadherin (lac) association with HUVECS by pre-incubation with HuMc3- 
isotype control (I Con) FACS-combined data 
Displayed is the percentage FL1+ve gated cells (b) and median FL1-H intensity of gated cells (c) data 
from three separate experiments as described in figure 5.29 and an average of the three (combo), (but 
only including the highest I Con concentration (333nM) and both a no-lactadherin with mAb2767 
detection positive and lactadherin + mAb2767 with no I Con negative control). (a) Statistical data 
table displaying the average of three separate experiments (combo data) and t-tests 
(a) 
Combo data         
Percentage FL1+ve 
gated cells 
No lac Lac + mAb2767 
- I Con 
I Con (333nM) t-test I con (333nM0/ no I con 
N 2 3 3 t Stat 0.61 
Mean 14.04 93.06 93.70 P(T<=t) one-tail 0.29 
SD 0.21 0.97 1.55 t Critical one-tail 2.13 
 
   P(T<=t) two-tail 0.58 
 
   t Critical two-tail 2.78 
Median FL1-H 
intensity of gated cells 
No lac Lac + mAb2767 
- I Con 
I Con (333nM) t-test I con (333nM0/ no I con 
N 2 3 3 t Stat 0.10 
Mean 2.49 18.68 19.93 P(T<=t) one-tail 0.46 
SD 0 13.33 16.86 t Critical one-tail 2.13 
 
   P(T<=t) two-tail 0.92 
 
   t Critical two-tail 2.78 
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Figure 5.31 
ELISA to determine the effects of HuMc3 on binding of mAb2767 to lactadherin 
(b) Included is a titration of HuMc3 concentrations added with mAb2767 (6.7nM) to plate-coated rHu-
lactadherin (lac), (transfected CHO supernatant) with detection of binding of mAb2767 with A9917 
(diluted 1 in 60,000). Controls include HuMc3 titrations with omission of lactadherin or mAb2767. 
Data representative of the results of a single experiment and each error bar denotes three assay 
repeats. (a) Statistical data table with t-tests 
 
(a) 
Statistics 
Lac + 
mAb2767 
+ HuMc3 
(167nM) 
Lac + 
mAb2767 
+ HuMc3 
(0.65nM) 
 
 
 
t-test 
HuMc3 
0.098nM/ 
0.39nM 
HuMc3 
0.39nM 
/1.56nM 
HuMc3 
1.56nM/ 
6.25nM 
HuMc3 
6.25nM/ 
25nM 
 
HuMc3 167nM + 
mAb2767/HuMc3 
167nM-mAb2767 
N 3 3 t Stat 24.44 5.03 5.37 1.48 7.06 
Mean 0.13 0.41 P(T<=t) one-tail 8.327E-06 3.67E-03 2.90E-03 0.11 1.06E-03 
SD  0.01 0 t Critical one-tail 2.13 2.13 2.13 2.13 2.13 
 
  P(T<=t) two-tail 1.674E-05 7.33E-03 5.81E-03 0.21 2.12E-03 
 
  t Critical two-tail 2.78 2.78 2.78 2.78 2.78 
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Figure 5.32 
Cell binding assay for detection of inhibition of HUVEC binding to lactadherin with HuMc3 
Shown is a cell-binding assay (b) detecting inhibition of HUVEC association with immobilised rHu-
lactadherin (lac), following pre-incubation of HuMc3 (2, 20 and 200nM) with lactadherin. Controls 
included are an isotype-matched IgG1 antibody (I Con) (200nM) and cells + lactadherin alone. 
Displayed is data from four separate assays and an average of the four (combo). Each error bar 
denotes 4-6 assay replicates. Absorbance corrected to zero using a cells alone control. (a) Statistical 
data table displaying the average of four separate experiments (combo data) and t-tests. 
 
 (a) 
 
Combo 
data     
       
Statistics 
Cells 
+ Lac 
Cells + 
Lac + 
HuMc3 
(200nM) 
Cells + 
Lac + 
HuMc3 
(20nM) 
Cells + 
Lac + 
HuMc3 
(2nM) 
Cells + 
Lac + I 
Con 
(200nM) 
 
 
 
t-test 
No 
HuMc3/ 
HuMc3 
(2nM) 
HuMc3 
(2nM)/ 
HuMc3 
(20nM) 
HuMc3 
(20nM)/ 
HuMc3 
(200nM) 
Cells + 
lac / I 
Con 
(200nM) 
I Con  
(200nM) 
/ HuMc3 
(2nM) 
N 19 14 23 12 14 t Stat 9.53 6.89 3.98 8.48 2.17 
Mean 100 -2.43 9.90 43.53 57.50 P(T<=t) one-tail 9.73E-11 3.57E-08 1.71E-04 7.03E-10 0.02 
SD  14.28 4.48 10.39 18.64 14.17 
t Critical one-
tail 1.70 1.70 1.70 1.70 1.71 
 
     P(T<=t) two-tail 1.95E-10 7.15E-08 3.41E-04 1.41E-09 0.04 
 
     
t Critical two-
tail 2.05 2.03 2.03 2.04 2.06 
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5.2.3 Investigating a role for lactadherin in vascular EC survival 
 
A role for lactadherin in promotion of survival through inhibition of apoptosis was 
investigated using an apoptosis assay designed to detect the activity of effector 
caspases 3 and 7 in HUVECs following incubation with the test substance (section 
2.2.5.8). The TRAIL receptor ligand staurosporine was chosen to promote extrinsic 
apoptosis and lactadherin tested for its ability to knock-down the signal through 
VEGF-independent and VEGFR-2-αv integrin coordinated signalling (section 
1.2.3.1). VEGF was tested for its ability to inhibit extrinsic apoptosis as a negative 
control to confirm its lack of survival promotion through this pathway in the absence 
of αv integrin ligand application (section 1.2.2.1).  
 
A cell number titration extrinsic apoptosis assay was first carried out in the presence 
and absence of 100nM staurosporine (figure 5.33a) to determine the optimum cell 
number for the greatest apoptosis signal in response to staurosporine application. The 
staurosporine concentration was chosen based on the results of past work showing a 
response in HUVECs [303]. The difference in signal (figure 5.33b) appeared highest 
between 8438 and 4746 cells per well. The cell number chosen for subsequent assays 
was therefore 5000 cells per well to ensure maximum signal separation.  A 
staurosporine titration assay (figure 5.34) was next performed to uncover the 
minimum staurosporine concentration for maximal extrinsic apoptosis signal, to use 
for detection of knockdown of signal in subsequent assays. The curve was sigmoidal 
with a maximum reached around 100nM staurosporine (EC100) (figure 5.34b) and a 
half maximal effect at 0.02nM (EC50) (figure 5.34b). The EC100 (100nM) 
concentration was therefore chosen for subsequent assays. A VEGF titration assay in 
the presence and absence of staurosporine (figure 5.35) was next carried out to 
confirm VEGF signalling does not activate extrinsic apoptosis in the absence of a αv 
integrin ligand. A significant (figure 5.35b) maximum of 30% signal inhibition for 
VEGF application of above 0.19nM was seen in the absence of staurosporine, 
indicating some intrinsic apoptosis inhibition. As expected VEGF appeared to have no 
effect on staurosporine mediated apoptosis when applied alone (figure 5.35a). This 
was supported by a staurosporine titration assay in the presence and absence of a high 
VEGF concentration of 5nM (figure 5.36). Shown are two sigmoidal curves (figure 
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5.36ai) in which the application of VEGF does not alter the staurosporine EC50 
(figure 5.36aii). There was however a small difference in signal between the curves, 
but the effect was equal throughout the curve, with no significant variation (figure 
5.36bii) between the difference in signal for the staurosporine concentrations in the 
presence and absence of VEGF. This suggested the small inhibitory effect of VEGF 
on caspase 3/7 activity was a result of intrinsic rather than extrinsic apoptosis 
inhibition. This was further supported by an experiment (figure 5.37) in which the 
percentage total caspase 3/7 activity (intrinsic and extrinsic apoptosis measurement) 
data with a single staurosporine concentration (100nM) in the presence and absence of 
VEGF was plotted alongside controls of cells alone and cells plus VEGF but no 
staurosporine (figure 5.37a). The data showed identical separation with no statistically 
significant difference (figure 5.37b) for addition of VEGF to cells in either the 
presence or absence of staurosporine. 
 
A role of lactadherin in extrinsic apoptosis though VEGFR-2 dependant and 
independent signalling was assessed by application of lactadherin (200nM) to 
staurosporine induced cells, alone, with 5nM VEGF, with HuMc3 (200nM) and with 
HuMc3 and VEGF (figure 5.38a). No significant reduction (figure 5.38b) in the 
staurosporine-mediated apoptosis signal was however apparent for application 
lactadherin alone. Although VEGF produced a small (just significant) inhibition alone 
and in the presence of lactadherin, no significant increase in inhibition was observed 
for the addition of lactadherin to VEGF. HuMc3 addition to either lactadherin or 
lactadherin with VEGF produced no significant effect either (figure 5.38b). Overall 
this data therefore suggested lactadherin plays no role in protection against the 
extrinsic pathway of apoptosis, either through VEGFR-2 dependent or independent 
signalling. 
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Figure 5.33 
HUVEC extrinsic apoptosis assay with detection of the optimal cell number for maximal increase in 
effector caspase 3/7 activity by staurosporine  
(a) Detection of caspase3/7 activity in HUVECS, with a HUVEC cell number titration in the presence 
and absence of staurosporine (100nM). (b) Chart showing the luminescence difference between 
staurosporine treated and untreated cells. (c) Statistical data table displaying the luminescence 
difference between treated and untreated cells. Displayed is data from a single experiment. Each error 
bar denotes 4 assay repeats. Luminescence corrected to zero using a no-cells control. 
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Figure 5.34 
HUVEC extrinsic apoptosis assay, with detection of an increase in effector caspase 3/7 activity 
caused by staurosporine application  
(a) Detection of caspase3/7 activity induced in HUVECS by treatment with a titration of staurosporine 
concentrations. Cells coated at 5000 cells per well. Displayed is data from three separate experiments. 
Each error bar denotes 4 experimental repeats. Luminescence corrected to zero using a cells alone 
control. (b) Statistical data table and t-tests for EC50 and EC100 values calculated from the curves 
using Sigmaplot11.0. 
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Curves fitted by Sigmaplot11.0; Equation sigmoidal logistic 4 parameter. Exp 1 Normality test (Shapiro-Wilk) Passed (P = 0.3165), W statistic= 
0.9197, significance level = 0.0500. Constant variance test passed (P = 0.7755).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 249
Figure 5.35 
HUVEC intrinsic/extrinsic apoptosis assay for detection of inhibition of effector caspase 3/7 activity 
by VEGF titration application to both untreated and staurosporine- induced cells  
Detected is inhibition of both percentage native and percentage staurosporine (100nM)-induced 
effector caspase 3/7 activity by application of a titration of VEGF to HUVECS (5000 cells/well). 
Displayed is data from a single experiment. Each error bar denotes 3 repeats. Luminescence corrected 
to zero using a cells alone control for the induced (+ staurosporine) and no cells for the native (- 
staurosporine) assay. (b) Statistical data table displaying the caspase3/7 activity at VEGF 
concentrations (0.025, 0.049 and 0.383nM) in the presence and absence of staurosporine. 
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P(T<=t) one-tail 0.25 2.84E-03 8.43E-05     
t Critical one-tail 2.13 2.13 2.13     
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Figure 5.36 
HUVEC extrinsic apoptosis assay for detection of inhibition of effector caspase 3/7 activity by VEGF 
application to cells treated with a staurosporine titration  
(a)(i) Detection of total (native and induced) caspase3/7 activity with a titration of staurosporine in the 
presence and absence of VEGF (5nM). Displayed is data from a single experiment. Each error bar 
denotes 3 replicates. Percentage Caspase3/7 activity corrected to zero using a cells alone control. (ii) 
Statistical data table for the EC50 values calculated from the curves in the presence and absence of 
VEGF. (b)(i) Chart showing the difference in percentage caspase 3/7 activity for staurosporine (staur) 
titration concentrations between VEGF-treated and untreated cells. (b)(ii) Statistical data table for the 
difference data with t-tests. 
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Curves fitted by Sigmaplot11.0 using the equation sigmoidal logistic 4 parameter. Exp 1 – VEGF, normality test (Shapiro-Wilk) Passed (P = 0.3780), W statistic= 0.8941, significance level = 0.0500. 
Constant variance test passed (P = 0.0500). Exp 1 + VEGF, normality test (Shapiro-Wilk) Passed (P = 0.7306), W statistic= 0.9491, significance level = 0.0500. Constant variance test passed (P = 0.0500). 
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Figure 5.37 
HUVEC intrinsic/extrinsic apoptosis assay for detection of inhibition of effector caspase 3/7 activity 
by VEGF application to both untreated and staurosporine- induced cells  
(a) Percentage total caspase3/7 activity (native and induced) detected in cells treated with VEGF 
(5nM) in the presence and absence of staurosporine (Staur 100nM). Included are cells alone and cells 
with staurosporine alone controls. Displayed is data from a single experiment. Each error bar denotes 
3 experimental replicates. Percentage Caspase3/7 activity corrected to zero using a no-cells control. 
(b) Statistical data table showing the difference between cells and cells plus VEGF, as well as cells 
plus staurosporine and cells plus staurosporine plus VEGF. Also included are t-tests. 
 
 
(a) 
 
(b)  
 
Statistics 
Diff cells and 
cells + VEGF 
Diff cells + staur and 
Cells + Staur + 
VEGF 
 
 
t test 
Diff cells and cell + VEGF / 
Diff cells + staur and cells + 
staur + VEGF 
N 3 3 t Stat 0.01 
Mean 5827 5800 P(T<=t) one-tail 0.49 
SD  3139 817.2 t Critical one-tail 2.13 
 
  P(T<=t) two-tail 0.99 
 
  t Critical two-tail 2.78 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
20000
40000
60000
80000
Co
rr
ec
te
d 
lu
m
in
es
ce
n
ce
 
(ca
sp
as
e 
3/
7 
ac
tiv
ity
)
  
 252
Figure 5.38 
HUVEC extrinsic apoptosis assays with determination of the effect of lactadherin, VEGF and 
HuMc3 on staurosporine- induced effector caspase 3/7 activity 
(a) Detection of caspase3/7 activity in HUVECS treated with staurosporine (Staur 100nM) in the 
presence and absence of rHu-lactadherin (lac 200nM), VEGF (5nM) and HuMc3 (200nM), both 
lactadherin and VEGF, lactadherin and HuMc3 and lactadherin with VEGF plus HuMc3. Controls 
included were cells plus staurosporine alone and cells alone. Displayed is data from three separate 
experiments. Each error bar denotes 3 experimental repeats. (b) Statistical data table for the average 
(combo) data with t-tests. 
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Further survival studies were carried out with HUVECS in the absence of 
staurosporine to confirm the role of both VEGF-dependent and VEGF-independent 
lactadherin signalling in intrinsic apoptosis and to determine any inhibitory effects of 
HuMc3 on these roles.  
 
A VEGF titration intrinsic apoptosis assay was first performed to ascertain the 
optimum concentration for maximal inhibition of caspase 3/7 activity (figure 5.39), 
with a significant effect (figure 5.39b) and sigmoidal curve evident (figure 5.39a). The 
data confirmed both past work showing significant inhibition of apoptosis with VEGF 
application at a similar concentration range [304][305][306] and data from figures 
5.35-5.37. The results were also in agreement with the known role of VEGF in 
survival through intrinsic apoptosis inhibition (section 1.2.2.1). A maximum 
inhibition of around 40% of intrinsic apoptosis was evident from the curve (figure 
5.39a). The minimum concentration for a maximal effect (IC100) was shown to be 
0.1nM (figure 5.39b). The concentration required for half-maximal apoptosis 
inhibition (IC50) was calculated from the curve to be 0.02nM and produced around 
30% inhibition. A concentration between these values of 0.05nM was chosen for 
subsequent assays to study the role of lactadherin in intrinsic apoptosis rather than the 
IC100, to avoid loss of the observed role of lactadherin through a saturation effect.   
 
The ability of bevacizumab to knock down VEGF inhibition of intrinsic apoptosis in 
the presence and absence of exogenously applied VEGF was next studied. The former 
to allow comparisons to be made with the effects of HuMc3 on lactadherin and the 
latter allow the optimum concentration to be chosen so lactadherin could be studied 
for inhibition of intrinsic apoptosis in the absence of VEGFR-2 signalling. The 
bevacizumab titration (figure 5.40a) in agreement with its proposed neutralisation of 
VEGF binding to VEGFR2 [97] showed apparent suppression of exogenous VEGF-
induced apoptosis inhibition with a statistically significant increase in caspase 3/7 
activity between the lowest and highest bevacizumab concentrations (figure 5.40b). 
The difference in native caspase 3/7 activity for the highest and lowest bevacizumab 
concentration was approximately 15%. In the absence of exogenously applied VEGF 
however, no effect of application of bevacizumab was evident, indicating a lack of 
endogenous VEGF. The quality of this data and the confidence in any inferences 
made from it should however have been improved by performance of repeats. 
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With the previous experiment indicating no endogenous VEGF activity, the effect of 
VEGF-dependent and VEGF-independent lactadherin signalling in intrinsic apoptosis 
was assessed by application of lactadherin (2, 20 and 200nM) in the presence and 
absence of VEGF (figure 5.41). Controls included cells alone and cells with VEGF 
alone.  In opposition with past findings [173], no effect of application of lactadherin at 
any concentration used was however observed, either alone or in the presence of 
VEGF. This indicated lactadherin does not play a role in promotion of survival 
through intrinsic apoptosis pathway inhibition, either in coordination with VEGFR-2 
signalling or independently.  To confirm the lack of a role of lactadherin in inhibition 
of intrinsic apoptosis, this assay was repeated with a single high 400nM lactadherin 
concentration (figure 5.42) in the presence and absence of VEGF and/or HuMc3, with 
controls of VEGF alone and HuMc3 alone. Again, no effect of application of 
lactadherin was observed. In addition, no significant (figure 5.42b) effect was evident 
for application of HuMc3 alone, with lactadherin or with lactadherin and VEGF.  
 
Taken together these results suggested that lactadherin does not promote survival 
through apoptosis inhibition, either through activation of direct integrin signalling 
pathways or through co-ordination of signalling with the VEGF receptor. 
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Figure 5.39 
HUVEC intrinsic apoptosis assay, for detection of a reduction in native effector caspase 3/7 activity 
caused by application of VEGF  
(a) Percentage native caspase3/7 activity detected in HUVECS (5000 cells/well) treated with a titration 
of VEGF concentrations. Displayed is data from three separate experiments. Each error bar denotes 3- 
4 experimental repeats. Percentage Caspase3/7 activity corrected to zero using a no-cells control. (b) 
Statistical data table displaying the EC50 and EC100 values calculated from the curves, as well as t-
tests 
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Curves fitted by Sigmaplot 11.0 using the equation sigmoidal logistic 4 parameter. Exp 1 Normality test (Shapiro-Wilk) Passed (P = 0.6686), W 
statistic= 0.9500, significance level = 0.0500. Constant variance test passed (P = 0.2915). 
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Figure 5.40 
HUVEC intrinsic apoptosis assays, for detection of an increase in effector caspase 3/7 activity 
caused by application of bevacizumab to VEGF-treated cells  
(a) Percentage native caspase3/7 activity detected in HUVECS (5000 cells/well) treated with a titration 
of bevacizumab (BV) concentrations in the presence and absence of VEGF (0.05nM). Displayed is data 
from a single experiment. Each error bar denotes 4 experimental repeats. Percentage Caspase3/7 
activity corrected to zero using a no-cells control. (b) Statistical data table displaying data at the 
highest (67nM) and lowest (0.5nM) bevacizumab concentrations in the presence and absence of VEGF 
and t-tests showing the significance of the difference in caspase activity for the highest and lowest 
concentrations. 
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Figure 5.41 
HUVEC intrinsic apoptosis assays with determination of the effect of lactadherin and VEGF on 
native caspase 3/7 activity 
(a) Percentage native caspase3/7 activity detected in HUVECS (5000 cells/well) treated with rHu-
lactadherin (Lac) (2, 20 and 200nM), in the presence and absence of VEGF (0.05nM). Controls 
included are cells alone and cells plus VEGF. Displayed is data from three separate experiments and 
an average of the three (combo). Each error bar denotes 4 experimental repeats. Percentage 
Caspase3/7 activity corrected to zero using a no-cells control. (b) Statistical data table displaying the 
average (combo) data and t-tests. 
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Figure 5.42 
HUVEC intrinsic apoptosis assays with determination of the effect of lactadherin, VEGF and 
HuMc3 on native caspase 3/7 activity 
(a) Percentage native caspase3/7 activity detected in HUVECS (5000 cells/well) treated with rHu-
lactadherin (Lac) (400nM), in the presence and absence of VEGF (0.05nM) and/or HuMc3 (200nM). 
Controls included are cells alone, cells plus VEGF and cells plus HuMc3. Displayed is data from three 
separate experiments and an average of the three (combo). Each error bar denotes 3 repeats. 
Percentage Caspase3/7 activity corrected to zero using a no-cells control. (b) Statistical data table 
displaying the average (combo) data and t-tests. 
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5.2.4 Investigating the role of lactadherin in vascular EC proliferation 
 
With a role for lactadherin in vascular EC survival indicated to be absent, a function 
in proliferation was tested using an MTS assay (section 2.2.5.7). The MTS assay 
detects live cell number so is a measure of both survival and proliferation. As 
however a role in survival through inhibition of apoptosis had not been detected, any 
increase in cell number was attributed to proliferation, as the favourable culture 
conditions made cell death through necrosis unlikely. The MTS assays were carried 
out by addition of the test substances to HUVECs and after 48 hours culture, cell 
proliferation assessed using a proliferation assay reagent. The effects of VEGF on 
proliferation were determined as a positive control for comparison with lactadherin. 
The effects of lactadherin on proliferation were assayed in the presence and absence 
of VEGF to determine its ability to promote proliferation through coordinated 
signalling with the VEGFR2 pathway and through an independent signalling 
mechanism. The effects of HuMc3 on these roles were also studied. As in the 
apoptosis assay studies the effects of bevacizumab on proliferation in the presence 
and absence of exogenously applied VEGF were investigated to respectively allow 
comparisons to be made with the effects of HuMc3 on lactadherin and allow the 
optimum concentration to be chosen so lactadherin could be studied for promotion of 
proliferation in the absence of VEGFR-2 signalling.  
 
A cell number titration assay was first carried out in the presence and absence of 
1.25nM VEGF (figure 5.43a) to determine the optimum cell number for the greatest 
proliferation signal increase in response to VEGF application. The point of greatest 
difference in proliferation between cells with and without VEGF application (figure 
5.43b) occurred at 4500-5000 cells/well, so 5000cells/well was chosen as the coating 
number for subsequent assays. This assay also confirmed the suitability of the assay in 
its sensitivity to detect VEGF promotion of HUVEC proliferation. The minimum 
concentration of VEGF for maximal stimulation of proliferation was determined by a 
VEGF titration assay (figure 5.44).  The results were shown to be similar to those seen 
in past work [304][206][307] with the induction of HUVEC proliferation by 
application of VEGF at a similar concentration range. A sigmoidal curve was evident 
(figure 5.44a) and the difference in signal between the EC100 and EC0 absorbance 
(490nm) of 0.2, shown to be statistically significant (figure 5.44b). This data however 
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showed a large variation between the repeats, which may have been improved by 
increasing the number of experiments performed or more tightly controlling the assay 
conditions. The EC100 value of 1nM was chosen for use in subsequent assays.  
 
In agreement with its proposed neutralisation of VEGF binding to VEGFR2 [97], the 
application of a titration of bevacizumab in the presence and absence of 1nM VEGF 
(figure 5.45), showed an apparently sigmoidal curve (figure 5.45a) for bevacizumab 
in the presence of exogenously applied VEGF. A significant difference between the 
absorbance (490nm) at EC0 and EC100 was also evident (figure 5.45b). No effect was 
however apparent in the absence of VEGF (figure 5.45a-b). This indicated 
bevacizumab inhibits the proliferative effects of VEGF in a concentration dependant 
manner, but that either no endogenous VEGF was present or that it exists in a form to 
which bevacizumab is unable to bind to. At bevacizumab EC100 however the 
absorbance was not returned to the baseline 0 that would have been expected if all 
VEGF activity had been removed, remaining around 0.05. This suggested the 
presence of some residual endogenous VEGF activity, bevacizumab was unable to 
remove. In light of this, any effects of lactadherin application in the absence of 
exogenously applied VEGF could not be wholly attributed to VEGFR-2-independent 
signalling, as it would not be possible to use bevacizumab application to knock down 
endogenous VEGF activity. The quality of this data and the confidence in any 
inferences made from it could have been improved by performance of repeats.  
 
A titration assay with lactadherin in the presence and absence of exogenous VEGF 
(figure 5.46) appeared to show no effect (figure 5.46a) on proliferation for application 
of lactadherin alone, with no significant difference (figure 5.46b) in proliferation 
between the highest and lowest lactadherin concentration, in agreement with past 
work [173]. For application with VEGF a borderline significant difference (figure 
5.46b) in proliferation signal was observed between the highest and lowest lactadherin 
concentrations. To further investigate a role of lactadherin in HUVEC proliferation 
therefore, further proliferation assays were carried out with HuMc3 and lactadherin in 
the presence and absence of VEGF (figure 5.47), as well as with HuMc3 and 
lactadherin alone (figure 5.48) and with HuMc3 alone (figure 5.49), but no significant 
increase in proliferation was observed for lactadherin application or inhibition by 
HuMc3, in the presence or absence of VEGF. Taken together this work indicated 
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lactadherin does not promote vascular EC proliferation, either independently or 
through coordinated signalling with VEGFR-2. 
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Figure 5.43 
HUVEC proliferation assay with detection of the optimal cell seeding number for maximal increase 
in cell proliferation induced by VEGF application 
(a) Detection of HUVEC live cell absorbance in an MTS assay, with a titration of cell number in the 
presence and absence of VEGF, (1.25nM). (b) Chart showing the absorbance difference between 
VEGF treated and untreated cells. (c) Statistical data table displaying the absorbance difference 
between treated and untreated cells. Displayed is data from a single experiment. Each error bar 
denotes 5 assay replicates. Absorbance corrected to zero using a no-cells control. 
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variance test passed (P = 0.3090). Exp 1 + VEGF normality Test (Shapiro-Wilk) passed (P = 0.9309), W statistic= 0.9749, significance level = 0.0500. Constant variance test failed (P = 0.0252). 
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Figure 5.44 
Detection of exogenous VEGF promotion of HUVEC proliferation 
(a) Detection of HUVEC live cell absorbance in an MTS assay with a titration of VEGF concentrations 
using a 5000cells/well seeding density. (b) Statistical data table of EC50 and EC100 values calculated 
from the curves, and t-tests. Displayed is data from three separate experiments. Each error bar denotes 
3/4 experimental replicates. Absorbance corrected to zero using a cells alone control. 
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Curves fitted by Sigmaplot 11.0 using the equation sigmoidal logistic 4 parameter. Exp 1 Normality test (Shapiro-Wilk) Passed (P = 0.0919), W statistic= 0.8669, significance level = 0.0500. Constant 
variance test passed (P = 0.4250). Exp 2 Normality test (Shapiro-Wilk) Passed (P = 0.8594), W statistic= 0.9668, significance level = 0.0500. Constant variance test passed (P = 0.0069).  Exp 3 Normality test 
(Shapiro-Wilk) Passed (P = 0.5410), W statistic= 0.9389, significance level = 0.0500. Constant variance test passed (P = 0.0892. 
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Figure 5.45 
Detection of bevacizumab inhibition of VEGF-induced HUVEC proliferation 
(a) Detection of HUVEC live-cell absorbance in an MTS assay with a titration of bevacizumab (BV) 
concentrations (using a 5000cells/well seeding density) in the presence and absence of VEGF 
(1.25nM). (b) Statistical data table displaying data at the highest (13nM) and lowest (0.05nM) 
bevacizumab concentrations in the presence and absence of VEGF and t-tests showing the significance 
of the difference in absorbance for the highest and lowest BV concentrations. Each error bar denotes 5 
experimental replicates. Absorbance corrected to zero using a cells alone control. 
(a) 
 
Bevacizumab concentration (nM)
0.01 0.1 1 10 100Co
rr
e
c
te
d 
a
bs
o
rb
a
n
c
e
 
49
0n
m
 
(vi
a
bl
e
 
c
e
lls
)
-0.2
-0.1
0.0
0.1
0.2
0.3
0.4
Exp 1 + VEGF (1.25nM)
Exp 1 - VEGF (1.25nM)
 
 
(b) 
 
Statistics 
BV (13nM) 
plus VEGF 
BV (13nM) 
minus VEGF 
 
BV (0.05nM) 
plus VEGF 
 
BV (0.05nM) 
minus VEGF 
 
 
t-test 
Diff BV 
(13nM)/(0.05nM) 
plus VEGF 
Diff BV 
(13nM)/(0.05nM) 
minus VEGF 
N 5 5 5 5 t Stat -4.68 0.58 
Mean 0.07 0.01 0.19 -0.01 P(T<=t) one-tail 7.94E-04 0.29 
SD 0.05 0.05 0.04 0.04 t Critical one-tail 1.86 1.86 
 
    P(T<=t) two-tail 1.59E-03 0.58 
 
    t Critical two-tail 2.31 2.31 
 
 
Curves fitted by Sigmaplot11.0 using the equation sigmoidal logistic 4 parameter. Exp 1 + VEGF normality test (Shapiro-Wilk) Passed (P = 0.5423), W statistic= 0.9300, significance level = 0.0500. 
Constant variance test failed (P = 0.0480). 
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Figure 5.46 
Detection of lactadherin promotion of HUVEC proliferation in the presence and absence of VEGF 
(a) Detection of HUVEC live cell absorbance in an MTS assay with a titration of rHu-lactadherin 
(Lac) in the presence and absence of VEGF (1nM), using a 5000cells/well seeding density. Displayed 
is data from three separate experiments. (c) Statistical data table displaying the average (combo) 
difference between upper (120-200nM) and lower (0.3-0.4) lactadherin concentrations, plus and minus 
VEGF, and t-tests. Each error bar denotes 4/5 experimental repeats. Absorbance corrected to zero 
using a cells alone control. 
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Figure 5.47 
Detection of lactadherin promotion and HuMc3 inhibition of HUVEC proliferation in the presence 
and absence of VEGF 
(a) Detection of HUVEC live cell absorbance in an MTS assay with rHu-lactadherin (Lac 100nM) in 
the presence and absence of VEGF (1nM) and/or HuMc3 (200nM). Controls included are cells alone 
and cells plus VEGF. Displayed is data from three separate experiments and an average of the three 
(combo). Each error bar denotes 3/4 experimental repeats. Absorbance corrected to zero using a no-
cells control. (b) Statistical data table displaying the average (combo) data and t-tests. 
(a) 
 
 
(b) 
 
Combo 
        
         
Statistics Cells 
Cells + 
Lac 
Cells + 
Lac + 
HuMc3 
Cells + 
VEGF 
Cells + 
Lac + 
VEGF 
Cells + Lac 
+ VEGF + 
HuMc3 t-test 
Cells/ 
cells 
+lac 
Lac/ Lac+ 
HuMc3 
 
VEGF/ 
VEGF 
+ lac 
VEGF+ lac/ 
VEGF+ lac 
+ HuMc3 
N 11 11 11 8 11 11 t Stat -0.41 0.89 -0.15 0.29 
Mean 0.46 0.47 0.44 0.62 0.62 0.62 P(T<=t) one-tail 0.34 0.19 0.44 0.39 
SD 0.09 0.06 0.09 0.03 0.04 0.05 t Critical one-tail 1.72 1.72 1.74 1.72 
 
      P(T<=t) two-tail 0.69 0.39 0.88 0.78 
 
      t Critical two-tail 2.09 2.09 2.11 2.09 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
Exp 1 Exp 2 Exp 3 Combo
Co
rr
ec
te
d 
ab
so
rb
an
ce
 
49
0n
m
 
(vi
ab
e 
ce
lls
)
Cells Cells + Lac Cells + Lac + HuMc3
Cells + VEGF Cells + Lac + VEGF Cells + Lac + VEGF + HuMc3
  
 267
Figure 5.48 
Detection of lactadherin promotion and HuMc3 inhibition of HUVEC proliferation 
(a) Detection of HUVEC live cell absorbance in an MTS assay with rHu-lactadherin, (Lac 100nM) in 
the presence and absence of HuMc3 (6.7, 67 and 667nM). Controls included are cells alone. Displayed 
is data from three separate experiments and an average of the three (combo). Each error bar denotes 
3/4 repeats. Absorbance corrected to zero using a no-cells control. (b) Statistical data table displaying 
the average (combo) data. 
(a)  
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Figure 5.49 
Detection of HuMc3 inhibition of HUVEC proliferation in the absence of exogenous lactadherin 
(a) Detection of HUVEC live cell absorbance in an MTS assay with a titration of HuMc3 
concentrations. Controls include a titration of an isotype-matched antibody (I Con). Displayed is data 
from a single experiment and each error bar denotes 5 replicates. Absorbance corrected to zero using 
a cells alone control. (b) Statistical data table displaying the absorbance data for the highest HuMc3 
and isotype control concentrations (1167nM), with t-tests. 
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5.3 Discussion 
 
In this chapter most of the objectives were attempted. The aims were however only 
partially met. Lactadherin expression by HUVECS could not be confirmed. 
Lactadherin binding to the surface of HUVECS was validated and this association 
was demonstrated to occur predominantly (82%) through association with the integrin 
αvβ3, though some non αv-integrin mediated adherence, presumed to be via the C2 
domain was also inferred. HuMc3 was shown to block all lactadherin binding to 
HUVECS, through predominantly specific means, though some (up to 40%) of the 
binding inhibition was suggested to be non-specific. HuMc3 was also able to bind to 
lactadherin on the surface of HUVECS, again suggesting lactadherin binds to this cell 
line through both an integrin and non-integrin mediated association. Cell proliferation 
assays and caspase 3/7 intrinsic and extrinsic apoptosis assays confirmed the role of 
VEGF-VEGFR signalling in intrinsic apoptosis and proliferation and that the assays 
were working correctly. A role for lactadherin or inhibition of its role by HuMc3, in 
any of these pathways was not however evident. This work therefore suggested that 
although lactadherin binds to the integrin avβ3, it plays no role in either VEGF-
mediated angiogenesis through activation of integrin signalling, or VEGFR2-
independent integrin signalling. It also suggested that any in vivo therapeutic effects 
of HuMc3 in chapter 6 could not be attributed to interference with the roles of 
lactadherin in tumour angiogenesis.   This was however at odds with past data 
demonstrating a role of lactadherin integrin signalling in VEGF-mediated 
angiogenesis, and angiogenesis through a VEGF-independent mechanism as well as 
more specifically integrin survival pathway signalling. This therefore suggested the in 
vitro assays used may have been in some way flawed and that the role of lactadherin 
in integrin-mediated angiogenesis pathways was missed.  
 
5.3.1 Lactadherin expression by HUVECS 
 
Lactadherin expression by HUVECS was examined in the form of detection of 
surface localisation using FACS analysis and IF confocal microscopy with both 
HuMc3 and mAb2767. All showed a lack of apparent lactadherin expression, with the 
exception of the mAb2767 FACS analysis in which significant, but barely visible 
expression was detected. One of the flaws in all this series of experiments was the 
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lack of inclusion of an antibody that detects the presence of lactadherin in its EGF-
domain associated integrin-bound form, with HuMc3 known [263] and mAb2767 
suggested (section 6.2.1) to bind to the EGF domain. The repetition of these 
experiments with anti-lactadherin C2-binding monoclonal antibodies Mc8 and/or 
Mc16 [151][194][263] would have achieved this, had it been possible to access these. 
In addition, the use of a FACS protocol for detection of lactadherin expression had 
been shown to be less than ideal in chapter 4, with lactadherin proposed to be 
removed from the cell surface despite the use of non-enzymatic cell dissociation 
methods. An alternative method of expression analysis by western blotting of 
HUVEC cell lysate also however suggested lack of lactadherin expression. If 
lactadherin had been apparent mAb2767 should have detected it, as it binds to 
lactadherin even under reducing conditions (demonstrated in chapter 3 sections 3.2.1 
and 3.2.2). With past work however suggesting lactadherin expression by HUVECS 
[173] this could have been investigated further, perhaps by RT-PCR, which would 
have confirmed at least if the lactadherin gene is transcribed.  
 
5.3.2 HuMc3 interference with lactadherin-integrin ligation 
 
Lactadherin ligation to HUVEC integrin αvβ3, but not αvβ5 was confirmed by a cell 
binding assay, with the αvβ3 integrin-blocking antibody LM609 and αvβ5 integrin-
blocking P1F6. The weakness of this data however is the lack of inclusion of a 
titration of antibody concentrations to confirm the effect to be concentration-
dependent and that a maximal effect has been reached, as well as the lack of an 
isotype control antibody to show the effect to be specific. This result was also not 
confirmed by other experiments. Attempts were made to confirm this data in the form 
of FACS assays with inhibition of lactadherin binding by other αvβ5 and/or αvβ3 
integrin ligands vitronectin and fibronectin, detected with mAb2767. No apparent 
inhibition of lactadherin binding to HUVECS was however detected. The reason for 
this was discovered retrospectively, when HuMc3 inhibited mAb2767 binding to 
lactadherin, suggesting both associate at nearby epitopes on the EGF domain. This 
inferred the lactadherin detected by mAb2767 is in the C2-bound form, (as 
demonstrated in other cell lines [151][152]), and so would not be expected to be 
inhibited in its cell association by an αv integrin-binding ligand.   This idea was 
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supported by the consistent, though not statistically significant detection of inhibition 
of lactadherin binding to HUVECS in a FACS assay by the recombinant extracellular 
domains of αvβ3. As this binds to lactadherin rather than HUVEC integrins it is likely 
to have caused inhibition of signal by interfering with lactadherin-EGF domain 
association with the antibody mAb2767. These experiments should have been 
repeated in the form of the cell binding assay used with P1F6 and LM609, in which 
both lactadherin association with HUVECS, through the EGF and C2 domains would 
have been expected. Alternatively, the antibody Mc16 which binds only to the EGF-
domain ligated form of lactadherin may have been used in a FACS assay for detection 
of inhibition of lactadherin-integrin ligation, had this antibody been available.  
 
HuMc3 inhibited all lactadherin association with HUVECS and a concentration 
dependant effect was observed. Only 60% of the binding inhibition could however be 
confirmed to be specific, with the isotype control producing 40% binding inhibition. 
As HuMc3 binding has been mapped to the EGF domain, this suggested that the 
specific binding inhibition was the result of interference with lactadherin association 
with the αvβ3 integrin. This was not however confirmed in this chapter. Attempts 
were made in chapter 3 to carry out an ELISA, with the recombinant extracellular 
domains of αvβ3 and lactadherin which could have been extended to test the ability of 
HuMc3 to inhibit αvβ3 integrin binding to lactadherin in vitro, but the results were 
negative and assumed to be due to a fault in the assay procedure (section 3.3.3). Other 
methods may have been to repeat the experiment with other αvβ3 ligands with RGD-
mediated association, to see if addition of HuMc3 could increase the binding 
inhibition effect above that of the isotype control. If HuMc3 inhibited association by 
anything but αvβ3 binding inhibition an effect would be expected.  
 
A general problem with much of the FACS analysis data was the lack of consistency 
between the results of experiments carried out on different days. This may have been 
improved by increasing the number of experimental repeats used or by more 
stringently normalising the conditions used.  
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5.3.3 Lactadherin integrin ligation and HuMc3 neutralisation in survival and 
proliferation 
 
Although lactadherin binding to HUVEC αvβ3 integrin was confirmed, no role in 
proliferation or survival through protection against intrinsic or extrinsic apoptosis 
pathways was apparent, either in the presence or absence of VEGF despite 
confirmation that the experimental protocols were effective using VEGF. As past 
work had shown a role for lactadherin in both VEGF mediated angiogenesis and 
angiogenesis though an independent mechanism and more specifically in intrinsic 
apoptosis inhibition by the detection of active Akt, a survival pathway intermediate 
[173], further study into a role for lactadherin in angiogenesis should have been 
attempted. A possible explanation for the lack of activity of lactadherin in promoting 
cell survival in this study was that although rHu-lactadherin ligated the HUVEC 
integrins it was unable to activate signalling due to the altered glycosylation of the 
recombinant form, indicated in section 3.2.4. This may have allowed lactadherin to 
retain affinity for its receptors but lose efficacy. This is supported by the fact that 
most of the past work showing lactadherin to be required for the VEGF angiogenesis 
pathway was carried out with anti-lactadherin antibodies or lactadherin null mutant 
mice, with loss of endogenous lactadherin reducing angiogenesis rather than using 
rHu-lactadherin to show an increase [173]. rHu-Lactadherin expressed in CHO cells 
has however been shown to increase the level of activated Akt in HUVECS [173], so 
this hypothesis is unlikely to hold true. It is alternatively possible that no effect in the 
intrinsic apoptosis assay was evident because of a redundancy in activating αvβ3 
integrin ligands or by the presence of negatively modulating ligands, due to either 
expression by HUVECS or by presence in the media. Observation of the effect of 
application of an αvβ3 integrin ligand known to activate signalling such as vitronectin 
or fibronectin may have been useful to determine this and so confirm whether an 
effect of lactadherin application was absent due to its lack of efficacy or due to a 
ligand redundancy. If the latter were the case and if this was due to the presence of 
ligands in the media, these could have been removed by the use of a αvβ3 integrin 
column. No effect on intrinsic apoptosis, extrinsic apoptosis or proliferation of 
HUVECS was evident, for application of HuMc3, either alone, with lactadherin or 
with lactadherin and VEGF, suggesting this antibody is unable to inhibit any roles of 
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HUVEC expressed or applied lactadherin in angiogenesis. Again however, the effects 
of lactadherin may have been missed by the experiments used in this study, so the 
potential of HuMc3 to interfere with lactadherin-mediated angiogenesis may have 
been missed also. With no effects evident for HuMc3 or lactadherin application to 
HUVECS in the apoptosis and proliferation assays, the question may be raised, are in 
vitro cell proliferation and apoptosis assays suitable for assessment of the effects of 
integrin ligands and anti-integrin therapeutics? Past work with vitronectin and other 
anti-αvβ3/αvβ5 integrin mAbs [60][308] however suggest that they are. In these 
assays however vitronectin was coated directly to the wells, rather than coating on 
collagen and adding the lactadherin in the media as was carried out here. A better 
outcome may therefore have been achieved if the cells had been added to wells pre-
coated with lactadherin. In this case, as shown in figure 5.26 (section 5.3.1) around 
80% of the cells would have been expected to be ligated to lactadherin through a 
specific-association with the receptor αvβ3, so if any survival/proliferation pathway 
activity were activated by lactadherin αvβ3 integrin ligation, this should certainly be 
observable, presuming the assay sensitivity was sufficient to detect it, which as 
described earlier could have been determined by a positive control experiment with 
vitronectin. An alternative starting point for this work may have been to have repeated 
the experiments which demonstrated lactadherin-induced increases in Akt activity in 
past work [173][197] and built on these for the study of extrinsic apoptosis pathway 
activity and the ability of HuMc3 to interfere with these pathways. 
 
One key failing in this work is the lack of any assessment of the effects of HuMc3 
neutralisation of lactadherin on tumour angiogenesis. This should have been carried 
out by detection of the effects of HuMc3 application on tumour vascularisation in 
vivo, by comparing tumour vascularisation following the application of HuMc3 to a 
lactadherin expressing human tumour xenograft model. This would have been 
relatively simple as an extension of the therapy studies described in chapter 6, simply 
involving tissue analysis of tumours removed at the conclusion of these studies. 
Alternatively the effects of HuMc3 application on lactadherin expressing tumour 
vascularisation could have been followed using a CAM assay to visualise tumour 
vascularisation, with tumour CAM grafting. 
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Chapter 6 Therapeutic effects of neutralising lactadherin binding to 
tumours with HuMc3 
 
6.1 Introduction 
 
Lactadherin expression by breast tumour line/cell line MX-1 and MCF-7 respectively 
was indicated in sections 4.2.1/4.22 with HuMc3 shown to target MX-1 and MCF-7 
tumours in vivo and to bind to the surface of MCF-7 tumour cells in vitro. HEK-293 
was indicated to be negative for HuMc3 association in vitro and confirmed to be 
negative for tumour targeting in vivo (section 4.2.2). These cell/tumour lines were 
therefore chosen for study of the mode of action and efficacy of HuMc3 as an anti-
tumour therapeutic. In addition the ovarian tumour cell line SKOV3 was assessed, as 
past work had demonstrated high lactadherin mRNA expression [176], though surface 
localisation of lactadherin by this cell line had not been detected in this study (section 
4.2.1).   
 
The ability of HuMc3 and anti-integrin antibodies to neutralise lactadherin binding to 
tumour cell lines would be determined prior to examining therapeutic efficacy, to help 
ascertain the mode of action of HuMc3. HuMc3 neutralisation of lactadherin binding 
to surface integrins was expected based on data (section 5.2.2) showing inhibition of 
lactadherin binding to the integrin αvβ3 on HUVECS by HuMc3 and by past work 
with MuMc3 [263][264]. 
 
The in vitro tumour growth inhibiting effects of HuMc3 would be tested by a MTS 
assay. The MTS assay detects live cell number following incubation of test substance 
so is a measure of both proliferation and survival. Based on the known integrin 
pathways, both inhibition of proliferation through interference with p42/44 MAPK 
pathway activity and survival through inhibition of intrinsic and extrinsic apoptosis 
pathways were possible through preventing integrin ligation (section 1.1.1). With a 
role for lactadherin in survival by inhibition of intrinsic apoptosis via αvβ3 ligation 
demonstrated in a melanoma model (section 1.3.3.2) as well as in HUVECS [173] an 
inhibitory effect of HuMc3 on cell growth through interference with integrin ligation 
was predicted. In addition to application alone, HuMc3 would be tested for its ability 
to combine with conventional chemotherapy drugs paclitaxel and cisplatin, used 
successfully in clinical breast and ovarian tumour therapy [309][310][311][312]. This 
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would potentially allow a greater therapeutic outcome as had been observed for other 
monoclonal antibody-chemotherapy combinations (section 1.2.5.1), (section 1.2.5.3) 
and (section 1.4.3.1) [312]. Cisplatin and paclitaxel were chosen as not only are they 
standard breast and ovarian cancer therapeutics [309] activating apoptosis through 
promotion of DNA damage [313] and inhibiting proliferation through altering 
microtubule dynamics [314] respectively, but they have been demonstrated to show 
cytotoxic effects on MX-1, MCF-7 and SKOV3 tumours in pre-clinical studies 
[285][286][314][315][316][317][318]. The affect on in vitro tumour growth of 
addition of HuMc3 to a titration of the chemotherapy drug would be examined by the 
change in concentration required for 50% inhibition of tumour growth (EC50). This 
would allow determination of whether HuMc3 could work alongside the drug in a 
non-interacting manner producing an additive effect, work synergistically to produce 
an increased affect than either drug applied alone (section 1.4.3.1) or whether the drug 
combination could produce an overall reduction in efficacy due to interference 
between the two modes of action. Paclitaxel, in addition to interfering with 
microtubule dynamics and promoting cell cycle arrest has been shown to alter tumour 
cell signalling, gene expression, activation of MAP Kinases, Raf-1 and protein 
tyrosine kinases and promote tumour cell apoptosis [314]. The effects of paclitaxel on 
cell signalling and apoptosis may provide a potential area for coordination of activity 
with HuMc3 in its inhibition of integrin signalling. A possible synergy between the 
effects of HuMc3 and paclitaxel were therefore possible. 
 
The in vitro assay would be carried out as it lacked the complications of tissue stroma, 
so immune effector functions could not confuse interpretation. Any effects seen in this 
assay could therefore be attributed directly to lactadherin neutralising activity of 
HuMc3 on tumour cell clonal expansion. HuMc3 would also however be tested in 
vivo for its ability to inhibit tumour growth, as this would provide the potential for 
observation of other effects of drug-target binding that could not be observed under 
tissue culture conditions, such as activation of effector functions (section 1.4.1). This 
would permit the full potential efficacy of HuMc3 to be examined. In addition, the 
presence of a normal tumour stroma and so an environment more closely resembling 
the clinical form was hoped to form a model more predictive of clinical outcome. 
Some effects of HuMc3 alone were expected for the MX-1 tumour as past work had 
shown a small growth inhibition with the non-humanised form of this drug (MuMc3) 
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when applied immediately after tumour implantation (section 1.5.2). The effects of 
HuMc3 in the presence and absence of chemotherapy would be compared to those of 
bevacizumab in the presence and absence of chemotherapy. Bevacizumab was chosen 
as a clinically successful anti-cancer therapeutic, with studies demonstrating anti-
ovarian tumour [319][320][321] and breast tumour effects (section 1.2.5.1), through 
angiogenesis inhibition. It would also be used as it had shown efficacy against MCF-7 
[120] and SKOV3 [284] tumours specifically using in vivo preclinical models and as 
it had demonstrated additive and synergistic effects on tumour growth inhibition in 
combination with conventional chemotherapeutics (section 1.2.5.1). The affect of 
combining HuMc3 and bevacizumab in the presence and absence of chemotherapy 
drugs would also be studied, to assess the potential of combining HuMc3 with other 
targeted drugs. An additive effect may have been predicted as HuMc3 is proposed to 
inhibit tumour cell growth directly and bevacizumab is known to inhibit vessel 
formation to supply the tumour. As however αvβ3/αvβ5 ligation on the surface of 
tumour cells has been shown to promote VEGF production [322][323], a synergistic 
effect could even be hypothesised. 
 
The athymic murine model was chosen as human xenografts could be perpetuated, 
due to impaired T cell immune function and because the effects of the drug needed to 
be tested on actual human tumour tissue to provide a better estimate of the likely 
clinical outcome. Severe-combined immune-deficient (SCID) mice with impaired B 
and T cell immunity [293][324][325] would also have been suitable and both are well 
documented in the literature for preclinical testing of anti-cancer therapeutics 
[138][139][326][327][328]. This model was however chosen as this was the mouse 
strain used in past work to detect the therapeutic effect of both radiolabelled HuMc3 
and Mc3 and unlabelled Mc3 on MX-1 tumours [257][267][268][270]. Athymic mice 
may also be a useful model for approximating the full effects of immunoglobulins of 
the IgG1 subclass (section 1.4.1) because they retain the capacity for innate immunity 
[325] and should therefore be capable of effector functions potentially leading to 
clearance of antibody-antigen immune complexes and activation of some of the 
effects of ADCC and CDC against tumour tissue (section 1.4.1).  
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A role of tumour cell αvβ3 and/or αvβ5 integrins in tumour pathology has been 
implicated by several past studies (section 1.1.2) and there has been some evidence 
for a role of lactadherin in tumour growth through αvβ3 integrin ligation (section 
1.3.3.2). This chapter aimed to find further evidence to support the hypothesis that 
lactadherin expression by tumours plays a role in tumour growth by promoting 
tumour cell clonal expansion through ligation of integrins αvβ3 and/or αvβ5. This 
chapter also aimed to find out whether HuMc3 as a lactadherin-neutralising antibody 
could inhibit tumour growth in vitro and in vivo through inhibition of tumour integrin 
ligation by lactadherin.  
 
The objectives were as follows; 
• Study HuMc3 neutralisation of lactadherin binding to tumour cell 
αvβ3 and/or αvβ5 integrins. 
• Study the tumour cytotoxic effects of HuMc3 in vitro, alone and with 
chemotherapy. 
• Study the cytotoxic effects of HuMc3 in vivo in presence and absence 
of conventional chemotherapy and bevacizumab and compare with 
bevacizumab and chemotherapy alone and the latter in combination.  
 
6.2 Results 
 
6.2.1 Confirming association of lactadherin with tumour cells via integrins 
αvβ3 and αvβ5 
 
Figures 6.1-6.8 show the results of a FACS analysis study (section 2.2.5.4) to confirm 
expression of integrins αvβ5 and/or αvβ3 on the surface of the tumour cell lines 
MCF-7 (figures 6.1-6.4) and SKOV3 (figures 6.5-6.6) with HEK-293 (figures 6.7-
6.8), included as a negative control for αvβ3/αvβ5 integrin expression. This involved 
detection of anti-αvβ3 antibody, mAb3050 and anti-αvβ5 antibody, mAb2528 cell 
association (using a FITC-conjugated secondary) relative to a secondary antibody 
alone control. The FACS data is presented as two figures including a representative 
data figure showing an overview table with information including percentage FL1+ve 
gated cells and median FL1-H intensity of gated cells (a). Also included are all shifts 
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overlaid on a single plot (b) and single shifts plotted with the negative control (c). In 
addition to the representative data, a second figure combines the percentage FL1+ve 
gated cells (c) and median FL1-H intensity of gated cells (b) data from multiple 
studies and a statistical data table with t-tests (a). 
 
The results demonstrated high levels of expression of the integrin αvβ5 (figures 6.1-
6.4) by MCF-7 cells, but no expression of αvβ3 (figures 6.1-6.2). They also 
demonstrated high levels of expression of both αvβ5 and αvβ3 integrins by SKOV3 
cells (figures 6.5-6.6). This is in good agreement with the results of past studies 
[22][231]. The HEK-293 cells (figures 6.7-6.8) were confirmed to be negative for 
αvβ3 integrin expression, but showed a significant (figure 6.8a) albeit very low levels 
of αvβ5 integrin expression. The observed expression was however very low relative 
to that observed for SKOV3 and MCF-7 cells with an increase in percentage FL1+ve 
gated cells and median FL1-H intensity from control of 5.7% and 0.5 respectively 
(figure 6.8a) for the 33.3nM mAb2528 concentration; far lower than those of MCF-7 
at 73.2% and 14.7 (figure 6.4a) and SKOV3 of 74% and 12.7 (figure 6.6a). 
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Figure 6.1 
Detection of MCF-7 cell surface expression of  integrins αvβ3 and αvβ5 by FACS analysis 
Binding of anti-αvβ3 antibody mAb3050 (66.7nM) and anti-αvβ5 antibody mAb2528 (33.3nM) 
detected with an anti-mouse FITC secondary F5262 (1 in 1000 dilution). Secondary antibody alone 
negative control included. (a) Overview table with the sample name and description, percentage gated 
cells, percentage of gated cells positive for fluorescence (FL1+), median fluorescent intensity of gated 
cells (FL1-H) and percentage FL1+ve total cells. (b) Individual sample shift for anti-αvβ5 (33.3nM) 
and (c) anti-αvβ3 (66.7nM), plotted against control with FSC-H, SSC-H plots attached. Figure data 
representative of the results of three separate experiments. 
(a) 
 
Sample description Sample name Percentage gated 
cells (%) 
Percentage 
FL1+ve gated cells 
(%) 
Median FL1-H 
intensity of gated cells 
Percentage 
FL1+ve total 
cells (%) 
Secondary antibody alone 
-ve control MCF-7 no primary. 001 94.76 2.78 2.67 2.63 
mAb3050 (66.7nM) MCF-7 10ug_ml avb3 
antibody. 002 94.02 2.79 2.76 2.62 
mAb2528 (33.3nM) MCF-7 5ug_ml avb5 
antibody.003 94.30 68.44 15.85 64.54 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(c) 
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Figure 6.2 
Detection of MCF-7 cell surface expression of integrins αvβ3 and αvβ5 by FACS analysis-combined 
data 
Displayed is the percentage FL1+ve gated cells (b) and median FL1-H intensity of gated cells (c) data 
from three experiments as described in figure 6.1 and an average (combo). (a) Statistical data table 
displaying the average of two separate experiments (combo data) and t-tests. 
(a) 
Combo data       
Percentage FL1+ve 
gated cells 
 
F5262 alone 
mAb2528 
(33.3nM) mAb3050 (66.7nM) 
t-test F5262 alone/ 
mAb2528 
F5262 alone/ 
mAb3050 
N 3 3 3 t Stat -8.90 -0.37 
Mean 3.59 86.36 4.10 P(T<=t) one-tail 4.41E-04 0.36 
SD 1.05 16.08 2.10 t Critical one-tail 2.13 2.13 
 
   P(T<=t) two-tail 8.81E-04 0.73 
 
   t Critical two-tail 2.78 2.78 
Median FL1-H 
intensity of gated cells 
 
F5262 alone 
mAb2528 
(33.3nM) mAb3050 (66.7nM) 
t-test F5262 alone/ 
mAb2528 
F5262 alone/ 
mAb3050 
N 3 3 3 t Stat -3.18 -0.37 
Mean 2.53 20.04 2.60 P(T<=t) one-tail 0.02 0.36 
SD 0.15 9.523 0.17 t Critical one-tail 2.13 2.13 
 
   P(T<=t) two-tail 0.03 0.73 
 
   t Critical two-tail 2.78 2.78 
(b) 
 
 
(c) 
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Figure 6.3 
Detection of MCF-7 cell surface expression of the integrin αvβ5 by FACS analysis 
Binding of anti-αvβ5 antibody mAb2528 (3.33, 6.67, 33.3 and 66.7nM) detected with an anti-mouse 
FITC secondary F5262 (1 in 1000 dilution). Secondary antibody alone negative control included. (a) 
Overview table with the sample name and description, percentage gated cells, percentage of gated cells 
positive for fluorescence (FL1+), median fluorescent intensity of gated cells (FL1-H) and percentage 
FL1+ve total cells. (b) Half offset overlay plot of all samples. (c) Individual sample shifts plotted 
against control with FSC-H, SSC-H plots attached; (i-iv) mAb2528 concentrations, (3.33, 6.67, 33.3 
and 66.7nM). Figure data representative of the results of three separate experiments. 
 (a) 
Sample description Sample name Percentage gated 
cells (%) 
Percentage 
FL1+ve gated cells 
(%) 
Median FL1-H 
intensity of gated cells 
Percentage 
FL1+ve total 
cells (%) 
Secondary antibody alone 
-ve control 
No primary just anti-
mouse.001 98.73 2.94 2.88 2.91 
mAb2528 (3.33nM) 0.5ug_ml avb5 integrin.006 98.72 12.22 5.31 12.06 
mAb2528 (6.67nM) 1ug_ml avb5 integrin.005 98.54 22.93 6.50 22.59 
mAb2528 (33.3nM) 5ug_ml avb5 integrin.004 98.73 47.50 9.36 46.90 
mAb2528 (66.7nM) 10ug_ml avb5 integrin.003 98.76 46.97 9.31 46.39 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(c) 
(i)       (ii) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(iii)       (iv) 
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Figure 6.4 
Detection of MCF-7 cell surface expression of the integrin αvβ5 by FACS analysis-combined data 
Displayed is the percentage FL1+ve gated cells (b) and median FL1-H intensity of gated cells (c) data 
from three/four experiments as described in figure 6.3 and an average (combo). (a) Statistical data 
table displaying the average (combo data) and t-tests. 
 
(a) 
Combo data        
 Percentage 
FL1+ve gated 
cells 
F5262 
alone 
mAb2528 
(3.3nM) 
mAb2528 
(6.7nM) 
mAb2528 
(33.3nM) 
mAb2528 
(66.7nM) 
t-test F5262 alone / 
mAb2528 (33.3nM) 
N 4 3 3 4 3 t Stat -6.24 
Mean 3.43 47.04 64.65 76.65 79.85 P(T<=t) one-tail 3.92E-04 
SD 0.92 41.11 38.26 23.45 28.64 t Critical one-tail 1.94 
 
     P(T<=t) two-tail 7.84E-04 
 
     t Critical two-tail 2.45 
Median FL1-H 
intensity of gated 
cells 
F5262 
alone 
mAb2528 
(3.3nM) 
mAb2528 
(6.7nM) 
mAb2528 
(33.3nM) 
mAb2528 
(66.7nM) 
t-test F5262 alone / 
mAb2528 (33.3nM) 
N 4 3 3 4 3 t Stat -3.13 
Mean 2.62 7.66 12.42 17.37 18.88 P(T<=t) one-tail 0.01 
SD 0.21 3.72 8.25 9.43 12.21 t Critical one-tail 1.94 
 
     P(T<=t) two-tail 0.02 
 
     t Critical two-tail 2.45 
(b) 
 
(c)  
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Figure 6.5 
Detection of SKOV3 cell surface expression of integrins αvβ3 and αvβ5 by FACS analysis 
Binding of anti-αvβ3 antibody mAb3050 (66.7nM) and anti-αvβ5 antibody mAb2528 (6.67, 16.7, 
33.3nM) detected with an anti-mouse FITC secondary F5262 (1 in 1000 dilution). Secondary antibody 
alone negative control included. (a) Overview table with the sample name and description, percentage 
gated cells, percentage of gated cells positive for fluorescence (FL1+), median fluorescent intensity of 
gated cells (FL1-H) and percentage FL1+ve total cells. (b) Half offset overlay plot of all samples. 
Individual sample shifts for mAb3050 (66.7nM) (c) and mAb2528 (d) plotted against control, with 
FSC-H, SSC-H plots attached, (d)(i-iii) mAb2528 (6.67, 16.7, 33.3nM). Data represents three 
experiments. 
(a) 
Sample description Sample name Percentage 
gated cells (%) 
Percentage 
FL1+ve gated 
cells (%) 
Median FL1-H 
intensity of gated 
cells 
Percentage FL1+ve 
total cells (%) 
mAb3050 (66.7nM) SKOV3 avb3 antibody 10ug_ml. 001 96.19 99.15 20.94 95.38 
Secondary antibody alone SKOV3 no primary. 002 95.88 2.63 2.90 2.52 
mAb2528 (6.67nM) SKOV3 1ug_ml anti avb5 a. 006 96.06 99.65 31.17 95.72 
mAb2528 (16.7nM) SKOV3 2.5ug_ml anti  avb5 a. 005 96.11 99.60 33.88 95.72 
mAb2528 (33.3nM) SKOV3 5ug_ml anti  avb5 a. 004 96.08 99.71 35.16 95.81 
(b)       (c) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(d) 
(i)       (ii) 
 
 
 
 
 
 
 
 
 
 
 
 
(iii) 
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Figure 6.6 
Detection of SKOV3 cell surface expression of integrins αvβ3 and αvβ5 by FACS analysis-combined 
data 
Displayed is the percentage FL1+ve gated cells (b) and median FL1-H intensity of gated cells  (c) data 
from three experiments as described in figure 6.5 and an average (combo). (a) Statistical data table 
displaying the average (combo data) and t-tests. 
(a) 
Combo data         
Percentage FL1+ve 
gated cells 
F5262 
alone 
mAb2528 
(6.7nM) 
mAb2528 
(16.7nM) 
mAb2528 
(33.3nM) 
mAb3050 
(66.7nM) 
t-test F5262 alone/ 
mAb2528 (33.3nM) 
F5262/mAb3050 
(66.7nM) 
N 3 3 3 3 3 t Stat -5.15 -6.17 
Mean 3.10 59.53 72.24 77.58 75.73 P(T<=t) one-tail 3.38E-03 1.75E-03 
SD 0.89 37.26 28.59 25.05 20.36 t Critical one-tail 2.13 2.13 
 
     P(T<=t) two-tail 6.76E-03 3.50E-03 
 
     t Critical two-tail 2.78 2.78 
Median FL1-H intensity 
of gated cells 
F5262 
alone 
mAb2528 
(6.7nM) 
mAb2528 
(16.7nM) 
mAb2528 
(33.3nM) 
mAb3050 
(66.7nM) 
t-test F5262 alone/ 
mAb2528 (33.3nM) 
F5262/mAb3050 
(66.7nM) 
N 3 3 3 3 3 t Stat -2.26 -5.19 
Mean 3.34 16.10 19.21 20.65 16.07 P(T<=t) one-tail 0.04 3.28E-03 
SD 0.52 13.24 13.23 13.28 4.22 t Critical one-tail 2.13 2.13 
 
     P(T<=t) two-tail 0.09 6.56E-03 
 
     t Critical two-tail 2.78 2.78 
(b) 
 
(c) 
 
 
 
0
10
20
30
40
50
60
70
80
90
100
Exp 1 Exp 2 Exp 3 Combo
Pe
rc
en
ta
ge
 
FL
1+
v
e 
ga
te
d 
ce
lls
F5262 alone mAb2528 (6.7nM) mAb2528 (16.7nM)
mAb2528 (33.3nM) mAb3050 (66.7nM)
0
5
10
15
20
25
30
35
40
45
Exp 1 Exp 2 Exp 3 Combo
M
ed
ia
n
 
FL
1-
H
 
in
te
n
si
ty
 
o
f g
at
ed
 
ce
lls
F5262 alone mAb2528 (6.7nM) mAb2528 (16.7nM)
mAb2528 (33.3nM) mAb3050 (66.7nM)
 285
Figure 6.7 
Detection of HEK-293 cell surface expression of integrins αvβ5 and αvβ3 by FACS analysis 
Binding of anti-αvβ3 antibody mAb3050 (66.7nM) and anti-αvβ5 antibody mAb2528 (33.3nM) 
detected with an anti-mouse FITC secondary F5262 (1 in 1000 dilution). Secondary antibody alone 
negative control included. (a) Overview table with the sample name and description, percentage gated 
cells, percentage of gated cells positive for fluorescence (FL1+), median fluorescent intensity of gated 
cells (FL1-H) and percentage FL1+ve total cells. (b) Half offset overlay plot of all samples. (c) (i-ii) 
Individual sample shifts for mAb3050 (66.7nM) and mAb2528 (33.3nM) plotted against control, with 
FSC-H, SSC-H plots attached.  Figure data representative of the results of three separate experiments. 
(a) 
Sample description Sample name Percentage gated 
cells (%) 
Percentage 
FL1+ve gated cells 
(%) 
Median FL1-H 
intensity of gated cells 
Percentage 
FL1+ve total 
cells (%) 
Secondary antibody alone 
-ve control HEK-293 no primary.004 98.36 2.54 1.75 2.49 
mAb3050 (66.7nM) HEK-293 10ug_ml avb3.002 92.31 3.24 1.73 2.99 
mAb2528 (33.3nM) HEK-293 5ug_ml avb5.005 98.30 10.74 2.31 10.56 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
(c) 
 
(i)       (ii) 
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Figure 6.8 
Detection of HEK-293 cell surface expression of integrins αvβ5 and αvβ3 by FACS analysis -
combined data 
Displayed is the percentage FL1+ve gated cells (b) and  median FL1-H intensity of gated cells (c) data 
from three experiments as described in figure 6.7 and an average (combo). (a) Statistical data table 
displaying the average (combo data) and t-tests. 
(a) 
Combo data       
Percentage FL1+ve gated 
cells 
F5262 
alone 
mAb2528 
(33.3nM) 
mAb3050 
(66.7nM) 
t-test F5262 
alone/mAb2528 
F5262/alone 
mAb3050 
N 3 3 3 t Stat -4.13 -0.73 
Mean 3.39 9.12 4.62 P(T<=t) one-tail 7.25E-03 0.25 
SD 1.61 1.79 2.47 t Critical one-tail 2.13 2.13 
 
   P(T<=t) two-tail 0.01 0.51 
 
   t Critical two-tail 2.78 2.78 
Median FL1-H intensity 
of gated cells 
F5262 
alone 
mAb2528 
(33.3nM) 
mAb3050 
(66.7nM) 
t-test F5262 
alone/mAb2528 
F5262/alone 
mAb3050 
N 3 3 3 t Stat -2.18 -0.29 
Mean 1.52 2.03 1.56 P(T<=t) one-tail 4.74E-02 0.39 
SD 0.24 0.33 0.14 t Critical one-tail 2.13 2.13 
 
   P(T<=t) two-tail 0.09 0.79 
 
   t Critical two-tail 2.78 2.78 
(b) 
 
(c) 
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With expression of the integrin αvβ5 on MCF-7 cells and both αvβ3 and αvβ5 on 
SKOV3 cells confirmed, the next step was to ascertain whether lactadherin bound to 
the two tumours when exogenously applied. A FACS analysis investigation was 
performed with MCF-7 and SKOV3 cells, including HEK-293 as a negative/near 
negative control for integrin expression (figures 6.9-6.14) and the data is presented as 
described in the previous section. rHu-Lactadherin binding (10, 50 and 100nM) was 
detected with mAb2767 and a FITC-conjugated secondary, and all data was 
considered relative to a detection antibodies alone control. Figures 6.9-6.10 show the 
FACS data for MCF-7 cells, with the representative data (figure 6.9) demonstrating 
what appears to be a concentration-dependent association of lactadherin, with 
increasing shifts for all three concentrations (figure 6.9b-c). Concentration-dependent 
association is confirmed by the combination data showing a statistically significant 
(figure 6.10a) increase in both percentage FL1+ve gated cells and median FL1-H 
intensity of gated cells from the no-lactadherin control, to 10nM concentration and the 
10nM concentration to the 50nM concentration. A significant difference in median 
FL1-H intensity of gated cells is also observed between the 50 and 100nM 
concentration, but not FL1+ve gated cells, indicating a maximum percentage binding 
had been reached after 50nM. The mean values for percentage FL1+ve gated cells 
(figure 6.10b) and median FL1-H intensity of gated cells (figure 6.10c) increase from 
8% and 2.7 for the control through 38%, 89% and 5.6, 22 to 94% and 36 for the top 
lactadherin concentration. Overall this data suggests high levels of lactadherin 
association with nearly all (over 90%) of MCF-7 cells. Figures 6.11-6.12 show the 
FACS data for SKOV3 cells with the representative data (figure 6.11) demonstrating 
what appears to be a concentration-dependent association of lactadherin, with 
increasing shifts for all three concentrations (figure 6.11b-c). The combination data 
also suggest a concentration dependent binding effect with percentage FL1+ve gated 
cells (figure 6.12b) and median FL1-H intensity of gated cells (figure 6.12c) 
increasing with lactadherin concentration from 7% and 4.4 for the control through 
33%, 86% and 6.7, 22 to 92% and 56 for the top lactadherin concentration. This 
would suggest similar, if slightly higher levels of association to MCF-7 cells with 
almost identical numbers of cells positive for lactadherin binding (over 90%). Due 
however to signal variation and the limited number of repeats it was not possible to 
confirm concentration-dependent association with statistical analysis. It was however 
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possible to confirm lactadherin association with this cell line with statistically 
significant increases (figure 6.12a) in both percentage FL1+ve gated cells and median 
FL1-H intensity of gated cells from the control to the 50nM lactadherin concentration. 
Figures 6.13-6.14 show the FACS data for HEK-293 cells, with the representative 
data (figure 6.13b-c) demonstrating shifts for the lower lactadherin concentrations (10 
and 50nM) with no further increase in binding for the 100nM lactadherin 
concentration suggesting a maximum has been reached. This indicated some binding 
of lactadherin to HEK-293 cells, despite the lack of αvβ3 or αvβ5 integrins. The 
combined data (figure 6.14) confirmed association of lactadherin with a statistically 
significant increase in percentage FL1+ve gated cells and median FL1-H intensity of 
gated cells (figure 6.14a) between the control and 50nM lactadherin concentration. 
The combination values for median FL1-H intensity of gated cells (figure 6.14c) and 
percentage FL1+ve gated cells (6.14b) began at 2.5 and 9.2% for the negative control, 
increasing through 3.1, 6.8 and 18%, 62% to 8.1 and 68% for the 100nM 
concentration. The median FL1-H intensity of gated cells signals were however 
significantly lower than those of both SKOV3 cells and MCF-7 cells (figures 6.10a 
and 6.12a) and the percentage FL1+ve gated cells appearing a little lower but with 
mixed significance levels (6.10a and 6.12a), suggesting lower levels of binding of 
lactadherin to HEK-293 cells despite binding to a similar percentage of cells. This 
indicated that a background level of association of lactadherin with most MCF-7 and 
SKOV3 cells may be due to a non- αv-integrin mediated mechanism. 
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Figure 6.9 
Detection of lactadherin binding to MCF-7 cells by FACS analysis 
Binding of pure rHu-lactadherin (10, 50 and 100nM) detected with mAb2767 (66.7nM), followed by an 
anti-mouse FITC secondary F5262 (1 in 1000 dilution). Primary and secondary antibodies alone 
negative control included. (a) Overview table with the sample name and description, percentage gated 
cells, percentage of gated cells positive for fluorescence (FL1+), median fluorescent intensity of gated 
cells (FL1-H) and percentage FL1+ve total cells. (b) Half offset overlay plot of all samples. (c) 
Individual sample shifts plotted against control with FSC-H, SSC-H plots attached; (i-iii) lactadherin 
concentrations (10, 50, 100nM). Figure data representative of the results of four separate experiments. 
(a) 
Sample description Sample name Percentage gated 
cells (%) 
Percentage 
FL1+ve gated cells 
(%) 
Median FL1-H 
intensity of gated 
cells 
Percentage 
FL1+ve total cells 
(%) 
mAb2767 detection alone 
–ve control 
MCF-7 no lactadherin. 005 
96.25 6.68 2.65 6.43 
Lactadherin (10nM) MCF-7 0.5ug_ml lactadherin. 006 95.92 40.89 5.68 39.22 
Lactadherin (50nM) MCF-7 2.5ug_ml lactadherin. 007 96.31 88.03 24.06 84.79 
Lactadherin (100nM) MCF-7 5ug_ml lactadherin. 008 96.20 94.35 44.99 90.76 
 
 (b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(c) 
 
(i)      
 
 
 
 
 
 
 
 
 
 
 
 
(ii)       (iii) 
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Figure 6.10 
Detection of lactadherin (Lac) binding to MCF-7 cells by FACS analysis-combined data 
Displayed is the percentage FL1+ve gated cells (b) and median FL1-H intensity of gated cells (c) data 
from four experiments as described in figure 6.9 and an average (combo). (a) Statistical data table 
displaying the average (combo data) and t-tests. 
(a) 
Combo data    
        
Percentage 
FL1+ve 
gated cells 
No 
Lac 
Lac 
10nM 
Lac 
50nM 
Lac 
100nM 
t-test No 
Lac/Lac 
10nM 
10nM/ 
50nM 
50nM/ 
100nM 
10nM/ 
HEK-293 
10nM 
50nM/ 
HEK-293 
50nM 
100nM/ 
HEK-293 
100nM 
N 4 4 4 4 t Stat -4.11 -7.34 -0.86 1.85 2.94 6.57 
Mean 8.24 38.05 88.79 93.91 P(T<=t) one-tail 3.14E-03 4.03E-05 0.21 
 
6.90E-02 
 
2.12E-02 1.38E-03 
SD 2.85 14.22 10.78 5.105 t Critical one-tail 1.94 1.86 1.94 2.13 2.13 2.13 
 
    P(T<=t) two-tail 6.28E-03 8.07E-05 0.42 0.14 0.04 
 
2.77E-03 
 
    t Critical two-tail 2.45 2.31 2.45 2.78 2.78 2.78 
Median 
FL1-H 
intensity of 
gated cells 
No 
Lac 
Lac 
10nM 
Lac 
50nM 
Lac 
100nM 
t-test No 
Lac/Lac 
10nM 
10nM/ 
50nM 
50nM/ 
100nM 
10nM/ 
HEK-293 
10nM 
50nM/ 
HEK-293 
50nM 
100nM/ 
HEK-293 
100nM 
N 4 4 4 4 t Stat -1.96 -4.17 -2.26 9.95 2.77 4.31 
Mean 2.67 5.58 22.33 34.90 P(T<=t) one-tail 
 
4.85E-02 
 
2.95E-03 0.03 
 
4.97E-03 0.03 
 
6.27E-03 
SD 0.19 2.96 7.47 8.25 t Critical one-tail 1.94 1.94 1.94 2.92 2.13 2.13 
 
    P(T<=t) two-tail 0.10 
 
4.90E-03 0.06 
 
9.95E-03 0.05 0.01 
 
    t Critical two-tail 2.45 2.45 2.45 4.30 2.78 2.78 
 (b)  
 
(c) 
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Figure 6.11 
Detection of lactadherin binding to SKOV3 cells by FACS analysis 
Binding of pure rHu-lactadherin (10, 50 and 100nM) detected with mAb2767 (66.7nM), followed by an 
anti-mouse FITC secondary F5262 (1 in 1000 dilution). Primary and secondary antibodies alone 
negative control included. (a) Overview table with the sample name and description, percentage gated 
cells, percentage of gated cells positive for fluorescence (FL1+), median fluorescent intensity of gated 
cells (FL1-H) and percentage FL1+ve total cells. (b) Half offset overlay plot of all samples. (c) 
Individual sample shifts plotted against control with FSC-H, SSC-H plots attached; (i-iii) lactadherin 
concentrations (10, 50 and 100nM). Figure data representative of the results of two separate 
experiments. 
(a) 
Sample description Sample name Percentage gated 
cells (%) 
Percentage 
FL1+ve gated cells 
(%) 
Median FL1-H 
intensity of gated 
cells 
Percentage 
FL1+ve total cells 
(%) 
mAb2767 detection alone  
–ve control 
SKOV3 no lactadherin. 001 
88.06 6.87 3.70 6.05 
Lactadherin (10nM) SKOV3 0.5ug_ml lactadherin. 002 88.41 57.60 7.65 50.92 
Lactadherin (50nM) SKOV3 2.5ug_ml lactadherin. 003 87.13 94.37 17.60 82.23 
Lactadherin (100nM) SKOV3 5ug_ml lactadherin. 004 87.29 99.75 74.17 87.07 
 (b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(c) 
(i)       (ii) 
 
 
 
 
 
 
 
 
 
 
 
 
(iii) 
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Figure 6.12 
Detection of lactadherin (Lac) binding to SKOV3 cells by FACS analysis-combined data 
Displayed is the percentage FL1+ve gated cells (b) and median FL1-H intensity of gated cells (c) data 
from two experiments as described in figure 6.11 and an average (combo). (a) Statistical data table 
displaying the average (combo data) and t-tests. 
(a) 
Combo data    
    
Percentage FL1+ve 
gated cells 
No Lac Lac (10nM) Lac (50nM) Lac (100nM) t-test No Lac/ 
Lac (50nM) 
(50nM)/ HEK-
293 (50nM) 
N 2 2 2 2 t Stat -9.45 2.25 
Mean 7.25 33.09 86.04 92.49 P(T<=t) one-tail 5.51E-03 0.08 
SD 0.53 34.66 11.78 10.27 t Critical one-tail 2.92 2.92 
 
    P(T<=t) two-tail 0.01 0.15 
 
    t Critical two-tail 4.30 4.30 
Median FL1-H 
intensity of gated 
cells 
No Lac Lac (10nM) Lac (50nM) Lac (100nM) t-test No Lac/ 
Lac (50nM) 
(50nM)/ HEK-
293 (50nM) 
N 2 2 2 2 t Stat -3.71 3.23 
Mean 4.37 6.67 22.41 56.03 P(T<=t) one-tail 0.03 0.04 
SD 0.95 1.39 6.80 25.65 t Critical one-tail 2.92 2.92 
 
    P(T<=t) two-tail 0.07 0.08 
 
    t Critical two-tail 4.30 4.30 
(b) 
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Figure 6.13 
Detection of lactadherin binding to αv-integrin-negative HEK-293 cells by FACS analysis 
Binding of pure rHu-lactadherin (10, 50 and 100nM) detected with mAb2767 (66.7nM), followed by an 
anti-mouse FITC secondary F5262 (1 in 1000 dilution). Primary and secondary antibodies alone 
negative control included. (a) Overview table with the sample name and description, percentage gated 
cells, percentage of gated cells positive for fluorescence (FL1+), median fluorescent intensity of gated 
cells (FL1-H) and percentage FL1+ve total cells. (b) Half offset overlay plot of all samples. (c) 
Individual sample shifts plotted against control with FSC-H, SSC-H plots attached; (i-iii) lactadherin 
concentrations (10, 50 and 100nM). Figure data representative of the results of two separate 
experiments. 
(a) 
Sample description Sample name Percentage 
gated cells (%) 
Percentage FL1+ve 
gated cells (%) 
Median FL1-H 
intensity of gated cells 
Percentage FL1+ve 
total cells (%) 
mAb2767 detection alone Data. 001 97.84 6.96 2.13 6.81 
Lactadherin (10nM) 0.5ug_ml lactadherin. 002 97.28 20.87 3.42 20.30 
Lactadherin (50nM) 2.5ug_ml lactadherin. 003 97.66 68.76 7.33 67.15 
Lactadherin (100nM) 5ug_ml lactadherin. 004 97.69 67.55 7.10 65.99 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(c) 
(i)       (ii) 
 
 
 
 
 
 
 
 
 
 
 
 
(iii) 
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Figure 6.14 
Detection of lactadherin (Lac) binding to αv-integrin-negative HEK-293 cells by FACS analysis-
combined data 
Displayed is the percentage FL1+ve gated cells (b) and median FL1-H intensity of gated cells (c) data 
from two experiments as described in figure 6.13 and an average (combo). (a) Statistical data table 
displaying the average (combo data) and t-tests. 
(a) 
Combo data       
Percentage FL1+ve gated cells No Lac La (10nM) Lac (50nM) Lac (100nM) t-test No Lac/ (50nM) 
N 2 2 2 2 t Stat -7.84 
Mean 9.15 18.08 62.34 68.47 P(T<=t) one-tail 7.94E-03 
SD  3.10 3.95 9.08 1.29 t Critical one-tail 2.92 
 
    P(T<=t) two-tail 0.02 
 
    t Critical two-tail 4.30 
Median FL1-H intensity of gated cells No Lac La (10nM) Lac (50nM) Lac (100nM) t-test No Lac/ (50nM) 
N 2 2 2 2 t Stat -6.28 
Mean 2.53 3.07 6.78 8.10 P(T<=t) one-tail 0.01 
SD 0.56 0.50 0.78 1.41 t Critical one-tail 2.92 
 
    P(T<=t) two-tail 0.02 
 
    t Critical two-tail 4.30 
(b) 
 
(c) 
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To determine whether lactadherin binds to SKOV3 and MCF-7 cells via the αvβ3 and 
αvβ5 integrins, a cell binding assay (section 2.2.5.6) was performed. This involved 
detection of MCF-7 (Figure 6.15) and SKOV3 (Figure 6.16) cell binding to surface-
associated rHu-lactadherin in the presence and absence of LM609 and P1F6, αvβ3 
and αvβ5 receptor blocking antibodies respectively. The effect of these antibodies on 
cell binding to vitronectin was also detected as a positive control. The results for the 
MCF-7 cells (figure 6.15) indicated binding of lactadherin (figure 6.15b) to just αvβ5 
with P1F6 reducing cell binding significantly (Figure 6.15a), by 58%, but with no 
significant inhibition observed with LM609, leaving 42% of cell association to 
lactadherin intact. This agreed fairly well with past data showing 80% inhibition of 
MCF-7 binding to lactadherin with P1F6, but none with LM609 [153]. The 
discrepancy between the magnitude of cell binding inhibition may be accounted for 
by the lower antibody concentration and higher lactadherin coating concentration used 
in this study, indicating the full binding inhibition capability of these antibodies had 
not been determined. Similar results were shown with the positive control vitronectin 
(figure 6.15c) with P1F6 significantly (figure 6.15a) reducing cell association, by 
45%. For the positive control however some apparently significant (15%), (figure 
6.15a) inhibition of cell association by P1F6 was observed despite the lack of 
expression of integrin αvβ3 by this cell line, suggesting that further repeats of this 
data may have led to better data confidence. The results for the SKOV3 cells indicated 
lactadherin binding (figure 6.16b) to both integrins αvβ3 and αvβ5, with both 
antibodies significantly (6.16a) inhibiting association with lactadherin, in agreement 
with past data with another αvβ3/αvβ5 expressing tumour cell line [153]. There was 
less inhibition with LM609, reducing cell binding by 11%, compared to the 22% for 
P1F6 and with 67% of cell association to lactadherin remaining when the binding 
inhibition was added together. In the positive control assays with vitronectin (6.16c), 
binding was reduced significantly (figure 6.16a) by 25% by P1F6 and binding reduced 
by 6% by LM609, though this was shown not to be statistically significant, again 
suggesting further repeats of this data should have been carried out. For both SKOV3 
and MCF-7 tumour lines, residual cell association with both vitronectin and 
lactadherin was apparent. As indicated for the MCF-7 tumour cell line this could 
suggest insufficient antibody concentrations. The fact that past data with higher 
antibody concentrations also showed some (around 20%) residual association, 
 296
however suggests both may also be able to bind to the cell surface by non-integrin 
mediated association, resulting in some of the residual binding. The latter agrees well 
with the HEK-293 FACS data showing lactadherin binding despite lack of αv integrin 
expression, the ability of HuMc3 to bind to MCF-7 cells, shown in chapter 4 (section 
4.2.1) and the detection of around 20% of HUVEC binding to a RGE mutant 
lactadherin, relative to native lactadherin in past work [173]. This does not however 
explain why vitronectin binding was not completely blocked by these antibodies and 
so this data should have been repeated with higher antibody concentrations and with 
the inclusion of isotype-matched controls to confirm the effect to be specific.  
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Figure 6.15 
Cell binding assays to detect inhibition of MCF-7 cell binding to lactadherin with integrin-blocking 
antibodies 
Shown is a cell-binding assay detecting inhibition of MCF-7 association with immobilised rHu-
lactadherin (lac) (b), or positive control vitronectin (vitron) (c), by incubation with, anti-αvβ3 antibody 
LM609 (166.7nM) and anti-αvβ5 antibody P1F6 (166.7nM). Negative controls included are cells + 
lactadherin alone and cells + vitronectin alone. Displayed is data from three assays and an average 
(combo). Each error bar denotes 3-5 assay repeats. Absorbance corrected to zero using a no-
lactadherin/vitronectin control. (a) Statistical data table displaying the average (combo data) and t-
tests. 
(a) 
Combo data          
Statistics 
Lac + 
P1F6 
Lac + 
LM609 
Vitron + 
P1F6 
Vitron + 
LM609 
t-test Lac/ lac + 
P1F6 
Lac/ lac + 
LM609 
Vitron/ vitron + 
P1F6 
Vitron/ vitron + 
LM609 
N 13 13 10 10 t Stat 6.46 0.72 3.47 2.90 
Mean 41.74 94.94 63.30 84.96 P(T<=t) one-tail 5.56E-07 0.24 1.37E-03 4.76E-03 
SD  27.93 19.51 32.69 14.76 t Critical one-tail 1.71 1.71 1.73 1.73 
 
    P(T<=t) two-tail 1.11E-06 0.48 2.74E-03 9.51E-03 
 
    t Critical two-tail 2.06 2.06 2.10 2.10 
(b) 
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Figure 6.16 
Cell binding assays to detect inhibition of SKOV3 cell binding to lactadherin with integrin-blocking 
antibodies 
Shown is a cell-binding assay detecting inhibition of SKOV3 association with immobilised rHu-
lactadherin (lac) (b), or positive control vitronectin (vitron) (c), by incubation with, anti-αvβ3 antibody 
LM609 (166.7nM) and anti-αvβ5 antibody P1F6 (166.7nM). Negative controls included are cells + 
lactadherin alone and cells + vitronectin alone. Displayed is data from three assays and an average 
(combo). Each error bar denotes 3 assay repeats. Absorbance corrected to zero using a no-
lactadherin/vitronectin control. (a) Statistical data table displaying the average (combo data) and t-
tests. 
(a) 
Combo 
data   
  
 
    
Statistics Lac + 
P1F6 
Lac + 
LM609 
Vitron + 
P1F6 
Vitron + 
LM609 
t-test Lac/ lac + 
P1F6 
Lac/ lac + 
LM609 
Vitron/ vitron + 
P1F6 
Vitron/ vitron + 
LM609 
N 9 9 9 9 t Stat 4.13 2.04 3.85 1.20 
Mean 
78.05 89.10 75.44 93.87 P(T<=t) one-tail 
 
3.92E-04 0.03 7.03E-04 0.12 
SD 9.48 9.57 13.10 8.93 t Critical one-tail 1.75 1.75 1.75 1.75 
 
    P(T<=t) two-tail 7.85E-04 0.06 1.41E-03 0.25 
 
    t Critical two-tail 2.12 2.12 2.12 2.12 
(b) 
 
(c) 
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6.2.2 HuMc3 neutralisation of lactadherin binding to tumour cells 
 
The ability of HuMc3 to neutralise lactadherin binding to MCF-7 and SKOV3 tumour 
cells was assessed using a cell binding assay as described in the previous section for 
anti-αv-integrin antibodies. MCF-7 association with lactadherin (figure 6.17b) 
appeared to be completely removed by HuMc3 (200nM) in agreement with past data 
with other αvβ3/αvβ5 expressing cell lines [154]. No significant (figure 6.17a) effect 
was observed for cell binding to vitronectin (figure 6.17c). This indicated the 
association of HuMc3 to be specific to lactadherin, leading to loss of adherence with 
MCF-7 cells. The isotype control antibody (200nM) however produced a significant 
(figure 6.17a) reduction in cell-association, suggesting some of the HuMc3 binding 
inhibition to be the result of a non-specific effect.  The binding inhibition of the 
isotype control, whilst being fairly consistent, was small relative to the effects of 
HuMc3, reducing binding by 20% and significantly (figure 6.17a) less than HuMc3. 
This suggested HuMc3 (200nM) may inhibit association of lactadherin to MCF-7 
cells by 80%, by its ligation of the EGF-domain of lactadherin and the remaining 20% 
by non-specific effects. SKOV3 cell binding to lactadherin (figure 6.18b) also 
appeared to be inhibited by HuMc3 (200nM), which showed a 99% reduction in cell 
association. There were again however some significant (figure 6.18a) background 
effects, with the isotype control (200nM) reducing cell binding by 20% and HuMc3 
reducing binding to vitronectin (figure 6.18c) by 18%. The effects of HuMc3 on 
lactadherin binding were however significantly (figure 6.18a) greater and even with 
20% of the binding inhibition of this antibody attributed to non-specific effects, 79% 
binding inhibition by specific association with the EGF-domain of lactadherin 
remained. HuMc3 was therefore suggested to inhibit lactadherin association with both 
MCF-7 and SKOV3 cells by both non-specific and specific lactadherin binding. 
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Figure 6.17 
Cell binding assay for detection of inhibition of MCF-7 cell binding to lactadherin with HuMc3 
Shown is a cell-binding assay detecting inhibition of MCF-7 association with immobilised rHu-
lactadherin (lac) (b), by pre-incubation of HuMc3 (1670, 830, 420 and 210nM).  Included is a 
vitronectin (vitron) negative control experiment (c) for HuMc3 (1670nM) binding inhibition. Controls 
also included are an isotype-matched IgG1 antibody (I Con 1670nM) and cells with lactadherin or 
vitronectin alone Displayed is data from three assays and an average (combo). Each error bar denotes 
3/4 assay repeats. Absorbance corrected to zero using a no-lactadherin/vitronectin control. (a) 
Statistical data table displaying the average (combo data) and t-tests. 
 (a) 
Combo data         
Statistics 
Lac + 
HuMc3 
(200nM) 
Lac + I Con 
(200nM) 
Vitron + 
HuMc3 
(200nM) 
t-test Lac/Lac+ 
HuMc3 
(200nM) 
Lac/ lac + 
I Con 
Vitron/ 
Vitron + 
HuMc3 
HuMc3 
(200nM)/ I Con 
(200nM) 
N 11 11 11 t Stat 30.86 3.61 1.27 -15.22 
Mean -4.97 80.09 95.01 P(T<=t) one-tail 1.2E-18 8.83E-04 0.11 9.22E-13 
SD 8.17 16.64 11.34 t Critical one-tail 1.72 1.72 1.72 1.72 
 
   P(T<=t) two-tail 2.4E-18 1.77E-03 0.22 1.84E-12 
 
   t Critical two-tail 2.09 2.09 2.09 2.09 
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Figure 6.18 
Cell binding assay for detection of inhibition of SKOV3 cell binding to lactadherin with HuMc3 
Shown is a cell-binding assay detecting inhibition of SKOV3 association with immobilised rHu-
lactadherin (lac) (b), by pre-incubation of HuMc3 (200nM) with lactadherin.  Included is a vitronectin 
(vitron) negative control (c) experiment for HuMc3 (200nM) binding inhibition. Controls also included 
are an isotype-matched IgG1 antibody (I Con 200nM) and cells with lactadherin or vitronectin alone. 
Displayed is data from three assays and an average (combo). Each error bar denotes 3/4 assay 
repeats. Absorbance corrected to zero using a no-lactadherin/vitronectin control. (a) Statistical data 
tables displaying the average (combo data) and t-tests. 
(a) 
Combo data          
Statistics 
Lac 
+HuMc3 
(200nM) 
Lac + I 
Con 
(200nM) 
Vitron + 
HuMc3 
(200nM) 
t-test Lac/ 
Lac+ 
HuMc3 
Lac/ 
Lac + 
I Con 
Vitron/ 
vitron + 
HuMc3 
HuMc3 
(200nM0/ I Con 
(200nM) 
Lac+ HuMc3/ 
vitron + 
HuMc3 
N 10 10 10 t Stat 23.56 2.49 2.12 -11.43 -10.50 
Mean 1.07 80.60 82.15 P(T<=t) one-tail 2.8E-15 0.01 0.02 5.49E-10 2.11E-09 
SD  5.18 21.38 23.87 t Critical one-tail 1.73 1.73 1.73 1.73 1.73 
 
   P(T<=t) two-tail 5.6E-15 0.02 4.82E-02 1.10E-09 4.22 
 
   t Critical two-tail 2.10 2.10 2.10 2.10 2.10 
(b) 
 
(c) 
  
-20
0
20
40
60
80
100
120
Exp 1 Exp 2 Exp 3 Combo
Pe
rc
en
ta
ge
 
ce
ll 
bi
n
di
n
g
Lac + cells
Lac + I Con (200nM)
Lac + HuMc3 (200nM)
0
20
40
60
80
100
120
Exp 1 Exp 2 Exp 3 Combo
Pe
rc
e
n
ta
ge
 
c
e
ll 
bi
n
di
n
g
Vitron + Cells
Vitron + HuMc3 (200nM)
 302
6.2.3 HuMc3 tumour toxicity in vitro in the presence and absence of 
chemotherapy 
 
The effect on tumour cell clonal expansion of HuMc3 neutralisation of lactadherin 
cell binding, in the presence and absence of conventional chemotherapy agents, was 
assessed by MTS assay, involving a 72-hour incubation of test substances (section 
2.2.5.7). A titration of concentrations of cisplatin and paclitaxel was first incubated 
with MCF-7, (figure 6.19) and SKOV3 (figure 6.20) cells, to confirm tumour cell 
sensitivity to these agents. In agreement with past studies [285][314][317] both MCF-
7 and SKOV3 cells can been seen to be sensitive to both agents, showing a similar 
response to cisplatin (figures 6.19a and 6.20a) and paclitaxel (figures 6.19b and 
6.20b) respectively with EC50 and EC100 values in the same order of magnitude, 
showing that a similar minimum drug concentration is needed for a half maximal 
effect/maximal effect respectively (the EC50 and EC100 values for MCF-7 and 
SKOV3 cells are shown in tables in figures 6.19 and 6.20 aii and bii for cisplatin and 
paclitaxel respectively). Both cell lines however show slightly lower EC50 and 
EC100 values for cisplatin, a difference which is significant for MCF-7 cells (figure 
6.19bii), but not for SKOV3 cells (6.20bii). The effect of HuMc3-lactadherin-
neutralisation alone on MCF-7 and SKOV3 tumour cell and control HEK-293 cell 
growth in vitro was next assessed by MTS assay, carried out by incubation of a 
titration of HuMc3 concentrations. Figure 6.21a shows the results of the HuMc3 
titration assay for MCF-7 cells. The results indicated a concentration-dependant 
reduction in viability at HuMc3 concentrations of above approximately 500nM, with a 
maximum of 24% cell death observed at the highest concentration used of just under 
2000nM, with no maximum growth inhibition reached and with the difference in cell 
viability between the lowest (3.9nM) and highest (2000nM) concentrations shown to 
be statistically significant (figure 6.21aii). There was however no significant effect for 
application of HuMc3 to either SKOV3 cells (figure 6.21b) or HEK-293 cells (figure 
6.21c). The very high concentration required for any effect to be observed (500nM) 
would however suggest the effect on MCF-7 cells to be non-specific, given figure 
6.17 shows complete removal of lactadherin binding to this cell line by HuMc3 
application at a lower (200nM) concentration. If growth inhibition had been caused by 
HuMc3-mediated lactadherin cell binding inhibition, a maximum effect would have 
been expected at 200nM HuMc3. HuMc3 is indicated by this data therefore not to 
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affect clonal expansion of MCF-7 or SKOV3 tumour cells by inhibition of lactadherin 
binding in vitro. The effects of combining conventional chemotherapy drugs with 
HuMc3 on MCF-7 tumour cell viability were next assessed by incubating a titration of 
concentrations of the chemotherapy drugs in the presence and absence of HuMc3. 
Figures 6.22a and 6.22b show respectively the effect on MCF-7 viability of 
application of a titration of cisplatin and paclitaxel concentrations in the presence and 
absence of a high concentration (3.3µM) of HuMc3. No significant increase in MCF-7 
cytotoxicity was however evident for application of HuMc3, with no significant 
increase in either the EC50 or EC100 of cisplatin (figure 6.22aii) or paclitaxel (figure 
6.22bii). At the lower cisplatin and paclitaxel concentrations a reduction in cell 
viability of 20-30% is evident for the plus HuMc3 assays. This however is likely to be 
simply the non-specific cell killing effect observed in figure 6.21a. This data therefore 
suggests HuMc3 is not able to increase the efficacy of conventional chemotherapy 
agents; cisplatin and paclitaxel in vitro, through specific neutralisation of lactadherin 
binding to MCF-7 cells. 
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Figure 6.19 
Viability assays to determine the effects of conventional chemotherapy drugs on MCF-7 cells 
Detection of live cell absorbance in an MTS assay, with MCF-7 cells incubated for 72 hours with a 
titration of (a)(i) cisplatin and (b)(i) paclitaxel concentrations. (a) and (b)(ii) Statistical data tables 
displaying the average EC50 and EC100 as well as t-tests. Displayed is data from four experiments. 
Each error bar denotes 3/4 experimental repeats. Percentage viability corrected to zero using a cells 
alone control  
(a)  
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Curves fitted by Sigmaplot11.0; Equation sigmoidal logistic 4 parameter.  (a) Exp 1 Normality test (Shapiro-Wilk) Passed (P = 0.8292), W statistic= 0.9639, significance level = 0.0500. Constant variance 
test passed (P = 0.4250). Exp 2 Normality test (Shapiro-Wilk) Passed (P = 0.5142), W statistic= 0.9364, significance level = 0.0500. Constant variance test failed (P = 0.0217). Exp 3 Normality test (Shapiro-
Wilk) Passed (P = 0.7883), W statistic= 0.9613, significance level = 0.0500. Constant variance test passed (P = 0.4162). (b) Exp 1 Normality test (Shapiro-Wilk) Passed (P = 0.5126), W statistic= 0.9363, 
significance level = 0.0500. Constant variance test passed (P = 0.8916). Exp 2 Normality test (Shapiro-Wilk) Passed (P = 0.9153), W statistic= 0.9723, significance level = 0.0500. Constant variance test 
passed (P = 0.1196). Exp 3 Normality test (Shapiro-Wilk) Passed (P = 0.1851), W statistic= 0.8934, significance level = 0.0500. Constant variance test passed (P = 0.7849). 
Combo data   
Statistics  EC50 (nM) EC100 (nM) 
N 4 4 
Mean 14410 48610 
SD  4995 16620 
Combo data  
 
Statistics EC50 (nM) IEC100 (nM) 
N 4 4 
Mean 50900 115000 
SD  27830 51930 
t-test 
EC50 cis/ EC50 
pac 
 EC100 cis/ EC100 
pac 
t Stat -2.58 -2.44 
P(T<=t) one-tail 0.02 0.03 
t Critical one-tail 1.94 1.94 
P(T<=t) two-tail 0.04 0.05 
t Critical two-tail 2.45 2.45 
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Figure 6.20 
Viability assays to determine the effects of conventional chemotherapy drugs on SKOV3 cells 
Detection of live cell absorbance in an MTS assay, with SKOV3 cells incubated for 72 hours with a 
titration of (a)(i) cisplatin and (b)(i) paclitaxel concentrations. (a) and (b)(ii) Statistical data tables 
displaying the average EC50 and EC100 as well as t-tests. Displayed is data from two/three separate 
experiments. Each error bar denotes 3/4 experimental repeats. Percentage viability corrected to zero 
using a cells alone control  
(a) 
(i)       (ii) 
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Curves fitted by Sigmaplot11.0; Equation sigmoidal logistic 4 parameter.  (a) Exp 1 Normality test (Shapiro-Wilk) Passed (P = 0.9027), W statistic= 0.9713, significance level = 0.0500. Constant variance 
test failed (P = 0.0332). (b) Exp 1 Normality test (Shapiro-Wilk) Passed (P = 0.4728), W statistic= 0.9325, significance level = 0.0500. Constant variance test passed (P = 0.0736. Exp 2 Normality test 
(Shapiro-Wilk) Passed (P = 0.8294), W statistic= 0.9637, significance level = 0.0500. Constant variance test passed (P = 0.5588). Exp 3 Normality test (Shapiro-Wilk) Passed (P = 0.9245), W statistic= 
0.9739, significance level = 0.0500. Constant variance test passed (P = 0.6814). 
 
 
Combo data  
 
Statistics EC50 (nM) EC100 (nM) 
N 2 2 
Mean 26270 178200 
SD 7703 19460 
Combo data  
 
Statistics EC50 (nM) EC100 (nM) 
N 3 3 
Mean 43250 18070 
SD 22490 9769 
t-test EC50 cis/ EC50 pac 
 EC100 cis/ EC100 
pac 
t Stat -0.98 0.98 
P(T<=t) one-tail 0.20 0.20 
t Critical one-tail 2.35 2.35 
P(T<=t) two-tail 0.40 0.40 
t Critical two-tail 3.18 3.18 
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Figure 6.21 
HuMc3 viability assays with tumour lines to determine the effect of neutralising lactadherin binding 
Detection of live cell absorbance in an MTS assay, with MCF-7 (a)(i), SKOV3 (b)(i) and HEK-293 
(c)(i) cells, incubated for 72 hours with a titration of HuMc3 concentrations. (ii) Statistical data tables 
displaying the average difference between highest (20nM) and lowest (3.9nM) HuMc3 concentrations, 
and t-tests. Data represents 3 experiments each and error bar 3-5 repeats. Absorbance corrected to 
zero using a no-cells control. 
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(c) (i)       (ii) 
HuMc3 concentration (nM)
1 10 100 1000 10000
Pe
rc
e
n
ta
ge
 
c
e
ll 
v
ia
bi
lit
y
0
20
40
60
80
100
120
140
Exp 1
Exp 2
  
Combo data 
Diff highest 
(2000nM) and 
lowest (3.9nM) 
concs 
 Highest/ 
lowest 
Statistics  t-test  
N 10 t Stat -6.78 
Mean 24.20 P(T<=t) one-tail 1.18E-06 
SD  8.05 t Critical one-tail 1.73 
 
 P(T<=t) two-tail 2.36E-06 
 
 t Critical two-tail 2.10 
Combo data 
Diff highest 
(2000nM) and 
lowest (3.9nM) 
concs 
 Highest/ 
lowest 
Statistics  t-test  
N 9 t Stat -0.40 
Mean 2.24 P(T<=t) one-tail 0.35 
SD 12.39 t Critical one-tail 1.75 
 
 P(T<=t) two-tail 0.70 
 
 t Critical two-tail 2.12 
 
Diff highest 
(2000nM) and 
lowest (3.9nM) 
concs 
 Highest/ 
lowest 
Statistics  t-test  
N 6 t Stat 0.40 
Mean -5.08 P(T<=t) one-tail 0.35 
SD 34.18 t Critical one-tail 1.81 
 
 P(T<=t) two-tail 0.70 
 
 t Critical two-tail 2.23 
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Figure 6.22 
MCF-7 viability assays to determine the effect of addition of HuMc3 to conventional chemotherapy. 
Detection of live cell absorbance in an MTS assay, with MCF-7 cells incubated for 72 hours with a 
titration of (a)(i) cisplatin and (b)(i) paclitaxel concentrations in the presence and absence of 
HuMc3(3.3µM). (ii) Statistical data tables displaying the average EC50 and EC100 as well as t-tests. 
Displayed is data from two/three experiments. Each error bar denotes 3 repeats. Percentage viability 
corrected to zero using a cells alone control  
 (a)      (ii) 
 (i)
 
Cisplatin concentration (nM)
100 1000 10000 100000 1000000
Pe
rc
e
n
ta
ge
 
c
e
ll 
v
ia
bi
lit
y
-20
0
20
40
60
80
100
120
140
Exp 1 minus HuMc3
Exp 1 plus HuMc3
Exp 2 plus HuMc3
Exp 2 minus HuMc3
Exp 3 plus HuMc3
Exp 3 minus HuMc3 
 
 (b)  
 (i)      (ii) 
Paclitaxel concentration (nM)
100 1000 10000 100000 1000000
Pe
rc
en
ta
ge
 
ce
ll 
v
ia
bi
lit
y
-20
0
20
40
60
80
100
120
140
Exp 1 minus HuMc3
Exp 1 plus HuMc3
Exp 2 minus HuMc3 
Exp 2 plus HuMc3
  
 
 
 
 
Curves fitted by Sigmaplot11.0; Equation sigmoidal logistic 4 parameter. (a) Exp 1 + HuMc3 Normality test (Shapiro-Wilk) Passed (P = 0.1470, W statistic= 0.8845, significance level = 0.0500. Constant 
variance test passed (P = 0.3090). Exp 1 – HuMc3 Normality test (Shapiro-Wilk) Passed (P = 0.9930), W statistic= 0.9876, significance level = 0.0500. Constant variance test passed (P = 0.1483). (b) Exp 1 + 
HuMc3 Normality test (Shapiro-Wilk) Passed (P = 0.8702), W statistic= 0.9692, significance level = 0.0500. Constant variance test passed (P = 0.0500). (b) Exp 1 – HuMc3 Normality test (Shapiro-Wilk) 
Passed (P = 0.7317), W statistic= 0.9492, significance level = 0.0500. Constant variance test passed (P = 0.0500). 
Statistics   
Minus HuMc3 EC50 (nM) EC100 (nM) 
N 3 3 
Mean 14020 45270 
SD 2637 3139 
Plus HuMc3 EC50 (nM) EC100 (nM) 
N 3 3 
Mean 12720 38040 
SD  4246 9496 
t-test EC50-HuMc3/ 
EC50 + HuMc3 
EC50-HuMc3/ EC50 + 
HuMc3 
t Stat -0.45 -1.25 
P(T<=t) one-tail 0.34 0.14 
t Critical one-tail 2.13 2.13 
P(T<=t) two-tail 0.67 0.28 
t Critical two-tail 2.78 2.78 
Statistics   
Minus HuMc3 EC50 (nM) EC100 (nM) 
N 2 2 
Mean 92190 208400 
SD 9952 155300 
Plus HuMc3 EC50 (nM) EC100 (nM) 
N 2 2 
Mean 77940 126600 
SD 10160 43680 
t-test EC50-HuMc3/ EC50 
+ HuMc3 
EC50-HuMc3/ EC50 + 
HuMc3 
t Stat 1.42 0.72 
P(T<=t) one-tail 0.15 0.27 
t Critical one-tail 2.92 2.92 
P(T<=t) two-tail 0.29 0.55 
t Critical two-tail 4.30 4.30 
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6.2.4 HuMc3 tumour toxicity studies using in vivo human tumour tissue 
models 
In vivo tumour toxicity studies were carried out to determine the effect of HuMc3 
application on the growth of established MX-1 (figure 6.23) and MCF-7 (figures 6.24-
6.26) tumours, implanted in an athymic mouse model (section 2.2.6.1). The effects of 
HuMc3 were assessed alone and in the presence and absence of paclitaxel and/or 
bevacizumab. The effects were also compared to those of paclitaxel and bevacizumab, 
alone or in combination. The data for these studies is presented as percentage increase 
in tumour size against time with the starting tumour size defined as 100% of the 
original size. In all studies a vehicle only control of PBS was injected for comparison 
and the effects of the therapeutic agents were considered relative to this. PBS control 
experiments were ceased after days 29 and 36 for the MX-1 and MCF-7 studies 
respectively, due to the presence of infected tumours and the need to cull the animals. 
The remainder of the data is presented to enable a view of how any tumour growth 
inhibition altered over a larger time scale, but statistical analysis for comparison of 
tumour volume data is carried out for day 29 and 36 data for the MX-1 and MCF-7 
studies respectively. Data was collected until day 54 for the MX-1 study and day 61 
for the MCF-7 study, with some experiments ceased before this, again due to the 
presence of infected tumours. 
 
6.2.4.1  MX-1 tumour toxicity study 
 
Figure 6.23b shows the percentage increase in MX-1 tumour size over the 54 day 
period following initial injection. A 4mg/kg (100µg/25g mouse) dose of HuMc3 
applied twice weekly showed significant (figure 6.23a) inhibition of tumour growth, 
with a reduction in tumour size relative to the PBS control at day 29 of 39%. 
Paclitaxel (applied three times weekly at 20mg/kg) also slowed the growth of the 
tumour significantly (figure 6.23a) and alone was more effective than HuMc3, 
reducing tumour size 54% relative to control. It also showed tumour growth inhibition 
similar to that described in past work for this tumour type [286][329]. When HuMc3 
and chemotherapy were combined however, a reduction in tumour size relative to 
control by 81% was achieved, a significantly (figure 6.23a) greater inhibition than 
paclitaxel alone. Combined, HuMc3 and conventional chemotherapy appeared 
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therefore to have a tumouristatic/tumouricidal effect, reducing tumour volume to 77% 
of staring tumour volume by day 29. The combined effect of the two drug regimens 
seemed to be additive of the individual drug effects. Bevacizumab (applied twice 
weekly at 4mg/kg) also showed therapeutic effect, with a significantly (figure 6.23a) 
greater tumour inhibition than either HuMc3 or chemotherapy alone, though less than 
the combination HuMc3/chemotherapy treatment, with a reduction in tumour size 
relative to control of 71.4%. When combined with paclitaxel, bevacizumab produced 
a significantly stronger growth inhibition than HuMc3/chemotherapy combination 
treatment, reducing tumour size relative to control by 93.5%, with the tumour 
shrinking in size to 27% of the starting size by day 29, indicating a tumouricidal 
effect. By day 54 the gap between the HuMc3 alone data and paclitaxel alone data and 
the remainder of the conditions had widened, with tumour sizes at 428% and 334% of 
starting size respectively for the former and 159% for the nearest result of 
bevacizumab alone. HuMc3 plus paclitaxel however retained its tumouristatic effect, 
with tumour size remaining just below 100% of starting volume. Bevacizumab plus 
paclitaxel however showed an even greater effect confirming its tumouricidal activity, 
with the tumour continuing to shrink until day 43 to 15.5% of starting volume, a size 
that was retained until the end of the experiment. The effects of HuMc3 on the 
established MX-1 tumour model were shown to be greater than the effects of Mc3 
tested on a MX-1 tumour formation model in past work [257]. The latter showed a 
reduction of control tumour mass by 27% compared to the 39% reduction from 
control in the established tumour model used in this study, even though the HuMc3 
concentrations used in this study were far lower at 100µg/mouse applied twice weekly 
for 6 weeks, compared with the 600µg/mouse applied 24 hours before tumour 
implantation and 3.5 times weekly for 6 weeks in past work [257]. Like the past work 
[257], no toxic effects of HuMc3 application were observed.   
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Figure 6.23 
In vivo therapy studies with established MX-1 tumour implants in BALB/c nu/nu mice to detect the 
effect on tumour viability of HuMc3 in the presence and absence of paclitaxel and/or bevacizumab.  
HuMc3 (4mg/kg) in the presence and absence of paclitaxel (pac), (20mg/kg) and bevacizumab (BV), 
(4mg/kg) was injected via the tail vein at day 0 and twice weekly (paclitaxel three times weekly) after 
this point. Tumour measurements were taken every 2/3 days. Controls included were paclitaxel 
(20mg/kg) alone and bevacizumab (4mg/kg) alone/plus paclitaxel. Results are shown as percentage 
increase in tumour size (100% = starting tumour) against days after injection. A vehicle only negative 
control (PBS) is also included. Five/six mice were included per treatment condition and an average is 
shown. This figure is representative of the results of a single experiment (b). Stats table and t-tests 
includes data at 29 days post injection (a). 
(a) 
Statistics 
PBS vehicle 
control Pac 20mg/kg HuMc3 4mg/kg BV 4mg/kg 
HuMc3 4mg/kg 
+ pac 20mg/kg 
BV 4mg/kg+ pac 
20mg/kg 
N 6 6 5 5 6 6 
Mean 448.14 196.18 267.96 124.17 76.79 23.67 
SD  94.02 45.81 43.69 46.81 38.69 9.45 
 
t-test PBS/pac PBS/HuMc3 PBS/BV Pac/pac+HuMc3 BV/ BV+Pac HuMc3/ pac 
t Stat 5.90 3.92 6.97 4.88 5.19 2.64 
P(T<=t) one-tail 7.54E-05 
 
1.75E-03 3.25E-05 
 
3.22E-04 
 
2.87E-04 1.34E-02 
t Critical one-tail 1.81 1.83 1.83 1.81 1.83 1.83 
P(T<=t) two-tail 
 
1.51E-04 
 
3.51E-03 6.501E-05 
 
6.44E-04 
 
5.73E-04 
 
2.69E-02 
t Critical two-tail 2.23 2.26 2.26 2.23 2.26 2.26 
t-test HuMc3/ BV BV/pac HuMc3+pac/ BV 
HuMc3 + pac/ BV + 
pac   
t Stat 5.02 -2.57 -1.84 3.27   
P(T<=t) one-tail 
 
5.12E-04 
 
1.51E-02 
 
4.93E-02 
 
4.23E-03   
t Critical one-tail 1.86 1.83 1.83 1.81   
P(T<=t) two-tail 
 
1.02E-03 
 
3.01E-02 9.86E-02 8.45E-03   
t Critical two-tail 2.31 2.26 2.26 2.23   
(b)  
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6.2.4.2  MCF-7 tumour toxicity study 
 
Figure 6.24b shows the percentage increase in MCF-7 tumour size relative to starting 
size over a 43 day period following initial injection of PBS control, paclitaxel 
(20mg/kg) alone or HuMc3 alone at 4, 8 and 12mg/kg. HuMc3 concentrations were 
applied twice and paclitaxel and PBS three times weekly. The data suggests HuMc3 
to inhibit tumour growth in a concentration-dependant manner, with the lowest 
concentration (4mg/kg) at day 36 producing an insignificant effect (figure 6.24a), the 
mid concentration (8mg/kg) a significant growth inhibitory effect (42% reduction in 
tumour size relative to PBS control) and the highest (12mg/kg) a significantly (figure 
6.24a) stronger effect than the mid concentration (69% reduction in tumour size 
relative to control). By the end of the experiment the gap between the mid and high 
HuMc3 concentrations had widened, with the tumour size 421% of starting volume 
for the mid concentration and 206% of starting volume for the highest HuMc3 
concentration, signifying a double growth inhibition effect for the higher HuMc3 
concentration. Paclitaxel shows a significant (figure 6.24a) 59% growth inhibition 
relative to the PBS control in agreement with past studies on this tumour type [286].  
The high concentration of HuMc3 shows no significant (figure 6.24a) difference in 
growth inhibition to paclitaxel, suggesting a similar growth inhibition to this 
conventional chemotherapeutic at the concentrations used. This is supported by the 
similar growth inhibition, continued until the end of the experiment. 
 
Figure 6.25b shows the percentage increase in MCF-7 tumour size relative to starting 
size over a 59 day period following initial injection of paclitaxel and paclitaxel plus 
HuMc3 concentrations (4, 8 and 12mg/kg). The lower HuMc3 concentration showed 
no effect as there was no significant difference (figure 6.25a) in tumour size at day 36 
for this and the chemotherapy alone. The two higher concentrations showed a 
significantly (figure 6.25a) increased effect than either HuMc3 or paclitaxel applied 
alone at day 36, but this was less that the combined individual growth inhibition of 
HuMc3 (8 or 12mg/kg) and paclitaxel alone of 102% and 128%, at 74.6 and 78.4% 
growth inhibition relative to control. The higher HuMc3 concentration combination 
reduced tumour size to 114% of starting volume and the mid concentration 135% of 
starting volume at day 36. Unlike the inhibition observed for 8mg/kg and 12mg/kg 
HuMc3 applied alone, there was small but insignificant (figure 6.25a) difference 
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between the inhibition exhibited by the two drug concentrations, when applied with 
paclitaxel. By the end of the experiment the gap between the mid and high HuMc3 
concentrations had widened but the difference was still insignificant, with a P(T<=t) 
one-tail of 0.14 (figure 6.25a). 
 
Figure 6.26 shows the results of the study with MCF-7 tumours in which 12mg/kg 
HuMc3 was applied twice weekly with bevacizumab (4mg/kg) and bevacizumab plus 
paclitaxel (20mg/kg applied three times weekly) and compared with bevacizumab 
alone and bevacizumab plus paclitaxel. Figure 6.26b shows the percentage increase in 
MCF-7 tumour size relative to starting size over a 61 day period following initial 
injection. Bevacizumab was shown to reduce tumour growth significantly at day 36 
(figure 6.28a), by 71% relative to the PBS control, which is not significantly (figure 
6.26a) different to the growth inhibition produced by HuMc3 (12mg/kg), though the 
drug concentration was lower than HuMc3 at 4mg/kg. When combined with 
paclitaxel, bevacizumab inhibited tumour growth relative to the control by 90% by 
day 36, reducing the tumour to 54% of the starting size, suggesting a tumouricidal 
effect. This was a significantly (figure 6.26a) greater inhibition than either paclitaxel 
or bevacizumab alone and was also significantly greater than HuMc3 (12mg/kg) plus 
paclitaxel. When applied together with bevacizumab, HuMc3 showed no (figure 
6.26a) increase in tumour growth inhibition over bevacizumab alone and with 
bevacizumab plus paclitaxel, there was a small but not significant increase in growth 
inhibition over bevacizumab and paclitaxel alone (figure 6.26a) at day 36. By the end 
of the experiment, the gap between bevacizumab plus paclitaxel and bevacizumab 
plus paclitaxel, plus HuMc3 had closed and still no effect of addition of HuMc3 to 
bevacizumab was evident. The bevacizumab alone group continued to show similar 
growth inhibition to HuMc3 alone and the bevacizumab plus paclitaxel tumours 
continued to shrink, with a minimum of 20.3% of original tumour size reached at day 
57 and maintained until the end of the experiment, confirming the tumouricidal effect 
of this combination. 
 
In this study bevacizumab produced growth inhibition of both MX-1 and MCF-7 
breast tumours in vivo when applied alone of around 71%. Bevacizumab has not been 
assessed for its effects on MX-1 tumours but this represents a greater effect than has 
been observed in past work for MCF-7 implants in which no tumour growth inhibition 
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was observed, just a reduction in vessel density [120]. This may however be explained 
by the fact that this experiment involved a longer time course, providing sufficient 
time for the secondary effects of tumour cell death due to vessel regression to be 
observed. The results were however comparable to those of past work with a nude 
mouse model implanted with A673 human rhabdomyosarcoma cells [119] and an 
androgen-independent human prostate cancer xenograft model CWR22R [330] in 
which application of bevacizumab at a similar dosing schedule to that used in this 
study, resulted in a tumour growth inhibition of 95% and 72% respectively. In this 
study, with both tumour models, bevacizumab produced a greater growth inhibition in 
combination with paclitaxel than either drug applied alone, with the combinations in 
MX-1 and MCF-7 models respectively inhibiting tumour growth by 94% and 90%. 
This agrees well with past work with a CWR22R xenograft model in which the 
combination of paclitaxel with bevacizumab produced a tumour growth inhibition of 
98% [330]. 
 
As with the MX-1 tumour model no toxic effects of HuMc3 application were evident. 
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Figure 6.24 
In vivo therapy studies with established MCF-7 tumour implants in BALB/c nu/nu mice to detect the 
effect on tumour viability of application of paclitaxel or various doses of HuMc3 
HuMc3 (4, 8 and 12mg/kg) or paclitaxel (pac 20mg/kg) was injected via the tail vein at day 0 and twice 
weekly (paclitaxel three times weekly) after this point. Tumour measurements were taken every 2/3 
days. A vehicle only negative control (PBS) is also included. Results are shown as percentage increase 
in tumour size (100% = starting tumour) against days after injection. Four/five mice were included per 
treatment condition and an average is shown. This figure is representative of the results of a single 
experiment (b). Stats table and t-tests includes data at 36 days post injection (a). 
 
(a) 
Statistics PBS Pac 20mg/kg 
HuMc3 
4mg/kg HuMc3 8mg/kg HuMc3 12mg/kg 
t-test 
PBS/pac 
N 5 4 4 4 4 t Stat 4.87 
Mean 530.87 215.63 439.22 309.81 163.42 P(T<=t) one-tail 
 
9.12E-04 
SD 114.87 64.61 157.38 85.37 36.95 t Critical one-tail 1.89 
 
     P(T<=t) two-tail 
 
1.82E-03 
 
     t Critical two-tail 2.36 
t-test 
PBS/HuMc3 
(4mg/kg) 
PBS/HuMc3 
(8mg/kg) 
PBS/HuMc3 
(12mg/kg) 
HuMc3 
(4mg/kg/8mg/kg) 
HuMc3 
(8mg/kg/12mg/kg) 
 
HuMc3 (8mg/kg)/ 
pac 
HuMc3 
(12mg/kg)/ 
pac 
t Stat 1.01 3.19 6.08 1.45 3.15 1.76 -1.40 
P(T<=t) one-tail 0.17 
 
7.62E-03 
 
2.51E-04 
 
0.10 
 
9.94E-03 0.06 0.11 
t Critical one-tail 1.89 1.89 1.89 1.94 1.94 1.94 1.94 
P(T<=t) two-tail 0.34 
 
1.52E-02 
 
5.02E-04 0.20 0.02 0.13 0.21 
t Critical two-tail 2.36 2.36 2.36 2.45 2.45 2.45 2.45 
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Figure 6.25 
In vivo therapy studies with established MCF-7 tumour implants in BALB/c nu/nu mice to detect the 
effect on tumour viability of application of HuMc3 in the presence of paclitaxel  
Paclitaxel (pac) applied at 20mg/kg in the presence and absence of HuMc3 (4, 8 and 12mg/kg) was 
injected via the tail vein at day 0 and three times weekly (HuMc3 two times weekly) after this point. 
Tumour measurements were taken every 2/3 days. Results are shown as percentage increase in tumour 
size (100% = starting tumour) against days after injection. A vehicle only negative control (PBS) is 
also included. Four/five mice were included per treatment condition and an average is shown. This 
figure is representative of the results of a single experiment (b).  Stats table and t-tests includes data at 
36 days post injection (a). 
 (a) 
 
Statistics PBS Pac 20mg/kg 
HuMc3 4mg/kg + 
pac 20mg/kg 
HuMc3 8mg/kg + 
pac 20mg/kg 
HuMc3 12mg/kg 
+ pac 20mg/kg  
N 5 4 4 4 4  
Mean 530.87 215.63 197.85 135.00 114.81  
SD 114.87 64.61 45.63 30.21 21.17  
t-test 
Pac/pac+HuMc3 
(4mg/kg) 
Pac/pac+HuMc3 
(8mg/kg) 
Pac/pac+HuMc3 
(12mg/kg) 
Pac+HuMc3 
(8mg/kg)/pac + 
HuMc3 (12mg/kg) 
HuMc3 (8mg/kg)/ 
pac + HuMc3 
(8mg/kg) 
HuMc3 
(12mg/kg)/ pac + 
HuMc3 (12mg/kg) 
t Stat 0.45 2.26 2.97 1.10 3.86 2.28 
P(T<=t) one-tail 0.33 0.03 0.01 0.16 
 
4.18E-03 0.03 
t Critical one-tail 1.94 1.94 1.94 1.94 1.94 1.94 
P(T<=t) two-tail 0.67 0.06 0.03 0.32 
 
8.35E-03 0.06 
t Critical two-tail 2.45 2.45 2.45 2.45 2.45 2.45 
 
(b) 
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Figure 6.26 
In vivo therapy study with established MCF-7 tumour implants in BALB/c nu/nu mice, to detect the 
effect on tumour viability of application of HuMc3 in the presence of bevacizumab/bevacizumab and 
paclitaxel 
HuMc3 (12mg/kg) in the presence of bevacizumab (BV) (4mg/kg) or bevacizumab (4mg/kg) plus 
paclitaxel (pac 20mg/kg) was injected via the tail vein at day 0 and twice weekly (paclitaxel three times 
weekly) after this point. Tumour measurements were taken every 2/3 days. Controls included 
bevacizumab alone, bevacizumab plus paclitaxel alone, HuMc3 alone, paclitaxel alone and HuMc3 
plus paclitaxel alone. A vehicle only negative control is also included. Results are shown as percentage 
increase in tumour size (100% = starting tumour) against days after injection. Three-five mice were 
included per treatment condition and an average is shown. This figure is representative of the results of 
a single experiment (b).  Stats table and t-tests include data at 36 days post injection (a). 
(a) 
 
Statistics PBS BV 4mg/kg 
BV 4mg/kg + 
pac 20mg/kg 
BV 4mg/kg + 
HuMc3 12mg/kg 
BV 4mg/kg + pac 
20mg/kg + HuMc3 
12mg/kg 
t-test 
PBS/BV 
N 5 4 4 3 5 t Stat 5.76 
Mean 530.87 154.97 53.89 179.21 35.16 P(T<=t) one-tail 
 
3.45E-04 
SD 114.87 66.90 13.38 53.52 20.09 t Critical one-tail 1.89 
 
     P(T<=t) two-tail 6.90E-04 
 
     t Critical two-tail 2.36 
t-test 
BV/HuMc3 
BV/ 
HuMc3+pac BV/ BV+ pac 
 
BV+ pac/ pac BV/ BV+HuMc3 
BV+pac/ 
BV+pac+HuMc3 
BV+pac/ 
HuMc3+pac 
t Stat -0.22 1.14 2.96 -4.90 -0.51 1.59 -4.87 
P(T<=t) one-tail 0.42 0.15 0.01 
 
1.35E-03 0.32 0.08 
 
1.40E-03 
t Critical one-tail 1.94 1.94 1.94 1.94 2.02 1.89 1.94 
P(T<=t) two-tail 0.83 0.30 0.03 
 
2.70E-03 0.63 0.16 
 
2.81E-03 
t Critical two-
tail 2.45 2.45 2.45 2.45 2.57 2.36 2.45 
 
(b) 
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6.3 Discussion 
 
In this chapter all of the objectives were attempted and the aims were partially met. 
The tumour cell lines under study; SKOV3 and MCF-7, were confirmed to express 
one or both of the αvβ5/αvβ3 integrins and the control cell line HEK-293 to be 
negative/near negative for both. Lactadherin binding to SKOV3 and MCF-7 cells via 
αv integrins was confirmed, though a second non-αv integrin method of association 
was also implied. HuMc3 was shown to block all tumour cell association with 
lactadherin, through both specific and non-specific effects. No specific cytotoxic 
effects of HuMc3 on MCF-7 or SKOV3 cells in vitro were detected, despite the use of 
very high antibody concentrations. The addition of HuMc3 to conventional 
chemotherapy drugs paclitaxel and cisplatin, failed to significantly increase the 
cytotoxicity of these drugs in vitro.  With past work providing evidence for a role of 
lactadherin in tumour growth through αv integrin survival signalling, a failing in the 
protocol design was however considered. HuMc3 tumour growth inhibition was 
demonstrated in vivo in both established MX-1 and MCF-7 tumour models, when 
applied alone, with a concentration-dependent tumour growth inhibition demonstrated 
in the MCF-7 tumour model. An effect similar to the approved anti-cancer 
monoclonal antibody therapeutic bevacizumab was observed in the MCF-7 model. In 
addition, in both models, HuMc3 was shown to combine favourably with paclitaxel, 
producing a significantly greater tumour inhibition than either drug applied alone and 
causing tumour stabilisation in both models. HuMc3 failed however to significantly 
increase the tumour growth inhibition of bevacizumab or bevacizumab plus paclitaxel. 
No adverse effects of HuMc3 application to mice was apparent at the concentrations 
used, suggesting the potential safety of this therapeutic. This chapter was unable to 
verify the mode of action of HuMc3 in its in vivo tumour growth inhibition. It could 
not be confirmed to be through inhibition of lactadherin binding to αv integrins as no 
growth inhibition was observed in vitro.  
 
6.3.1 HuMc3 neutralisation of lactadherin binding to αvβ3/αvβ5 integrins 
 
Although HuMc3 was shown to completely inhibit lactadherin association with both 
SKOV3 and MCF-7 cells, it inhibited lactadherin association both via a αv-integrin 
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and a non-αv integrin mediated mechanism. This was suggested by the lactadherin-
tumour cell binding FACS data which showed lactadherin association, albeit at a 
lower level, to the αv integrin negative HEK-293 cell line. It was also indicated by the 
fact that the αvβ5/αvβ3 integrin blocking antibodies P1F6 and LM609 failed to block 
all association of lactadherin with these cell lines. With lactadherin demonstrated in 
past work to be transported to the cell surface following expression in association with 
membrane phospholipids and to be detected on the cell surface, associated via the C2 
domain [151][153][155], it is likely that the lactadherin bound to the surface by a non-
αv integrin mediated attachment is associated via its C2 domain. HuMc3 would not 
be expected to inhibit association by specific attachment in this case, as it binds to the 
EGF-like domain of lactadherin [263], leaving the C2 domain free to bind to the cell 
surface. It is likely therefore that the C2 domain attachment inhibition occurs through 
non-specific association of this antibody to the lactadherin C2 domain. This is 
supported by the fact that the isotype control antibody showed a significant level of 
inhibition of lactadherin binding to both tumour cell lines. To confirm this, it would 
have been useful to have repeated the HuMc3/isotype control lactadherin binding 
inhibition experiment with the HEK-293 cell line. With no lactadherin-αv integrin 
association it would have been expected that HuMc3 and the isotype control would 
have inhibited binding to this cell line to the same extent. In addition, to confirm the 
observed P1F6 and LM609 inhibition of lactadherin binding to SKOV3 and MCF-7 
cells to be the result of a specific effect, an isotype-matched control should have been 
used along with the repeat of this experiment using HEK-293 cells. As HEK-293 cells 
are αvβ3/αvβ5 integrin negative, lactadherin binding should not be affected by these 
antibodies. In addition, the specificity of the effects of LM609, P1F6 and HuMc3 
could have been confirmed by carrying out these experiments with titrations of these 
antibodies to determine if the effect is concentration dependent and to confirm the 
maximum level of binding inhibition and so cell binding through αvβ3/αvβ5 ligation.  
A general problem in the FACS studies for this chapter was a lack of signal 
reproducibility. Although the data from many of the studies suggested a concentration 
dependent effect in all or most repeats, it was not possible to confirm this as 
statistically significant due to the variation in signal from assay to assay. It was 
considered that there may be small variations in the conditions of the experiment and 
perhaps they were responsible for this effect. Some factors such as instrument day-to-
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day variability could not be controlled, but absolute care with incubation length 
precision and closer control of temperature fluctuations may have perhaps improved 
this. Another possibility was to have increased the number of experimental repeats. 
 
6.3.2 The tumour cytotoxic effects of HuMc3 in vitro 
 
In this work, no specific cytotoxic effects of HuMc3 were observed in vitro, despite 
application to the confirmed lactadherin-expression positive tumour cell line MCF-7 
[176][195]. At very high concentrations some apparent cytotoxicity was observed, but 
this was presumed to be a non-specific effect, as the concentration required far 
outstripped that needed to completely remove MCF-7 association with plate-coated 
lactadherin. This should have been verified however by the repeat of these 
experiments using an isotype control. As past work had provided evidence for a role 
of lactadherin in αv integrin cell survival signalling, in HUVECS [173], a Rip1-Tag2 
transgenic mouse pancreatic carcinoma model [210] and in a melanoma tumour model 
[197], further investigations should have been carried out. It should have been 
considered that something in the culture media may have caused the role of 
lactadherin in tumour expansion to be redundant in a cell culture system. It was 
possible that vitronectin for MCF-7 cells or any of the αvβ3 signal transduction-
inducing ligands for SKOV3 cells were present in the media. In the case of the MCF-
7 cells this could have been verified by detection of vitronectin, by a binding assay 
such as a western blot or ELISA using an anti-vitronectin antibody. The media could 
then have been passed though an integrin affinity chromatography column (αvβ3 and 
αvβ5 for SKOV3 cells or αvβ5 for MCF-7 cells) to remove any ligands to these 
receptors. Alternatively a more defined media could have been prepared. Another 
possibility however was that the tumour cells produced alternative αvβ3/αvβ5 
integrin ligands to high concentrations. SKOV3 tumour cell vitronectin expression in 
culture has been noted in past work [24]. This again should have been ascertained for 
MCF-7 cells by detection of vitronectin in the spent media, by a binding assay and 
then RNAi used to remove vitronectin expression. The repeat of this experiment with 
the use of lactadherin and αvβ3 and/or αvβ5 integrin ligands would also have been 
useful to confirm whether the lack of response is simply ligand redundancy or 
whether it is due to lack of lactadherin efficacy. 
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With no in vitro therapeutic effects evident for HuMc3 application to a lactadherin 
expressing tumour cell line, the question may be raised, are in vitro cell 
proliferation/cell kill assays a useful predictor for in vivo therapeutic effect? Past work 
with other monoclonal antibody therapies [22][127][139][331], including other anti-
αvβ3/αvβ5 integrin antibodies [60][308] as well as small molecule cytotoxic agents 
however suggest this is often the case [102][105][285][314][317]. In the anti-
αvβ3/αvβ5 integrin antibodies assays however, the effect of addition of antibody to 
cells bound to vitronectin, coated directly to the wells was assessed. With no effect of 
addition HuMc3 alone, the effects of HuMc3 addition to tumour cells added to wells 
pre-coated with lactadherin may have been assessed. In this case, as shown in figure 
6.15 (section 6.21) around 60% of the cells would have been expected to be ligated to 
lactadherin through a specific-association with the receptor αvβ5, so if any 
survival/proliferation pathway activity is activated by lactadherin αvβ5 integrin 
ligation, an effect of HuMc3 application should have been observed. This would have 
answered the question of whether HuMc3 application can inhibit lactadherin tumour 
cell signalling leading to tumour toxicity. It would not however tell us whether it 
actually does in the case of MCF-7 cells, as the lactadherin is not tumour derived. 
This could however have been achieved by coating the wells with media cultured 
from the cells, which should contain lactadherin. 
 
 6.3.3 The tumour cytotoxic effects of HuMc3 in vivo 
 
HuMc3 application to established human MCF-7 and MX-1 tumour xenograft models 
in vivo showed an apparent therapeutic effect alone Application with paclitaxel 
produced a greater effect than either drug alone, with an additive effect observed for 
MX-1 and a sub-additive effect for MCF-7. The latter suggested paclitaxel and 
HuMc3 may work at least partially by a similar mechanism, causing a redundancy 
when both are applied together. This therefore validates to some extent the idea that 
the anti-tumour effects of HuMc3 act at least partially through interference with 
lactadherin tumour cell signalling, as the modes of action of paclitaxel includes 
interference with tumour signalling [314]. If HuMc3 acted solely through activation 
of intrinsic immunity or by vasculature effects, no interference would have been 
expected with addition to paclitaxel.  
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In the MCF-7 model HuMc3 (12mg/kg) was shown alone to produce a similar 
therapeutic effect to bevacizumab (4mg/kg), an approved anti-cancer antibody and a 
greater effect than the approved anti-cancer drug paclitaxel at the concentrations used. 
This suggested the potential for HuMc3 as a therapeutic for lactadherin-expressing 
tumours. With past studies suggesting no further effect to be expected for the use of 
higher bevacizumab concentrations [97], but with HuMc3 showing a concentration 
dependent effect with no indication that the maximum has been reached it was 
possible that an even greater effect for HuMc3 than bevacizumab could have been 
achieved had higher HuMc3 concentrations been used. When combined with 
chemotherapy however a much greater effect was observed for the bevacizumab 
combination. This may however be the result of using a chemotherapy drug which 
interferes with the mode of action of HuMc3, whereas the effects of bevacizumab and 
paclitaxel appeared to be additive, so the comparison may not be a fair one. The latter 
was expected as bevacizumab and paclitaxel act independently; bevacizumab by 
inhibiting blood vessel growth (section 1.2.5.1) and paclitaxel by acting on the tumour 
cell itself [314]. Ideally the effects of addition of HuMc3 to a panel of cytotoxic 
chemotherapy agents as well as targeted anti-tumour monoclonal antibody therapies 
would have been carried out to find a combination that produces either additive 
effects through an independent mechanism or synergistic effects through 
complementary mechanisms. These drug combinations could then have been 
compared with the action of bevacizumab or other approved anti-cancer monoclonal 
antibodies in similar combinations.  
 
The lack of effect of addition of HuMc3 to bevacizumab or bevacizumab plus 
paclitaxel suggested HuMc3 exerts an effect on the vasculature, creating a 
redundancy. One possibility is that these antibodies may exert their effects on the 
same pathways, with HuMc3 inhibiting lactadherin-mediated αv integrin activation 
on the vascular EC surface and thereby interfering with VEGFR2-integin signalling. 
If that were the case however, an increased effect may still be expected for application 
of HuMc3 by its effects on the tumour cell surface, suggested by the interference of 
paclitaxel with its activity. It is alternatively possible that bevacizumab by its effects 
on newly formed blood vessels may inhibit survival of newly formed tumour cells, 
thereby providing a connection with the activity of HuMc3, which is proposed to act 
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by inhibiting the roles of lactadherin in tumour cell survival. Another possibility 
however is that HuMc3 acts on the vasculature simply by its ability to bind to 
lactadherin associated with vascular endothelial cells as was demonstrated in chapter 
5, thereby directing intrinsic immunity against the tumour vasculature. A weakness of 
this data is the lack of tumour tissue analysis to examine the effects of HuMc3 
application to the tissue architecture. If HuMc3 were shown to exert its effects wholly 
or partially through vasculature-lactadherin association, a reduced vascular density 
may have been expected. In addition, tissue analysis could have assessed the effects of 
HuMc3 application, alone or with chemotherapy, on antigen depletion that could have 
been predictive of later potential for development of resistance.  
 
The in vivo therapy data results in terms of expected therapeutic effects may to some 
degree be misleading as the animal model can never be an exact predictor for 
therapeutic outcome [293][324]. In this model for example it is unlikely that the full 
effects of ADCC would be achieved as T-cell function is required for mounting an 
adaptive immune response against the processed tumour antigens [235]. In addition it 
is unlikely that the tumour tissue architecture or chemical environment of the tumour 
would be the same as that observed in a primary tumour of a patient [293]. One way 
to improve the predictability of the results could be implantation in the site of tissue 
origin (orthotopic implantation) or to use primary patient tissue samples [293][324]. 
Due to the difficulty in assessing tumour growth with orthotopic implantation and the 
variability of primary tumour samples and difficulty in obtaining them, another 
predictor of potential clinical outcome is to compare in vivo data with similar data 
from clinically successful monoclonal antibody therapeutics.  HuMc3 compares well 
with an approved anti-breast/ovarian cancer therapeutic trastuzumab, with murine in 
vivo studies using HER-2 overexpressing MCF-7 xenografts. Like the HuMc3 studies, 
a significant but sub-cytostatic effect was observed with antibody alone, reducing 
tumour size relative to the control at day 21 by around 31% and 61% for 1mg/kg and 
3mg/kg concentrations respectively, a lesser effect than observed for HuMc3 alone in 
the MCF-7 studies. With cisplatin combination studies a greater effect was observed 
than antibody alone, sub-cytostatic for 1mg/kg antibody and cytostatic for the higher 
3mg/kg antibody concentration [138], as observed for the higher HuMc3 
concentrations in the MCF-7 study. The concentrations used were however lower than 
the 4mg/kg concentration of HuMc3 in this study which showed no significant effect 
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alone or in combination, suggesting higher potency of trastuzumab. The xenograft 
model used was however grown from a cell line induced to express HER-2 and so 
may not be an accurate representation of the effects of this antibody on a human 
tumour. In a naturally HER-2 over-expressing CAOV3 breast tumour xenograft 
model, higher antibody concentrations were required for a significant effect to be 
observed. No significant effect of this antibody were observed at 3mg/kg when 
applied alone, but with a significant though sub-cytostatic effect demonstrated for a 
10mg/kg concentration, representing around a 53% reduction in tumour volume 
relative to control [138]. HuMc3 also compares well with pre-clinical studies of anti 
αvβ3/αvβ5 antibody therapeutics in late stage clinical development. A superior effect 
was observed compared to anti-αvβ3 antibody cilengitide which showed no effect in 
monotherapy against breast tumour xenografts, when applied at high concentrations of 
9-40mg/kg [126][127]. A lesser effect was observed compared with the anti 
αvβ3/αvβ5 antibody CNTO 95, which in a murine model with human melanoma 
tumour xenografts (A375.S2) showed an 80% reduction in tumour volume relative to 
control 26 days after application in monotherapy at 10mg/kg [60]. A superior effect 
was however observed in the xenograft models used for HuMc3 than that observed for 
anti αvβ3 integrin antibody abegrin which demonstrated a 36%-49% reduction in 
tumour size relative to control in SKOV3 and A2780 models and with a significant 
but small increase in effect than antibody or paclitaxel alone shown only for 
combination studies for the SKOV3 model, but not for A2780 [332]. This data 
therefore suggested the potential for success of HuMc3 as a therapeutic antibody for 
lactadherin over-expressing tumours, as the in vivo efficacy of this antibody alone and 
in combination with chemotherapy compares well with other anti-tumour antibodies 
which have been approved/are in late stage clinical development for cancer therapy. 
In addition, as other antibodies have shown variation in the success of combination 
with chemotherapy agents and with other monoclonal antibody therapies, with some 
combinations yielding better results than others due to the different ways in which the 
therapeutics interact [96][123][244][249][281], the full potential of HuMc3 
combinations may not have been determined in this study. 
 
In chapter 4 (section 4.3.2), a short serum t1/2β of HuMc3 was predicted in the murine 
model of only 4 days. This was however suggested to be an artefact of the low 
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stability of the conjugate, as HuMc3 was radioiodinated, given that HuMc3 is a whole 
IgG1 antibody with an expected 21 days t1/2β [233]. The therapy data supports this 
with sufficient HuMc3 retained in the tumour for a therapeutic effect of HuMc3 alone 
relative to the PBS control, observed for the whole experimental period of 29 days 
and 36 days for MX-1 and MCF-7 tumours respectively. This data also agrees well 
with the biodistribution data showing specific tumour uptake and retention throughout 
the experimental period despite clearance from the blood (section 4.3.2). This does 
not however take into account the repeated applications of HuMc3. The affect of 
clearance of HuMc3 may have been better assessed by application of higher doses of 
this drug, less frequently. 
  
6.3.4 The mode of action of HuMc3 
Although HuMc3 has been shown in vivo to inhibit growth of the lactadherin-
expressing MCF-7 and MX-1 tumours, the mode of action of HuMc3 has not been 
established and this is one of the main weaknesses of this chapter. It is possible as 
stated in section 6.3.2 that HuMc3 is acting through a signalling mechanism, 
inhibiting lactadherin activation of αv integrins on the tumour cell and/or vasculature 
and a more conclusive answer for this should have been attained, as previously 
described (section 5.3.3)(section 6.3.2). As HuMc3 has been suggested in this thesis 
and in past studies to bind to C2-associated lactadherin on the surface of both tumour 
and vasculature endothelial cells, it was possible that as for other clinically successful 
antibodies [235][281] the in vivo effects of HuMc3 were partially or wholly a result of 
the activation of intrinsic immunity against both tumour tissue and its nourishing 
vasculature. With the murine model used known to retain some of the effects of 
ADCC as well as CDC and phagocytosis [325], and with HuMc3 of the IgG1 isotype 
[270] it was possible the observed in vivo effects of HuMc3 were a result of its 
tumour targeting and retention demonstrated in chapter 4. This should however have 
been confirmed in this study. The role of effector functions in the in vivo cytotoxic 
effect of HuMc3 may have been assessed by many means. The expression of HuMc3 
in an alternative cell system producing altered glycosylation leading to loss of effector 
functions [238] or the engineering of HuMc3 by point mutation to remove effector 
functions [236][237] and performance of side-by-side therapy studies for comparison 
of tumour toxicity as has been carried out for other antibodies [236] [333], could have 
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been a possibility or the use of a knockout mouse strain incapable of ADCC as used 
for other therapeutic antibodies [334], CDC or phagocytosis. This would have been 
useful as it would have confirmed not only whether effector functions have an effect, 
but to what extent, with any remaining tumour inhibition of the modified HuMc3 
antibodies attributed to a signalling mechanism. 
 
One key failing of the in vivo therapy data is the lack of isotype control experiments 
to compare with the HuMc3 data and to allow confirmation that the effects observed 
are a result of specific association of HuMc3 with tumour lactadherin. It must be 
considered as a possibility that the growth inhibition observed was a non-specific 
effect of the antibody isotype. 
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Chapter 7 End Discussion 
 
The aims and objectives of this thesis of were all attempted, but with mixed levels of 
success. Both lactadherin and HuMc3 were successfully expressed and purified and 
the affinity for the association quantified and shown to be within the range of other 
successful monoclonal antibody therapeutics, including neutralising antibodies 
(section 3.2.8). HuMc3 was shown to detect lactadherin on the surface of a human 
breast tumour cell line MCF-7 (section 4.2.1) and to target two human breast tumours 
MCF-7 and MX-1 selectively as xenografts in a murine model, with no specific 
uptake in any normal murine tissue or a human non-tumour tissue mass (section 
4.2.2). HuMc3 inhibited αvβ3 and/or αvβ5 integrin-mediated lactadherin association 
with tumour cell lines MCF-7 and SKOV3 (section 6.2.1) as well as with HUVECS 
(section 5.2.1), but failed to show any tumour growth inhibition in vitro either alone 
or in the presence of chemotherapy drugs cisplatin and paclitaxel. No effect on 
HUVEC survival or proliferation for application of lactadherin and/or HuMc3 in the 
presence or absence of VEGF was observed in vitro. A tumour growth inhibitory 
effect, was however evident for HuMc3 application to MX-1 and MCF-7 tumour 
xenografts in vivo (section 6.2.4). The omission of an isotype-matched control in the 
therapy studies however weakened this data and any inferences made based on these 
results.  A concentration-dependent growth inhibition was observed for the MCF-7 
model (section 6.2.4.2) and a greater effect for application with the chemotherapy 
drug paclitaxel was observed in both models, than either agent applied alone, resulting 
in a cytostatic growth inhibition (section 6.4.2). This was however shown with the 
more in-depth MCF-7 study to be sub-additive. HuMc3 in the MCF-7 xenograft 
model showed a similar growth inhibition to the approved breast cancer therapeutic 
and anti-angiogenesis drug bevacizumab, though a lesser effect was observed for 
paclitaxel combinations, perhaps due to the additive effects of the bevacizumab and 
paclitaxel combination. No effect for addition of HuMc3 to bevacizumab, or 
bevacizumab plus paclitaxel was observed, suggesting these antibodies may exert 
their effects on similar pathways (section 6.2.4.2). No toxicity for application of 
HuMc3 and its drug combinations was evident (section 6.2.4). This data therefore 
indicated the ability of HuMc3 to inhibit growth of lactadherin-expressing human 
breast tumours and suggested its potential as an anticancer therapeutic with little 
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toxicity, for treatment of patients with lactadherin-over-expressing tumours, 
(presuming that the effects observed were a result of the specific action of HuMc3). 
The failure of the in vitro assays to show any effect of HuMc3 on tumour clonal 
expansion or HuMc3 or lactadherin on HUVEC proliferation or survival however 
made it difficult to make any meaningful conclusions on the mode of action of 
HuMc3. The in vivo data suggested some potential anti-vasculature effects and direct 
effects on the tumour cell, by the failure of HuMc3 to produce additive effects with 
bevacizumab and paclitaxel. It was not however possible from this data to confirm 
this, nor to determine if any of the observed growth inhibition was the result of 
activation of effector functions 
 
Immediate work to extend these finding would be to repeat the therapy experiments 
with an isotype control antibody, to confirm the effects of HuMc3 in vivo to be 
specific. In addition, the in vitro assays as described in section 5.3.3 and section 6.3.2 
should be repeated, but using the methods successfully described in past papers for 
vitronectin and anti αvβ3/αvβ5 antibodies CNTO-95 and cilengitide. Vitronectin and 
CNTO-95/cilengitide would be included in these as a positive control to check the 
experimental protocol is working correctly. In addition, the lactadherin αvβ3/αvβ5 
integrin signalling studies of past work [173][197] could be repeated. This would 
provide more information on whether the mode of action of HuMc3 in tumour growth 
inhibition in vivo is the result, at least partially, of inhibition of tumour and/or 
vascular growth, through inhibition of lactadherin-integrin ligation. This could also 
have been supplemented by analysing the tumour xenograft samples after treatment 
and comparing the vascular density and architecture with that of an untreated tumour, 
as well as by investigating the role of effector functions in the action of HuMc3 in 
vivo (as described in section 6.3.4). As HuMc3 was suggested to combine sub-
additively with paclitaxel in vivo, other combinations may be subsequently found to 
produce greater growth inhibition. Further work may examine alternative HuMc3 
combinations with chemotherapy drugs and potentially other targeted therapeutics 
with the ultimate aim of completely eradicating the tumour and avoiding development 
of resistance. In addition, as a monotherapy the full effects of HuMc3 may not have 
been ascertained, with this work showing an increasing effect for the two higher drug 
concentrations used (section 6.2.4.2), so further higher concentrations may be tested.  
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HuMc3 was shown to compare fairly well in vivo with the in vivo data published for 
other approved breast cancer and anti-vasculature therapeutics including trastuzumab, 
bevacizumab and anti αvβ3/αvβ5 antibody therapies (section 6.3.3), suggesting the 
clinical potential for HuMc3, (presuming the effects of HuMc3 are shown to be 
specific).  
 
Ultimately however the effects of most therapies are limited by the development of 
resistance, due to the highly mutagenic nature of tumours and so their ability to alter 
their signalling and gene expression profiles to adapt and survive in the presence of 
therapy [335]. As described in section 1.2.5.3 and section 1.4.3.1 the ultimate answer 
to cancer therapy may be much the same as for more aggressive infectious disease; 
multi-targeted agents and combination therapy, to attack the tumour within many 
pathways and processes and reduce the potential for development of resistance before 
complete eradication of all tumour cells. HuMc3 may have the potential to be a multi-
targeted agent if it is able to interfere with signalling of both the tumour vasculature 
and the tumour cell itself. As an antibody of the IgG1 isotype and as HuMc3 was 
shown in this study to bind to lactadherin on the tumour and vascular EC surface, 
HuMc3 may also be able to activate both ADCC and CDC against the tumour cells 
and/or vasculature, as well as promote phagocytosis and removal of lactadherin in the 
form of immune complexes. As described above and validated by the HuMc3-
paclitaxel in vivo combination results, this effect may be further augmented by 
combination with other anti-cancer therapeutics such as the many approved cytotoxic 
drugs, with effects on pathways and processes necessary for cell survival. An 
alternative is combination with targeted therapies acting or on different pathways 
commonly involved in tumour development [235], or complex combinations with 
both conventional chemotherapy and monoclonal antibody therapeutics. The timing of 
combination therapy may also be considered, with some mAb therapies including 
both trastuzumab and anti-VEGF therapeutics showing a greater effect when the 
timing of chemotherapy is carefully controlled allowing synergy [138]. The latter is 
thought to be the result of the vascular normalisation window, with anti-VEGF 
therapies normalising the interstitial tissue pressure temporarily, allowing greater 
perfusion of the chemotherapy drug (section 1.2.5.3). As one of the potential effects 
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of HuMc3 inhibition of lactadherin αvβ3/αvβ5 integrin ligation is through inhibition 
of vascular development, this may well be relevant.   
 
Other ways in which the therapeutic effects of HuMc3 could be improved and which 
have shown some success or therapeutic promise for other monoclonal antibodies in 
pre-clinical and clinical studies [107][233][234][236][238][336][337][338][339][340], 
take advantage of the new technology and methodologies which have been developed 
since HuMc3 was produced. These include improving affinity/avidity of the antibody 
for its antigen and optimising the kinetic constants by CDR mutation and selection 
using molecular biology and display methods [336]. Though the Kd for HuMc3 
antigen association was sufficiently optimal to probably make avidity improvement 
overall unnecessary, a decrease in the rate of dissociation may improve the potential 
of this HuMc3 as a neutralising antibody. They also include increasing the capacity 
for ADCC and CDC through altered glycosylation or point mutation 
[236][237][238][333][338][341][342][343][344][345], or the development of 
fragments/modified fragments with better tumour perfusion [107][234][238] 
[337][339][346][347][348], whilst maintaining a sufficiently high serum half-life for 
therapy [234][349][350][351][352][353]. Immunoconjugate therapy it not currently a 
route that is advisable however despite some promising in vivo results in past work 
with HuMc3 radioimmunoconjugates (section 1.5.2 and section 1.5.3), as studies have 
shown limited success in solid tumours and high toxicity, despite the development of 
new conjugates and approaches [107][339][340]. In addition, MCF-7 cell staining 
data from this thesis suggested fairly uniform expression of lactadherin by these cells, 
at least in tissue culture conditions (section 4.2.1), so the “bystander effect,” of 
immunoconjugate therapy on non-expressing tumour cells may not have been of any 
benefit, except potentially for removal of cells that subsequently may lose lactadherin 
expression. 
 
The yields of HuMc3 attained in this study of 18mg/l after purification, though 
sufficient for all pre-clinical work and comparable with other glycosylated proteins 
produced in the SP2/0 cell line [276], would be unlikely to be sufficient for 
performance of clinical studies, or for scaling-up for industrial production. The yields 
of HuMc3 could be improved by expression in yeast, which divide more rapidly than 
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mammalian cells and have higher protein expression. A possibility would be a strain 
of the yeast Pichia pastoris, engineered to produce human glycosylation patterns 
[354]. Alternative methods for improving yields under laboratory conditions could 
involve the use of spinner flasks and roller bottles for culture of the SP2/0 cell line. 
Humanised antibodies expressed in SP2/0 myeloma lines have been successfully 
expressed industrially for commercial use using bioreactors [355], so this may 
ultimately be the answer if HuMc3 were to be approved down the line for cancer 
therapy.   
 
If HuMc3 were to be taken into the clinic, considerations would be both its potential 
for a therapeutic effect and for toxicity. With the results of this study showing no 
specific uptake by any normal murine tissues or uptake by a tissue mass formed from 
a non-tumour human cell line and with therapy data suggesting no toxic effects for 
any of the concentrations used or combinations, the potential for limited toxicity in 
the clinic was suggested. This was also supported by past data showing MuMc3 
association with primary human tumour tissues but not with any normal human 
tissues [265] and by the limited clinical toxicity of anti αvβ3 and/or αvβ5 
therapeutics (section 1.2.5.2). The many known normal roles of lactadherin in the 
human body however provide potential for toxicity through inhibition of these 
functions (section 1.3.1). As for bevacizumab, which has shown many clinical side 
effects through inhibition of the normal role of VEGF in angiogenesis, it may 
however be possible to manage the side effects though drug application and careful 
timing of treatment to minimise toxicity and allow time for recovery, between 
applications as well as after surgery, (which is particularly important for a drug which 
may interfere with angiogenesis and therefore wound healing) [124]. As the sequence 
of human lactadherin has shown significant variation by alignment to the murine 
form, with a 45% difference in the EGF domain to which HuMc3 binds [175], further 
in vivo toxicity studies are advisable before clinical application is attempted. These 
may include application of HuMc3 to a murine model engineered to express both 
human αvβ3/αvβ5 integrins and lactadherin, or selection of an alternative animal 
model with lactadherin more closely resembling the human form in sequence.  
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To maximise the effect of therapy, patients likely to respond may be selected for 
treatment as has been carried out for other mAb therapies including trastuzumab, with 
a significant improvement of outcome [356]. For HuMc3 therapy, selection of patients 
may be carried out as a simple blood test as lactadherin is shed at detectable levels 
into the circulation [266]. Combination therapy may be attempted, as is performed 
routinely in clinical studies with monoclonal antibody therapies (section 1.2.5.3) 
(section 1.4.3.1), with emphasis on the agents showing superior effect in combination 
with HuMc3 in pre-clinical studies.  
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Appendix 3 pcDNA4/myc-His A vector information 
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Appendix 4 Superdex™200 size exclusion standard curve with 1ml/min flow rate 
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